{"PMC7228725": [["IntroductionOn Dec 31, 2019, Chinese officials reported a cluster of cases of pneumonia in Wuhan, China.", [["pneumonia", "DISEASE", 78, 87], ["pneumonia", "PROBLEM", 78, 87], ["pneumonia", "OBSERVATION", 78, 87]]], ["The newly discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified to be responsible for the ensuing outbreak.1 As of May 13, 2020, more than 4\u00b71 million confirmed cases of COVID-19 have been reported with more than 280 000 attributable deaths worldwide.2", [["acute respiratory syndrome coronavirus", "DISEASE", 28, 66], ["deaths", "DISEASE", 267, 273], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 21, 68], ["SARS-CoV-2", "ORGANISM", 70, 80], ["severe acute respiratory syndrome coronavirus", "SPECIES", 21, 66], ["SARS-CoV-2", "SPECIES", 70, 80], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 21, 66], ["SARS-CoV", "TEST", 70, 78], ["COVID", "TEST", 203, 208], ["severe", "OBSERVATION_MODIFIER", 21, 27], ["acute", "OBSERVATION_MODIFIER", 28, 33], ["respiratory syndrome coronavirus", "OBSERVATION", 34, 66]]]], "PMC7126898": [["A previously healthy 14-year-old teenaged girl presented to the emergency department (ED) complaining of dysphagia associated with liquids and solids and difficulty swallowing her own saliva.", [["dysphagia", "DISEASE", 105, 114], ["girl", "ORGANISM", 42, 46], ["saliva", "ORGANISM_SUBSTANCE", 184, 190], ["girl", "SPECIES", 42, 46], ["dysphagia", "PROBLEM", 105, 114], ["liquids and solids", "PROBLEM", 131, 149], ["difficulty swallowing her own saliva", "PROBLEM", 154, 190], ["dysphagia", "OBSERVATION", 105, 114]]], ["The patient also reported a \u201cpain in the chest\u201d for the previous 2 days that appeared to begin after eating a turkey sandwich.", [["chest", "ANATOMY", 41, 46], ["pain", "DISEASE", 29, 33], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["turkey", "SPECIES", 110, 116], ["a \u201cpain in the chest", "PROBLEM", 26, 46], ["pain", "OBSERVATION", 29, 33], ["chest", "ANATOMY", 41, 46]]], ["The pain was substernal, sharp, and pleuritic.", [["pain", "DISEASE", 4, 8], ["The pain", "PROBLEM", 0, 8], ["substernal", "PROBLEM", 13, 23], ["pleuritic", "PROBLEM", 36, 45], ["sharp", "OBSERVATION_MODIFIER", 25, 30], ["pleuritic", "OBSERVATION", 36, 45]]], ["She reported fever and chills, but denied abdominal pain, vomiting, diarrhea, or hematemesis.", [["abdominal", "ANATOMY", 42, 51], ["fever", "DISEASE", 13, 18], ["chills", "DISEASE", 23, 29], ["abdominal pain", "DISEASE", 42, 56], ["vomiting", "DISEASE", 58, 66], ["diarrhea", "DISEASE", 68, 76], ["hematemesis", "DISEASE", 81, 92], ["abdominal", "ORGANISM_SUBDIVISION", 42, 51], ["fever", "PROBLEM", 13, 18], ["chills", "PROBLEM", 23, 29], ["abdominal pain", "PROBLEM", 42, 56], ["vomiting", "PROBLEM", 58, 66], ["diarrhea", "PROBLEM", 68, 76], ["hematemesis", "PROBLEM", 81, 92], ["fever", "OBSERVATION", 13, 18], ["chills", "OBSERVATION", 23, 29], ["abdominal", "ANATOMY", 42, 51], ["pain", "OBSERVATION", 52, 56], ["diarrhea", "OBSERVATION", 68, 76], ["hematemesis", "OBSERVATION", 81, 92]]], ["She denied any history of gastroesophageal reflux, nonsteroidal anti-inflammatory drug, tobacco or alcohol use, unusual ingestions, trying to induce vomiting, or having ever been sexually active.", [["gastroesophageal", "ANATOMY", 26, 42], ["gastroesophageal reflux", "DISEASE", 26, 49], ["alcohol", "CHEMICAL", 99, 106], ["vomiting", "DISEASE", 149, 157], ["alcohol", "CHEMICAL", 99, 106], ["gastroesophageal", "ORGAN", 26, 42], ["tobacco", "ORGANISM", 88, 95], ["alcohol", "SIMPLE_CHEMICAL", 99, 106], ["tobacco", "SPECIES", 88, 95], ["gastroesophageal reflux", "PROBLEM", 26, 49], ["nonsteroidal anti-inflammatory drug", "TREATMENT", 51, 86], ["unusual ingestions", "PROBLEM", 112, 130], ["vomiting", "PROBLEM", 149, 157], ["gastroesophageal", "ANATOMY", 26, 42], ["reflux", "OBSERVATION", 43, 49]]]], "2f9a9b479d33af87d6abf9e26de55fccec15c11c": [["INTRODUCTIONThe atypical pneumonia caused by novel corona virus (SARS-CoV 2) detected in Wuhan, Hubei province, China at the end of 2019 has subsequently spread across five continents at a remarkable speed, with Europe and North America being the most affected regions of the world.", [["pneumonia", "DISEASE", 25, 34], ["corona virus", "ORGANISM", 51, 63], ["SARS-CoV 2", "ORGANISM", 65, 75], ["corona virus", "SPECIES", 51, 63], ["SARS-CoV", "SPECIES", 65, 73], ["atypical pneumonia", "PROBLEM", 16, 34], ["novel corona virus", "PROBLEM", 45, 63], ["atypical", "OBSERVATION_MODIFIER", 16, 24], ["pneumonia", "OBSERVATION", 25, 34], ["corona virus", "OBSERVATION", 51, 63]]], ["The World Health Organisation (WHO) declared COVID-19 to be a pandemic of proportions similar to the Spanish Influenza of 1918.", [["Influenza", "DISEASE", 109, 118], ["COVID", "TEST", 45, 50]]], ["As of the 1 st May 2020, there have been over 224,172 deaths related to COVID-19 infection worldwide.", [["deaths", "DISEASE", 54, 60], ["COVID-19", "CHEMICAL", 72, 80], ["infection", "DISEASE", 81, 90], ["COVID-19", "SPECIES", 72, 80], ["COVID-19 infection", "PROBLEM", 72, 90], ["infection", "OBSERVATION", 81, 90]]], ["1 Data collated from across the world suggest that the overall case fatality rate is around 7%, with country-level estimates ranging between 0.5-14%.", [["fatality rate", "TEST", 68, 81]]], ["2 These figures however are not useful for universal comparison as testing rates also vary by country and there is a lag phase in reported deaths that occur in the community.", [["deaths", "DISEASE", 139, 145], ["testing rates", "TEST", 67, 80], ["a lag phase", "PROBLEM", 115, 126]]], ["Consequently, there is wide variation in the reported country-specific death rates which may be attributed to variation in testing rates, underreporting or real differences in environmental, sociodemographic and health system parameters.INTRODUCTIONThe only previous ecological study to date assessing country-level predictors of the severity of the COVID-19 pandemic including data on 65 countries 3 has found that the cumulative number of infected patients in each country was directly associated with the case fatality rate, whilst testing intensity was inversely associated with case fatality rate.INTRODUCTIONThis study found no association between health expenditure and case fatality rate.INTRODUCTIONHowever, other important country-level predictors were not evaluated and thus their relationship with pandemic severity remains unknown.INTRODUCTIONSeveral risk factors for COVID-related mortality have been proposed, including older population, 4 higher population co-morbid burden, 5 smoking, 6 obesity, 7 pollution levels 8 and healthcare system performance.", [["death", "DISEASE", 71, 76], ["infected", "DISEASE", 441, 449], ["pandemic", "DISEASE", 810, 818], ["COVID", "DISEASE", 881, 886], ["obesity", "DISEASE", 1004, 1011], ["patients", "ORGANISM", 450, 458], ["patients", "SPECIES", 450, 458], ["wide variation", "PROBLEM", 23, 37], ["testing rates", "TEST", 123, 136], ["previous ecological study", "TEST", 258, 283], ["the COVID", "TEST", 346, 355], ["INTRODUCTIONThis study", "TEST", 602, 624], ["pandemic severity", "PROBLEM", 810, 827], ["COVID", "PROBLEM", 881, 886], ["6 obesity", "PROBLEM", 1002, 1011], ["pollution levels", "TEST", 1015, 1031], ["wide", "OBSERVATION_MODIFIER", 23, 27], ["variation", "OBSERVATION_MODIFIER", 28, 37], ["may be attributed to", "UNCERTAINTY", 89, 109], ["variation", "OBSERVATION_MODIFIER", 110, 119], ["infected", "OBSERVATION", 441, 449], ["no association", "UNCERTAINTY", 631, 645]]], ["9 Furthermore, countries outside China most severely hit by the pandemic were those with a high income, high GDP per capita and well-established healthcare systems, such as Italy, Spain, France, the United Kingdom and the United States.", [["GDP", "CHEMICAL", 109, 112]]], ["10 In contrast, lower-and middle-income countries reported much lower COVID-19 incidence and mortality rates.", [["mortality rates", "TEST", 93, 108], ["lower", "ANATOMY_MODIFIER", 16, 21], ["middle", "ANATOMY_MODIFIER", 26, 32]]], ["10 Whilst these differences may be attributable to case underreporting due to inadequate testing facilities in poorer countries, other factors may also be involved.INTRODUCTIONIn this study, we aimed to derive a comparable measure of COVID related death rates.", [["death", "DISEASE", 248, 253], ["this study", "TEST", 179, 189], ["COVID related death rates", "PROBLEM", 234, 259]]], ["In addition, we aimed to assess the determinants for this measure by examining the association between potential country level determinants driven by hypothesis based on currently available evidence and this measure using country level publicly available data and an ecological study design.Study DesignAn ecological study design was used.", [["an ecological study", "TEST", 264, 283], ["Study DesignAn ecological study", "TEST", 291, 322]]], ["The chosen outcome was the steepness of the ascending curve of country specific daily reports of COVID related deaths from January to 1 st May 2020.", [["COVID", "DISEASE", 97, 102], ["deaths", "DISEASE", 111, 117], ["ascending", "ANATOMY_MODIFIER", 44, 53]]], ["The following predictors were used: demographic predictors (population and population density, percentage population living in urban areas, median age, average body mass index (BMI), smoking prevalence), economic predictors (gross Domestic Product (GDP) per capita), environmental predictors (pollution levels, mean temperature (January-April) [2010] [2011] [2012] [2013] [2014] [2015] [2016] ), prevalent co-morbidities (diabetes, hypertension and cancer), health systems predictors (WHO Health Index and hospital beds per 10, 000 population) and international arrivals, as a proxy measure of the globalisation status of each country.Ethics Committee ApprovalGiven the study design and the use of publicly available data, no ethical approval was necessary.Selection criteriaCountries reporting at least 25 daily deaths up to the 1 st of May 2020 with available data for all chose predictors were included.", [["body", "ANATOMY", 160, 164], ["cancer", "ANATOMY", 449, 455], ["diabetes", "DISEASE", 422, 430], ["hypertension", "DISEASE", 432, 444], ["cancer", "DISEASE", 449, 455], ["deaths", "DISEASE", 813, 819], ["body", "ORGANISM_SUBDIVISION", 160, 164], ["cancer", "CANCER", 449, 455], ["pollution levels", "TEST", 293, 309], ["prevalent co-morbidities (diabetes", "PROBLEM", 396, 430], ["hypertension", "PROBLEM", 432, 444], ["cancer", "PROBLEM", 449, 455], ["ethical approval", "TREATMENT", 726, 742], ["cancer", "OBSERVATION", 449, 455]]], ["No reuse allowed without permission.Data Sources(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["med", "ANATOMY", 127, 130]]], ["The data regarding the median population age and population density were 18 The world health organisation health index was extracted from the WHO Global Partnership for Education (GPE) paper series published in 2000.", [["population density", "PROBLEM", 49, 67]]], ["No reuse allowed without permission.Definition of outcome and predictors(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Definition of outcome and predictorsThe copyright holder for this preprint this version posted May 16, 2020. . https://doi.org/10.1101/2020.05.13.20100677 doi: medRxiv preprintOutcomeWhilst previous ecological studies of other epidemics have utilised case or death counts as outcome, 21 these variables may be prone to bias due to variations in country level control measures including different testing strategies, 22 variations in population movement controls and differences in secondary attack rates within community cohorts 23 .", [["death", "DISEASE", 466, 471], ["The copyright holder", "TREATMENT", 243, 263], ["other epidemics", "PROBLEM", 428, 443], ["death counts", "PROBLEM", 466, 478], ["country level control measures", "TREATMENT", 552, 582], ["different testing strategies", "TREATMENT", 593, 621], ["population movement controls", "TREATMENT", 640, 668], ["secondary attack rates", "PROBLEM", 688, 710], ["med", "ANATOMY", 151, 154]]], ["The mean mortality rate was thus chosen as outcome instead, since it is independent of these highly variable parameters and may thus represent a more reliable indicator of the country-level severity of the COVID-19 pandemic Mean mortality rate was defined as the slope of the mean mortality curve (Figure 1 ), measured from the first day when more than 2 COVID-19 deaths were reported until either the mortality curve reached a peak value or the 1 st of May 2020, whichever occurred first.OutcomeBefore slope calculation, the mortality curve in each country was smoothed using a locally weighted (Lowess) regression using a bandwidth of 0.4.", [["COVID", "DISEASE", 206, 211], ["deaths", "DISEASE", 364, 370], ["The mean mortality rate", "TEST", 0, 23], ["the COVID", "TEST", 202, 211], ["Mean mortality rate", "TEST", 224, 243], ["the mean mortality curve", "TEST", 272, 296], ["the mortality curve", "TEST", 398, 417], ["a peak value", "TEST", 426, 438], ["OutcomeBefore slope calculation", "TREATMENT", 489, 520], ["the mortality curve", "TEST", 522, 541], ["a locally weighted (Lowess) regression", "TREATMENT", 577, 615], ["a bandwidth", "TEST", 622, 633]]], ["In order to ensure a good fit of the Lowess regression line, only countries having reported at least 25 daily deaths until the 1 st of May 2020 were included.", [["deaths", "DISEASE", 110, 116], ["Lowess regression line", "CELL_LINE", 37, 59], ["the Lowess regression line", "TREATMENT", 33, 59]]], ["The mean mortality rate thus represents an estimate of the country-level daily increase in reported deaths during the ascending phase of the epidemic curve.PredictorsData on population density were extracted as the country-level population per square kilometre in 2019.", [["deaths", "DISEASE", 100, 106], ["The mean mortality rate", "TEST", 0, 23], ["increase", "OBSERVATION_MODIFIER", 79, 87], ["ascending phase", "OBSERVATION_MODIFIER", 118, 133], ["population", "OBSERVATION_MODIFIER", 174, 184], ["density", "OBSERVATION", 185, 192]]], ["24 Data on ambient air pollution were extracted as the countrylevel mean concentration of fine particulate matter (PM2.5) measured in 2016.", [["ambient air pollution", "TREATMENT", 11, 32]]], ["25 Temperature data were extracted as the mean temperature recorded in each country between January and April between 2010 and 2016.", [["Temperature data", "TEST", 3, 19], ["the mean temperature", "TEST", 38, 58]]], ["No reuse allowed without permission.Predictors(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.PredictorsThe copyright holder for this preprint this version posted May 16, 2020. . https://doi.org/10.1101/2020.05.13.20100677 doi: medRxiv preprint Data on prevalent diabetes were extracted as the percentage of the population aged 20 to 79 years in 2019.", [["diabetes", "DISEASE", 350, 358], ["prevalent diabetes", "PROBLEM", 340, 358], ["med", "ANATOMY", 125, 128]]], ["16 Data on prevalent cancers were extracted as the age-standardized cancer prevalence among both sexes in 2017, expressed as percentages.", [["cancers", "ANATOMY", 21, 28], ["cancer", "ANATOMY", 68, 74], ["cancers", "DISEASE", 21, 28], ["cancer", "DISEASE", 68, 74], ["cancers", "CANCER", 21, 28], ["cancer", "CANCER", 68, 74], ["prevalent cancers", "PROBLEM", 11, 28], ["cancers", "OBSERVATION", 21, 28], ["cancer", "OBSERVATION", 68, 74]]], ["27 Data on prevalent hypertension were extracted as the age-standardised percentage of the population over 18 years of age with systolic blood pressure \u2265140 mmHg or diastolic blood pressure \u226590 mmHg in 2015.", [["blood", "ANATOMY", 137, 142], ["blood", "ANATOMY", 175, 180], ["hypertension", "DISEASE", 21, 33], ["blood", "ORGANISM_SUBSTANCE", 137, 142], ["blood", "ORGANISM_SUBSTANCE", 175, 180], ["prevalent hypertension", "PROBLEM", 11, 33], ["systolic blood pressure", "TEST", 128, 151], ["diastolic blood pressure", "TEST", 165, 189], ["hypertension", "OBSERVATION", 21, 33]]], ["28 Data on BMI were extracted as the age-standardised mean body mass index trend estimates for both sexes amongst adults (\u226518 years) in 2016.", [["body", "ANATOMY", 59, 63], ["body", "ORGANISM_SUBDIVISION", 59, 63], ["BMI", "TEST", 11, 14], ["the age", "TEST", 33, 40]]], ["30 Data on GDP were extracted as GDP per capita by Purchasing Power Parity (PPP) in current international dollars in 2018.", [["GDP", "CHEMICAL", 11, 14], ["GDP", "CHEMICAL", 33, 36], ["GDP", "CHEMICAL", 11, 14], ["GDP", "CHEMICAL", 33, 36], ["GDP", "SIMPLE_CHEMICAL", 11, 14], ["GDP", "SIMPLE_CHEMICAL", 33, 36]]], ["31 The percentage of population living in urban areas was defined as the percentage of de facto population living in areas classified as urban according to the criteria used by each area or country.", [["percentage", "OBSERVATION_MODIFIER", 7, 17], ["population", "OBSERVATION_MODIFIER", 21, 31]]], ["The index uses five weighted parameters: overall or average disability-adjusted life expectancy (25%), distribution or equality of disability-adjusted life expectancy (25%), overall or average healthcare system responsiveness (including speed of provision and quality of amenities; 12.5%), distribution or equality of healthcare system responsiveness (12.5%) and healthcare expenditure (25%).", [["The index", "TEST", 0, 9], ["healthcare expenditure", "TEST", 363, 385]]], ["No reuse allowed without permission.Predictors(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.PredictorsThe copyright holder for this preprint this version posted May 16, 2020. . https://doi.org/10.1101/2020.05.13.20100677 doi: medRxiv preprint hospitals and rehabilitation centers.", [["rehabilitation centers", "TREATMENT", 346, 368], ["med", "ANATOMY", 125, 128]]], ["In most cases beds for both acute and chronic care are included.", [["chronic care", "TREATMENT", 38, 50], ["acute", "OBSERVATION_MODIFIER", 28, 33], ["chronic", "OBSERVATION_MODIFIER", 38, 45]]], ["20Statistical analysisAll analyses were performed in Stata 15.1SE, Stata Statistical Software.", [["20Statistical analysis", "TEST", 0, 22], ["All analyses", "TEST", 22, 34]]], ["A 5% threshold of statistical significance was utilised for all analyses (P <0.05).", [["all analyses", "TEST", 60, 72]]], ["Linear regression was performed to assess the univariable relationship between each country-level predictor and the calculated mean mortality rate for each country.", [["Linear regression", "PROBLEM", 0, 17], ["regression", "OBSERVATION", 7, 17]]], ["The following predictors were included in the univariable analyses: population in 2018, median age, pollution levels, mean temperature (January-April), international arrivals, population density, prevalent diabetes, prevalent neoplasms, median BMI, prevalent hypertension, smoking prevalence, hospital beds (per 10,000 population), WHO health index, percentage population living in urban areas and GDP per capita (PPP).", [["neoplasms", "ANATOMY", 226, 235], ["diabetes", "DISEASE", 206, 214], ["neoplasms", "DISEASE", 226, 235], ["hypertension", "DISEASE", 259, 271], ["smoking", "CHEMICAL", 273, 280], ["GDP", "CHEMICAL", 398, 401], ["neoplasms", "CANCER", 226, 235], ["GDP", "SIMPLE_CHEMICAL", 398, 401], ["pollution levels", "TEST", 100, 116], ["mean temperature", "TEST", 118, 134], ["prevalent diabetes", "PROBLEM", 196, 214], ["prevalent neoplasms", "PROBLEM", 216, 235], ["median BMI", "PROBLEM", 237, 247], ["prevalent hypertension", "PROBLEM", 249, 271], ["median BMI", "OBSERVATION", 237, 247], ["hypertension", "OBSERVATION", 259, 271]]], ["Predictors reaching a P-value <0.3 at univariable level were then included in a multivariable logistic regression model to predict the mean mortality rate outcome: median age, pollution levels, international arrivals, prevalent neoplasms, median BMI, prevalent hypertension, WHO health index, percentage of population living in urban areas and GDP per capita. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.RESULTSThe copyright holder for this preprint this version posted May 16, 2020. .", [["neoplasms", "ANATOMY", 228, 237], ["neoplasms", "DISEASE", 228, 237], ["hypertension", "DISEASE", 261, 273], ["GDP", "CHEMICAL", 344, 347], ["GDP", "CHEMICAL", 344, 347], ["neoplasms", "CANCER", 228, 237], ["GDP", "SIMPLE_CHEMICAL", 344, 347], ["Predictors", "TEST", 0, 10], ["a P-value", "TEST", 20, 29], ["prevalent neoplasms", "PROBLEM", 218, 237], ["median BMI", "PROBLEM", 239, 249], ["prevalent hypertension", "PROBLEM", 251, 273], ["neoplasms", "OBSERVATION", 228, 237], ["median BMI", "OBSERVATION", 239, 249], ["hypertension", "OBSERVATION", 261, 273], ["med", "ANATOMY", 439, 442]]], ["Table 2Principal findingsIn this ecological study including data from 31 countries which were most severely affected by COVID-19 in the first wave of current Global pandemic, we assessed 14 countrylevel socioeconomic, environmental, health and healthcare system, and globalisation parameters as potential predictors of variation in death rates from COVID 19 infection.", [["death", "DISEASE", 332, 337], ["infection", "DISEASE", 358, 367], ["this ecological study", "TEST", 28, 49], ["COVID", "TEST", 120, 125], ["globalisation parameters", "TEST", 267, 291], ["variation in death rates", "PROBLEM", 319, 343], ["COVID 19 infection", "PROBLEM", 349, 367], ["infection", "OBSERVATION", 358, 367]]], ["No reuse allowed without permission.Principal findings(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Principal findingsThe copyright holder for this preprint this version posted May 16, 2020. . https://doi.org/10.1101/2020.05.13.20100677 doi: medRxiv preprintComparison with literature.A recently published ecological study analysed the country-level predictors of the case fatality rate of the COVID-19 pandemic using data from 65 countries.", [["Principal findings", "PROBLEM", 189, 207], ["The copyright holder", "TREATMENT", 207, 227], ["A recently published ecological study", "TEST", 374, 411], ["the COVID", "TEST", 479, 488], ["med", "ANATOMY", 133, 136]]], ["3 This study found that upon adjustment for epidemic age, health expenditure and world region, the case fatality rate was significantly associated with increasing cumulative number of COVID-19 cases and decreasing testing intensity.", [["This study", "TEST", 2, 12], ["COVID", "TEST", 184, 189], ["decreasing testing intensity", "PROBLEM", 203, 231]]], ["3 Nevertheless, no other country-level predictors were included in this study.", [["this study", "TEST", 67, 77]]], ["Comorbidities may account for differences in mortality rates across countries.", [["Comorbidities", "PROBLEM", 0, 13], ["may account for", "UNCERTAINTY", 14, 29]]], ["A study among laboratory-confirmed cases of COVID-19 in China showed that patients with any comorbidity, including diabetes, malignancy and hypertension, had poorer clinical outcomes than those without.", [["diabetes", "DISEASE", 115, 123], ["malignancy", "DISEASE", 125, 135], ["hypertension", "DISEASE", 140, 152], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["A study", "TEST", 0, 7], ["COVID", "TEST", 44, 49], ["any comorbidity", "PROBLEM", 88, 103], ["diabetes", "PROBLEM", 115, 123], ["malignancy", "PROBLEM", 125, 135], ["hypertension", "PROBLEM", 140, 152], ["diabetes", "OBSERVATION", 115, 123], ["malignancy", "OBSERVATION", 125, 135], ["hypertension", "OBSERVATION", 140, 152]]], ["5 We thus accounted for country-level data on a selection of key comorbidities in our analysis which included prevalent diabetes mellitus, neoplasms, and hypertension.", [["neoplasms", "ANATOMY", 139, 148], ["diabetes mellitus", "DISEASE", 120, 137], ["neoplasms", "DISEASE", 139, 148], ["hypertension", "DISEASE", 154, 166], ["neoplasms", "CANCER", 139, 148], ["key comorbidities", "PROBLEM", 61, 78], ["our analysis", "TEST", 82, 94], ["prevalent diabetes mellitus", "PROBLEM", 110, 137], ["neoplasms", "PROBLEM", 139, 148], ["hypertension", "PROBLEM", 154, 166], ["diabetes mellitus", "OBSERVATION", 120, 137], ["neoplasms", "OBSERVATION", 139, 148], ["hypertension", "OBSERVATION", 154, 166]]], ["Diabetes mellitus is significantly associated with all-cause and cardiovascular disease mortality globally.", [["cardiovascular", "ANATOMY", 65, 79], ["Diabetes mellitus", "DISEASE", 0, 17], ["cardiovascular disease", "DISEASE", 65, 87], ["Diabetes mellitus", "PROBLEM", 0, 17], ["cardiovascular disease mortality globally", "PROBLEM", 65, 106], ["mellitus", "OBSERVATION", 9, 17], ["cardiovascular", "ANATOMY", 65, 79], ["disease", "OBSERVATION", 80, 87]]], ["BMI \u226540kg/m2 has been identified as an independent risk factor for severe COVID-19 illness.", [["COVID", "DISEASE", 74, 79], ["illness", "DISEASE", 83, 90], ["BMI", "TEST", 0, 3], ["severe COVID-19 illness", "PROBLEM", 67, 90]]], ["7 Finally, a recent systematic review on 5 studies from China showed that smoking is likely associated with negative outcomes and progression of COVID-19.", [["smoking", "CHEMICAL", 74, 81], ["5 studies", "TEST", 41, 50], ["COVID", "TEST", 145, 150], ["likely associated with", "UNCERTAINTY", 85, 107]]], ["No reuse allowed without permission.Comparison with literature.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Comparison with literature.The copyright holder for this preprint this version posted May 16, 2020.", [["The copyright holder", "TREATMENT", 225, 245], ["med", "ANATOMY", 142, 145]]], ["Interestingly, during the COVID-19 pandemic, some countries (such as Thailand) have adopted aggressive international travel screening and isolation policies, which may have led to lower infection rates.", [["infection", "DISEASE", 186, 195], ["aggressive international travel screening", "TREATMENT", 92, 133], ["isolation policies", "TREATMENT", 138, 156], ["lower infection rates", "PROBLEM", 180, 201], ["lower", "OBSERVATION_MODIFIER", 180, 185], ["infection", "OBSERVATION", 186, 195]]], ["38 Our study suggests that travel restrictions have the potential to influence the impact of the COVID-19 pandemic and should be part of a structured and rapidly instigated pandemic preparedness plan.", [["Our study", "TEST", 3, 12], ["the COVID", "TREATMENT", 93, 102]]], ["No reuse allowed without permission.Comparison with literature.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Comparison with literature.The copyright holder for this preprint this version posted May 16, 2020. . https://doi.org/10.1101/2020.05.13.20100677 doi: medRxiv preprint travel should be developed taking into account the economic and social impacts of such restrictions.Strengths and Limitations.The main strength of this study lies in its use of comparable and relevant outcome data derived from contemporary death reporting from countries affected by COVID-19.", [["death", "DISEASE", 606, 611], ["The copyright holder", "TREATMENT", 225, 245], ["medRxiv preprint travel", "TREATMENT", 349, 372], ["this study", "TEST", 513, 523], ["COVID", "TEST", 649, 654], ["med", "ANATOMY", 142, 145], ["main", "OBSERVATION_MODIFIER", 496, 500], ["strength", "OBSERVATION_MODIFIER", 501, 509]]], ["As testing rates for the virus vary across countries, the incidence or prevalence of the disease cannot be compared between countries.", [["testing rates", "TEST", 3, 16], ["the virus", "PROBLEM", 21, 30], ["the disease", "PROBLEM", 85, 96], ["disease", "OBSERVATION", 89, 96]]], ["While death from the disease is a hard outcome, the denominator information to calculate death rates make between-country comparisons difficult.", [["death", "DISEASE", 6, 11], ["death", "DISEASE", 89, 94], ["death rates", "TEST", 89, 100], ["disease", "OBSERVATION", 21, 28]]], ["In addition, the deaths in the community, particularly in the elderly living in care homes, often go untested and thus firm diagnosis remains impossible.", [["deaths", "DISEASE", 17, 23]]], ["Therefore, in this study we have adopted an outcome that is comparable in terms of the increase in the rate of death, rather than death rates per se.", [["death", "DISEASE", 111, 116], ["death", "DISEASE", 130, 135], ["this study", "TEST", 14, 24], ["death", "PROBLEM", 111, 116], ["increase", "OBSERVATION_MODIFIER", 87, 95]]], ["Therefore, this may better represent the spread and seriousness of pandemic in individual countries when comparing countries at different stages of the pandemic.", [["pandemic", "PROBLEM", 67, 75], ["the pandemic", "PROBLEM", 148, 160], ["may better represent", "UNCERTAINTY", 16, 36]]], ["The country-level parameters assessed as potential predictors have all been implicated at some point to be associated with severity and consequently mortality.Strengths and Limitations.We however found that the only significant predictor to be total number of international arrivals in the country (2018 figures), signifying transmission of the infection through travel.Strengths and Limitations.Although the data was from 2018, there is no reason to believe that international travel figures between countries would be different in early 2020.", [["infection", "DISEASE", 345, 354], ["severity", "PROBLEM", 123, 131], ["the infection", "PROBLEM", 341, 354], ["the data", "TEST", 405, 413], ["infection", "OBSERVATION", 345, 354], ["no reason to", "UNCERTAINTY", 438, 450]]], ["Our model had a reasonably good fit to the data, explaining around 77% of the between country variation in mean death rates.Strengths and Limitations.The main limitation of the study stems from the ecological study design.", [["death", "DISEASE", 112, 117], ["mean death rates", "PROBLEM", 107, 123], ["the study stems", "TEST", 173, 188], ["the ecological study", "TEST", 194, 214], ["mean death", "OBSERVATION", 107, 117], ["main", "OBSERVATION_MODIFIER", 154, 158], ["limitation", "OBSERVATION_MODIFIER", 159, 169]]], ["Despite the fact that we did not find any association between comorbidities such as diabetes, cancer All rights reserved.", [["cancer", "ANATOMY", 94, 100], ["diabetes", "DISEASE", 84, 92], ["cancer", "DISEASE", 94, 100], ["cancer", "CANCER", 94, 100], ["comorbidities", "PROBLEM", 62, 75], ["diabetes", "PROBLEM", 84, 92], ["cancer", "PROBLEM", 94, 100], ["diabetes", "OBSERVATION", 84, 92], ["cancer", "OBSERVATION", 94, 100]]], ["No reuse allowed without permission.Strengths and Limitations.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Strengths and Limitations.The copyright holder for this preprint this version posted May 16, 2020.CONCLUSIONOut of all the country-level parameters assessed, international travel was the only significant predictor of the severity of the first global wave of the COVID-19 pandemic.CONCLUSIONGiven that many of world middle and lower-income countries are showing signs of continued rise in infection rates, international travel restrictions applied early in the pandemic course may be an effective measure to avoid rapidly increasing infection and death rates globally.CONCLUSIONAll rights reserved.", [["infection", "DISEASE", 585, 594], ["infection", "DISEASE", 729, 738], ["death", "DISEASE", 743, 748], ["The copyright holder", "TREATMENT", 223, 243], ["the COVID", "TEST", 455, 464], ["continued rise in infection rates", "PROBLEM", 567, 600], ["international travel restrictions", "TREATMENT", 602, 635], ["rapidly increasing infection", "PROBLEM", 710, 738], ["death rates globally", "PROBLEM", 743, 763], ["med", "ANATOMY", 141, 144], ["rise", "OBSERVATION_MODIFIER", 577, 581], ["infection", "OBSERVATION", 585, 594], ["increasing", "OBSERVATION_MODIFIER", 718, 728], ["infection", "OBSERVATION", 729, 738]]], ["No reuse allowed without permission.CONCLUSION(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.CONCLUSIONThe copyright holder for this preprint this version posted May 16, 2020.", [["med", "ANATOMY", 125, 128]]], ["Observed mean mortality rate and number of international arrivals in 2018 (millions) for each country included in the analyses.", [["mean mortality rate", "TEST", 9, 28]]], ["Countries were categorised in 3 groups: high mean mortality rate group (>20 additional daily deaths), medium mean mortality rate group (2-20 additional daily deaths) and low mean mortality rate group (<2 additional daily deaths). (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.CountryThe copyright holder for this preprint this version posted May 16, 2020. .", [["deaths", "DISEASE", 93, 99], ["deaths", "DISEASE", 158, 164], ["deaths", "DISEASE", 221, 227], ["low mean mortality rate group", "PROBLEM", 170, 199], ["The copyright holder", "TREATMENT", 372, 392], ["med", "ANATOMY", 309, 312]]], ["No reuse allowed without permission.Country(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.CountryThe copyright holder for this preprint this version posted May 16, 2020. .", [["The copyright holder", "TREATMENT", 185, 205], ["med", "ANATOMY", 122, 125]]], ["BMI -body mass index; WHO -world health organisation; GDP -gross domestic product; PPP -purchasing power parity; Figure 1 .", [["body", "ANATOMY", 5, 9], ["body", "ORGANISM_SUBDIVISION", 5, 9], ["GDP", "SIMPLE_CHEMICAL", 54, 57], ["BMI", "TEST", 0, 3], ["body mass index", "PROBLEM", 5, 20], ["GDP", "TEST", 54, 57], ["gross domestic product", "PROBLEM", 59, 81], ["PPP", "PROBLEM", 83, 86], ["body", "ANATOMY", 5, 9], ["mass", "OBSERVATION", 10, 14]]], ["Graphical representation of the smoothed* number of daily deaths of each country (before reaching mortality peak, if applicable) as a function of the number of days passed since the first day when an excess of 3 deaths were reported.", [["deaths", "DISEASE", 58, 64], ["deaths", "DISEASE", 212, 218]]], ["Countries with higher mortality rates are depicted in blue, while those with lower mortality rates are depicted in red. *smoothed using a local regression (lowess) function with a bandwidth of 0.4FIGURESAll rights reserved.", [["lower mortality rates", "PROBLEM", 77, 98], ["a local regression", "TREATMENT", 136, 154], ["a bandwidth of 0.4FIGURESAll rights", "TREATMENT", 178, 213]]], ["No reuse allowed without permission.FIGURES(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.FIGURESThe copyright holder for this preprint this version posted May 16, 2020. . https://doi.org/10.1101/2020.05.13.20100677 doi: medRxiv preprint Figure 2 .", [["med", "ANATOMY", 122, 125]]], ["Predicted (based on the results of the multivariable linear regression) and observed country-level mortality rate (mean daily increase in deaths until the peak in mortality) as a function of the recorded country-level number of international arrivals in 2018 (millions).", [["deaths", "DISEASE", 138, 144], ["mortality rate", "TEST", 99, 113]]]], "bd1739f5546fa2c28bade3b394d157887af503e4": [["Study PopulationCoronavirus Disease 2019 infection was confirmed by usage of polymerase chain reaction tests on either nasopharyngeal or lower respiratory tract swab samples ordered at intensive care unit (ICU) admission.Study PopulationConsideration of ECMO was based on the presence of severe respiratory failure (Murray score >3.0 or pH <7.20 under protective ventilation 2,6-8 ) with sustained clinical deterioration despite optimal conventional treatment and refractory prone positioning.", [["nasopharyngeal", "ANATOMY", 119, 133], ["lower respiratory tract swab samples", "ANATOMY", 137, 173], ["respiratory", "ANATOMY", 295, 306], ["infection", "DISEASE", 41, 50], ["respiratory failure", "DISEASE", 295, 314], ["nasopharyngeal", "CANCER", 119, 133], ["Study PopulationCoronavirus Disease", "PROBLEM", 0, 35], ["infection", "PROBLEM", 41, 50], ["polymerase chain reaction tests", "TEST", 77, 108], ["ECMO", "TREATMENT", 254, 258], ["severe respiratory failure", "PROBLEM", 288, 314], ["Murray score", "TEST", 316, 328], ["pH", "TEST", 337, 339], ["protective ventilation", "TREATMENT", 352, 374], ["sustained clinical deterioration", "PROBLEM", 388, 420], ["optimal conventional treatment", "TREATMENT", 429, 459], ["refractory prone positioning", "TREATMENT", 464, 492], ["infection", "OBSERVATION", 41, 50], ["nasopharyngeal", "ANATOMY", 119, 133], ["lower", "ANATOMY_MODIFIER", 137, 142], ["respiratory tract", "ANATOMY", 143, 160], ["ECMO", "OBSERVATION", 254, 258], ["severe", "OBSERVATION_MODIFIER", 288, 294], ["respiratory failure", "OBSERVATION", 295, 314]]], ["This has been in accordance with Extracorporeal Life Support Organization (ELSO) guidelines document for the adult patient with COVID-19.", [["patient", "ORGANISM", 115, 122], ["patient", "SPECIES", 115, 122], ["Extracorporeal Life Support", "TREATMENT", 33, 60], ["COVID", "TEST", 128, 133]]], ["2, [6] [7] [8] Diffuse bilateral lung injury by SARS-CoV-2 was confirmed by chest x-ray or computed tomography (CT) scan in all patients [3] [4] [5] 7 (Figure 1 ).Study PopulationAggressive mechanical ventilation (peak or plateau airway pressure >30 cm H2O or fraction of inspired oxygen [FIO2] >0.8) for more than 7 days, uncontrolled active bleeding, severe comorbidity, multiple organ failure, sepsis, disseminated intravascular coagulation, age >65 years, and neurologic damage were used as contraindications for VV ECMO institution.", [["lung", "ANATOMY", 33, 37], ["airway", "ANATOMY", 230, 236], ["organ", "ANATOMY", 382, 387], ["intravascular", "ANATOMY", 418, 431], ["neurologic", "ANATOMY", 464, 474], ["lung injury", "DISEASE", 33, 44], ["H2O", "CHEMICAL", 253, 256], ["oxygen", "CHEMICAL", 281, 287], ["bleeding", "DISEASE", 343, 351], ["multiple organ failure", "DISEASE", 373, 395], ["sepsis", "DISEASE", 397, 403], ["disseminated intravascular coagulation", "DISEASE", 405, 443], ["neurologic damage", "DISEASE", 464, 481], ["H2O", "CHEMICAL", 253, 256], ["oxygen", "CHEMICAL", 281, 287], ["FIO2", "CHEMICAL", 289, 293], ["[6] [7] [8", "SIMPLE_CHEMICAL", 3, 13], ["lung", "ORGAN", 33, 37], ["patients", "ORGANISM", 128, 136], ["airway", "MULTI-TISSUE_STRUCTURE", 230, 236], ["oxygen", "SIMPLE_CHEMICAL", 281, 287], ["organ", "ORGAN", 382, 387], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 418, 431], ["patients", "SPECIES", 128, 136], ["SARS-CoV", "SPECIES", 48, 56], ["VV", "SPECIES", 517, 519], ["Diffuse bilateral lung injury", "PROBLEM", 15, 44], ["SARS", "PROBLEM", 48, 52], ["chest x-ray", "TEST", 76, 87], ["computed tomography (CT) scan", "TEST", 91, 120], ["Study PopulationAggressive mechanical ventilation", "TREATMENT", 163, 212], ["peak", "TEST", 214, 218], ["plateau airway pressure", "TEST", 222, 245], ["inspired oxygen", "TREATMENT", 272, 287], ["FIO2", "TEST", 289, 293], ["uncontrolled active bleeding", "PROBLEM", 323, 351], ["severe comorbidity", "PROBLEM", 353, 371], ["multiple organ failure", "PROBLEM", 373, 395], ["sepsis", "PROBLEM", 397, 403], ["disseminated intravascular coagulation", "PROBLEM", 405, 443], ["neurologic damage", "PROBLEM", 464, 481], ["VV ECMO institution", "TREATMENT", 517, 536], ["Diffuse", "OBSERVATION_MODIFIER", 15, 22], ["bilateral", "ANATOMY_MODIFIER", 23, 32], ["lung", "ANATOMY", 33, 37], ["injury", "OBSERVATION", 38, 44], ["chest", "ANATOMY", 76, 81], ["mechanical ventilation", "OBSERVATION", 190, 212], ["airway", "ANATOMY", 230, 236], ["active", "OBSERVATION_MODIFIER", 336, 342], ["bleeding", "OBSERVATION", 343, 351], ["severe", "OBSERVATION_MODIFIER", 353, 359], ["comorbidity", "OBSERVATION", 360, 371], ["multiple", "OBSERVATION_MODIFIER", 373, 381], ["organ", "ANATOMY", 382, 387], ["failure", "OBSERVATION", 388, 395], ["sepsis", "OBSERVATION", 397, 403], ["disseminated", "OBSERVATION_MODIFIER", 405, 417], ["intravascular coagulation", "OBSERVATION", 418, 443]]], ["2, 7, 8 Patients have been considered for ECMO by a multidisciplinary team consisting of experts from Anesthesiology and Intensive Care, Cardiac Surgery, Cardiology, and Infectious Diseases.Study PopulationThe study has been approved by our institutional review board.", [["Cardiac", "ANATOMY", 137, 144], ["Cardiac Surgery", "DISEASE", 137, 152], ["Infectious Diseases", "DISEASE", 170, 189], ["Patients", "ORGANISM", 8, 16], ["Patients", "SPECIES", 8, 16], ["ECMO", "TREATMENT", 42, 46], ["Cardiac Surgery", "TREATMENT", 137, 152], ["The study", "TEST", 206, 215], ["Infectious", "OBSERVATION", 170, 180]]], ["Informed consent was not required for ECMO treatment, as the use of mechanical support was considered a rescue therapy in all patients.Extracorporeal Membrane Oxygenation Support SettingThe ultracompact Cardiohelp (Getinge, Maquet-Cardiopulmonary AG, Rastatt, Germany) has been adopted as ECMO system.", [["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["ECMO treatment", "TREATMENT", 38, 52], ["mechanical support", "TREATMENT", 68, 86], ["a rescue therapy", "TREATMENT", 102, 118], ["Extracorporeal Membrane Oxygenation Support", "TREATMENT", 135, 178], ["The ultracompact Cardiohelp (Getinge", "TREATMENT", 186, 222], ["Cardiopulmonary AG", "TREATMENT", 231, 249], ["Membrane Oxygenation", "OBSERVATION", 150, 170]]], ["For inflow, the right femoral vein was cannulated percutaneously using the Seldinger technique with a 38 cm long, 21-23 Fr heparin-coated cannula (Bio-Medicus NextGen, Medtronic Inc., Minneapolis, MN).", [["right femoral vein", "ANATOMY", 16, 34], ["heparin", "CHEMICAL", 123, 130], ["right femoral vein", "MULTI-TISSUE_STRUCTURE", 16, 34], ["heparin", "SIMPLE_CHEMICAL", 123, 130], ["inflow", "TREATMENT", 4, 10], ["the Seldinger technique", "TREATMENT", 71, 94], ["21-23 Fr heparin-coated cannula", "TREATMENT", 114, 145], ["Medtronic Inc., Minneapolis, MN)", "TREATMENT", 168, 200], ["right femoral vein", "ANATOMY", 16, 34]]], ["For reinfusion (outflow), a 15 cm long, 15-17 Fr heparin-coated cannula (Bio-Medicus NextGen, Medtronic Inc.) was used, implanted into the right internal jugular vein.Extracorporeal Membrane Oxygenation Support SettingAll the components of the ECMO system and tubings were heparin coated (Bioline coating; Getinge, Maquet-Cardiopulmonary AG), and systemic anticoagulation was maintained using unfractionated heparin to a partial thromboplastin time of 1.5 normal.", [["right internal jugular vein", "ANATOMY", 139, 166], ["heparin", "CHEMICAL", 49, 56], ["heparin", "CHEMICAL", 273, 280], ["heparin", "CHEMICAL", 408, 415], ["heparin", "SIMPLE_CHEMICAL", 49, 56], ["right internal jugular vein", "MULTI-TISSUE_STRUCTURE", 139, 166], ["heparin", "SIMPLE_CHEMICAL", 273, 280], ["heparin", "SIMPLE_CHEMICAL", 408, 415], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 429, 443], ["reinfusion (outflow", "TREATMENT", 4, 23], ["a 15 cm long, 15-17 Fr heparin-coated cannula (Bio-Medicus NextGen", "TREATMENT", 26, 92], ["Medtronic Inc.)", "TREATMENT", 94, 109], ["Extracorporeal Membrane Oxygenation Support", "TREATMENT", 167, 210], ["the ECMO system", "TREATMENT", 240, 255], ["tubings", "TREATMENT", 260, 267], ["heparin coated (Bioline coating", "TREATMENT", 273, 304], ["Getinge", "TREATMENT", 306, 313], ["Maquet", "TREATMENT", 315, 321], ["Cardiopulmonary AG", "TREATMENT", 322, 340], ["systemic anticoagulation", "TREATMENT", 347, 371], ["unfractionated heparin", "TREATMENT", 393, 415], ["a partial thromboplastin time", "TEST", 419, 448], ["right", "ANATOMY_MODIFIER", 139, 144], ["internal jugular vein", "ANATOMY", 145, 166], ["Membrane Oxygenation", "OBSERVATION", 182, 202], ["ECMO", "OBSERVATION", 244, 248], ["Cardiopulmonary", "ANATOMY", 322, 337]]], ["2, 6, 7 Pressures on the ECMO circuit, blood gas analysis, general laboratories, and complete blood coagulation study were also monitored daily.", [["blood", "ANATOMY", 39, 44], ["blood", "ANATOMY", 94, 99], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["blood", "ORGANISM_SUBSTANCE", 94, 99], ["the ECMO circuit", "TREATMENT", 21, 37], ["blood gas analysis", "TEST", 39, 57], ["general laboratories", "TEST", 59, 79], ["complete blood coagulation study", "TEST", 85, 117]]], ["Echocardiography was not performed routinely.Patient Management and Weaning from Extracorporeal Membrane OxygenationAfter cannulation, patient management was optimized to minimize further ventilator-induced lung injury (VILI).", [["lung", "ANATOMY", 207, 211], ["ventilator-induced lung injury", "DISEASE", 188, 218], ["VILI", "DISEASE", 220, 224], ["patient", "ORGANISM", 135, 142], ["lung", "ORGAN", 207, 211], ["Patient", "SPECIES", 45, 52], ["patient", "SPECIES", 135, 142], ["Echocardiography", "TEST", 0, 16], ["Patient Management", "TREATMENT", 45, 63], ["Extracorporeal Membrane OxygenationAfter cannulation", "TREATMENT", 81, 133], ["patient management", "TREATMENT", 135, 153], ["further ventilator", "TREATMENT", 180, 198], ["induced lung injury", "PROBLEM", 199, 218], ["lung", "ANATOMY", 207, 211], ["injury", "OBSERVATION", 212, 218]]], ["2, [6] [7] [8] Regarding oxygenation, ECMO blood flow was maximized to reduce the FIO2 less than 0.6 and maintain hemoglobin Veno-venous Extracorporeal Membrane Oxygenation Support in COVID-19 Respiratory Distress Syndrome: Initial Experience saturation more than 85%.", [["blood", "ANATOMY", 43, 48], ["Respiratory Distress Syndrome", "DISEASE", 193, 222], ["[6] [7] [8]", "SIMPLE_CHEMICAL", 3, 14], ["blood", "ORGANISM_SUBSTANCE", 43, 48], ["hemoglobin", "PROTEIN", 114, 124], ["oxygenation", "TEST", 25, 36], ["ECMO blood flow", "TEST", 38, 53], ["the FIO2", "TEST", 78, 86], ["hemoglobin", "TEST", 114, 124], ["venous Extracorporeal Membrane Oxygenation Support", "TREATMENT", 130, 180], ["Respiratory Distress Syndrome", "PROBLEM", 193, 222], ["saturation", "TEST", 243, 253], ["venous", "ANATOMY", 130, 136], ["Extracorporeal Membrane", "OBSERVATION", 137, 160], ["Respiratory Distress", "OBSERVATION", 193, 213]]], ["Positive end-expiratory pressure (PEEP) was maintained above 8 cm H 2 O. If severe hypoxemia (PaO2, <60 mm Hg) still subsisted, the threshold for red blood cell transfusion was elevated from 7.0 to 9.0 g/dl.", [["red blood cell", "ANATOMY", 146, 160], ["hypoxemia", "DISEASE", 83, 92], ["Hg", "CHEMICAL", 107, 109], ["red blood cell", "CELL", 146, 160], ["expiratory pressure", "TEST", 13, 32], ["PEEP", "TREATMENT", 34, 38], ["severe hypoxemia", "PROBLEM", 76, 92], ["PaO2", "TEST", 94, 98], ["mm Hg", "TEST", 104, 109], ["the threshold", "TEST", 128, 141], ["red blood cell transfusion", "TEST", 146, 172], ["elevated", "PROBLEM", 177, 185], ["end", "OBSERVATION_MODIFIER", 9, 12], ["expiratory pressure", "OBSERVATION", 13, 32], ["severe", "OBSERVATION_MODIFIER", 76, 82], ["hypoxemia", "OBSERVATION", 83, 92]]], ["The threshold for prophylactic platelet transfusion was 35.000/\u03bcl, whereas the targeted post-transfusion goal was 100,000/\u03bcl in the presence of active bleeding.", [["platelet", "ANATOMY", 31, 39], ["bleeding", "DISEASE", 151, 159], ["platelet", "CELL", 31, 39], ["prophylactic platelet transfusion", "TREATMENT", 18, 51], ["active bleeding", "PROBLEM", 144, 159], ["active", "OBSERVATION_MODIFIER", 144, 150], ["bleeding", "OBSERVATION", 151, 159]]], ["Regarding CO2 removal, sweep gas flow was maximized to allow a normal pH, small tidal volumes (<6 ml/kg/predicted body weight), and plateau pressures less than 25 cm H 2 O. Paralysis and sedation were maintained.Patient Management and Weaning from Extracorporeal Membrane OxygenationAfter improvement of native lung function (FIO2 <0.5, PEEP <10 cm H 2 O, peak inspiratory pressure in pressure-controlled ventilation [PIP] <25 cm H 2 O), ECMO flow was gradually reduced to 2.0 L/min.", [["body", "ANATOMY", 114, 118], ["lung", "ANATOMY", 311, 315], ["CO2", "CHEMICAL", 10, 13], ["Paralysis", "DISEASE", 173, 182], ["CO2", "CHEMICAL", 10, 13], ["CO2", "SIMPLE_CHEMICAL", 10, 13], ["body", "ORGANISM_SUBDIVISION", 114, 118], ["lung", "ORGAN", 311, 315], ["Patient", "SPECIES", 212, 219], ["CO2 removal", "TREATMENT", 10, 21], ["sweep gas flow", "TEST", 23, 37], ["small tidal volumes", "TEST", 74, 93], ["body weight", "TEST", 114, 125], ["plateau pressures", "TEST", 132, 149], ["Paralysis", "PROBLEM", 173, 182], ["sedation", "TREATMENT", 187, 195], ["Patient Management", "TREATMENT", 212, 230], ["Extracorporeal Membrane", "TREATMENT", 248, 271], ["FIO2", "TEST", 326, 330], ["PEEP", "TEST", 337, 341], ["peak inspiratory pressure", "TEST", 356, 381], ["pressure-controlled ventilation", "TREATMENT", 385, 416], ["PIP", "TEST", 418, 421], ["ECMO flow", "TEST", 438, 447], ["small", "OBSERVATION_MODIFIER", 74, 79], ["tidal", "OBSERVATION_MODIFIER", 80, 85], ["plateau", "OBSERVATION_MODIFIER", 132, 139], ["pressures", "OBSERVATION_MODIFIER", 140, 149], ["Paralysis", "OBSERVATION", 173, 182], ["lung", "ANATOMY", 311, 315], ["inspiratory pressure", "OBSERVATION", 361, 381]]], ["2,6-8 Sweep gas flow was then tapered and finally shut off for 40 minutes.", [["Sweep gas flow", "TEST", 6, 20]]], ["If blood gases remained stable for more than 6 hours, the ECMO system was removed, and decannulation was carried out.Statistical AnalysisVariables are reported as median and interquartile ranges.", [["blood", "ANATOMY", 3, 8], ["blood", "ORGANISM_SUBSTANCE", 3, 8], ["blood gases", "TEST", 3, 14], ["the ECMO system", "TREATMENT", 54, 69], ["decannulation", "TREATMENT", 87, 100], ["stable", "OBSERVATION_MODIFIER", 24, 30]]], ["For statistical analysis, we used SPSS 24.0 (SPSS, Inc., Chicago, IL).ResultsAs of March 1, 2020, during COVID-19 pandemic outbreak, 59 consecutive adult patients with confirmed infection were admitted at our Cardio-Thorac-Vascular Department (out of >300 confirmed cases throughout S. Orsola University Hospital, Bologna; Tables 1, 2).ResultsAll patients suffered severe respiratory failure and were admitted to our ICU.", [["Vascular", "ANATOMY", 223, 231], ["respiratory", "ANATOMY", 372, 383], ["infection", "DISEASE", 178, 187], ["respiratory failure", "DISEASE", 372, 391], ["patients", "ORGANISM", 154, 162], ["patients", "ORGANISM", 347, 355], ["patients", "SPECIES", 154, 162], ["patients", "SPECIES", 347, 355], ["statistical analysis", "TEST", 4, 24], ["SPSS", "TEST", 34, 38], ["infection", "PROBLEM", 178, 187], ["severe respiratory failure", "PROBLEM", 365, 391], ["infection", "OBSERVATION", 178, 187], ["Vascular", "ANATOMY", 223, 231], ["severe", "OBSERVATION_MODIFIER", 365, 371], ["respiratory failure", "OBSERVATION", 372, 391]]], ["Our ECMO population had no severe comorbidities.ResultsThe clinical course consisted of rapid in-hospital deterioration with early ICU admission for ventilatory support.", [["severe comorbidities", "PROBLEM", 27, 47], ["ventilatory support", "TREATMENT", 149, 168], ["no", "UNCERTAINTY", 24, 26], ["severe", "OBSERVATION_MODIFIER", 27, 33], ["comorbidities", "OBSERVATION", 34, 47], ["ventilatory support", "OBSERVATION", 149, 168]]], ["The Murray score 2,6-8 was used to evaluate respiratory failure severity before VV ECMO implantation.", [["respiratory", "ANATOMY", 44, 55], ["respiratory failure", "DISEASE", 44, 63], ["VV", "SPECIES", 80, 82], ["The Murray score", "TEST", 0, 16], ["respiratory failure severity", "PROBLEM", 44, 72], ["VV ECMO implantation", "TREATMENT", 80, 100], ["respiratory", "ANATOMY", 44, 55], ["failure", "OBSERVATION", 56, 63]]], ["In all patients, alternative rescue therapies such as prone position and inhaled nitric oxide (NO) were used before ECMO referral.ResultsIntensive care unit survival has been 75% ( Table 3) .", [["nitric oxide", "CHEMICAL", 81, 93], ["NO", "CHEMICAL", 95, 97], ["nitric oxide", "CHEMICAL", 81, 93], ["NO", "CHEMICAL", 95, 97], ["patients", "ORGANISM", 7, 15], ["inhaled nitric oxide", "SIMPLE_CHEMICAL", 73, 93], ["NO", "SIMPLE_CHEMICAL", 95, 97], ["patients", "SPECIES", 7, 15], ["alternative rescue therapies", "TREATMENT", 17, 45], ["prone position", "TREATMENT", 54, 68], ["inhaled nitric oxide", "TREATMENT", 73, 93]]], ["Three patients were weaned from VV ECMO (75%).", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["VV", "SPECIES", 32, 34], ["VV ECMO", "TREATMENT", 32, 39]]], ["Computed tomography scan and chest x-ray typical ground-glass features and consolidations decreased (Figure 1) .", [["Computed tomography scan", "TEST", 0, 24], ["chest x-ray", "TEST", 29, 40], ["consolidations", "PROBLEM", 75, 89], ["chest", "ANATOMY", 29, 34], ["ground-glass features", "OBSERVATION", 49, 70], ["consolidations", "OBSERVATION", 75, 89], ["decreased", "OBSERVATION_MODIFIER", 90, 99]]], ["However, the first weaned patient suffered acute recurrence of pneumonia and eventually died on day 9 after VV ECMO removal.", [["pneumonia", "DISEASE", 63, 72], ["patient", "ORGANISM", 26, 33], ["patient", "SPECIES", 26, 33], ["VV", "SPECIES", 108, 110], ["acute recurrence", "PROBLEM", 43, 59], ["pneumonia", "PROBLEM", 63, 72], ["VV ECMO removal", "TREATMENT", 108, 123], ["acute", "OBSERVATION_MODIFIER", 43, 48], ["recurrence", "OBSERVATION", 49, 59], ["pneumonia", "OBSERVATION", 63, 72]]], ["The second weaned patient has been successfully extubated and fully mobilized thus joining a rehabilitation care.", [["patient", "ORGANISM", 18, 25], ["patient", "SPECIES", 18, 25], ["a rehabilitation care", "TREATMENT", 91, 112]]], ["The third weaned patient is still intubated and on inhaled NO with a slight resolution of the pulmonary disease.ResultsThe remaining patient suffered severe gastrointestinal bleeding, while on ECMO, with high transfusion requirements, namely, of red blood cells (RBC/day 0.57 [0.30-0.10]) and platelets (PLT/ day 0.45 [0.10-0.70]), which resulted to be fatal ( Table 3) .", [["pulmonary", "ANATOMY", 94, 103], ["gastrointestinal", "ANATOMY", 157, 173], ["red blood cells", "ANATOMY", 246, 261], ["RBC", "ANATOMY", 263, 266], ["platelets", "ANATOMY", 293, 302], ["NO", "CHEMICAL", 59, 61], ["pulmonary disease", "DISEASE", 94, 111], ["gastrointestinal bleeding", "DISEASE", 157, 182], ["NO", "CHEMICAL", 59, 61], ["patient", "ORGANISM", 17, 24], ["NO", "SIMPLE_CHEMICAL", 59, 61], ["pulmonary", "ORGAN", 94, 103], ["patient", "ORGANISM", 133, 140], ["gastrointestinal", "ORGANISM_SUBDIVISION", 157, 173], ["red blood cells", "CELL", 246, 261], ["RBC", "CELL", 263, 266], ["platelets", "CELL", 293, 302], ["red blood cells", "CELL_TYPE", 246, 261], ["RBC", "CELL_TYPE", 263, 266], ["platelets", "CELL_TYPE", 293, 302], ["patient", "SPECIES", 17, 24], ["patient", "SPECIES", 133, 140], ["intubated", "TREATMENT", 34, 43], ["the pulmonary disease", "PROBLEM", 90, 111], ["severe gastrointestinal bleeding", "PROBLEM", 150, 182], ["ECMO", "TREATMENT", 193, 197], ["high transfusion requirements", "PROBLEM", 204, 233], ["red blood cells", "TEST", 246, 261], ["RBC", "TEST", 263, 266], ["platelets", "TEST", 293, 302], ["PLT", "TEST", 304, 307], ["slight", "OBSERVATION_MODIFIER", 69, 75], ["resolution", "OBSERVATION_MODIFIER", 76, 86], ["pulmonary", "ANATOMY", 94, 103], ["disease", "OBSERVATION", 104, 111], ["severe", "OBSERVATION_MODIFIER", 150, 156], ["gastrointestinal", "ANATOMY", 157, 173], ["bleeding", "OBSERVATION", 174, 182]]], ["BMI, body mass index; BSA, body surface area; BUN, blood urea nitrogen; CPR, C-reactive protein; CT, computed tomography; DBP, diastolic blood pressure; FIO 2 , fraction of inspired oxygen; GFR, glomerular filtration; Hct, hematocrit; HR, heart rate; IL, interleukin; LDH, lactate dehydrogenase; LVEF, left ventricular ejection fraction; PBW, predicted body weight; PaCO 2 , partial pressure of carbon dioxide in arterial blood; PaO 2 , partial pressure of oxygen in arterial blood; PCT, procalcitonin; PEEP, positive end-expiratory pressure; PLT, platelets; SaO 2 , arterial oxygen saturation; SBP, systolic blood pressure; WBC, white blood cells.", [["body", "ANATOMY", 5, 9], ["body surface area", "ANATOMY", 27, 44], ["blood", "ANATOMY", 51, 56], ["blood", "ANATOMY", 137, 142], ["glomerular", "ANATOMY", 195, 205], ["heart", "ANATOMY", 239, 244], ["left ventricular", "ANATOMY", 302, 318], ["body", "ANATOMY", 353, 357], ["arterial blood", "ANATOMY", 413, 427], ["arterial blood", "ANATOMY", 467, 481], ["platelets", "ANATOMY", 548, 557], ["arterial", "ANATOMY", 567, 575], ["blood", "ANATOMY", 609, 614], ["WBC", "ANATOMY", 625, 628], ["white blood cells", "ANATOMY", 630, 647], ["blood urea nitrogen", "CHEMICAL", 51, 70], ["oxygen", "CHEMICAL", 182, 188], ["lactate", "CHEMICAL", 273, 280], ["carbon dioxide", "CHEMICAL", 395, 409], ["oxygen", "CHEMICAL", 457, 463], ["oxygen", "CHEMICAL", 576, 582], ["urea", "CHEMICAL", 57, 61], ["nitrogen", "CHEMICAL", 62, 70], ["oxygen", "CHEMICAL", 182, 188], ["lactate", "CHEMICAL", 273, 280], ["carbon dioxide", "CHEMICAL", 395, 409], ["PaO 2", "CHEMICAL", 429, 434], ["oxygen", "CHEMICAL", 457, 463], ["oxygen", "CHEMICAL", 576, 582], ["body", "ORGANISM_SUBDIVISION", 5, 9], ["BSA", "SIMPLE_CHEMICAL", 22, 25], ["body", "ORGANISM_SUBDIVISION", 27, 31], ["BUN", "SIMPLE_CHEMICAL", 46, 49], ["blood", "ORGANISM_SUBSTANCE", 51, 56], ["urea", "SIMPLE_CHEMICAL", 57, 61], ["blood", "ORGANISM_SUBSTANCE", 137, 142], ["oxygen", "SIMPLE_CHEMICAL", 182, 188], ["glomerular", "TISSUE", 195, 205], ["Hct", "SIMPLE_CHEMICAL", 218, 221], ["heart", "ORGAN", 239, 244], ["IL", "GENE_OR_GENE_PRODUCT", 251, 253], ["interleukin", "GENE_OR_GENE_PRODUCT", 255, 266], ["LDH", "GENE_OR_GENE_PRODUCT", 268, 271], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 273, 294], ["ventricular", "MULTI-TISSUE_STRUCTURE", 307, 318], ["body", "ORGANISM_SUBDIVISION", 353, 357], ["carbon dioxide", "SIMPLE_CHEMICAL", 395, 409], ["blood", "ORGANISM_SUBSTANCE", 422, 427], ["oxygen", "SIMPLE_CHEMICAL", 457, 463], ["arterial", "MULTI-TISSUE_STRUCTURE", 467, 475], ["blood", "ORGANISM_SUBSTANCE", 476, 481], ["platelets", "CELL", 548, 557], ["SaO 2", "GENE_OR_GENE_PRODUCT", 559, 564], ["arterial", "MULTI-TISSUE_STRUCTURE", 567, 575], ["oxygen", "SIMPLE_CHEMICAL", 576, 582], ["blood", "ORGANISM_SUBSTANCE", 609, 614], ["white blood cells", "CELL", 630, 647], ["C-reactive protein", "PROTEIN", 77, 95], ["interleukin", "PROTEIN", 255, 266], ["LDH", "PROTEIN", 268, 271], ["lactate dehydrogenase", "PROTEIN", 273, 294], ["PLT", "PROTEIN", 543, 546], ["platelets", "CELL_TYPE", 548, 557], ["WBC", "CELL_TYPE", 625, 628], ["white blood cells", "CELL_TYPE", 630, 647], ["BMI", "TEST", 0, 3], ["body mass index", "TEST", 5, 20], ["BSA", "TEST", 22, 25], ["body surface area", "TEST", 27, 44], ["BUN", "TEST", 46, 49], ["blood urea nitrogen", "TEST", 51, 70], ["CPR", "TEST", 72, 75], ["C", "TEST", 77, 78], ["CT", "TEST", 97, 99], ["computed tomography", "TEST", 101, 120], ["DBP", "TEST", 122, 125], ["diastolic blood pressure", "TEST", 127, 151], ["FIO", "TEST", 153, 156], ["inspired oxygen", "TREATMENT", 173, 188], ["GFR", "TEST", 190, 193], ["glomerular filtration", "TEST", 195, 216], ["Hct", "TEST", 218, 221], ["hematocrit", "TEST", 223, 233], ["HR", "TEST", 235, 237], ["heart rate", "TEST", 239, 249], ["IL", "TEST", 251, 253], ["interleukin", "TEST", 255, 266], ["LDH", "TEST", 268, 271], ["lactate dehydrogenase", "TEST", 273, 294], ["LVEF", "TEST", 296, 300], ["left ventricular ejection fraction", "TEST", 302, 336], ["PBW", "TEST", 338, 341], ["predicted body weight", "TEST", 343, 364], ["PaCO", "TEST", 366, 370], ["partial pressure", "TEST", 375, 391], ["carbon dioxide", "TEST", 395, 409], ["arterial blood", "TEST", 413, 427], ["PaO", "TEST", 429, 432], ["partial pressure of oxygen", "TREATMENT", 437, 463], ["arterial blood", "TEST", 467, 481], ["PCT", "TEST", 483, 486], ["procalcitonin", "TEST", 488, 501], ["PEEP", "TEST", 503, 507], ["expiratory pressure", "TEST", 522, 541], ["PLT", "TEST", 543, 546], ["platelets", "TEST", 548, 557], ["SaO", "TEST", 559, 562], ["arterial oxygen saturation", "TEST", 567, 593], ["SBP", "TEST", 595, 598], ["systolic blood pressure", "TEST", 600, 623], ["WBC", "TEST", 625, 628], ["white blood cells", "TEST", 630, 647], ["body", "ANATOMY", 5, 9], ["mass", "OBSERVATION", 10, 14], ["glomerular", "ANATOMY", 195, 205], ["heart", "ANATOMY", 239, 244], ["left ventricular", "ANATOMY", 302, 318], ["ejection fraction", "OBSERVATION", 319, 336], ["arterial", "ANATOMY", 413, 421], ["arterial", "ANATOMY", 467, 475], ["arterial", "ANATOMY", 567, 575]]], ["Neither oxygenator failure nor ECMO circuit failure occurred.", [["oxygenator failure", "PROBLEM", 8, 26], ["ECMO circuit failure", "PROBLEM", 31, 51], ["oxygenator failure", "OBSERVATION", 8, 26], ["ECMO circuit failure", "OBSERVATION", 31, 51]]], ["No neurologic complications occurred.Table 1.", [["neurologic", "ANATOMY", 3, 13], ["neurologic complications", "PROBLEM", 3, 27], ["neurologic", "OBSERVATION_MODIFIER", 3, 13], ["complications", "OBSERVATION", 14, 27]]], ["Demographics and Origin of Patients with Confirmed SARS-CoV-2 Infection Requiring ECMO SupportIn all patients, lung-protective ventilation was sustained during ECMO support and maintained in the three weaned patients on the first day after ECMO cessation.", [["lung", "ANATOMY", 111, 115], ["Patients", "ORGANISM", 27, 35], ["patients", "ORGANISM", 101, 109], ["lung", "ORGAN", 111, 115], ["patients", "ORGANISM", 208, 216], ["Patients", "SPECIES", 27, 35], ["patients", "SPECIES", 101, 109], ["patients", "SPECIES", 208, 216], ["SARS", "PROBLEM", 51, 55], ["CoV", "PROBLEM", 56, 59], ["2 Infection", "PROBLEM", 60, 71], ["ECMO", "TREATMENT", 82, 86], ["lung-protective ventilation", "TREATMENT", 111, 138], ["ECMO support", "TREATMENT", 160, 172], ["ECMO cessation", "TREATMENT", 240, 254], ["SARS", "OBSERVATION", 51, 55], ["Infection", "OBSERVATION", 62, 71], ["lung", "ANATOMY", 111, 115], ["protective ventilation", "OBSERVATION", 116, 138]]], ["The level of PEEP was gradually decreased during weaning from ECMO and afterward during weaning from mechanical ventilation.", [["PEEP", "TREATMENT", 13, 17], ["ECMO", "TREATMENT", 62, 66], ["mechanical ventilation", "TREATMENT", 101, 123], ["gradually", "OBSERVATION_MODIFIER", 22, 31], ["decreased", "OBSERVATION_MODIFIER", 32, 41], ["mechanical ventilation", "OBSERVATION", 101, 123]]], ["Percutaneous tracheostomy was performed in three patients.Table 1.", [["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["Percutaneous tracheostomy", "TREATMENT", 0, 25], ["tracheostomy", "OBSERVATION", 13, 25]]], ["Demographics and Origin of Patients with Confirmed SARS-CoV-2 Infection Requiring ECMO SupportAll patients received tocilizumab and hydroxychloroquine ( Table 3) .", [["tocilizumab", "CHEMICAL", 116, 127], ["hydroxychloroquine", "CHEMICAL", 132, 150], ["hydroxychloroquine", "CHEMICAL", 132, 150], ["Patients", "ORGANISM", 27, 35], ["patients", "ORGANISM", 98, 106], ["tocilizumab", "SIMPLE_CHEMICAL", 116, 127], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 132, 150], ["Patients", "SPECIES", 27, 35], ["patients", "SPECIES", 98, 106], ["SARS", "PROBLEM", 51, 55], ["CoV", "PROBLEM", 56, 59], ["Infection", "PROBLEM", 62, 71], ["ECMO SupportAll", "TREATMENT", 82, 97], ["tocilizumab", "TREATMENT", 116, 127], ["hydroxychloroquine", "TREATMENT", 132, 150], ["SARS", "OBSERVATION", 51, 55], ["Infection", "OBSERVATION", 62, 71]]], ["3, 4 Lopinavir/ritonavir antiviral therapy was used in two patients.", [["Lopinavir", "CHEMICAL", 5, 14], ["ritonavir", "CHEMICAL", 15, 24], ["Lopinavir", "CHEMICAL", 5, 14], ["ritonavir", "CHEMICAL", 15, 24], ["Lopinavir", "SIMPLE_CHEMICAL", 5, 14], ["ritonavir", "SIMPLE_CHEMICAL", 15, 24], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["4 Lopinavir/ritonavir antiviral therapy", "TREATMENT", 3, 42]]], ["Piperacillin/tazobactam antibiotic prophylaxis was used in all patients while azithromycin was adopted, additionally, in one.", [["Piperacillin/tazobactam", "CHEMICAL", 0, 23], ["azithromycin", "CHEMICAL", 78, 90], ["Piperacillin", "CHEMICAL", 0, 12], ["tazobactam", "CHEMICAL", 13, 23], ["azithromycin", "CHEMICAL", 78, 90], ["Piperacillin/tazobactam", "SIMPLE_CHEMICAL", 0, 23], ["patients", "ORGANISM", 63, 71], ["azithromycin", "SIMPLE_CHEMICAL", 78, 90], ["patients", "SPECIES", 63, 71], ["Piperacillin", "TREATMENT", 0, 12], ["tazobactam antibiotic prophylaxis", "TREATMENT", 13, 46], ["azithromycin", "TREATMENT", 78, 90]]], ["3, 4, 7 Corticosteroids were used in a single case while on ECMO.Table 1.", [["Corticosteroids", "TREATMENT", 8, 23], ["ECMO", "TREATMENT", 60, 64]]], ["Demographics and Origin of Patients with Confirmed SARS-CoV-2 Infection Requiring ECMO SupportLow dosage of vasoactive drugs (norepinephrine) infusion and consecutive positive fluid balance was frequently needed during VV ECMO support (Table 3) .", [["fluid", "ANATOMY", 176, 181], ["norepinephrine", "CHEMICAL", 126, 140], ["norepinephrine", "CHEMICAL", 126, 140], ["Patients", "ORGANISM", 27, 35], ["vasoactive drugs", "SIMPLE_CHEMICAL", 108, 124], ["norepinephrine", "SIMPLE_CHEMICAL", 126, 140], ["Patients", "SPECIES", 27, 35], ["VV", "SPECIES", 219, 221], ["SARS", "PROBLEM", 51, 55], ["CoV", "PROBLEM", 56, 59], ["Infection", "PROBLEM", 62, 71], ["ECMO", "TREATMENT", 82, 86], ["vasoactive drugs", "TREATMENT", 108, 124], ["norepinephrine) infusion", "TREATMENT", 126, 150], ["consecutive positive fluid balance", "TREATMENT", 155, 189], ["VV ECMO support", "TREATMENT", 219, 234]]], ["2, 7, 8 Low dosage of corticosteroids have been used as anti-inflammatory agents after ECMO removal.ConclusionsSARS-CoV-2 may cause severe respiratory failure due to massive alveolar damage.", [["respiratory", "ANATOMY", 139, 150], ["alveolar", "ANATOMY", 174, 182], ["respiratory failure", "DISEASE", 139, 158], ["alveolar damage", "DISEASE", 174, 189], ["corticosteroids", "CHEMICAL", 22, 37], ["corticosteroids", "SIMPLE_CHEMICAL", 22, 37], ["alveolar", "TISSUE", 174, 182], ["corticosteroids", "TREATMENT", 22, 37], ["anti-inflammatory agents", "TREATMENT", 56, 80], ["ECMO removal", "TREATMENT", 87, 99], ["ConclusionsSARS", "TEST", 100, 115], ["severe respiratory failure", "PROBLEM", 132, 158], ["massive alveolar damage", "PROBLEM", 166, 189], ["severe", "OBSERVATION_MODIFIER", 132, 138], ["respiratory failure", "OBSERVATION", 139, 158], ["massive", "OBSERVATION_MODIFIER", 166, 173], ["alveolar damage", "OBSERVATION", 174, 189]]], ["[2] [3] [4] [5] [6] [7] The rate of ARDS ranges from 15% to 30% among patients who require hospitalization.", [["ARDS", "DISEASE", 36, 40], ["[2] [3] [4] [5] [6] [7]", "SIMPLE_CHEMICAL", 0, 23], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["The rate", "TEST", 24, 32], ["ARDS ranges", "TEST", 36, 47], ["ARDS", "OBSERVATION", 36, 40]]], ["1, 2, 7 Currently, no adequate curative therapy for COVID-19 disease exists.", [["adequate curative therapy", "TREATMENT", 22, 47], ["COVID-19 disease exists", "PROBLEM", 52, 75], ["no", "UNCERTAINTY", 19, 21], ["adequate", "OBSERVATION_MODIFIER", 22, 30], ["curative", "OBSERVATION", 31, 39], ["disease", "OBSERVATION", 61, 68]]], ["[3] [4] [5] [6] [7] By considering overall impact of COVID-19 pandemic outbreak, an increased need of ECMO support becomes evident.", [["[3] [4] [5] [6] [7", "SIMPLE_CHEMICAL", 0, 18], ["COVID", "TEST", 53, 58], ["pandemic outbreak", "PROBLEM", 62, 79], ["ECMO support", "TREATMENT", 102, 114], ["increased", "OBSERVATION_MODIFIER", 84, 93]]], ["2,6-8 So far, the ELSO registry accounts 143 COVID-19 respiratory ECMO running systems worldwide, mostly being in Europe and the United States.", [["COVID", "TEST", 45, 50], ["respiratory ECMO running systems", "TREATMENT", 54, 86], ["respiratory ECMO", "OBSERVATION", 54, 70]]], ["2, 8 As of April 4, 2020, Euro COVID-19 survey/study showed 253 ongoing VV ECMO patients while 52 have been successfully weaned from ECMO support.", [["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["VV", "SPECIES", 72, 74], ["Euro COVID", "TEST", 26, 36], ["survey/study", "TEST", 40, 52], ["ongoing VV ECMO", "TREATMENT", 64, 79], ["ECMO support", "TREATMENT", 133, 145]]], ["2, 8 In COVID-19 patients, the initial pulmonary pattern is not similar to ARDS, as hypoxia is prevalent and pulmonary compliance is generally high.", [["pulmonary", "ANATOMY", 39, 48], ["pulmonary", "ANATOMY", 109, 118], ["ARDS", "DISEASE", 75, 79], ["hypoxia", "DISEASE", 84, 91], ["patients", "ORGANISM", 17, 25], ["pulmonary", "ORGAN", 39, 48], ["pulmonary", "ORGAN", 109, 118], ["patients", "SPECIES", 17, 25], ["ARDS", "PROBLEM", 75, 79], ["hypoxia", "PROBLEM", 84, 91], ["pulmonary", "ANATOMY", 39, 48], ["not similar to", "UNCERTAINTY", 60, 74], ["ARDS", "OBSERVATION", 75, 79], ["pulmonary", "ANATOMY", 109, 118], ["compliance", "OBSERVATION", 119, 129], ["high", "OBSERVATION_MODIFIER", 143, 147]]], ["[3] [4] [5] [6] [7] The main finding is hypoxic vasoconstriction.", [["[3] [4] [5] [6] [7]", "SIMPLE_CHEMICAL", 0, 19], ["hypoxic vasoconstriction", "PROBLEM", 40, 64], ["hypoxic vasoconstriction", "OBSERVATION", 40, 64]]], ["The lungs are inflated and increasing PEEP or prone positioning does not help.", [["lungs", "ANATOMY", 4, 9], ["lungs", "ORGAN", 4, 9], ["increasing PEEP", "TREATMENT", 27, 42], ["prone positioning", "TREATMENT", 46, 63], ["lungs", "ANATOMY", 4, 9], ["inflated", "OBSERVATION", 14, 22], ["increasing", "OBSERVATION_MODIFIER", 27, 37], ["PEEP", "OBSERVATION", 38, 42]]], ["Lung CT scans in those patients confirm that there are no significant areas to recruit.", [["Lung", "ANATOMY", 0, 4], ["Lung", "ORGAN", 0, 4], ["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["Lung CT scans", "TEST", 0, 13], ["no", "UNCERTAINTY", 55, 57], ["significant", "OBSERVATION_MODIFIER", 58, 69], ["areas", "OBSERVATION", 70, 75]]], ["Moreover, high PEEP levels may compromise right cardiac filling and an increase of the need for fluid intake and/or norepinephrine.", [["right cardiac", "ANATOMY", 42, 55], ["fluid", "ANATOMY", 96, 101], ["norepinephrine", "CHEMICAL", 116, 130], ["norepinephrine", "CHEMICAL", 116, 130], ["cardiac", "ORGAN", 48, 55], ["fluid", "ORGANISM_SUBSTANCE", 96, 101], ["norepinephrine", "SIMPLE_CHEMICAL", 116, 130], ["high PEEP levels", "TEST", 10, 26], ["right cardiac filling", "PROBLEM", 42, 63], ["fluid intake", "TREATMENT", 96, 108], ["norepinephrine", "TREATMENT", 116, 130], ["right", "ANATOMY_MODIFIER", 42, 47], ["cardiac", "ANATOMY", 48, 55], ["filling", "OBSERVATION", 56, 63], ["increase", "OBSERVATION_MODIFIER", 71, 79]]], ["[5] [6] [7] Ventilator-induced lung injury, volutrauma, barotrauma, oxygen toxicity should be avoided and \"lung-protective ventilation\" is the recommended strategy for COVID-19 patients.", [["lung", "ANATOMY", 31, 35], ["lung", "ANATOMY", 107, 111], ["lung injury", "DISEASE", 31, 42], ["volutrauma", "DISEASE", 44, 54], ["barotrauma", "DISEASE", 56, 66], ["oxygen", "CHEMICAL", 68, 74], ["toxicity", "DISEASE", 75, 83], ["oxygen", "CHEMICAL", 68, 74], ["[5] [6] [7] Ventilator", "SIMPLE_CHEMICAL", 0, 22], ["lung", "ORGAN", 31, 35], ["oxygen", "SIMPLE_CHEMICAL", 68, 74], ["lung", "ORGAN", 107, 111], ["patients", "ORGANISM", 177, 185], ["patients", "SPECIES", 177, 185], ["Ventilator", "TREATMENT", 12, 22], ["lung injury", "PROBLEM", 31, 42], ["volutrauma", "PROBLEM", 44, 54], ["barotrauma", "PROBLEM", 56, 66], ["oxygen toxicity", "TREATMENT", 68, 83], ["lung-protective ventilation", "TREATMENT", 107, 134], ["lung", "ANATOMY", 31, 35], ["injury", "OBSERVATION", 36, 42], ["barotrauma", "OBSERVATION", 56, 66]]], ["2, [5] [6] [7] In addition to viral pneumonia, consequently, those patients likely have had self-inflicted VILI, due to diffusely initial type ICUs management and misunderstanding with subsequent decrease in compliance and edema in the lower lobes.", [["edema", "ANATOMY", 223, 228], ["lower lobes", "ANATOMY", 236, 247], ["viral pneumonia", "DISEASE", 30, 45], ["VILI", "DISEASE", 107, 111], ["edema", "DISEASE", 223, 228], ["[5] [6] [7]", "SIMPLE_CHEMICAL", 3, 14], ["patients", "ORGANISM", 67, 75], ["edema", "PATHOLOGICAL_FORMATION", 223, 228], ["lower lobes", "MULTI-TISSUE_STRUCTURE", 236, 247], ["patients", "SPECIES", 67, 75], ["viral pneumonia", "PROBLEM", 30, 45], ["self-inflicted VILI", "PROBLEM", 92, 111], ["diffusely initial type ICUs management", "PROBLEM", 120, 158], ["edema in the lower lobes", "PROBLEM", 223, 247], ["viral", "OBSERVATION_MODIFIER", 30, 35], ["pneumonia", "OBSERVATION", 36, 45], ["diffusely", "OBSERVATION_MODIFIER", 120, 129], ["decrease", "OBSERVATION_MODIFIER", 196, 204], ["edema", "OBSERVATION", 223, 228], ["lower lobes", "ANATOMY", 236, 247]]], ["4-7 Those patients present a pattern similar to ARDS and they benefit from PEEP and prone positioning.ConclusionsIf the conservative treatment is not effective, VV ECMO support might be considered.", [["ARDS", "DISEASE", 48, 52], ["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["VV", "SPECIES", 161, 163], ["ARDS", "PROBLEM", 48, 52], ["PEEP", "TREATMENT", 75, 79], ["prone positioning", "TREATMENT", 84, 101], ["the conservative treatment", "TREATMENT", 116, 142], ["VV ECMO support", "TREATMENT", 161, 176], ["ARDS", "OBSERVATION", 48, 52]]], ["2,6-8 Unfortunately, ECMO infrastructures and resources are limited, globally.", [["ECMO infrastructures", "TREATMENT", 21, 41]]], ["7,8 Our small sample of COVID-19 ECMO patients presented young age and showed no severe comorbidities but severe ARDS occurred in all of them.", [["ARDS", "DISEASE", 113, 117], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["COVID", "TEST", 24, 29], ["severe comorbidities", "PROBLEM", 81, 101], ["severe ARDS", "PROBLEM", 106, 117], ["small", "OBSERVATION_MODIFIER", 8, 13], ["no", "UNCERTAINTY", 78, 80], ["severe", "OBSERVATION_MODIFIER", 81, 87], ["comorbidities", "OBSERVATION", 88, 101], ["severe", "OBSERVATION_MODIFIER", 106, 112], ["ARDS", "OBSERVATION", 113, 117]]], ["Thus, warm caution and thoughtful approaches for timely detection and treatment should be taken for people who are currently living in high-density COVID-19-infected areas 1 to preserve life.", [["people", "ORGANISM", 100, 106], ["people", "SPECIES", 100, 106], ["warm caution", "TREATMENT", 6, 18], ["treatment", "TREATMENT", 70, 79]]]], "fd59ac341dd5d160d4e63b567558875d242c8536": [["IntroductionThe development and application of magnetic beads (MBs) in separation and detection methodologies has attracted strong interest in the last years.", [["MBs", "SIMPLE_CHEMICAL", 63, 66], ["application of magnetic beads (MBs", "TREATMENT", 32, 66]]], ["This is mainly due to the versatility, high surface area, chemical and physical stability, low toxicity and high biocompatibility exhibited by MBs [1] .", [["surface", "ANATOMY", 44, 51], ["toxicity", "DISEASE", 95, 103], ["MBs", "SIMPLE_CHEMICAL", 143, 146], ["high surface area", "PROBLEM", 39, 56], ["low toxicity", "PROBLEM", 91, 103], ["high biocompatibility", "PROBLEM", 108, 129], ["mainly due to", "UNCERTAINTY", 8, 21], ["high", "OBSERVATION_MODIFIER", 39, 43], ["surface", "OBSERVATION_MODIFIER", 44, 51], ["physical stability", "OBSERVATION_MODIFIER", 71, 89], ["low toxicity", "OBSERVATION_MODIFIER", 91, 103]]], ["Their size, similar to that of molecules in nature, range from nm to a few mm, and the particleslinked molecules can quickly agglomerate and be separated from a matrix or resuspended in an appropriate working medium without retaining any residual magnetism as a consequence of a change in an external magnetic force [2, 3] .IntroductionMBs consist of a paramagnetic or superparamagnetic core surrounded by a polymeric outer layer suitable for the immobilization of biomolecules [4] .", [["matrix", "ANATOMY", 161, 167], ["matrix", "CELLULAR_COMPONENT", 161, 167], ["particleslinked molecules", "PROTEIN", 87, 112], ["any residual magnetism", "PROBLEM", 234, 256], ["a change", "PROBLEM", 277, 285], ["an external magnetic force", "TEST", 289, 315], ["IntroductionMBs", "TREATMENT", 324, 339], ["a paramagnetic or superparamagnetic core", "TREATMENT", 351, 391], ["a polymeric outer layer", "TREATMENT", 406, 429], ["the immobilization of biomolecules", "TREATMENT", 443, 477], ["size", "OBSERVATION_MODIFIER", 6, 10], ["few mm", "OBSERVATION_MODIFIER", 71, 77], ["residual magnetism", "OBSERVATION", 238, 256]]], ["The magnetic core is readily available in different iron oxide forms, among which magnetite (Fe 3 O 4 ) and maghemite (g-Fe 2 O 3 , ferrimagnetic) stand out since their compatibility has been proven in bio-labelling and bio-separation [3, 5, 6] .", [["iron oxide", "CHEMICAL", 52, 62], ["magnetite", "CHEMICAL", 82, 91], ["Fe 3 O 4", "CHEMICAL", 93, 101], ["maghemite", "CHEMICAL", 108, 117], ["g-Fe 2 O", "CHEMICAL", 119, 127], ["iron oxide", "CHEMICAL", 52, 62], ["magnetite", "CHEMICAL", 82, 91], ["Fe 3 O 4", "CHEMICAL", 93, 101], ["maghemite", "CHEMICAL", 108, 117], ["Fe 2 O 3", "CHEMICAL", 121, 129], ["iron oxide", "SIMPLE_CHEMICAL", 52, 62], ["magnetite", "SIMPLE_CHEMICAL", 82, 91], ["Fe 3 O 4", "SIMPLE_CHEMICAL", 93, 101], ["maghemite", "SIMPLE_CHEMICAL", 108, 117], ["g-Fe 2 O 3", "SIMPLE_CHEMICAL", 119, 129], ["different iron oxide forms", "TREATMENT", 42, 68], ["maghemite (g-Fe 2 O", "TREATMENT", 108, 127]]], ["The development of coatings for the magnetic core of MBs was necessary to address their limitations including (a) high surface energies which lead to aggregation, (b) high chemical activity leading to their oxidation, loss of magnetic properties and dispersibility when exposed to air, and (c) biodegradation with subsequent changes in magnetic properties.", [["surface", "ANATOMY", 119, 126], ["aggregation", "DISEASE", 150, 161], ["MBs", "SIMPLE_CHEMICAL", 53, 56], ["a) high surface energies", "PROBLEM", 111, 135], ["aggregation", "PROBLEM", 150, 161], ["high chemical activity", "PROBLEM", 167, 189], ["their oxidation", "PROBLEM", 201, 216], ["loss of magnetic properties", "PROBLEM", 218, 245], ["air, and (c) biodegradation", "PROBLEM", 281, 308], ["subsequent changes in magnetic properties", "PROBLEM", 314, 355], ["coatings", "OBSERVATION_MODIFIER", 19, 27], ["magnetic properties", "OBSERVATION_MODIFIER", 226, 245], ["air", "OBSERVATION", 281, 284]]], ["Consequently, protective shells, mainly composed of agarose, cellulose, silica, silicone, porous glass, mica or polystyrene [7] , were developed to protect and preserve the stability of iron oxide MBs.", [["silica", "CHEMICAL", 72, 78], ["silicone", "CHEMICAL", 80, 88], ["polystyrene", "CHEMICAL", 112, 123], ["iron oxide", "CHEMICAL", 186, 196], ["silica", "CHEMICAL", 72, 78], ["polystyrene", "CHEMICAL", 112, 123], ["iron oxide", "CHEMICAL", 186, 196], ["agarose", "SIMPLE_CHEMICAL", 52, 59], ["cellulose", "SIMPLE_CHEMICAL", 61, 70], ["silica", "SIMPLE_CHEMICAL", 72, 78], ["silicone", "SIMPLE_CHEMICAL", 80, 88], ["polystyrene [7]", "SIMPLE_CHEMICAL", 112, 127], ["iron oxide MBs", "SIMPLE_CHEMICAL", 186, 200], ["protective shells", "TREATMENT", 14, 31], ["agarose, cellulose, silica, silicone, porous glass, mica or polystyrene", "TREATMENT", 52, 123], ["iron oxide MBs", "TREATMENT", 186, 200], ["protective shells", "OBSERVATION_MODIFIER", 14, 31]]], ["These shells also allowed further functionalization, thus promoting MBs performance as recognition elements in sensing and (bio)chemical arrays [3] .", [["MBs", "SIMPLE_CHEMICAL", 68, 71], ["recognition elements", "DNA", 87, 107], ["further functionalization", "TREATMENT", 26, 51]]], ["Moreover, nowadays there are commercially available MBs modified with biomolecules that allow their use in different types of bioassays.", [["MBs", "SIMPLE_CHEMICAL", 52, 55], ["biomolecules", "TREATMENT", 70, 82]]], ["So, MBs functionalized with: (a) streptavidin suitable for capturing biotinylated nucleic acids, aptamers, peptides, proteins, etc.; (b) protein A (protA) or protein G (protG), which specifically bind antibodies; (c) oligonucleotides; or (d) affinity ligands for specific capture of tagged recombinant proteins, etc. [7] can be purchased from different companies.", [["nucleic acids", "CHEMICAL", 82, 95], ["MBs", "SIMPLE_CHEMICAL", 4, 7], ["streptavidin", "SIMPLE_CHEMICAL", 33, 45], ["biotinylated nucleic acids", "SIMPLE_CHEMICAL", 69, 95], ["protein A (protA)", "GENE_OR_GENE_PRODUCT", 137, 154], ["protein G", "GENE_OR_GENE_PRODUCT", 158, 167], ["protG", "GENE_OR_GENE_PRODUCT", 169, 174], ["protein A", "PROTEIN", 137, 146], ["protA", "PROTEIN", 148, 153], ["protein G", "PROTEIN", 158, 167], ["protG", "PROTEIN", 169, 174], ["antibodies", "PROTEIN", 201, 211], ["tagged recombinant proteins", "PROTEIN", 283, 310], ["a) streptavidin", "TREATMENT", 30, 45], ["biotinylated nucleic acids", "TEST", 69, 95], ["aptamers", "TEST", 97, 105], ["peptides", "TEST", 107, 115], ["proteins", "TEST", 117, 125], ["protein G (protG)", "TEST", 158, 175], ["bind antibodies", "TEST", 196, 211], ["oligonucleotides", "TEST", 217, 233], ["affinity ligands", "TEST", 242, 258], ["tagged recombinant proteins", "PROBLEM", 283, 310]]], ["MBs modification has resulted in important practical advantages from an analytical point of view, including (a) shorter reaction times between dissolved species and biomolecules immobilized on the surface of the beads which is also favoured by the easy dispersion of MBs into solution with only gentle shaking, (b) readily miniaturization of the assay system by using MBs as a mobile solid phase, (c) reduction of the required volumes of reagents and produced waste, and (d) obtaining lower detection limits with shorter assay times [1] .IntroductionOwing to all these properties, MBs constitute an attractive platform for the design of electrochemical biosensors which also add their inherent advantages such as system miniaturization, low cost and ease of operation [2] .", [["surface", "ANATOMY", 197, 204], ["MBs", "SIMPLE_CHEMICAL", 0, 3], ["surface", "CELLULAR_COMPONENT", 197, 204], ["MBs", "SIMPLE_CHEMICAL", 267, 270], ["MBs", "SIMPLE_CHEMICAL", 368, 371], ["MBs", "SIMPLE_CHEMICAL", 581, 584], ["a) shorter reaction", "PROBLEM", 109, 128], ["dissolved species", "PROBLEM", 143, 160], ["gentle shaking", "PROBLEM", 295, 309], ["the assay system", "TEST", 342, 358], ["volumes of reagents", "TREATMENT", 427, 446], ["electrochemical biosensors", "TREATMENT", 637, 663], ["system miniaturization", "TREATMENT", 713, 735], ["low cost and ease of operation", "TREATMENT", 737, 767], ["beads", "ANATOMY_MODIFIER", 212, 217]]], ["In fact, electrochemical enzyme-based biosensors, immunosensors and nucleic acid hybridization-based sensors have been described in literature and cited in several reviews [1] [2] [3] [4] [5] [7] [8] [9] .IntroductionNowadays, there is a great concern on detecting the presence of toxic and infectious agents in environmental and food samples, not only due to their toxicity to human beings, animals or plants, but also because many of them are prone to be used in terrorism attacks.", [["samples", "ANATOMY", 335, 342], ["nucleic acid", "CHEMICAL", 68, 80], ["toxicity", "DISEASE", 366, 374], ["nucleic acid", "SIMPLE_CHEMICAL", 68, 80], ["[1] [2] [3] [4] [5] [7] [8] [9]", "SIMPLE_CHEMICAL", 172, 203], ["human", "ORGANISM", 378, 383], ["human", "SPECIES", 378, 383], ["human", "SPECIES", 378, 383], ["electrochemical enzyme", "TEST", 9, 31], ["immunosensors", "TEST", 50, 63], ["nucleic acid hybridization", "TEST", 68, 94], ["toxic and infectious agents", "PROBLEM", 281, 308], ["their toxicity", "PROBLEM", 360, 374], ["toxic", "OBSERVATION_MODIFIER", 281, 286], ["infectious", "OBSERVATION", 291, 301]]], ["These agents can be classified in two main groups: one is constituted by chemical agents while the second one involves complex bioengineered microorganisms and pathogens.IntroductionAmong chemical agents, insecticides and organophosphorous (OP) nerve gases can be highlighted.", [["organophosphorous", "CHEMICAL", 222, 239], ["OP", "CHEMICAL", 241, 243], ["organophosphorous", "CHEMICAL", 222, 239], ["organophosphorous", "SIMPLE_CHEMICAL", 222, 239], ["OP", "SIMPLE_CHEMICAL", 241, 243], ["chemical agents", "TREATMENT", 73, 88], ["complex bioengineered microorganisms", "PROBLEM", 119, 155], ["pathogens", "PROBLEM", 160, 169], ["Among chemical agents", "TREATMENT", 182, 203], ["insecticides", "TREATMENT", 205, 217], ["organophosphorous (OP) nerve gases", "TEST", 222, 256]]], ["OP nerve gases are the most harmful chemical agents.", [["OP nerve", "ANATOMY", 0, 8], ["OP", "CHEMICAL", 0, 2], ["OP nerve gases", "TEST", 0, 14], ["nerve", "ANATOMY", 3, 8]]], ["They act in a similar way as insecticides, irreversibly inhibiting the catalytic active site of acetylcholinesterase (AchE), the enzyme that catalyzes the hydrolysis of the neurotransmitter acetylcholine.", [["acetylcholine", "CHEMICAL", 190, 203], ["acetylcholine", "CHEMICAL", 190, 203], ["acetylcholinesterase", "GENE_OR_GENE_PRODUCT", 96, 116], ["AchE", "GENE_OR_GENE_PRODUCT", 118, 122], ["acetylcholine", "SIMPLE_CHEMICAL", 190, 203], ["catalytic active site", "PROTEIN", 71, 92], ["acetylcholinesterase", "PROTEIN", 96, 116], ["AchE", "PROTEIN", 118, 122], ["the enzyme", "TEST", 125, 135], ["the neurotransmitter acetylcholine", "TREATMENT", 169, 203]]], ["However, their mammalian toxicity is much higher [10] .", [["toxicity", "DISEASE", 25, 33], ["their mammalian toxicity", "PROBLEM", 9, 33]]], ["Examples include sarin, soman, fonofos and VX agent.", [["sarin", "CHEMICAL", 17, 22], ["soman", "CHEMICAL", 24, 29], ["fonofos", "CHEMICAL", 31, 38], ["VX", "CHEMICAL", 43, 45], ["sarin", "CHEMICAL", 17, 22], ["soman", "CHEMICAL", 24, 29], ["fonofos", "CHEMICAL", 31, 38], ["sarin", "SIMPLE_CHEMICAL", 17, 22], ["soman", "SIMPLE_CHEMICAL", 24, 29], ["fonofos", "SIMPLE_CHEMICAL", 31, 38], ["VX agent", "SIMPLE_CHEMICAL", 43, 51], ["VX agent", "TREATMENT", 43, 51]]], ["The most widely used insecticides belong essentially to two families: organophosphorus (such as paraoxon, parathion, chlorpyriphos, ethyl oxon, or malathion) and carbamate (such as carbofuran, or carbaryl).", [["organophosphorus", "CHEMICAL", 70, 86], ["paraoxon", "CHEMICAL", 96, 104], ["parathion", "CHEMICAL", 106, 115], ["chlorpyriphos, ethyl oxon", "CHEMICAL", 117, 142], ["malathion", "CHEMICAL", 147, 156], ["carbamate", "CHEMICAL", 162, 171], ["carbofuran", "CHEMICAL", 181, 191], ["carbaryl", "CHEMICAL", 196, 204], ["organophosphorus", "CHEMICAL", 70, 86], ["paraoxon", "CHEMICAL", 96, 104], ["parathion", "CHEMICAL", 106, 115], ["chlorpyriphos", "CHEMICAL", 117, 130], ["ethyl oxon", "CHEMICAL", 132, 142], ["malathion", "CHEMICAL", 147, 156], ["carbamate", "CHEMICAL", 162, 171], ["carbofuran", "CHEMICAL", 181, 191], ["carbaryl", "CHEMICAL", 196, 204], ["organophosphorus", "SIMPLE_CHEMICAL", 70, 86], ["paraoxon", "SIMPLE_CHEMICAL", 96, 104], ["parathion", "SIMPLE_CHEMICAL", 106, 115], ["chlorpyriphos", "SIMPLE_CHEMICAL", 117, 130], ["ethyl oxon", "SIMPLE_CHEMICAL", 132, 142], ["malathion", "SIMPLE_CHEMICAL", 147, 156], ["carbamate", "SIMPLE_CHEMICAL", 162, 171], ["carbofuran", "SIMPLE_CHEMICAL", 181, 191], ["carbaryl", "SIMPLE_CHEMICAL", 196, 204], ["organophosphorus", "TREATMENT", 70, 86], ["paraoxon", "TREATMENT", 96, 104], ["parathion", "TREATMENT", 106, 115], ["chlorpyriphos", "TREATMENT", 117, 130], ["ethyl oxon", "TREATMENT", 132, 142], ["malathion)", "TREATMENT", 147, 157], ["carbamate", "TREATMENT", 162, 171], ["carbofuran", "TREATMENT", 181, 191], ["carbaryl", "TREATMENT", 196, 204], ["most widely", "OBSERVATION_MODIFIER", 4, 15]]], ["Vesicants (mustards, lewisite) and pulmonary agents (chlorine, phosgene) are also used as chemical toxic agents.IntroductionUnlike a chemical agent attack, biological attacks do not cause an immediate reaction.", [["pulmonary", "ANATOMY", 35, 44], ["Vesicants", "CHEMICAL", 0, 9], ["chlorine", "CHEMICAL", 53, 61], ["phosgene", "CHEMICAL", 63, 71], ["chlorine", "CHEMICAL", 53, 61], ["phosgene", "CHEMICAL", 63, 71], ["Vesicants", "SIMPLE_CHEMICAL", 0, 9], ["mustards", "SIMPLE_CHEMICAL", 11, 19], ["lewisite", "SIMPLE_CHEMICAL", 21, 29], ["pulmonary", "ORGAN", 35, 44], ["chlorine", "SIMPLE_CHEMICAL", 53, 61], ["phosgene", "SIMPLE_CHEMICAL", 63, 71], ["Vesicants (mustards", "TREATMENT", 0, 19], ["pulmonary agents", "TREATMENT", 35, 51], ["chlorine, phosgene)", "TREATMENT", 53, 72], ["chemical toxic agents", "TREATMENT", 90, 111], ["a chemical agent attack", "PROBLEM", 131, 154], ["biological attacks", "PROBLEM", 156, 174], ["an immediate reaction", "PROBLEM", 188, 209], ["pulmonary", "ANATOMY", 35, 44]]], ["Bioterrorism agents are pathogenic organisms (bacteria, viruses) or biological toxins used to produce death and disease in humans, animals or plants for terrorist purposes.", [["death", "DISEASE", 102, 107], ["humans", "ORGANISM", 123, 129], ["humans", "SPECIES", 123, 129], ["humans", "SPECIES", 123, 129], ["Bioterrorism agents", "TREATMENT", 0, 19], ["pathogenic organisms", "PROBLEM", 24, 44], ["bacteria", "PROBLEM", 46, 54], ["viruses", "PROBLEM", 56, 63], ["biological toxins", "PROBLEM", 68, 85], ["death", "PROBLEM", 102, 107], ["disease in humans", "PROBLEM", 112, 129], ["terrorist purposes", "TEST", 153, 171]]], ["Although these agents are typically microorganisms found in nature, they can be modified to increase their virulence, to make them resistant to current antibiotics or vaccines, or to enhance the ability of these agents to be disseminated throughout the environment.", [["typically microorganisms", "PROBLEM", 26, 50], ["current antibiotics", "TREATMENT", 144, 163], ["vaccines", "TREATMENT", 167, 175], ["these agents", "TREATMENT", 206, 218]]], ["While any germ, bacteria or virus could potentially be utilized by terrorists, there are a number of biological agents that have been recognized as being more likely to be used.", [["germ", "ANATOMY", 10, 14], ["germ", "TISSUE", 10, 14], ["bacteria", "PROBLEM", 16, 24], ["virus", "PROBLEM", 28, 33], ["biological agents", "TREATMENT", 101, 118], ["bacteria", "OBSERVATION", 16, 24]]], ["Table 1 lists the main biological warfare agents (BWAs) together with the diseases they cause.", [["the diseases", "PROBLEM", 70, 82]]], ["The presence of microorganisms in food is also a natural and unavoidable occurrence.", [["microorganisms in food", "PROBLEM", 16, 38], ["microorganisms", "OBSERVATION", 16, 30]]], ["Cooking generally destroys most harmful bacteria, but undercooked foods, processed ready-to-eat foods, and minimally processed foods can contain harmful bacteria that are serious health threats.IntroductionTo minimize the effects of natural outbreaks or deliberate attacks, near real-time detection of infectious agents is an essential first step in mounting an appropriate response.IntroductionThese infectious agents were traditionally detected and identified using standard microbiological and biochemical assays that are accurate but time-consuming.", [["harmful bacteria", "PROBLEM", 145, 161], ["IntroductionTo", "TREATMENT", 194, 208], ["deliberate attacks", "PROBLEM", 254, 272], ["infectious agents", "TREATMENT", 302, 319], ["These infectious agents", "TREATMENT", 395, 418], ["biochemical assays", "TEST", 497, 515], ["infectious", "OBSERVATION", 302, 312], ["infectious", "OBSERVATION", 401, 411]]], ["These methods require isolation and/or culturing of large quantities of the infectious agents, and therefore the analysis requires several days to be completed.", [["isolation", "TREATMENT", 22, 31], ["culturing", "TREATMENT", 39, 48], ["the infectious agents", "TREATMENT", 72, 93], ["the analysis", "TEST", 109, 121], ["large", "OBSERVATION_MODIFIER", 52, 57], ["infectious", "OBSERVATION", 76, 86]]], ["More recently, molecular approaches, such as the polymerase chain reaction (PCR) amplification and analysis of unique DNA sequences and/or rRNA, have supplanted traditional microbiological methods because they are highly accurate and sensitive, and take less time [12] .", [["DNA", "CELLULAR_COMPONENT", 118, 121], ["rRNA", "CELLULAR_COMPONENT", 139, 143], ["DNA sequences", "DNA", 118, 131], ["rRNA", "DNA", 139, 143], ["the polymerase chain reaction", "PROBLEM", 45, 74], ["PCR", "TEST", 76, 79], ["unique DNA sequences", "TEST", 111, 131], ["rRNA", "PROBLEM", 139, 143], ["traditional microbiological methods", "TEST", 161, 196]]], ["However, these assays require specialized instruments and still take several hours to be performed.", [["these assays", "TEST", 9, 21], ["specialized instruments", "TREATMENT", 30, 53]]], ["In addition, DNA-based molecular techniques are limited to the detection of whole organisms and cannot detect toxins and other extracellular products or infectious agents.", [["extracellular", "ANATOMY", 127, 140], ["DNA", "CELLULAR_COMPONENT", 13, 16], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 127, 140], ["DNA", "TEST", 13, 16], ["whole organisms", "PROBLEM", 76, 91], ["toxins", "PROBLEM", 110, 116], ["extracellular products", "TREATMENT", 127, 149], ["infectious agents", "TREATMENT", 153, 170], ["infectious", "OBSERVATION", 153, 163]]], ["Her areas of interest include the development of enzymatic, immuno-and DNA-electrochemical and impedimetric sensors, bioelectrocatalysis, and electrode modification for the ultrasensitive detection of bacteria and cardiac markers.", [["cardiac", "ANATOMY", 214, 221], ["DNA", "CELLULAR_COMPONENT", 71, 74], ["cardiac", "ORGAN", 214, 221], ["immuno", "TEST", 60, 66], ["DNA", "TEST", 71, 74], ["impedimetric sensors", "TEST", 95, 115], ["bioelectrocatalysis", "TREATMENT", 117, 136], ["electrode modification", "TREATMENT", 142, 164], ["the ultrasensitive detection", "TEST", 169, 197], ["bacteria", "PROBLEM", 201, 209], ["cardiac markers", "TEST", 214, 229]]], ["She is also involved in the development of electrochemical arrays for multiplexed detection.", [["electrochemical arrays", "TREATMENT", 43, 65], ["multiplexed detection", "TEST", 70, 91]]], ["He is Professor of Analytical Chemistry at Complutense University of Madrid and head of the group \"Electroanalysis and electrochemical (bio)sensors\".", [["head", "ORGANISM_SUBDIVISION", 80, 84]]], ["Current research includes the development of nanostructured electrochemical biosensors, including enzyme electrodes, immunosensors and genosensors for the ultrasensitive detection of bacteria, low molecule weight hormones and cancer markers as well as electrochemical arrays for multiplexed detection.", [["cancer", "ANATOMY", 226, 232], ["cancer", "CANCER", 226, 232], ["nanostructured electrochemical biosensors", "TREATMENT", 45, 86], ["enzyme electrodes", "TREATMENT", 98, 115], ["immunosensors", "TEST", 117, 130], ["genosensors", "TREATMENT", 135, 146], ["the ultrasensitive detection", "TEST", 151, 179], ["bacteria", "PROBLEM", 183, 191], ["low molecule weight hormones", "PROBLEM", 193, 221], ["cancer markers", "PROBLEM", 226, 240], ["multiplexed detection", "TEST", 279, 300]]], ["He has authored over 240 research papers and several books and book chapters Biosensor technology brings together the accuracy and sensitivity of standard approaches with improvement in rapidity of detection.", [["the accuracy", "TEST", 114, 126]]], ["Electrochemical sensors, in particular, offer several advantages compared to PCR and other molecular detection approaches, including a broad range of target analytes, minimal sample preparation, ability to analyze complex body fluids, high sensitivity, miniaturization, and compatibility with compact instrumentation.", [["sample", "ANATOMY", 175, 181], ["body fluids", "ANATOMY", 222, 233], ["Electrochemical sensors", "TEST", 0, 23], ["PCR", "TEST", 77, 80], ["a broad range of target analytes", "TREATMENT", 133, 165], ["minimal sample preparation", "TREATMENT", 167, 193], ["high sensitivity", "PROBLEM", 235, 251], ["compact instrumentation", "TREATMENT", 293, 316]]], ["Biosensors also offer the possibility of continuous and real-time monitoring of the environment for the presence of infectious agents to allow timely implementation of preventive and protective measurements.", [["infectious agents", "TREATMENT", 116, 133], ["preventive and protective measurements", "TREATMENT", 168, 206]]], ["In fact, the majority of existing technologies for detecting biological agents rely on either antibodies as the recognition molecules, which bind with a surface feature of the BWA, or on the recognition of a nucleic acid sequence known to be found in the BWA being tested.", [["surface", "ANATOMY", 153, 160], ["nucleic acid", "CHEMICAL", 208, 220], ["antibodies", "PROTEIN", 94, 104], ["recognition molecules", "PROTEIN", 112, 133], ["nucleic acid sequence", "PROTEIN", 208, 229], ["biological agents", "TREATMENT", 61, 78], ["a nucleic acid sequence", "PROBLEM", 206, 229]]], ["A few other types of recognition molecules such as peptides, glycolipids and aptamers have also been used with similar transduction schemes [13] .", [["recognition molecules", "PROTEIN", 21, 42], ["recognition molecules", "PROBLEM", 21, 42], ["glycolipids", "TREATMENT", 61, 72], ["aptamers", "TREATMENT", 77, 85], ["similar transduction schemes", "TREATMENT", 111, 139], ["few", "OBSERVATION_MODIFIER", 2, 5]]], ["All these recognition elements can also be employed in the development of electrochemical biosensors.IntroductionThe combination of functionalized MBs with electrochemical detection constitutes a powerful and efficient strategy for the development of magnetobiosensors which can be applied to the rapid and sensitive detection of many agents of environmental and clinical significance.", [["MBs", "SIMPLE_CHEMICAL", 147, 150], ["recognition elements", "DNA", 10, 30], ["electrochemical biosensors", "TREATMENT", 74, 100], ["electrochemical detection", "TEST", 156, 181], ["magnetobiosensors", "TREATMENT", 251, 268]]], ["This review focuses on current research regarding the use of MBs in the electrochemical sensing of bioterrorism and biohazard agents.", [["MBs", "SIMPLE_CHEMICAL", 61, 64], ["MBs", "TREATMENT", 61, 64], ["biohazard agents", "TREATMENT", 116, 132]]], ["Strategies involving methods based on the use of immuno-and nucleic acid-MB-based sensors by means of different amplification systems to achieve sensitive and specific electrochemical detection of these agents are discussed.MBs-Based Electrochemical ImmunosensorsSeveral advantages have been claimed for immunoassays making use of MBs over conventional ones.", [["nucleic acid-MB", "CHEMICAL", 60, 75], ["nucleic acid", "SIMPLE_CHEMICAL", 60, 72], ["MBs", "SIMPLE_CHEMICAL", 224, 227], ["MBs", "SIMPLE_CHEMICAL", 331, 334], ["immuno", "TEST", 49, 55], ["nucleic acid", "TEST", 60, 72], ["different amplification systems", "TREATMENT", 102, 133], ["these agents", "TREATMENT", 197, 209], ["MBs", "TEST", 224, 227], ["MBs over conventional ones", "TREATMENT", 331, 357]]], ["They can be summarized as: (1) high reaction kinetics in a small volume, high surface area and high dispersion capability of MBs leading to an increase in surface-to-volume ratio, together with a decrease of matrix effects and, consequently, to a substantial shortening of the immunoreaction times; (2) versatile manipulation and optimization of experimental conditions, as a consequence of the separation between the electrochemical detection and the immunoreaction steps, as it will be illustrated below; (3) less time consuming due to decreased coating, competition and blocking times; (4) modification of MBs in numerous ways allowing different immobilization strategies; and (5) the immunocomplexes formed on the MBs surface can be easily detected without preconcentration or purification steps, which are normally required for standard immunoassays [1, 14, 15] .", [["surface area", "ANATOMY", 78, 90], ["surface", "ANATOMY", 155, 162], ["matrix", "ANATOMY", 208, 214], ["MBs surface", "ANATOMY", 718, 729], ["MBs", "SIMPLE_CHEMICAL", 125, 128], ["MBs", "SIMPLE_CHEMICAL", 609, 612], ["immunocomplexes", "GENE_OR_GENE_PRODUCT", 688, 703], ["immunocomplexes", "PROTEIN", 688, 703], ["high reaction kinetics", "PROBLEM", 31, 53], ["a small volume", "PROBLEM", 57, 71], ["high surface area", "PROBLEM", 73, 90], ["high dispersion capability of MBs", "PROBLEM", 95, 128], ["a decrease of matrix effects", "PROBLEM", 194, 222], ["versatile manipulation", "TREATMENT", 303, 325], ["experimental conditions", "PROBLEM", 346, 369], ["the electrochemical detection", "TEST", 414, 443], ["decreased coating", "PROBLEM", 538, 555], ["modification of MBs", "PROBLEM", 593, 612], ["different immobilization strategies", "TREATMENT", 639, 674], ["the immunocomplexes", "PROBLEM", 684, 703], ["standard immunoassays", "TEST", 833, 854], ["small volume", "OBSERVATION_MODIFIER", 59, 71], ["high", "OBSERVATION_MODIFIER", 73, 77], ["surface", "OBSERVATION_MODIFIER", 78, 85], ["high dispersion", "OBSERVATION", 95, 110], ["increase", "OBSERVATION_MODIFIER", 143, 151], ["substantial", "OBSERVATION_MODIFIER", 247, 258], ["shortening", "OBSERVATION_MODIFIER", 259, 269]]], ["In summary, the good analytical performance of the immunodevices using functionalized MBs can be attributed to the increased surface area and reactivity, high effectiveness of blocking reagents, and improved washing and separation steps.Detection of Chemical AgentsDirect competitive immunoassay schemes, where the analyte and enzyme-analyte conjugates (using mainly alkaline phosphatase (AP) and horseradish peroxidase (HRP) as enzyme labels) compete for a limited amount of antibodies-coated MBs have been used to develop magnetoimmunosensors to detect 2,4-dichlorophenoxiacetic acid (2,4-D) [16] , polychlorinated biphenyls (PCBs) [17] [18] [19] , atrazine [20, 21] , and the insecticide biomarker trichloropyridinol (TCP) [22] .", [["surface area", "ANATOMY", 125, 137], ["2,4-dichlorophenoxiacetic acid", "CHEMICAL", 555, 585], ["2,4-D) [16] , polychlorinated biphenyls", "CHEMICAL", 587, 626], ["PCBs", "CHEMICAL", 628, 632], ["[17] [18] [19] , atrazine [20, 21]", "CHEMICAL", 634, 668], ["trichloropyridinol", "CHEMICAL", 701, 719], ["TCP", "CHEMICAL", 721, 724], ["2,4-dichlorophenoxiacetic acid", "CHEMICAL", 555, 585], ["2,4-D", "CHEMICAL", 587, 592], ["polychlorinated biphenyls", "CHEMICAL", 601, 626], ["PCBs", "CHEMICAL", 628, 632], ["atrazine", "CHEMICAL", 651, 659], ["trichloropyridinol", "CHEMICAL", 701, 719], ["TCP", "CHEMICAL", 721, 724], ["MBs", "SIMPLE_CHEMICAL", 86, 89], ["enzyme-analyte conjugates", "SIMPLE_CHEMICAL", 327, 352], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 367, 387], ["AP", "SIMPLE_CHEMICAL", 389, 391], ["horseradish peroxidase", "GENE_OR_GENE_PRODUCT", 397, 419], ["HRP", "SIMPLE_CHEMICAL", 421, 424], ["MBs", "SIMPLE_CHEMICAL", 494, 497], ["2,4-dichlorophenoxiacetic acid", "SIMPLE_CHEMICAL", 555, 585], ["2,4-D) [16] , polychlorinated biphenyls", "SIMPLE_CHEMICAL", 587, 626], ["PCBs) [17] [18] [19]", "SIMPLE_CHEMICAL", 628, 648], ["atrazine [20, 21]", "SIMPLE_CHEMICAL", 651, 668], ["trichloropyridinol", "SIMPLE_CHEMICAL", 701, 719], ["TCP", "SIMPLE_CHEMICAL", 721, 724], ["alkaline phosphatase", "PROTEIN", 367, 387], ["AP", "PROTEIN", 389, 391], ["horseradish peroxidase", "PROTEIN", 397, 419], ["HRP", "PROTEIN", 421, 424], ["antibodies", "PROTEIN", 476, 486], ["horseradish", "SPECIES", 397, 408], ["the immunodevices using functionalized MBs", "TREATMENT", 47, 89], ["the increased surface area", "PROBLEM", 111, 137], ["blocking reagents", "TREATMENT", 176, 193], ["the analyte and enzyme-analyte conjugates", "TEST", 311, 352], ["mainly alkaline phosphatase", "TEST", 360, 387], ["horseradish peroxidase", "TEST", 397, 419], ["enzyme labels", "TEST", 429, 442], ["antibodies-coated MBs", "TREATMENT", 476, 497], ["magnetoimmunosensors", "TEST", 524, 544], ["dichlorophenoxiacetic acid", "TREATMENT", 559, 585], ["polychlorinated biphenyls (PCBs)", "TREATMENT", 601, 633], ["atrazine", "TREATMENT", 651, 659], ["the insecticide biomarker trichloropyridinol (TCP)", "TREATMENT", 675, 725], ["increased", "OBSERVATION_MODIFIER", 115, 124], ["surface", "OBSERVATION_MODIFIER", 125, 132], ["high", "OBSERVATION_MODIFIER", 154, 158]]], ["As can be seen, the performance of some of these immunosensing systems was successfully evaluated using spiked environmental samples (soils, marine sediment extracts, foods, and river and bottled water samples).", [["samples", "ANATOMY", 125, 132], ["extracts", "ANATOMY", 157, 165], ["samples", "ANATOMY", 202, 209], ["extracts", "ORGANISM_SUBSTANCE", 157, 165], ["marine sediment extracts", "TREATMENT", 141, 165]]], ["The obtained results indicate that these convenient and sensitive methodologies offer great prom-ise for decentralized environmental applications.", [["decentralized environmental applications", "TREATMENT", 105, 145]]], ["In fact, they constitute interesting approaches which can be further used in the development of easy-to-use inexpensive tests for preliminary sample screening directly in-field.", [["sample", "ANATOMY", 142, 148], ["inexpensive tests", "TEST", 108, 125], ["preliminary sample screening", "TEST", 130, 158]]], ["Moreover, these strategies can be readily transferred to the detection of other environmental contaminants through the development of specific antibodies against these contaminants and are expected to open new opportunities for environmental monitoring and public health.Detection of Viral, Bacterial and Antibacterial AgentsThe development of magnetoimmunosensors for the detection of pathogen bacteria was firstly described by Kradtap et al. [23] and Che et al. [24] .", [["specific antibodies", "PROTEIN", 134, 153], ["other environmental contaminants", "PROBLEM", 74, 106], ["specific antibodies", "PROBLEM", 134, 153], ["environmental monitoring", "TEST", 228, 252], ["Viral, Bacterial", "TREATMENT", 284, 300], ["Antibacterial Agents", "TREATMENT", 305, 325], ["magnetoimmunosensors", "TREATMENT", 344, 364], ["the detection", "TEST", 369, 382], ["pathogen bacteria", "PROBLEM", 386, 403], ["Viral", "OBSERVATION", 284, 289]]], ["Kradtap et al. used an artificial microorganism called \"Bugbead\" as stimulant for the development of microbial sensors without introducing potential experimental hazards or other variables coming in when using real microorganisms [23] .", [["an artificial microorganism", "PROBLEM", 20, 47], ["microbial sensors", "PROBLEM", 101, 118], ["experimental hazards", "PROBLEM", 149, 169], ["artificial microorganism", "OBSERVATION", 23, 47]]], ["The applicability of these bugbeads in the development of immunosensors was demonstrated by the analysis of extracts containing serotype antigens of Escherichia coli O157 : H7 (E. coli O157 : H7).", [["extracts", "ANATOMY", 108, 116], ["extracts", "ORGANISM_SUBSTANCE", 108, 116], ["Escherichia coli O157 : H7", "ORGANISM", 149, 175], ["E. coli", "ORGANISM", 177, 184], ["O157 : H7", "ORGANISM", 185, 194], ["serotype antigens", "PROTEIN", 128, 145], ["Escherichia coli O157", "SPECIES", 149, 170], ["E. coli O157", "SPECIES", 177, 189], ["Escherichia coli O157 : H7", "SPECIES", 149, 175], ["E. coli O157 : H7", "SPECIES", 177, 194], ["immunosensors", "PROBLEM", 58, 71], ["the analysis", "TEST", 92, 104], ["Escherichia coli", "PROBLEM", 149, 165], ["Escherichia coli", "OBSERVATION", 149, 165]]], ["However, to our knowledge, these beads have never been used again in the development of electrochemical immunosensors.", [["electrochemical immunosensors", "TEST", 88, 117]]], ["On the other hand, Che et al. developed an immunomagnetic separation (IMS) procedure to isolate the enteropathogen Campylobacter jejuni (C. jejuni) cells from the sample solution [24] .", [["cells", "ANATOMY", 148, 153], ["sample", "ANATOMY", 163, 169], ["Campylobacter jejuni", "DISEASE", 115, 135], ["enteropathogen", "ORGANISM", 100, 114], ["Campylobacter jejuni", "ORGANISM", 115, 135], ["C. jejuni) cells", "CELL", 137, 153], ["Campylobacter jejuni", "SPECIES", 115, 135], ["C. jejuni", "SPECIES", 137, 146], ["Campylobacter jejuni", "SPECIES", 115, 135], ["C. jejuni", "SPECIES", 137, 146], ["an immunomagnetic separation (IMS) procedure", "TREATMENT", 40, 84], ["the enteropathogen Campylobacter jejuni", "PROBLEM", 96, 135], ["immunomagnetic separation", "OBSERVATION", 43, 68], ["enteropathogen Campylobacter jejuni", "OBSERVATION", 100, 135]]], ["The developed sensor that made use of a tyrosinase-modified electrode was applied to the analysis of pure culture and poultry samples.", [["samples", "ANATOMY", 126, 133], ["tyrosinase", "GENE_OR_GENE_PRODUCT", 40, 50], ["tyrosinase", "PROTEIN", 40, 50], ["a tyrosinase-modified electrode", "TREATMENT", 38, 69], ["the analysis", "TEST", 85, 97], ["pure culture", "TEST", 101, 113], ["poultry samples", "TEST", 118, 133]]], ["The potential application of this immunosensor in the poultry industry was demonstrated by the rapidity of the assay (2.5 h), the detection limit at the lowest concentration level expected in these samples, and the simple system setup.", [["samples", "ANATOMY", 198, 205], ["this immunosensor", "TEST", 29, 46], ["the assay", "TEST", 107, 116], ["the detection", "TEST", 126, 139], ["these samples", "TEST", 192, 205]]], ["A fully-automated fluidic system implying a beadbased sandwich immunoassay with electrochemical detection was described for bacteriophage MS2 and ovalbumin (OVA) detection [25] .", [["ovalbumin", "SIMPLE_CHEMICAL", 146, 155], ["a beadbased sandwich immunoassay", "TEST", 42, 74], ["electrochemical detection", "TEST", 80, 105], ["bacteriophage MS2", "PROBLEM", 124, 141]]], ["The sandwich immunosensor was constructed by attaching a biotinylated antibody to streptavidin-coated beads, capturing the antigen, and exposing the conjugate to a b-galactosidase-labelled antibody.", [["streptavidin", "SIMPLE_CHEMICAL", 82, 94], ["b-galactosidase", "SIMPLE_CHEMICAL", 164, 179], ["biotinylated antibody", "PROTEIN", 57, 78], ["streptavidin", "PROTEIN", 82, 94], ["b-galactosidase-labelled antibody", "PROTEIN", 164, 197], ["The sandwich immunosensor", "TREATMENT", 0, 25], ["a biotinylated antibody to streptavidin-coated beads", "TREATMENT", 55, 107], ["a b-galactosidase", "TEST", 162, 179]]], ["The detection limits for MS2 and OVA were 990 and 470 ng mL \u00c01 , respectively.Detection of Viral, Bacterial and Antibacterial AgentsAnother magnetoimmunosensing sandwich approach was developed for the detection of Salmonella allowing, in 50 min and without any pretreatment, a detection limit of 7.5 10 3 colony forming units (cfu) mL \u00c01 to be obtained in 10 times diluted milk samples [26] .", [["milk samples", "ANATOMY", 373, 385], ["Salmonella", "SPECIES", 214, 224], ["The detection", "TEST", 0, 13], ["MS2", "TEST", 25, 28], ["OVA", "TEST", 33, 36], ["Viral, Bacterial", "TREATMENT", 91, 107], ["Antibacterial Agents", "TREATMENT", 112, 132], ["Another magnetoimmunosensing sandwich approach", "TREATMENT", 132, 178], ["Salmonella", "PROBLEM", 214, 224], ["a detection limit", "TEST", 275, 292], ["Viral", "OBSERVATION", 91, 96]]], ["In this approach, the bacteria were captured and preconcentrated from milk samples with MBs through an immunological reaction.", [["milk samples", "ANATOMY", 70, 82], ["milk samples", "ORGANISM_SUBSTANCE", 70, 82], ["MBs", "SIMPLE_CHEMICAL", 88, 91], ["the bacteria", "PROBLEM", 18, 30], ["milk samples", "TEST", 70, 82], ["MBs", "TREATMENT", 88, 91], ["an immunological reaction", "PROBLEM", 100, 125], ["bacteria", "OBSERVATION", 22, 30], ["immunological reaction", "OBSERVATION", 103, 125]]], ["A polyclonal anti-Salmonella antibody labelled with HRP was used as serological confirmation with electrochemical detection at a magnetoelectrode.Detection of Viral, Bacterial and Antibacterial AgentsA disposable magnetoimmunosensor for the detection of Streptococcus pneumoniae (S. pneumoniae) was reported using a similar sandwich format where protA-coated MBs were employed as a solid phase to immobilize specific S. pneumoniae capture antibodies.", [["Streptococcus pneumoniae", "DISEASE", 254, 278], ["protA", "CHEMICAL", 346, 351], ["HRP", "GENE_OR_GENE_PRODUCT", 52, 55], ["Viral", "ORGANISM", 159, 164], ["Streptococcus pneumoniae", "ORGANISM", 254, 278], ["S. pneumoniae", "ORGANISM", 280, 293], ["protA-coated MBs", "SIMPLE_CHEMICAL", 346, 362], ["S. pneumoniae", "ORGANISM", 417, 430], ["polyclonal anti-Salmonella antibody", "PROTEIN", 2, 37], ["HRP", "PROTEIN", 52, 55], ["protA", "PROTEIN", 346, 351], ["S. pneumoniae capture antibodies", "PROTEIN", 417, 449], ["Streptococcus pneumoniae", "SPECIES", 254, 278], ["S. pneumoniae", "SPECIES", 280, 293], ["S. pneumoniae", "SPECIES", 417, 430], ["Streptococcus pneumoniae", "SPECIES", 254, 278], ["S. pneumoniae", "SPECIES", 280, 293], ["S. pneumoniae", "SPECIES", 417, 430], ["A polyclonal anti-Salmonella antibody", "TEST", 0, 37], ["HRP", "TEST", 52, 55], ["serological confirmation", "TEST", 68, 92], ["electrochemical detection", "TEST", 98, 123], ["Viral, Bacterial", "PROBLEM", 159, 175], ["Antibacterial AgentsA disposable magnetoimmunosensor", "TREATMENT", 180, 232], ["Streptococcus pneumoniae", "PROBLEM", 254, 278], ["S. pneumoniae", "PROBLEM", 280, 293], ["protA-coated MBs", "TREATMENT", 346, 362], ["S. pneumoniae capture antibodies", "PROBLEM", 417, 449], ["Viral", "OBSERVATION", 159, 164], ["Streptococcus pneumoniae", "OBSERVATION", 254, 278]]], ["As can be seen in Figure 2 , the same antibody but conjugated to HRP as enzyme label was used as the detection antibody to recognize the captured S. pneumoniae cells.", [["cells", "ANATOMY", 160, 165], ["HRP", "GENE_OR_GENE_PRODUCT", 65, 68], ["S. pneumoniae cells", "CELL", 146, 165], ["HRP", "PROTEIN", 65, 68], ["captured S. pneumoniae cells", "CELL_LINE", 137, 165], ["S. pneumoniae", "SPECIES", 146, 159], ["S. pneumoniae", "SPECIES", 146, 159], ["enzyme label", "TEST", 72, 84], ["the detection antibody", "TEST", 97, 119], ["S. pneumoniae cells", "PROBLEM", 146, 165], ["pneumoniae cells", "OBSERVATION", 149, 165]]], ["The electrochemical detection of the enzyme reaction product was accomplished at disposable gold screen-printed electrodes (Au/ SPEs) modified with tetrathiafulvalene (TTF) as electron transfer mediator and using H 2 O 2 as the enzyme substrate [27] .", [["Au/ SPEs", "CHEMICAL", 124, 132], ["tetrathiafulvalene", "CHEMICAL", 148, 166], ["Au", "CHEMICAL", 124, 126], ["tetrathiafulvalene", "CHEMICAL", 148, 166], ["TTF", "CHEMICAL", 168, 171], ["H 2 O 2", "CHEMICAL", 213, 220], ["Au/ SPEs", "SIMPLE_CHEMICAL", 124, 132], ["tetrathiafulvalene", "SIMPLE_CHEMICAL", 148, 166], ["TTF", "SIMPLE_CHEMICAL", 168, 171], ["electron", "SIMPLE_CHEMICAL", 176, 184], ["H 2 O 2", "SIMPLE_CHEMICAL", 213, 220], ["The electrochemical detection", "TEST", 0, 29], ["the enzyme reaction product", "PROBLEM", 33, 60], ["printed electrodes (Au/ SPEs)", "TREATMENT", 104, 133], ["tetrathiafulvalene (TTF", "TREATMENT", 148, 171], ["the enzyme substrate", "TEST", 224, 244]]], ["The developed methodology was shown to be suitable for detecting 1.0 10 4 cfu of S. pneumoniae in inoculated urine samples without any sample pretreatment.Detection of Viral, Bacterial and Antibacterial AgentsSome strategies have also been developed for the quantification of human antibodies against some bacterial agents or their specific toxins.", [["urine samples", "ANATOMY", 109, 122], ["sample", "ANATOMY", 135, 141], ["S. pneumoniae", "ORGANISM", 81, 94], ["urine samples", "ORGANISM_SUBSTANCE", 109, 122], ["human", "ORGANISM", 276, 281], ["human antibodies", "PROTEIN", 276, 292], ["S. pneumoniae", "SPECIES", 81, 94], ["human", "SPECIES", 276, 281], ["S. pneumoniae", "SPECIES", 81, 94], ["human", "SPECIES", 276, 281], ["S. pneumoniae", "PROBLEM", 81, 94], ["inoculated urine samples", "TEST", 98, 122], ["Viral, Bacterial", "TREATMENT", 168, 184], ["Antibacterial Agents", "TREATMENT", 189, 209], ["human antibodies", "TREATMENT", 276, 292], ["some bacterial agents", "TREATMENT", 301, 322], ["pneumoniae", "OBSERVATION", 84, 94], ["Viral", "OBSERVATION", 168, 173]]], ["Interesting examples of these approaches are the electrochemical magnetoimmunosensing assays developed for the rapid, selective and sensitive quantification of anti-Helicobacter pylori [28] , anti-Clostridium tetani [14] , and anti-hepatitis B virus [29] IgG antibodies.", [["anti-Helicobacter pylori", "ORGANISM", 160, 184], ["anti-Clostridium tetani [14]", "SIMPLE_CHEMICAL", 192, 220], ["anti-hepatitis B virus", "ORGANISM", 227, 249], ["anti-hepatitis B virus [29] IgG antibodies", "PROTEIN", 227, 269], ["anti-Helicobacter pylori", "SPECIES", 160, 184], ["anti-hepatitis B virus", "SPECIES", 227, 249], ["anti-Helicobacter pylori", "SPECIES", 160, 184], ["anti-hepatitis B virus", "SPECIES", 227, 249], ["the electrochemical magnetoimmunosensing assays", "TEST", 45, 92], ["anti-Helicobacter pylori", "PROBLEM", 160, 184], ["anti-Clostridium tetani", "TREATMENT", 192, 215], ["anti-hepatitis B virus", "TEST", 227, 249], ["IgG antibodies", "TEST", 255, 269]]], ["The detection of these antibodies in serum was carried out by indirect antibody capture assays based on the use of purified antigens immobilized on magnetic microspheres.", [["serum", "ANATOMY", 37, 42], ["serum", "ORGANISM_SUBSTANCE", 37, 42], ["antibodies", "PROTEIN", 23, 33], ["purified antigens", "PROTEIN", 115, 132], ["these antibodies in serum", "TEST", 17, 42], ["indirect antibody capture assays", "TEST", 62, 94], ["purified antigens", "TREATMENT", 115, 132], ["magnetic microspheres", "TREATMENT", 148, 169]]], ["The IgG antibodies present in the serum samples were allowed to react immunologically with the immobilized antigens, and the bound antibodies were quantified by enzyme-labelled [14, 28] or gold nanoparticles (AuNPs)-conjugated [29] secondary antibodies specific to human IgG.", [["serum samples", "ANATOMY", 34, 47], ["AuNPs", "CHEMICAL", 209, 214], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 4, 18], ["serum samples", "ORGANISM_SUBSTANCE", 34, 47], ["[14, 28]", "SIMPLE_CHEMICAL", 177, 185], ["gold nanoparticles", "SIMPLE_CHEMICAL", 189, 207], ["AuNPs", "SIMPLE_CHEMICAL", 209, 214], ["conjugated [29] secondary antibodies", "SIMPLE_CHEMICAL", 216, 252], ["human", "ORGANISM", 265, 270], ["IgG", "GENE_OR_GENE_PRODUCT", 271, 274], ["IgG antibodies", "PROTEIN", 4, 18], ["immobilized antigens", "PROTEIN", 95, 115], ["bound antibodies", "PROTEIN", 125, 141], ["human IgG", "PROTEIN", 265, 274], ["human", "SPECIES", 265, 270], ["human", "SPECIES", 265, 270], ["The IgG antibodies", "TEST", 0, 18], ["the serum samples", "TEST", 30, 47], ["the immobilized antigens", "TEST", 91, 115], ["the bound antibodies", "TEST", 121, 141], ["enzyme", "TEST", 161, 167], ["gold nanoparticles (AuNPs", "TEST", 189, 214], ["secondary antibodies", "TEST", 232, 252], ["human IgG", "TEST", 265, 274]]], ["These original approaches may be extended to on site applications dealing with the screening of antibody levels in complex samples.Detection of Viral, Bacterial and Antibacterial AgentsSome novel strategies for the detection of viruses and bacteria based on magnetoimmunosensors have been described recently.", [["samples", "ANATOMY", 123, 130], ["the screening of antibody levels", "TEST", 79, 111], ["Viral, Bacterial", "TREATMENT", 144, 160], ["Antibacterial Agents", "TREATMENT", 165, 185], ["viruses", "PROBLEM", 228, 235], ["bacteria", "PROBLEM", 240, 248], ["magnetoimmunosensors", "TREATMENT", 258, 278], ["Viral", "OBSERVATION", 144, 149], ["viruses", "OBSERVATION", 228, 235]]], ["A magnetic gold electrode was fabricated for the direct sensing of Japanese encephalitis virus (JEV) [30] .", [["Japanese encephalitis", "DISEASE", 67, 88], ["Japanese encephalitis virus", "ORGANISM", 67, 94], ["JEV", "ORGANISM", 96, 99], ["Japanese encephalitis virus", "SPECIES", 67, 94], ["Japanese encephalitis virus", "SPECIES", 67, 94], ["JEV", "SPECIES", 96, 99], ["A magnetic gold electrode", "TREATMENT", 0, 25], ["Japanese encephalitis virus", "PROBLEM", 67, 94], ["gold electrode", "OBSERVATION", 11, 25]]], ["Gold-coated MBs were employed as the platforms for the immobilization and immunoreaction processes, and HRP was chosen as an enzymatic tracer.", [["Gold-coated MBs", "SIMPLE_CHEMICAL", 0, 15], ["HRP", "SIMPLE_CHEMICAL", 104, 107], ["HRP", "PROTEIN", 104, 107], ["Gold-coated MBs", "TREATMENT", 0, 15], ["the immobilization", "TREATMENT", 51, 69], ["immunoreaction processes", "PROBLEM", 74, 98], ["HRP", "TEST", 104, 107], ["an enzymatic tracer", "PROBLEM", 122, 141], ["coated MBs", "OBSERVATION", 5, 15], ["enzymatic tracer", "OBSERVATION", 125, 141]]], ["After the immunoreactions, multiwalled carbon nanotubes (MWCNTs) were mixed with the immunocomplex coated Au-coated MBs to improve the sensitivity of the assay.", [["multiwalled carbon nanotubes", "CHEMICAL", 27, 55], ["MWCNTs", "CHEMICAL", 57, 63], ["carbon", "CHEMICAL", 39, 45], ["multiwalled carbon nanotubes", "SIMPLE_CHEMICAL", 27, 55], ["MWCNTs", "SIMPLE_CHEMICAL", 57, 63], ["Au-coated MBs", "SIMPLE_CHEMICAL", 106, 119], ["the immunoreactions", "TREATMENT", 6, 25], ["multiwalled carbon nanotubes (MWCNTs)", "TREATMENT", 27, 64], ["the immunocomplex coated Au-coated MBs", "TREATMENT", 81, 119], ["the assay", "TEST", 150, 159]]], ["A detection limit two orders of magnitude lower than that of immunochromatographic strip and similar to that obtained by reverse transcriptase polymerase chain reaction (RT-PCR) was obtained ( Table 3 ).", [["reverse transcriptase", "PROTEIN", 121, 142], ["A detection", "TEST", 0, 11], ["immunochromatographic strip", "TEST", 61, 88], ["reverse transcriptase polymerase chain reaction", "PROBLEM", 121, 168], ["RT-PCR", "TEST", 170, 176]]], ["The method was successfully applied in clinical samples (brain tissue of swine, mosquito and cerebrospinal fluid of human patients).Detection of Viral, Bacterial and Antibacterial AgentsAlso, novel magnetoimmunoassay-based strategies for the detection of Plasmodium falciparum histidine-rich protein 2 (HRP2), a malaria parasite biomarker, have been described.", [["samples", "ANATOMY", 48, 55], ["brain tissue", "ANATOMY", 57, 69], ["cerebrospinal fluid", "ANATOMY", 93, 112], ["Plasmodium falciparum", "DISEASE", 255, 276], ["histidine", "CHEMICAL", 277, 286], ["malaria parasite", "DISEASE", 312, 328], ["histidine", "CHEMICAL", 277, 286], ["brain tissue", "TISSUE", 57, 69], ["swine", "ORGANISM", 73, 78], ["mosquito", "ORGANISM_SUBDIVISION", 80, 88], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 93, 112], ["human", "ORGANISM", 116, 121], ["patients", "ORGANISM", 122, 130], ["Plasmodium falciparum", "ORGANISM", 255, 276], ["histidine-rich protein 2", "GENE_OR_GENE_PRODUCT", 277, 301], ["HRP2", "GENE_OR_GENE_PRODUCT", 303, 307], ["Plasmodium falciparum histidine-rich protein 2", "PROTEIN", 255, 301], ["HRP2", "PROTEIN", 303, 307], ["swine", "SPECIES", 73, 78], ["human", "SPECIES", 116, 121], ["patients", "SPECIES", 122, 130], ["Plasmodium falciparum", "SPECIES", 255, 276], ["swine", "SPECIES", 73, 78], ["human", "SPECIES", 116, 121], ["Plasmodium falciparum", "SPECIES", 255, 276], ["The method", "TREATMENT", 0, 10], ["clinical samples", "TEST", 39, 55], ["Viral", "PROBLEM", 145, 150], ["Antibacterial Agents", "TREATMENT", 166, 186], ["novel magnetoimmunoassay", "TEST", 192, 216], ["the detection", "TEST", 238, 251], ["Plasmodium falciparum histidine", "TEST", 255, 286], ["rich protein", "TEST", 287, 299], ["a malaria parasite biomarker", "PROBLEM", 310, 338], ["Viral", "OBSERVATION", 145, 150], ["malaria", "OBSERVATION", 312, 319]]], ["Two different kinds of magnetic supports were employed for this purpose: 1 mm tosyl-activated MBs, and 300 nm active magnetic nanoparticles [31] .", [["MBs", "SIMPLE_CHEMICAL", 94, 97]]], ["This is the first report of a procedure based on a sandwich magnetoimmunoassay between the protein in the sample and two commercially available monoclonal antibodies that recognize two different epitopes of the antigen, one of them covalently coupled to MBs and the other labelled with the enzyme HRP.", [["sample", "ANATOMY", 106, 112], ["MBs", "SIMPLE_CHEMICAL", 254, 257], ["HRP", "GENE_OR_GENE_PRODUCT", 297, 300], ["monoclonal antibodies", "PROTEIN", 144, 165], ["epitopes", "PROTEIN", 195, 203], ["enzyme HRP", "PROTEIN", 290, 300], ["a procedure", "TREATMENT", 28, 39], ["a sandwich magnetoimmunoassay", "TEST", 49, 78], ["monoclonal antibodies", "TEST", 144, 165], ["the enzyme HRP", "TEST", 286, 300]]], ["The electrochemical magnetoimunosensor showed better analytical performance than other methods in terms of limit of detection (see Table 3 ).", [["The electrochemical magnetoimunosensor", "TEST", 0, 38]]], ["Due to the high sensitivity achieved, this strategy offers great promise to implement rapid, simple, inexpensive and user-friendly analytical methods for on-site detection of falciparum malaria disease in patients, and also to screen out at-risk blood samples for prevention of trans-fusion-transmitted malaria, as well as for in vitro drug sensitivity testing.Detection of Viral, Bacterial and Antibacterial AgentsMoreover, a novel electrochemical immunosensing assay for bacterial detection that combines a one-step sandwich immunoassay, MBs target preconcentration, microfluidic technology, and amperometric detection using HRP as the label enzyme has recently been described [32] .", [["blood samples", "ANATOMY", 246, 259], ["falciparum malaria disease", "DISEASE", 175, 201], ["malaria", "DISEASE", 303, 310], ["falciparum", "ORGANISM", 175, 185], ["patients", "ORGANISM", 205, 213], ["blood samples", "ORGANISM_SUBSTANCE", 246, 259], ["MBs", "SIMPLE_CHEMICAL", 540, 543], ["HRP", "SIMPLE_CHEMICAL", 627, 630], ["HRP", "PROTEIN", 627, 630], ["patients", "SPECIES", 205, 213], ["the high sensitivity", "PROBLEM", 7, 27], ["falciparum malaria disease", "PROBLEM", 175, 201], ["blood samples", "TEST", 246, 259], ["trans-fusion", "TREATMENT", 278, 290], ["transmitted malaria", "PROBLEM", 291, 310], ["vitro drug sensitivity testing", "TEST", 330, 360], ["Viral", "PROBLEM", 374, 379], ["Antibacterial Agents", "TREATMENT", 395, 415], ["a novel electrochemical immunosensing assay", "TEST", 425, 468], ["bacterial detection", "PROBLEM", 473, 492], ["microfluidic technology", "TEST", 569, 592], ["amperometric detection", "TEST", 598, 620], ["the label enzyme", "TEST", 634, 650], ["falciparum malaria", "OBSERVATION", 175, 193], ["malaria", "OBSERVATION", 303, 310], ["Viral", "OBSERVATION", 374, 379]]], ["The enzymatic reaction takes place in an incubation micro-chamber where the MBs are confined, upstream from the working electrode.", [["MBs", "SIMPLE_CHEMICAL", 76, 79], ["The enzymatic reaction", "PROBLEM", 0, 22], ["enzymatic reaction", "OBSERVATION", 4, 22], ["working electrode", "OBSERVATION", 112, 129]]], ["The enzyme product is then pumped along a microchannel, where it is amperometrically detected by a set of microelectrodes.", [["The enzyme product", "TEST", 0, 18]]], ["The system provided a significant improvement in terms of limit of detection and assay time (1 h) compared to classical ELISA detection.", [["classical ELISA detection", "TEST", 110, 135], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["improvement", "OBSERVATION_MODIFIER", 34, 45]]], ["Also, it provides the possibility of addressing relatively complex sample matrices so that it could be potentially applicable to the food, pharmaceuti-cal and medical fields if preconcentration and/or preenrichment strategies were implemented.", [["preconcentration", "TREATMENT", 177, 193], ["preenrichment strategies", "TREATMENT", 201, 225]]], ["Table 3 summarizes the analytical characteristics of the reported methods for the detection of viral, bacterial and anti-bacterial agents using electrochemical magnetoimmunosensors.Detection of Biological ToxinsCompetitive magnetoimmunoassays have been described for the determination of several biological toxins.", [["the detection", "TEST", 78, 91], ["viral, bacterial", "TREATMENT", 95, 111], ["anti-bacterial agents", "TREATMENT", 116, 137], ["electrochemical magnetoimmunosensors", "TREATMENT", 144, 180], ["Biological ToxinsCompetitive magnetoimmunoassays", "PROBLEM", 194, 242], ["viral", "OBSERVATION", 95, 100]]], ["An electrochemical immunoassay for the determination of aflatoxin B 1 (AFB 1 ) in food has been reported.", [["aflatoxin B 1 (AFB 1 )", "CHEMICAL", 56, 78], ["aflatoxin B 1", "CHEMICAL", 56, 69], ["AFB 1", "CHEMICAL", 71, 76], ["aflatoxin B 1", "SIMPLE_CHEMICAL", 56, 69], ["AFB 1", "SIMPLE_CHEMICAL", 71, 76], ["An electrochemical immunoassay", "TEST", 0, 30], ["aflatoxin B", "TREATMENT", 56, 67]]], ["The approach was based on the use of multifunctional MBs as probes, which comprised magnetic CoFe 2 O 4 and Prussian Blue nanoparticles and were used as an affinity support for the immobilization of the AFB 1 -bovine serum albumin conjugate (AFB 1 -BSA) [33] .", [["serum", "ANATOMY", 217, 222], ["CoFe 2 O", "CHEMICAL", 93, 101], ["Prussian Blue", "CHEMICAL", 108, 121], ["AFB 1 -BSA", "CHEMICAL", 242, 252], ["CoFe 2 O 4", "CHEMICAL", 93, 103], ["Prussian Blue", "CHEMICAL", 108, 121], ["AFB", "CHEMICAL", 203, 206], ["AFB", "CHEMICAL", 242, 245], ["MBs", "SIMPLE_CHEMICAL", 53, 56], ["CoFe 2 O 4", "SIMPLE_CHEMICAL", 93, 103], ["Prussian Blue nanoparticles", "SIMPLE_CHEMICAL", 108, 135], ["bovine", "ORGANISM", 210, 216], ["serum", "ORGANISM_SUBSTANCE", 217, 222], ["albumin conjugate", "SIMPLE_CHEMICAL", 223, 240], ["AFB 1 -BSA", "SIMPLE_CHEMICAL", 242, 252], ["bovine", "SPECIES", 210, 216], ["Prussian Blue nanoparticles", "TREATMENT", 108, 135], ["an affinity support", "TREATMENT", 153, 172], ["the immobilization", "TREATMENT", 177, 195], ["the AFB", "TEST", 199, 206], ["bovine serum albumin conjugate", "TEST", 210, 240], ["AFB", "TEST", 242, 245]]], ["The concentrations ofTOPICAL CLUSTERElectroanalysis 2012, 24, No. 3, 470 -482 AFB 1 were determined by means of a competitive-type immunoassay using AuNPs modified with HRP-labelled anti-AFB 1 as detection antibodies for the amplification of the electrochemical signal ( Figure 3 ).", [["AuNPs", "CHEMICAL", 149, 154], ["AuNPs", "SIMPLE_CHEMICAL", 149, 154], ["HRP", "SIMPLE_CHEMICAL", 169, 172], ["anti-AFB 1", "GENE_OR_GENE_PRODUCT", 182, 192], ["HRP", "PROTEIN", 169, 172], ["anti-AFB 1", "PROTEIN", 182, 192], ["TOPICAL CLUSTERElectroanalysis", "TEST", 21, 51], ["AFB", "TEST", 78, 81], ["HRP", "TEST", 169, 172], ["detection antibodies", "TEST", 196, 216]]], ["This strategy gave rise to a high sensitivity, enhanced by the use of AuNPs, together with avoiding the need of adding an electron mediator in the detection solution due to the presence of Prussian Blue NPs, thus providing a convenient platform for clinical testing and drug screening.TOPICAL CLUSTERA related approach has been described for the detection of deoxynivalenol (DON), a mycotoxin produced by Fusarium fungi which represents a serious threat for the safety of cereal-based food and feedstuffs [34] .", [["AuNPs", "CHEMICAL", 70, 75], ["Prussian Blue", "CHEMICAL", 189, 202], ["deoxynivalenol", "CHEMICAL", 359, 373], ["DON", "CHEMICAL", 375, 378], ["Fusarium fungi", "DISEASE", 405, 419], ["Prussian Blue", "CHEMICAL", 189, 202], ["deoxynivalenol", "CHEMICAL", 359, 373], ["DON", "CHEMICAL", 375, 378], ["AuNPs", "SIMPLE_CHEMICAL", 70, 75], ["electron", "SIMPLE_CHEMICAL", 122, 130], ["Prussian Blue NPs", "SIMPLE_CHEMICAL", 189, 206], ["deoxynivalenol", "SIMPLE_CHEMICAL", 359, 373], ["DON", "SIMPLE_CHEMICAL", 375, 378], ["Fusarium fungi", "ORGANISM", 405, 419], ["cereal", "ORGANISM_SUBDIVISION", 472, 478], ["a high sensitivity", "PROBLEM", 27, 45], ["AuNPs", "TREATMENT", 70, 75], ["an electron mediator", "TREATMENT", 119, 139], ["clinical testing", "TEST", 249, 265], ["drug screening", "TEST", 270, 284], ["TOPICAL CLUSTERA related approach", "TREATMENT", 285, 318], ["deoxynivalenol (DON", "TREATMENT", 359, 378], ["a mycotoxin", "TREATMENT", 381, 392], ["Fusarium fungi", "PROBLEM", 405, 419], ["Prussian Blue NPs", "OBSERVATION", 189, 206]]], ["This methodology was based on the use of a novel anti-DON Fab fragment and of immunomagnetic beads coupled with eight magnetized SPEs as electrochemical transducers.", [["SPEs", "SIMPLE_CHEMICAL", 129, 133], ["anti-DON Fab fragment", "PROTEIN", 49, 70], ["a novel anti-DON Fab fragment", "TREATMENT", 41, 70], ["immunomagnetic beads", "TREATMENT", 78, 98]]], ["The experimental procedure consisted of coating MBs with the conjugated toxin and performing a competitive assay by adding the free toxin together with the Fab fragment, conjugated with a biotin group.", [["biotin", "CHEMICAL", 188, 194], ["biotin", "CHEMICAL", 188, 194], ["MBs", "SIMPLE_CHEMICAL", 48, 51], ["biotin", "SIMPLE_CHEMICAL", 188, 194], ["Fab fragment", "PROTEIN", 156, 168], ["The experimental procedure", "TREATMENT", 0, 26], ["coating MBs", "TREATMENT", 40, 51], ["the conjugated toxin", "TREATMENT", 57, 77], ["the free toxin", "TREATMENT", 123, 137], ["the Fab fragment", "TREATMENT", 152, 168], ["a biotin group", "TREATMENT", 186, 200]]], ["In order to carry out the electrochemical detection, the immunological complex was linked to HRP via an avidin-biotin binding.", [["biotin", "CHEMICAL", 111, 117], ["biotin", "CHEMICAL", 111, 117], ["HRP", "GENE_OR_GENE_PRODUCT", 93, 96], ["avidin", "GENE_OR_GENE_PRODUCT", 104, 110], ["biotin", "SIMPLE_CHEMICAL", 111, 117], ["immunological complex", "PROTEIN", 57, 78], ["HRP", "PROTEIN", 93, 96], ["avidin", "PROTEIN", 104, 110], ["the electrochemical detection", "TEST", 22, 51], ["HRP", "TEST", 93, 96], ["an avidin-biotin binding", "TREATMENT", 101, 125]]], ["Although the developed system resulted in sensitivity and selectivity characteristics similar to those offered by ELISA or SPR methodologies, the employed multielectrode strip could be applied to multianalyte detection.", [["sensitivity", "TEST", 42, 53], ["ELISA or SPR methodologies", "TEST", 114, 140], ["the employed multielectrode strip", "TREATMENT", 142, 175], ["multianalyte detection", "TEST", 196, 218]]], ["Also, this kind of transducer is easily miniaturized in a cost-effective and mass producible way thus opening a door to the development of a portable electrochemical instrument and miniaturized strip for lab-on-a-chip approach.", [["a portable electrochemical instrument", "TREATMENT", 139, 176], ["miniaturized strip", "TEST", 181, 199], ["a-chip approach", "TREATMENT", 211, 226], ["mass", "OBSERVATION", 77, 81]]], ["Another example is that described for the determination of okadaic acid (OA), a lipophilic marine biotoxin ingested by various species of shellfish, involving the use of super paramagnetic nanobeads [15] .", [["okadaic acid", "CHEMICAL", 59, 71], ["OA", "CHEMICAL", 73, 75], ["biotoxin", "CHEMICAL", 98, 106], ["okadaic acid", "CHEMICAL", 59, 71], ["okadaic acid", "SIMPLE_CHEMICAL", 59, 71], ["OA", "SIMPLE_CHEMICAL", 73, 75], ["biotoxin", "SIMPLE_CHEMICAL", 98, 106], ["okadaic acid (OA", "PROBLEM", 59, 75], ["a lipophilic marine biotoxin", "TREATMENT", 78, 106], ["super paramagnetic nanobeads", "TREATMENT", 170, 198]]], ["Immobilized OA on streptavidin-coated MBs competed with free OA in solution for the anti-OA monoclonal antibody also in solution.", [["OA", "SIMPLE_CHEMICAL", 12, 14], ["streptavidin-coated MBs", "SIMPLE_CHEMICAL", 18, 41], ["OA", "SIMPLE_CHEMICAL", 61, 63], ["anti-OA monoclonal antibody", "PROTEIN", 84, 111], ["Immobilized OA", "PROBLEM", 0, 14], ["streptavidin-coated MBs", "TREATMENT", 18, 41], ["free OA in solution", "TREATMENT", 56, 75], ["the anti-OA monoclonal antibody", "TREATMENT", 80, 111]]], ["A secondary antibody labelled with AP was used in the detection step which was carried out by DPV.", [["AP", "SIMPLE_CHEMICAL", 35, 37], ["secondary antibody", "PROTEIN", 2, 20], ["AP", "PROTEIN", 35, 37], ["A secondary antibody", "TEST", 0, 20], ["AP", "TEST", 35, 37], ["the detection step", "TEST", 50, 68]]], ["The developed method was applied successfully to the determination of AO in mussels extracts demonstrating that the use of MBs reduced the analysis time and eliminated matrix effect and interferences.", [["extracts", "ANATOMY", 84, 92], ["matrix", "ANATOMY", 168, 174], ["AO", "CHEMICAL", 70, 72], ["AO", "SIMPLE_CHEMICAL", 70, 72], ["mussels extracts", "ORGANISM_SUBSTANCE", 76, 92], ["MBs", "SIMPLE_CHEMICAL", 123, 126], ["matrix", "CELLULAR_COMPONENT", 168, 174], ["method", "TREATMENT", 14, 20]]], ["Some electrochemical MBs-based immunosensing approaches exhibiting successful integration in microfluidic devices have been also reported.", [["MBs", "SIMPLE_CHEMICAL", 21, 24], ["Some electrochemical MBs", "PROBLEM", 0, 24], ["successful integration in microfluidic devices", "TREATMENT", 67, 113], ["electrochemical MBs", "OBSERVATION", 5, 24], ["microfluidic devices", "OBSERVATION", 93, 113]]], ["One of them, based on a sandwich configuration, was developed for the detection of cholera toxin subunit B (CTB) [35] .", [["cholera toxin subunit B", "CHEMICAL", 83, 106], ["cholera toxin subunit B", "GENE_OR_GENE_PRODUCT", 83, 106], ["CTB", "GENE_OR_GENE_PRODUCT", 108, 111], ["cholera toxin subunit B", "PROTEIN", 83, 106], ["CTB", "PROTEIN", 108, 111], ["the detection", "TEST", 66, 79], ["cholera toxin", "TREATMENT", 83, 96]]], ["The sandwich format used comprised anti-CTB antibody and ferri/ferrocyanide encapsulating ganglioside GM 1 liposomes for signal amplification.", [["ferri/ferrocyanide", "CHEMICAL", 57, 75], ["GM", "CHEMICAL", 102, 104], ["ferrocyanide", "CHEMICAL", 63, 75], ["ganglioside", "CHEMICAL", 90, 101], ["anti-CTB antibody", "SIMPLE_CHEMICAL", 35, 52], ["ferri", "SIMPLE_CHEMICAL", 57, 62], ["ferrocyanide", "SIMPLE_CHEMICAL", 63, 75], ["ganglioside GM 1 liposomes", "SIMPLE_CHEMICAL", 90, 116], ["anti-CTB antibody", "PROTEIN", 35, 52], ["The sandwich format", "TEST", 0, 19], ["anti-CTB antibody", "TREATMENT", 35, 52], ["ferri/ferrocyanide encapsulating ganglioside", "TREATMENT", 57, 101], ["signal amplification", "PROBLEM", 121, 141]]], ["Fluorescence and electrochemical detections were compared finding out that the electrochemical approach showed advantages in terms of flexibility and reliability of signal recording.", [["Fluorescence and electrochemical detections", "TEST", 0, 43], ["the electrochemical approach", "TEST", 75, 103], ["signal recording", "TEST", 165, 181]]], ["A microfluidic device has been developed for a simplified detection of zearalenone (ZEA) on the basis of a competition scheme where this mycotoxin and an enzyme-labelled derivative compete for the binding sites of a specific antibody immobilized on protG-modified MBs.TOPICAL CLUSTERAlso, the possibility of using electrochemical detection coupled with a MBs-based immunoassay for the detection of ZEA in baby food was demonstrated [36, 37] .", [["zearalenone", "CHEMICAL", 71, 82], ["ZEA", "CHEMICAL", 84, 87], ["mycotoxin", "CHEMICAL", 137, 146], ["ZEA", "CHEMICAL", 398, 401], ["zearalenone", "CHEMICAL", 71, 82], ["ZEA", "CHEMICAL", 84, 87], ["ZEA", "CHEMICAL", 398, 401], ["zearalenone", "SIMPLE_CHEMICAL", 71, 82], ["ZEA", "SIMPLE_CHEMICAL", 84, 87], ["protG", "SIMPLE_CHEMICAL", 249, 254], ["MBs", "SIMPLE_CHEMICAL", 264, 267], ["MBs", "SIMPLE_CHEMICAL", 355, 358], ["ZEA", "SIMPLE_CHEMICAL", 398, 401], ["binding sites", "PROTEIN", 197, 210], ["protG", "PROTEIN", 249, 254], ["A microfluidic device", "TREATMENT", 0, 21], ["zearalenone (ZEA", "TREATMENT", 71, 87], ["this mycotoxin", "TREATMENT", 132, 146], ["an enzyme", "TEST", 151, 160], ["the binding sites", "PROBLEM", 193, 210], ["a specific antibody", "TEST", 214, 233], ["electrochemical detection", "TEST", 314, 339], ["a MBs", "TEST", 353, 358], ["microfluidic device", "OBSERVATION", 2, 21]]], ["Subsequently, the developed system was integrated in microfluidic chips following the scheme displayed in Figure 4 , where the simple channel layout of a double-T microchip was used to perform sequentially the immunoreaction and the enzyme reaction by applying a program of electric fields [38] .", [["microfluidic chips", "TREATMENT", 53, 71], ["a double-T microchip", "TREATMENT", 152, 172], ["the immunoreaction", "TEST", 206, 224], ["the enzyme reaction", "PROBLEM", 229, 248]]], ["Another system for the determination of ZEA in feedstuffs samples has been recently reported using a microbiochip microfluidic immunosensor coupled with flow injection (FIA) with Au/SPEs as the working electrode showing good sensitivity and accuracy, and minimizing the use of expensive reagents [39] .", [["samples", "ANATOMY", 58, 65], ["ZEA", "CHEMICAL", 40, 43], ["Au", "CHEMICAL", 179, 181], ["ZEA", "CHEMICAL", 40, 43], ["Au", "CHEMICAL", 179, 181], ["ZEA", "SIMPLE_CHEMICAL", 40, 43], ["Au/SPEs", "SIMPLE_CHEMICAL", 179, 186], ["ZEA in feedstuffs samples", "PROBLEM", 40, 65], ["a microbiochip microfluidic immunosensor", "TREATMENT", 99, 139], ["flow injection", "TREATMENT", 153, 167], ["Au/SPEs", "TREATMENT", 179, 186], ["accuracy", "TEST", 241, 249], ["expensive reagents", "TREATMENT", 277, 295]]], ["Table 4 summarizes the main characteristics reported for the detection of biological toxins using electrochemical magnetoimmunosensors.MBs-Based Electrochemical DNA SensorsMBs have demonstrated to be versatile tools not only for the separation of nucleic acids but also as a platform for optimized DNA hybridization [7] .", [["nucleic acids", "CHEMICAL", 247, 260], ["MBs", "SIMPLE_CHEMICAL", 135, 138], ["DNA", "CELLULAR_COMPONENT", 161, 164], ["nucleic acids", "SIMPLE_CHEMICAL", 247, 260], ["DNA", "CELLULAR_COMPONENT", 298, 301], ["biological toxins", "PROBLEM", 74, 91], ["electrochemical magnetoimmunosensors", "TREATMENT", 98, 134], ["MBs", "TEST", 135, 138], ["Electrochemical DNA SensorsMBs", "TEST", 145, 175], ["nucleic acids", "TREATMENT", 247, 260], ["optimized DNA hybridization", "TREATMENT", 288, 315]]], ["The hybridization event is detected at a different surface, the working electrode, the detection being based either on the intrinsic DNA electroactivity or on DNA labelling in order to amplify the measured signals.", [["surface", "ANATOMY", 51, 58], ["surface", "CELLULAR_COMPONENT", 51, 58], ["DNA", "CELLULAR_COMPONENT", 133, 136], ["DNA", "CELLULAR_COMPONENT", 159, 162], ["The hybridization event", "PROBLEM", 0, 23], ["the detection", "TEST", 83, 96], ["DNA labelling", "TREATMENT", 159, 172]]], ["Moreover, MBs have been used to discriminate genetic alleles and thus identify the presence of single nucleotide polymorphisms (SNPs), in the study of mutational status or genotyping of an organism, drug discovery, and genetic disorders associated with point mutations, as well as in the detection of viruses, bacteria and food-borne pathogens [9] .MBs-Based Electrochemical DNA SensorsLaGier et al. developed a label-free electrochemical method based on the use of DNA probe-coated MBs for the selective detection of E. coli 16S rRNA directly from lysed cells, by monitoring the guanine oxidation signal [40] .", [["cells", "ANATOMY", 555, 560], ["genetic disorders", "DISEASE", 219, 236], ["guanine", "CHEMICAL", 580, 587], ["guanine", "CHEMICAL", 580, 587], ["MBs", "SIMPLE_CHEMICAL", 10, 13], ["MBs", "SIMPLE_CHEMICAL", 349, 352], ["DNA", "CELLULAR_COMPONENT", 466, 469], ["MBs", "SIMPLE_CHEMICAL", 483, 486], ["E. coli", "ORGANISM", 518, 525], ["16S", "GENE_OR_GENE_PRODUCT", 526, 529], ["rRNA", "CELLULAR_COMPONENT", 530, 534], ["cells", "CELL", 555, 560], ["guanine", "SIMPLE_CHEMICAL", 580, 587], ["DNA probe", "DNA", 466, 475], ["E. coli 16S rRNA", "DNA", 518, 534], ["lysed cells", "CELL_TYPE", 549, 560], ["E. coli", "SPECIES", 518, 525], ["E. coli", "SPECIES", 518, 525], ["MBs", "TEST", 10, 13], ["genetic alleles", "PROBLEM", 45, 60], ["single nucleotide polymorphisms (SNPs)", "PROBLEM", 95, 133], ["an organism", "PROBLEM", 186, 197], ["genetic disorders", "PROBLEM", 219, 236], ["point mutations", "PROBLEM", 253, 268], ["viruses", "PROBLEM", 301, 308], ["bacteria", "PROBLEM", 310, 318], ["food-borne pathogens", "PROBLEM", 323, 343], ["MBs", "TEST", 349, 352], ["free electrochemical method", "TREATMENT", 418, 445], ["DNA probe-coated MBs", "TREATMENT", 466, 486], ["the selective detection", "TEST", 491, 514], ["E. coli 16S rRNA", "PROBLEM", 518, 534], ["the guanine oxidation signal", "TEST", 576, 604], ["viruses", "OBSERVATION", 301, 308], ["E. coli", "OBSERVATION", 518, 525], ["lysed cells", "OBSERVATION", 549, 560]]], ["Using this approach, 10 7 E. coli cells could be detected in 4 h.", [["cells", "ANATOMY", 34, 39], ["E. coli cells", "CELL", 26, 39], ["E. coli", "SPECIES", 26, 33], ["E. coli", "SPECIES", 26, 33], ["this approach", "TREATMENT", 6, 19], ["E. coli cells", "TEST", 26, 39]]], ["A sensitive and selective genomagnetic assay for the electrochemical detection of Salmonella spp. was developed based on a double labelling polymerase chain reaction (PCR) strategy that generated an amplicon of the IS200 insertion sequence with double labelling: with a biotinylated capture primer to achieve immobilization on streptavidin-coated MBs, and with a digoxigenin signalling primer for electrochemical detection [41] .", [["Salmonella spp", "ORGANISM", 82, 96], ["streptavidin", "SIMPLE_CHEMICAL", 327, 339], ["MBs", "SIMPLE_CHEMICAL", 347, 350], ["digoxigenin", "SIMPLE_CHEMICAL", 363, 374], ["IS200 insertion sequence", "DNA", 215, 239], ["streptavidin", "PROTEIN", 327, 339], ["digoxigenin signalling primer", "DNA", 363, 392], ["selective genomagnetic assay", "TEST", 16, 44], ["the electrochemical detection", "TEST", 49, 78], ["Salmonella spp", "PROBLEM", 82, 96], ["a double labelling polymerase chain reaction", "PROBLEM", 121, 165], ["the IS200 insertion sequence", "TREATMENT", 211, 239], ["a biotinylated capture primer", "TREATMENT", 268, 297], ["immobilization on streptavidin-coated MBs", "TREATMENT", 309, 350], ["a digoxigenin signalling primer", "TREATMENT", 361, 392], ["electrochemical detection", "TEST", 397, 422], ["Salmonella spp", "OBSERVATION", 82, 96]]], ["A PCR reactor for real-time electrochemical detection of Salmonella genome, in which the amplification and double-labelling were directly performed on the streptavidin-MBs by using magnetic primers, was also reported.MBs-Based Electrochemical DNA SensorsA highly sensitive assay for rapidly screening-out Mycobacterium bovis (M. bovis) DNA in contaminated samples was also developed using electrochemical magnetogenosensing [42] .", [["samples", "ANATOMY", 356, 363], ["streptavidin-MBs", "SIMPLE_CHEMICAL", 155, 171], ["MBs", "SIMPLE_CHEMICAL", 217, 220], ["DNA", "CELLULAR_COMPONENT", 243, 246], ["Mycobacterium bovis", "ORGANISM", 305, 324], ["M. bovis", "ORGANISM", 326, 334], ["DNA", "CELLULAR_COMPONENT", 336, 339], ["Salmonella genome", "DNA", 57, 74], ["streptavidin", "PROTEIN", 155, 167], ["Mycobacterium bovis", "SPECIES", 305, 324], ["M. bovis", "SPECIES", 326, 334], ["Salmonella", "SPECIES", 57, 67], ["Mycobacterium bovis", "SPECIES", 305, 324], ["M. bovis", "SPECIES", 326, 334], ["A PCR reactor", "TEST", 0, 13], ["Salmonella genome", "PROBLEM", 57, 74], ["magnetic primers", "TEST", 181, 197], ["MBs", "TEST", 217, 220], ["Electrochemical DNA SensorsA", "TEST", 227, 255], ["rapidly screening", "TEST", 283, 300], ["Mycobacterium bovis", "PROBLEM", 305, 324], ["DNA in contaminated samples", "PROBLEM", 336, 363], ["Salmonella genome", "OBSERVATION", 57, 74]]], ["The assay consisted on specific amplification and double-tagging of the IS6110 DNA fragment, highly related to M. bovis, followed by electrochemical detection of the amplified product.", [["DNA", "CELLULAR_COMPONENT", 79, 82], ["M. bovis", "ORGANISM", 111, 119], ["IS6110 DNA fragment", "DNA", 72, 91], ["M. bovis", "SPECIES", 111, 119], ["M. bovis", "SPECIES", 111, 119], ["The assay", "TEST", 0, 9], ["specific amplification", "TREATMENT", 23, 45], ["double-tagging", "TREATMENT", 50, 64], ["the IS6110 DNA fragment", "PROBLEM", 68, 91], ["electrochemical detection", "TEST", 133, 158], ["bovis", "OBSERVATION", 114, 119]]], ["PCR amplification, carried out using a labelled set of primers, resulted in a double-tagged amplicon with both biotin and digoxigenin at each terminus.", [["biotin", "CHEMICAL", 111, 117], ["digoxigenin", "CHEMICAL", 122, 133], ["biotin", "CHEMICAL", 111, 117], ["digoxigenin", "CHEMICAL", 122, 133], ["biotin", "SIMPLE_CHEMICAL", 111, 117], ["digoxigenin", "SIMPLE_CHEMICAL", 122, 133], ["PCR amplification", "TEST", 0, 17], ["a labelled set of primers", "TREATMENT", 37, 62], ["a double-tagged amplicon", "TREATMENT", 76, 100], ["both biotin and digoxigenin at each terminus", "TREATMENT", 106, 150]]], ["The double-tagged amplicon was detected using a magnetosensor combined with streptavidinmodified MBs ( Figure 5 ).", [["double-tagged amplicon", "DNA", 4, 26], ["The double-tagged amplicon", "TREATMENT", 0, 26], ["a magnetosensor combined with streptavidinmodified MBs", "TREATMENT", 46, 100]]], ["The assay allowed the detection of 10 fmol of PCR amplicon and showed promising features for the detection of M. bovis on dairy farms by screening for the presence of the bacterial DNA in milk samples.MBs-Based Electrochemical DNA SensorsIntegration of streptavidin-coated paramagnetic microbeads modified with a biotinylated capture probe, with a commercially available microfluidic platform, resulted in a rapid and sensitive (0.2 nM detection limit) enzymelinked electrochemical genosensor used for the determination of a PCR amplified fragment of the Cor a 1.04 gene (182 bp) of hazelnut [43] .", [["milk samples", "ANATOMY", 188, 200], ["M. bovis", "ORGANISM", 110, 118], ["DNA", "CELLULAR_COMPONENT", 181, 184], ["milk samples", "ORGANISM_SUBSTANCE", 188, 200], ["MBs", "SIMPLE_CHEMICAL", 201, 204], ["DNA", "CELLULAR_COMPONENT", 227, 230], ["streptavidin", "SIMPLE_CHEMICAL", 253, 265], ["Cor", "GENE_OR_GENE_PRODUCT", 555, 558], ["PCR amplicon", "DNA", 46, 58], ["bacterial DNA", "DNA", 171, 184], ["streptavidin-coated paramagnetic microbeads", "CELL_LINE", 253, 296], ["PCR amplified fragment", "DNA", 525, 547], ["Cor a 1.04 gene", "DNA", 555, 570], ["M. bovis", "SPECIES", 110, 118], ["M. bovis", "SPECIES", 110, 118], ["The assay", "TEST", 0, 9], ["the detection", "TEST", 18, 31], ["PCR amplicon", "TEST", 46, 58], ["M. bovis", "PROBLEM", 110, 118], ["screening", "TEST", 137, 146], ["the bacterial DNA in milk samples", "PROBLEM", 167, 200], ["MBs", "TEST", 201, 204], ["Electrochemical DNA SensorsIntegration of streptavidin-coated paramagnetic microbeads", "TREATMENT", 211, 296], ["a biotinylated capture probe", "TREATMENT", 311, 339], ["a commercially available microfluidic platform", "TEST", 346, 392], ["a PCR", "TEST", 523, 528], ["bacterial DNA", "OBSERVATION", 171, 184]]], ["A gravity-driven microfluidic-based electrochemical platform using micromagnetic beads as solid support for nucleic acid detection has been recently described and applied to the detection of specific DNA sequences of Legionella pneumophila with a detection limit of 0.33 nM [44] .", [["nucleic acid", "CHEMICAL", 108, 120], ["nucleic acid", "SIMPLE_CHEMICAL", 108, 120], ["DNA", "CELLULAR_COMPONENT", 200, 203], ["Legionella pneumophila", "ORGANISM", 217, 239], ["DNA sequences", "DNA", 200, 213], ["Legionella pneumophila", "SPECIES", 217, 239], ["Legionella pneumophila", "SPECIES", 217, 239], ["A gravity", "TEST", 0, 9], ["micromagnetic beads", "TREATMENT", 67, 86], ["solid support", "TREATMENT", 90, 103], ["nucleic acid detection", "TEST", 108, 130], ["Legionella pneumophila", "PROBLEM", 217, 239], ["a detection limit", "TEST", 245, 262], ["Legionella pneumophila", "OBSERVATION", 217, 239]]], ["The developed device combined a special chip containing eight polymer microchannels with a portable, computer-controlled, instrument where both hybridization and labelling events were performed on streptavidin-coated paramagnetic microparticles functionalized with a biotinylated capture probe.MBs-Based Electrochemical DNA SensorsMBs covered with biotin-labelled oligonucleotides have recently been used to isolate viral DNA sequences of human immunodeficiency virus (HIV) and influenza virus subtype H5N1 [45] .", [["biotin", "CHEMICAL", 348, 354], ["human immunodeficiency virus (HIV) and influenza virus subtype H5N1", "DISEASE", 439, 506], ["biotin", "CHEMICAL", 348, 354], ["streptavidin", "SIMPLE_CHEMICAL", 197, 209], ["paramagnetic microparticles", "SIMPLE_CHEMICAL", 217, 244], ["MBs", "SIMPLE_CHEMICAL", 294, 297], ["biotin", "SIMPLE_CHEMICAL", 348, 354], ["DNA", "CELLULAR_COMPONENT", 422, 425], ["human immunodeficiency virus", "ORGANISM", 439, 467], ["HIV", "ORGANISM", 469, 472], ["influenza virus subtype H5N1", "ORGANISM", 478, 506], ["streptavidin-coated paramagnetic microparticles", "CELL_LINE", 197, 244], ["viral DNA sequences", "DNA", 416, 435], ["human immunodeficiency virus (HIV", "SPECIES", 439, 472], ["influenza virus subtype H5N1", "SPECIES", 478, 506], ["human immunodeficiency virus", "SPECIES", 439, 467], ["HIV", "SPECIES", 469, 472], ["device", "TREATMENT", 14, 20], ["a special chip containing eight polymer microchannels", "TREATMENT", 30, 83], ["a portable", "TEST", 89, 99], ["both hybridization and labelling events", "PROBLEM", 139, 178], ["streptavidin-coated paramagnetic microparticles", "TREATMENT", 197, 244], ["a biotinylated capture probe", "TREATMENT", 265, 293], ["MBs", "TEST", 294, 297], ["Electrochemical DNA SensorsMBs", "TREATMENT", 304, 334], ["biotin-labelled oligonucleotides", "TREATMENT", 348, 380], ["viral DNA sequences", "TEST", 416, 435], ["human immunodeficiency virus", "PROBLEM", 439, 467], ["HIV", "PROBLEM", 469, 472], ["influenza virus subtype H5N1", "PROBLEM", 478, 506]]], ["The viral nucleic acids were detected with carbon nanotubes (CNTs)-modified SPEs coupled with a micro-flow instrument.", [["nucleic acids", "CHEMICAL", 10, 23], ["carbon nanotubes", "CHEMICAL", 43, 59], ["carbon", "CHEMICAL", 43, 49], ["carbon nanotubes", "SIMPLE_CHEMICAL", 43, 59], ["The viral nucleic acids", "TEST", 0, 23], ["carbon nanotubes (CNTs", "TREATMENT", 43, 65], ["modified SPEs", "PROBLEM", 67, 80], ["a micro-flow instrument", "TREATMENT", 94, 117], ["viral", "OBSERVATION", 4, 9], ["nucleic acids", "OBSERVATION", 10, 23], ["carbon nanotubes", "OBSERVATION", 43, 59]]], ["The described system could be useful for easy-to-use and rapid detection of viral nucleic acid.MBs-Based Electrochemical DNA SensorsThe development of magnetoelectrochemical disposable DNA sensors for the detection of E. coli, based on the use of MBs and enzymatic signal amplification and the recognition of a characteristic region of the lacZ gene, was reported [46, 47] .", [["nucleic acid", "CHEMICAL", 82, 94], ["MBs", "SIMPLE_CHEMICAL", 95, 98], ["DNA", "CELLULAR_COMPONENT", 185, 188], ["E. coli", "ORGANISM", 218, 225], ["MBs", "SIMPLE_CHEMICAL", 247, 250], ["lacZ", "GENE_OR_GENE_PRODUCT", 340, 344], ["lacZ gene", "DNA", 340, 349], ["E. coli", "SPECIES", 218, 225], ["E. coli", "SPECIES", 218, 225], ["rapid detection", "TEST", 57, 72], ["viral nucleic acid", "PROBLEM", 76, 94], ["MBs", "TEST", 95, 98], ["magnetoelectrochemical disposable DNA sensors", "TREATMENT", 151, 196], ["E. coli", "PROBLEM", 218, 225], ["MBs", "TREATMENT", 247, 250], ["enzymatic signal amplification", "TREATMENT", 255, 285], ["viral nucleic acid", "OBSERVATION", 76, 94], ["E. coli", "OBSERVATION", 218, 225]]], ["326-bp amplicons were obtained by asymmetric PCR (aPCR) using genomic DNA or directly from cell cultures (daPCR) and hybridized on streptavidin-MBs modified with a specific biotinylated capture probe.", [["cell cultures", "ANATOMY", 91, 104], ["DNA", "CELLULAR_COMPONENT", 70, 73], ["cell cultures", "CELL", 91, 104], ["streptavidin-MBs", "SIMPLE_CHEMICAL", 131, 147], ["326-bp amplicons", "DNA", 0, 16], ["genomic DNA", "DNA", 62, 73], ["bp amplicons", "TEST", 4, 16], ["asymmetric PCR", "TEST", 34, 48], ["aPCR", "TEST", 50, 54], ["genomic DNA", "PROBLEM", 62, 73], ["cell cultures", "TEST", 91, 104], ["daPCR", "TEST", 106, 111], ["streptavidin-MBs", "TREATMENT", 131, 147], ["a specific biotinylated capture probe", "TREATMENT", 162, 199]]], ["After binding of a streptavidin-HRP polymer to the resultant biotinylated hybrids, the modified MBs were captured by a magnetic field on the surface of TTF-modified Au/SPEs.", [["surface", "ANATOMY", 141, 148], ["Au", "CHEMICAL", 165, 167], ["TTF", "CHEMICAL", 152, 155], ["Au", "CHEMICAL", 165, 167], ["streptavidin", "GENE_OR_GENE_PRODUCT", 19, 31], ["HRP polymer", "SIMPLE_CHEMICAL", 32, 43], ["MBs", "SIMPLE_CHEMICAL", 96, 99], ["TTF-modified Au/SPEs", "SIMPLE_CHEMICAL", 152, 172], ["resultant biotinylated hybrids", "CELL_LINE", 51, 81], ["TTF", "PROTEIN", 152, 155], ["a streptavidin-HRP polymer", "TREATMENT", 17, 43], ["the resultant biotinylated hybrids", "PROBLEM", 47, 81], ["the modified MBs", "TREATMENT", 83, 99], ["modified Au/SPEs", "TREATMENT", 156, 172], ["biotinylated hybrids", "OBSERVATION", 61, 81]]], ["A further approach involved the obtaining of the 326-bp amplicons directly from cell cultures (daPCR) achieving E. coli detection at a concentration level of 1 cfu /100 mL with no need for culture preconcentration steps.", [["cell cultures", "ANATOMY", 80, 93], ["cell cultures", "CELL", 80, 93], ["E. coli", "ORGANISM", 112, 119], ["326-bp amplicons", "DNA", 49, 65], ["cell cultures", "CELL_LINE", 80, 93], ["E. coli", "SPECIES", 112, 119], ["E. coli", "SPECIES", 112, 119], ["bp amplicons", "TEST", 53, 65], ["cell cultures", "TEST", 80, 93], ["E. coli detection", "PROBLEM", 112, 129], ["a concentration level", "TEST", 133, 154], ["culture preconcentration steps", "TREATMENT", 189, 219]]], ["These results demonstrated the usefulness of the developed sensors as screening or alarm devices indicating the possible presence of coliforms, together with their applicability to drinking water quality assurance (no coliform bacteria per 100 mL of water).", [["screening", "TEST", 70, 79], ["alarm devices", "TREATMENT", 83, 96], ["coliform bacteria", "PROBLEM", 218, 235], ["coliforms", "OBSERVATION", 133, 142]]], ["The same research group employed similar strategies in the development of DNA sensors for the detection of a characteristic 235-bp region of the gene coding for autolysin (LytA), a specific pneumococcus virulent factor [48] .", [["DNA", "CELLULAR_COMPONENT", 74, 77], ["autolysin", "GENE_OR_GENE_PRODUCT", 161, 170], ["LytA", "GENE_OR_GENE_PRODUCT", 172, 176], ["235-bp region", "DNA", 124, 137], ["autolysin", "PROTEIN", 161, 170], ["LytA", "PROTEIN", 172, 176], ["pneumococcus virulent factor", "PROTEIN", 190, 218], ["DNA sensors", "TREATMENT", 74, 85], ["the detection", "TEST", 90, 103], ["autolysin (LytA", "TEST", 161, 176], ["a specific pneumococcus virulent factor", "PROBLEM", 179, 218]]], ["The obtained results demonstrated the usefulness of the developed methodology for rapid, simple, specific, quantitative, and sensitive detection of aPCR amplicons with a detection limit of 1.1 nM.", [["aPCR amplicons", "DNA", 148, 162], ["aPCR amplicons", "PROBLEM", 148, 162], ["a detection limit", "TEST", 168, 185]]], ["Moreover, amplified daPCR products could be prepared with as few as 2 cfu from S. pneumoniae cultures, which make these devices very promising for the rapid identification of these bioagents.", [["cultures", "ANATOMY", 93, 101], ["S. pneumoniae", "ORGANISM", 79, 92], ["daPCR products", "PROTEIN", 20, 34], ["S. pneumoniae", "SPECIES", 79, 92], ["S. pneumoniae", "SPECIES", 79, 92], ["amplified daPCR products", "TREATMENT", 10, 34], ["S. pneumoniae cultures", "TEST", 79, 101], ["these devices", "TREATMENT", 114, 127], ["these bioagents", "TREATMENT", 175, 190]]], ["Under the experimental conditions employed, the assay was capable of distinguishing between S. pneumoniae and other streptococci of the mitis group also known to contain a lytA-like gene.", [["S. pneumoniae", "ORGANISM", 92, 105], ["lytA", "GENE_OR_GENE_PRODUCT", 172, 176], ["lytA-like gene", "DNA", 172, 186], ["S. pneumoniae", "SPECIES", 92, 105], ["mitis group", "SPECIES", 136, 147], ["S. pneumoniae", "SPECIES", 92, 105], ["the assay", "TEST", 44, 53], ["S. pneumoniae", "PROBLEM", 92, 105], ["other streptococci", "PROBLEM", 110, 128], ["the mitis group", "PROBLEM", 132, 147], ["a lytA", "TEST", 170, 176], ["pneumoniae", "OBSERVATION", 95, 105], ["streptococci", "OBSERVATION", 116, 128], ["mitis", "OBSERVATION", 136, 141]]], ["An electrochemical competitive aptasensor for the detection of the mycotoxin ochratoxin A (OTA) has been described.", [["ochratoxin A", "CHEMICAL", 77, 89], ["OTA", "CHEMICAL", 91, 94], ["ochratoxin A", "CHEMICAL", 77, 89], ["mycotoxin ochratoxin A", "SIMPLE_CHEMICAL", 67, 89], ["OTA", "SIMPLE_CHEMICAL", 91, 94], ["the detection", "TEST", 46, 59], ["the mycotoxin ochratoxin A (OTA", "PROBLEM", 63, 94], ["mycotoxin ochratoxin", "OBSERVATION", 67, 87]]], ["The aptasensor was based on competition between the mycotoxin conjugated to the enzyme HRP and free OTA for streptavidin-MBs functionalized with a biotinylated aptamer [49] .", [["OTA", "CHEMICAL", 100, 103], ["streptavidin-MBs", "CHEMICAL", 108, 124], ["HRP", "SIMPLE_CHEMICAL", 87, 90], ["OTA", "SIMPLE_CHEMICAL", 100, 103], ["streptavidin-MBs", "SIMPLE_CHEMICAL", 108, 124], ["enzyme HRP", "PROTEIN", 80, 90], ["the mycotoxin", "TEST", 48, 61], ["the enzyme HRP", "TEST", 76, 90], ["streptavidin", "TEST", 108, 120], ["a biotinylated aptamer", "TREATMENT", 145, 167]]], ["This magnetic aptasensor showed a detection limit of 0.07 ng mL \u00c01 and was accurately applied to extracts of certified and spiked wheat samples.", [["extracts", "ANATOMY", 97, 105], ["samples", "ANATOMY", 136, 143], ["extracts", "ORGANISM_SUBSTANCE", 97, 105], ["wheat", "SPECIES", 130, 135], ["wheat", "SPECIES", 130, 135], ["This magnetic aptasensor", "TEST", 0, 24]]], ["Table 5 summarizes the main analytical characteristics exhibited by electrochemical nucleic acid magnetosensors for the detection of bioterrorism and biohazard agents.Magnetoimmuno-PCR ApproachesThe combination of IMS, PCR, and electrochemical magnetogenosensing of the resulting amplicons allows the im- Electroanalysis 2012, 24, No. 3, 470 -482 plementation of rapid, sensitive, and selective assays for the detection of bacterial agents.TOPICAL CLUSTERSalmonella was detected using a strategy based on capturing and preconcentrating the bacteria from milk samples by IMS [50] .The bacteria attached to the MBs were then lysed by heating treatment to release the genomic DNA.", [["milk samples", "ANATOMY", 554, 566], ["MBs", "ANATOMY", 609, 612], ["nucleic acid", "CHEMICAL", 84, 96], ["milk samples", "ORGANISM_SUBSTANCE", 554, 566], ["MBs", "SIMPLE_CHEMICAL", 609, 612], ["DNA", "CELLULAR_COMPONENT", 673, 676], ["genomic DNA", "DNA", 665, 676], ["electrochemical nucleic acid magnetosensors", "TREATMENT", 68, 111], ["bioterrorism", "PROBLEM", 133, 145], ["biohazard agents", "TREATMENT", 150, 166], ["Magnetoimmuno-PCR", "TEST", 167, 184], ["IMS", "TEST", 214, 217], ["PCR", "TEST", 219, 222], ["the resulting amplicons", "PROBLEM", 266, 289], ["selective assays", "TEST", 385, 401], ["bacterial agents", "TREATMENT", 423, 439], ["TOPICAL CLUSTERSalmonella", "TREATMENT", 440, 465], ["a strategy", "TREATMENT", 485, 495], ["the bacteria", "PROBLEM", 536, 548], ["The bacteria", "PROBLEM", 580, 592], ["the MBs", "TREATMENT", 605, 612], ["heating treatment", "TREATMENT", 632, 649], ["the genomic DNA", "PROBLEM", 661, 676], ["bacterial agents", "OBSERVATION", 423, 439], ["bacteria", "OBSERVATION", 584, 592], ["genomic DNA", "OBSERVATION", 665, 676]]], ["Amplification of the genetic material with a double-tagging set of primers was performed and the am-plicons were detected by electrochemical measurement (Figure 6 ).", [["am-plicons", "DNA", 97, 107], ["a double-tagging set of primers", "TREATMENT", 43, 74], ["the am-plicons", "TEST", 93, 107]]], ["Using this approach, a detection limit of 0.04 cfu mL \u00c01 was obtained in skim milk samples preenriched for 6 h.TOPICAL CLUSTERAn electrochemical magnetoimmuno-PCR approach has been recently described for direct and highly sensitive detection of S. pneumoniae [51] .", [["milk samples", "ANATOMY", 78, 90], ["skim milk samples", "ORGANISM_SUBSTANCE", 73, 90], ["S. pneumoniae", "ORGANISM", 245, 258], ["S. pneumoniae", "SPECIES", 245, 258], ["S. pneumoniae", "SPECIES", 245, 258], ["this approach", "TREATMENT", 6, 19], ["electrochemical magnetoimmuno-PCR approach", "TREATMENT", 129, 171], ["S. pneumoniae", "PROBLEM", 245, 258], ["pneumoniae", "OBSERVATION", 248, 258]]], ["The amplified products obtained by daPCR from bacteria attached to specific capture antibody-modified MBs were detected similarly to that commented above using the electrochemical genosensor [48] .", [["daPCR", "SIMPLE_CHEMICAL", 35, 40], ["MBs", "SIMPLE_CHEMICAL", 102, 105], ["daPCR", "PROTEIN", 35, 40], ["The amplified products", "TREATMENT", 0, 22], ["bacteria", "PROBLEM", 46, 54], ["specific capture antibody", "TEST", 67, 92], ["modified MBs", "TEST", 93, 105]]], ["The developed methodology allowed an easy discrimination between only 100 cfu mL \u00c01 S. pneumoniae cultures and high concentrations (~1.0 10 8 cfu mL \u00c01 ) of other streptococci, thus demonstrating the reliability of the assay for the specific detection of low pneumococcus concentrations.Other Magnetosensor Approaches Employed in the Detection of Bioterrorism/Biohazard AgentsSome other approaches for the determination of bioterrorism/biohazard agents making use of other types of receptors and MBs have been described.", [["cultures", "ANATOMY", 98, 106], ["MBs", "SIMPLE_CHEMICAL", 496, 499], ["S. pneumoniae", "SPECIES", 84, 97], ["S. pneumoniae", "SPECIES", 84, 97], ["S. pneumoniae cultures", "TEST", 84, 106], ["high concentrations", "PROBLEM", 111, 130], ["other streptococci", "PROBLEM", 157, 175], ["the assay", "TEST", 215, 224], ["low pneumococcus concentrations", "PROBLEM", 255, 286], ["Other Magnetosensor Approaches", "TREATMENT", 287, 317], ["Bioterrorism/Biohazard Agents", "TREATMENT", 347, 376], ["bioterrorism/biohazard agents", "TREATMENT", 423, 452], ["receptors and MBs", "TREATMENT", 482, 499], ["streptococci", "OBSERVATION", 163, 175], ["low pneumococcus concentrations", "OBSERVATION", 255, 286]]], ["A method for detecting wheat germ agglutininin (WGA) based on the use of glucosamine-modified MBs and daunomycin-labelled glucose as a probe was reported [52] .", [["glucosamine", "CHEMICAL", 73, 84], ["MBs", "CHEMICAL", 94, 97], ["daunomycin", "CHEMICAL", 102, 112], ["glucose", "CHEMICAL", 122, 129], ["glucosamine", "CHEMICAL", 73, 84], ["daunomycin", "CHEMICAL", 102, 112], ["glucose", "CHEMICAL", 122, 129], ["wheat", "ORGANISM", 23, 28], ["germ agglutininin", "SIMPLE_CHEMICAL", 29, 46], ["WGA", "SIMPLE_CHEMICAL", 48, 51], ["glucosamine", "SIMPLE_CHEMICAL", 73, 84], ["MBs", "SIMPLE_CHEMICAL", 94, 97], ["daunomycin", "SIMPLE_CHEMICAL", 102, 112], ["glucose", "SIMPLE_CHEMICAL", 122, 129], ["wheat germ agglutininin", "PROTEIN", 23, 46], ["wheat", "SPECIES", 23, 28], ["wheat", "SPECIES", 23, 28], ["A method", "TEST", 0, 8], ["wheat germ agglutininin", "TREATMENT", 23, 46], ["glucosamine", "TREATMENT", 73, 84], ["modified MBs", "TREATMENT", 85, 97], ["daunomycin", "TREATMENT", 102, 112]]], ["When labelled glucose was held in the binding site of WGA to the sugar, the peak current decreased.", [["glucose", "CHEMICAL", 14, 21], ["glucose", "CHEMICAL", 14, 21], ["sugar", "CHEMICAL", 65, 70], ["glucose", "SIMPLE_CHEMICAL", 14, 21], ["WGA", "SIMPLE_CHEMICAL", 54, 57], ["sugar", "SIMPLE_CHEMICAL", 65, 70], ["labelled glucose", "TEST", 5, 21], ["the sugar", "TEST", 61, 70], ["decreased", "OBSERVATION_MODIFIER", 89, 98]]], ["Given that the binding between WGA and labelled glucose depended on the glucosamine concentration of glucosamine-modified beads, the concentration was estimated from the change in the peak current.", [["glucose", "CHEMICAL", 48, 55], ["glucosamine", "CHEMICAL", 72, 83], ["glucosamine", "CHEMICAL", 101, 112], ["glucose", "CHEMICAL", 48, 55], ["glucosamine", "CHEMICAL", 72, 83], ["glucosamine", "CHEMICAL", 101, 112], ["WGA", "SIMPLE_CHEMICAL", 31, 34], ["glucose", "SIMPLE_CHEMICAL", 48, 55], ["glucosamine", "SIMPLE_CHEMICAL", 72, 83], ["glucosamine", "SIMPLE_CHEMICAL", 101, 112], ["the binding between WGA", "PROBLEM", 11, 34], ["labelled glucose", "TEST", 39, 55], ["the glucosamine concentration", "TREATMENT", 68, 97], ["glucosamine-modified beads", "TREATMENT", 101, 127], ["the concentration", "TREATMENT", 129, 146]]], ["Other lectins not having the binding site to glucosamine or glucose did not produce any change of peak current.", [["glucosamine", "CHEMICAL", 45, 56], ["glucose", "CHEMICAL", 60, 67], ["glucosamine", "CHEMICAL", 45, 56], ["glucose", "CHEMICAL", 60, 67], ["lectins", "GENE_OR_GENE_PRODUCT", 6, 13], ["glucosamine", "SIMPLE_CHEMICAL", 45, 56], ["glucose", "SIMPLE_CHEMICAL", 60, 67], ["the binding site", "PROBLEM", 25, 41], ["glucosamine", "TREATMENT", 45, 56]]], ["Therefore, this method would be powerful for evaluation of interaction between protein and sugar chain existing at cell surface.", [["cell surface", "ANATOMY", 115, 127], ["sugar", "CHEMICAL", 91, 96], ["sugar", "SIMPLE_CHEMICAL", 91, 96], ["cell surface", "CELLULAR_COMPONENT", 115, 127], ["sugar chain", "PROTEIN", 91, 102], ["evaluation", "TEST", 45, 55], ["interaction between protein and sugar chain", "PROBLEM", 59, 102], ["sugar chain", "OBSERVATION_MODIFIER", 91, 102]]], ["An ultrasensitive method to evaluate toxicity due to pesticides in a glass lab-on-a-chip by means of enzymatic inhibition of acetylcholinesterase immobilised on MBs and amperometric detection has been developed and applied to the detection of carbofuram down to the nanomolar (sub-ppb) level [53] .ConclusionsMicro-and nano-MBs play an important role in the development of electrochemical detection methodologies for biohazard and bioterrorism agents.", [["toxicity", "DISEASE", 37, 45], ["pesticides", "CHEMICAL", 53, 63], ["carbofuram", "CHEMICAL", 243, 253], ["carbofuram", "CHEMICAL", 243, 253], ["acetylcholinesterase", "SIMPLE_CHEMICAL", 125, 145], ["MBs", "SIMPLE_CHEMICAL", 161, 164], ["carbofuram", "SIMPLE_CHEMICAL", 243, 253], ["nano-MBs", "SIMPLE_CHEMICAL", 319, 327], ["acetylcholinesterase", "PROTEIN", 125, 145], ["An ultrasensitive method", "TEST", 0, 24], ["toxicity", "PROBLEM", 37, 45], ["a glass lab", "TEST", 67, 78], ["a-chip", "TREATMENT", 82, 88], ["enzymatic inhibition of acetylcholinesterase immobilised", "PROBLEM", 101, 157], ["MBs", "TEST", 161, 164], ["amperometric detection", "TEST", 169, 191], ["carbofuram", "TREATMENT", 243, 253], ["the nanomolar", "TEST", 262, 275], ["ConclusionsMicro", "TEST", 298, 314], ["biohazard", "TREATMENT", 417, 426], ["bioterrorism agents", "TREATMENT", 431, 450]]], ["MBs-based electrochemical immunosensors have been widely employed with this purpose, making possible to analyze environmental and food samples as long as antibodies against specific bioagents are available.", [["samples", "ANATOMY", 135, 142], ["MBs", "SIMPLE_CHEMICAL", 0, 3], ["antibodies", "PROTEIN", 154, 164], ["MBs", "TEST", 0, 3], ["electrochemical immunosensors", "TEST", 10, 39]]], ["There are not so many examples on magnetic genosensors, although interesting approaches have also been developed in this field, where high sensitivities are obtained through different amplification systems, such as PCR or enzymatic signal amplification.", [["magnetic genosensors", "TEST", 34, 54], ["high sensitivities", "PROBLEM", 134, 152], ["different amplification systems", "PROBLEM", 174, 205], ["PCR", "TEST", 215, 218], ["enzymatic signal amplification", "TREATMENT", 222, 252]]], ["Sensitivity and specificity can be improved in a high extent using magnetoimmuno-PCR approaches, although very few examples have been described based on this innovative and combined new methodology.", [["Sensitivity", "TEST", 0, 11], ["magnetoimmuno-PCR approaches", "TREATMENT", 67, 95]]], ["Future prospects should be focused on the extension of these magnetobioassays to develop highly demanded easy-to-use miniaturized and multiplexed bio-platforms for the automated detection of multiple biohazard and/or bioterrorism agents on one shot.", [["the automated detection", "TEST", 164, 187], ["multiple biohazard", "TREATMENT", 191, 209], ["bioterrorism agents", "TREATMENT", 217, 236]]], ["In this regard, combination of MBs-based bioassays with microfluidic devices should facilitate implementing this kind of advanced bio-platforms for the direct decentralized detection and with a short time from sample acquisition to readout.", [["MBs", "CHEMICAL", 31, 34], ["MBs", "SIMPLE_CHEMICAL", 31, 34], ["MBs", "TEST", 31, 34], ["microfluidic devices", "TREATMENT", 56, 76], ["the direct decentralized detection", "TEST", 148, 182], ["sample acquisition", "TEST", 210, 228], ["microfluidic devices", "OBSERVATION", 56, 76]]], ["Moreover, integration of the biosensing platforms in the clothing of risk people, such as soldiers, constitutes also an exciting new field of work involving multidisciplinary strategies and economical interests.", [["people", "ORGANISM", 74, 80], ["people", "SPECIES", 74, 80], ["multidisciplinary strategies", "TREATMENT", 157, 185]]]], "fef647620a1799737eab093bf35aa444a6d68208": [["I. INTRODUCTIONM ODERN lung ventilators are equipped with a variety of support techniques that provide the clinician various ways of artificially ventilating patients.", [["lung", "ANATOMY", 23, 27], ["lung", "ORGAN", 23, 27], ["patients", "ORGANISM", 158, 166], ["patients", "SPECIES", 158, 166], ["lung ventilators", "TREATMENT", 23, 39], ["support techniques", "TREATMENT", 71, 89], ["artificially ventilating patients", "TREATMENT", 133, 166], ["lung", "ANATOMY", 23, 27], ["ventilators", "OBSERVATION", 28, 39]]], ["Mandatory minute ventilation (MMV) is one such ventilation technique that interact with the patient in such a way that the delivery of a preset minimum minute volume (inhaled volume per minute) is guaranteed.", [["patient", "ORGANISM", 92, 99], ["patient", "SPECIES", 92, 99], ["Mandatory minute ventilation", "TREATMENT", 0, 28], ["MMV", "TREATMENT", 30, 33], ["such ventilation technique", "TREATMENT", 42, 68], ["a preset minimum minute volume (inhaled volume per minute)", "TREATMENT", 135, 193]]], ["The concept of MMV appears attractive in that it provides the ability to increase or decrease the number of volume control breaths in a given time span.", [["volume control breaths", "TREATMENT", 108, 130]]], ["Thus, if the patient is apneic, an appropriate number of volume control breaths are delivered, and as the patient resumes spontaneous ventilation, the number of volume control breaths decreases gradually.", [["patient", "ORGANISM", 13, 20], ["patient", "ORGANISM", 106, 113], ["patient", "SPECIES", 13, 20], ["patient", "SPECIES", 106, 113], ["apneic", "PROBLEM", 24, 30], ["volume control breaths", "TREATMENT", 57, 79], ["spontaneous ventilation", "TREATMENT", 122, 145], ["volume control breaths", "TREATMENT", 161, 183]]], ["This support scheme provides flexibility for a patient to automatically take up the work load of breathing and for the machine to gradually wind down at the same time.I. INTRODUCTIONFor a patient ventilated in MMV, the clinician selects the level of minimum minute ventilation and this setting remains unaltered until a change is requested by the clinician.", [["patient", "ORGANISM", 47, 54], ["patient", "ORGANISM", 188, 195], ["patient", "SPECIES", 47, 54], ["patient", "SPECIES", 188, 195], ["the machine", "TREATMENT", 115, 126], ["MMV", "TREATMENT", 210, 213], ["minimum minute ventilation", "TREATMENT", 250, 276]]], ["In the event of an increase or decrease in arterial CO tension, the MMV setting may be decreased or increased respectively by the clinician to correct the disturbed arterial CO tension.", [["arterial", "ANATOMY", 43, 51], ["arterial", "ANATOMY", 165, 173], ["CO", "CHEMICAL", 52, 54], ["CO", "CHEMICAL", 174, 176], ["arterial", "MULTI-TISSUE_STRUCTURE", 43, 51], ["CO", "SIMPLE_CHEMICAL", 52, 54], ["arterial", "MULTI-TISSUE_STRUCTURE", 165, 173], ["an increase", "PROBLEM", 16, 27], ["arterial CO tension", "TREATMENT", 43, 62], ["the MMV setting", "TREATMENT", 64, 79], ["the disturbed arterial CO tension", "PROBLEM", 151, 184], ["increase", "OBSERVATION_MODIFIER", 19, 27], ["decrease", "OBSERVATION_MODIFIER", 31, 39], ["arterial", "ANATOMY", 43, 51], ["CO tension", "OBSERVATION", 52, 62], ["arterial", "ANATOMY", 165, 173], ["CO tension", "OBSERVATION", 174, 184]]], ["Regulating the MMV setting to maintain an acceptable arterial CO tension could be performed automatically.", [["arterial", "ANATOMY", 53, 61], ["CO", "CHEMICAL", 62, 64], ["arterial CO", "MULTI-TISSUE_STRUCTURE", 53, 64]]], ["This paper deals with such an automatic ventilation scheme that maintains the arterial CO tension less than a specified level determined by a clinician.", [["arterial", "ANATOMY", 78, 86], ["CO", "CHEMICAL", 87, 89], ["arterial", "MULTI-TISSUE_STRUCTURE", 78, 86], ["an automatic ventilation scheme", "TREATMENT", 27, 58], ["the arterial CO tension", "PROBLEM", 74, 97], ["arterial", "ANATOMY", 78, 86]]], ["1 A volume control breath delivers a fixed volume specified by an operator.II. RESPIRATORY DEAD SPACEDuring respiration not all inhaled air reaches the alveoli, as part of it remains in the conducting portion of the airway.", [["alveoli", "ANATOMY", 152, 159], ["airway", "ANATOMY", 216, 222], ["II", "CHEMICAL", 75, 77], ["alveoli", "MULTI-TISSUE_STRUCTURE", 152, 159], ["airway", "MULTI-TISSUE_STRUCTURE", 216, 222], ["A volume control breath", "TREATMENT", 2, 25], ["RESPIRATORY DEAD SPACEDuring respiration", "PROBLEM", 79, 119], ["DEAD SPACEDuring", "OBSERVATION", 91, 107], ["all", "OBSERVATION_MODIFIER", 124, 127], ["inhaled", "OBSERVATION_MODIFIER", 128, 135], ["air", "OBSERVATION", 136, 139], ["alveoli", "ANATOMY", 152, 159], ["airway", "ANATOMY", 216, 222]]], ["The region of the respiratory system where gas exchange does not take place is termed the respiratory dead space.", [["respiratory system", "ANATOMY", 18, 36], ["respiratory", "ANATOMY", 90, 101], ["gas exchange", "PROBLEM", 43, 55], ["the respiratory dead space", "PROBLEM", 86, 112], ["region", "ANATOMY_MODIFIER", 4, 10], ["respiratory system", "ANATOMY", 18, 36], ["gas exchange", "OBSERVATION", 43, 55], ["respiratory", "OBSERVATION", 90, 101], ["dead space", "OBSERVATION", 102, 112]]], ["By examining the CO content of the exhaled air, Bohr formulated the following relationship [1] : (1) where is the dead space, is the tidal volume (i.e., volume inhaled per breath), is the arterial CO tension, and is the average CO tension in exhaled air.", [["arterial", "ANATOMY", 188, 196], ["CO", "CHEMICAL", 17, 19], ["CO", "CHEMICAL", 197, 199], ["CO", "CHEMICAL", 228, 230], ["CO", "SIMPLE_CHEMICAL", 17, 19], ["arterial", "MULTI-TISSUE_STRUCTURE", 188, 196], ["CO", "SIMPLE_CHEMICAL", 197, 199], ["CO", "SIMPLE_CHEMICAL", 228, 230], ["the dead space", "PROBLEM", 110, 124], ["the tidal volume", "TEST", 129, 145], ["the arterial CO tension", "PROBLEM", 184, 207], ["the average CO tension in exhaled air", "PROBLEM", 216, 253], ["exhaled air", "OBSERVATION", 35, 46], ["arterial", "ANATOMY", 188, 196], ["tension", "OBSERVATION", 200, 207], ["tension", "OBSERVATION_MODIFIER", 231, 238], ["exhaled air", "OBSERVATION", 242, 253]]], ["A typical trace of exhaled CO tension against exhaled volume (i.e., SBT-CO plot 2 ) consists of three phases [1] : phase 1 comprising the CO -free gas from the airways, phase 2 a transition phase characterized by a S-shaped up-swing in the tracing representing the washout of airway with alveolar gas, and phase 3 comprising CO -bearing gas from the alveoli (see Fig. 1 ).", [["airways", "ANATOMY", 160, 167], ["airway", "ANATOMY", 276, 282], ["alveolar", "ANATOMY", 288, 296], ["alveoli", "ANATOMY", 350, 357], ["CO", "CHEMICAL", 27, 29], ["CO", "CHEMICAL", 72, 74], ["CO", "CHEMICAL", 138, 140], ["CO", "CHEMICAL", 325, 327], ["CO", "SIMPLE_CHEMICAL", 27, 29], ["CO", "SIMPLE_CHEMICAL", 138, 140], ["airways", "MULTI-TISSUE_STRUCTURE", 160, 167], ["airway", "MULTI-TISSUE_STRUCTURE", 276, 282], ["alveolar", "MULTI-TISSUE_STRUCTURE", 288, 296], ["CO", "SIMPLE_CHEMICAL", 325, 327], ["alveoli", "MULTI-TISSUE_STRUCTURE", 350, 357], ["exhaled CO tension", "PROBLEM", 19, 37], ["exhaled volume", "TEST", 46, 60], ["SBT", "TEST", 68, 71], ["CO plot", "TEST", 72, 79], ["the CO", "TEST", 134, 140], ["a S", "TEST", 213, 216], ["the tracing", "TEST", 236, 247], ["the washout of airway", "PROBLEM", 261, 282], ["alveolar gas", "TEST", 288, 300], ["CO -bearing gas", "TEST", 325, 340], ["trace", "OBSERVATION_MODIFIER", 10, 15], ["exhaled CO tension", "OBSERVATION", 19, 37], ["free gas", "OBSERVATION", 142, 150], ["airways", "ANATOMY", 160, 167], ["washout", "OBSERVATION", 265, 272], ["airway", "ANATOMY", 276, 282], ["alveolar gas", "OBSERVATION", 288, 300], ["alveoli", "ANATOMY", 350, 357]]], ["The initial volume of expirate which includes the volume of fresh air down to the alveolar/fresh air interface represents the airway dead space.", [["alveolar", "ANATOMY", 82, 90], ["airway", "ANATOMY", 126, 132], ["alveolar", "MULTI-TISSUE_STRUCTURE", 82, 90], ["airway", "PATHOLOGICAL_FORMATION", 126, 132], ["fresh air", "PROBLEM", 60, 69], ["the alveolar/fresh air interface", "PROBLEM", 78, 110], ["the airway dead space", "PROBLEM", 122, 143], ["volume", "OBSERVATION_MODIFIER", 12, 18], ["volume", "OBSERVATION_MODIFIER", 50, 56], ["fresh air", "OBSERVATION", 60, 69], ["alveolar", "ANATOMY_MODIFIER", 82, 90], ["fresh", "OBSERVATION", 91, 96], ["air interface", "OBSERVATION", 97, 110], ["airway", "ANATOMY", 126, 132], ["dead space", "OBSERVATION", 133, 143]]], ["Airway dead space is, therefore, defined as the volume of air that does not reach the sites of gas exchange (i.e., alveolus).", [["Airway", "ANATOMY", 0, 6], ["sites", "ANATOMY", 86, 91], ["alveolus", "ANATOMY", 115, 123], ["Airway", "MULTI-TISSUE_STRUCTURE", 0, 6], ["alveolus", "ORGAN", 115, 123], ["Airway dead space", "PROBLEM", 0, 17], ["gas exchange", "TEST", 95, 107], ["dead space", "OBSERVATION", 7, 17], ["air", "OBSERVATION", 58, 61], ["gas exchange", "OBSERVATION", 95, 107], ["alveolus", "ANATOMY", 115, 123]]], ["On the SBT-CO plot this corresponds to an exhaled volume in phase 2.", [["CO", "CHEMICAL", 11, 13], ["the SBT", "TEST", 3, 10], ["CO plot", "TEST", 11, 18], ["an exhaled volume in phase", "TEST", 39, 65], ["exhaled volume", "OBSERVATION", 42, 56]]], ["The exact location of this position on the SBT-CO plot is reported in [2] and [3] , and here it is taken as the exhaled volume corresponding to the point of inflection on the SBT-CO curve.", [["CO", "CHEMICAL", 47, 49], ["CO", "CHEMICAL", 179, 181], ["the SBT", "TEST", 39, 46], ["CO plot", "TEST", 47, 54], ["the exhaled volume", "TEST", 108, 126], ["the SBT", "TEST", 171, 178], ["CO curve", "TEST", 179, 187]]], ["Alveolar tidal volume is the part of inhaled volume that reach the alveoli (2) where is alveolar tidal volume and is airway dead space.", [["Alveolar", "ANATOMY", 0, 8], ["alveoli", "ANATOMY", 67, 74], ["alveolar", "ANATOMY", 88, 96], ["airway", "ANATOMY", 117, 123], ["Alveolar tidal", "MULTI-TISSUE_STRUCTURE", 0, 14], ["alveoli", "MULTI-TISSUE_STRUCTURE", 67, 74], ["alveolar tidal", "MULTI-TISSUE_STRUCTURE", 88, 102], ["Alveolar tidal volume", "TEST", 0, 21], ["inhaled volume", "TEST", 37, 51], ["alveolar tidal volume", "TEST", 88, 109], ["airway dead space", "PROBLEM", 117, 134], ["tidal volume", "OBSERVATION", 9, 21], ["alveoli", "ANATOMY", 67, 74], ["alveolar", "OBSERVATION", 88, 96], ["tidal volume", "OBSERVATION", 97, 109], ["airway", "ANATOMY", 117, 123], ["dead space", "OBSERVATION", 124, 134]]], ["However, not all inhaled air that reaches the gas exchanging zone takes part in the mixing process.", [["air", "OBSERVATION", 25, 28], ["gas", "OBSERVATION", 46, 49], ["zone", "OBSERVATION_MODIFIER", 61, 65], ["mixing process", "OBSERVATION", 84, 98]]], ["This fractional volume in alveoli that does not contribute to gas exchange is termed alveolar dead space.", [["alveoli", "ANATOMY", 26, 33], ["alveolar", "ANATOMY", 85, 93], ["alveoli", "MULTI-TISSUE_STRUCTURE", 26, 33], ["This fractional volume in alveoli", "PROBLEM", 0, 33], ["gas exchange", "PROBLEM", 62, 74], ["alveolar dead space", "PROBLEM", 85, 104], ["fractional volume", "OBSERVATION", 5, 22], ["alveoli", "ANATOMY_MODIFIER", 26, 33], ["does not contribute to", "UNCERTAINTY", 39, 61], ["gas exchange", "OBSERVATION", 62, 74], ["alveolar dead space", "OBSERVATION", 85, 104]]], ["Combination of alveolar dead space and airway dead space defines the total dead space of the respiratory system (3) where is alveolar dead space.", [["alveolar dead space", "ANATOMY", 15, 34], ["airway", "ANATOMY", 39, 45], ["respiratory system", "ANATOMY", 93, 111], ["alveolar", "ANATOMY", 125, 133], ["alveolar", "MULTI-TISSUE_STRUCTURE", 15, 23], ["airway", "MULTI-TISSUE_STRUCTURE", 39, 45], ["alveolar dead space", "PROBLEM", 15, 34], ["airway dead space", "PROBLEM", 39, 56], ["alveolar dead space", "PROBLEM", 125, 144], ["alveolar", "ANATOMY_MODIFIER", 15, 23], ["dead space", "OBSERVATION", 24, 34], ["airway", "ANATOMY", 39, 45], ["dead space", "OBSERVATION", 46, 56], ["total", "OBSERVATION_MODIFIER", 69, 74], ["dead space", "OBSERVATION", 75, 85], ["respiratory system", "ANATOMY", 93, 111], ["alveolar", "ANATOMY_MODIFIER", 125, 133], ["dead space", "OBSERVATION", 134, 144]]], ["The effective alveolar ventilation is the difference between alveolar tidal volume and alveolar dead space (4) where is the effective alveolar ventilation.", [["alveolar", "ANATOMY", 14, 22], ["alveolar", "ANATOMY", 61, 69], ["alveolar", "ANATOMY", 87, 95], ["alveolar", "ANATOMY", 134, 142], ["alveolar", "MULTI-TISSUE_STRUCTURE", 14, 22], ["alveolar tidal", "MULTI-TISSUE_STRUCTURE", 61, 75], ["alveolar", "MULTI-TISSUE_STRUCTURE", 134, 142], ["The effective alveolar ventilation", "TREATMENT", 0, 34], ["alveolar tidal volume", "TEST", 61, 82], ["alveolar dead space", "PROBLEM", 87, 106], ["the effective alveolar ventilation", "TREATMENT", 120, 154], ["effective", "OBSERVATION_MODIFIER", 4, 13], ["alveolar ventilation", "OBSERVATION", 14, 34], ["alveolar", "ANATOMY_MODIFIER", 61, 69], ["tidal volume", "OBSERVATION", 70, 82], ["alveolar", "ANATOMY_MODIFIER", 87, 95], ["dead space", "OBSERVATION", 96, 106], ["effective", "OBSERVATION_MODIFIER", 124, 133], ["alveolar ventilation", "OBSERVATION", 134, 154]]], ["The alveolar dead space can be related to areas of SBT-CO plot (see Fig. 2 ).", [["alveolar", "ANATOMY", 4, 12], ["CO", "CHEMICAL", 55, 57], ["The alveolar dead space", "PROBLEM", 0, 23], ["SBT", "TEST", 51, 54], ["CO plot", "TEST", 55, 62], ["alveolar", "ANATOMY_MODIFIER", 4, 12], ["dead space", "OBSERVATION", 13, 23]]], ["In Fig. 2 , the dashed vertical line falls through the point of inflection of the SBT-CO curve.", [["CO", "CHEMICAL", 86, 88], ["vertical line", "CELL", 23, 36], ["the dashed vertical line falls", "TREATMENT", 12, 42], ["the SBT", "TEST", 78, 85], ["CO curve", "TEST", 86, 94], ["vertical line", "OBSERVATION", 23, 36]]], ["The areas and represents the following.II. RESPIRATORY DEAD SPACEArea-Efficient part of ventilation.II. RESPIRATORY DEAD SPACEArea-A defect in CO elimination that represents wasted ventilation due to alveolar dead space.II. RESPIRATORY DEAD SPACEArea-A defect in CO elimination that represents wasted ventilation due to airway dead space.II. RESPIRATORY DEAD SPACEThe alveolar dead space can be defined using Area-and Area- [1] , [4] Area-Area-Area-II.", [["alveolar", "ANATOMY", 200, 208], ["airway", "ANATOMY", 320, 326], ["alveolar", "ANATOMY", 368, 376], ["II", "CHEMICAL", 39, 41], ["II", "CHEMICAL", 100, 102], ["II", "CHEMICAL", 220, 222], ["II", "CHEMICAL", 338, 340], ["CO", "CHEMICAL", 143, 145], ["CO", "CHEMICAL", 263, 265], ["CO", "SIMPLE_CHEMICAL", 143, 145], ["alveolar", "MULTI-TISSUE_STRUCTURE", 200, 208], ["CO", "SIMPLE_CHEMICAL", 263, 265], ["[4] Area-Area-Area-II", "SIMPLE_CHEMICAL", 430, 451], ["RESPIRATORY DEAD SPACEArea", "PROBLEM", 43, 69], ["ventilation", "TREATMENT", 88, 99], ["RESPIRATORY DEAD SPACEArea", "PROBLEM", 104, 130], ["A defect in CO elimination", "PROBLEM", 131, 157], ["wasted ventilation", "TREATMENT", 174, 192], ["alveolar dead space", "PROBLEM", 200, 219], ["RESPIRATORY DEAD SPACEArea", "PROBLEM", 224, 250], ["A defect in CO elimination", "PROBLEM", 251, 277], ["wasted ventilation", "TREATMENT", 294, 312], ["airway dead space", "PROBLEM", 320, 337], ["RESPIRATORY DEAD SPACEThe alveolar dead space", "PROBLEM", 342, 387], ["DEAD SPACEArea", "OBSERVATION", 55, 69], ["DEAD SPACEArea", "OBSERVATION", 116, 130], ["defect", "OBSERVATION", 133, 139], ["CO elimination", "OBSERVATION", 143, 157], ["wasted ventilation", "OBSERVATION", 174, 192], ["alveolar", "ANATOMY_MODIFIER", 200, 208], ["dead space", "OBSERVATION", 209, 219], ["DEAD SPACEArea", "OBSERVATION", 236, 250], ["defect", "OBSERVATION", 253, 259], ["CO elimination", "OBSERVATION", 263, 277], ["wasted ventilation", "OBSERVATION", 294, 312], ["airway", "ANATOMY", 320, 326], ["dead space", "OBSERVATION", 327, 337], ["alveolar", "ANATOMY_MODIFIER", 368, 376], ["dead space", "OBSERVATION", 377, 387]]], ["RESPIRATORY DEAD SPACERefer to the Appendix for a clinical trial on the measurement of airway deadspace and alveolar deadspace of a mechanically ventilated patient in the Intensive Care Unit (ICU) at the Royal Melbourne Hospital (RMH).III. ARTERIAL CO TENSION ESTIMATIONThis section describes two algorithms [5] that can estimate arterial CO tension of mechanically ventilated patients.", [["airway", "ANATOMY", 87, 93], ["alveolar", "ANATOMY", 108, 116], ["arterial", "ANATOMY", 330, 338], ["CO", "CHEMICAL", 339, 341], ["airway deadspace", "MULTI-TISSUE_STRUCTURE", 87, 103], ["alveolar", "MULTI-TISSUE_STRUCTURE", 108, 116], ["patient", "ORGANISM", 156, 163], ["arterial CO", "MULTI-TISSUE_STRUCTURE", 330, 341], ["patients", "ORGANISM", 377, 385], ["patient", "SPECIES", 156, 163], ["patients", "SPECIES", 377, 385], ["airway deadspace", "TREATMENT", 87, 103], ["a mechanically ventilated", "TREATMENT", 130, 155], ["ARTERIAL CO TENSION ESTIMATIONThis section", "TREATMENT", 240, 282], ["DEAD SPACERefer", "OBSERVATION", 12, 27], ["Appendix", "ANATOMY", 35, 43], ["airway", "ANATOMY", 87, 93], ["alveolar deadspace", "OBSERVATION", 108, 126], ["mechanically ventilated", "OBSERVATION", 132, 155], ["TENSION", "OBSERVATION", 252, 259], ["arterial", "ANATOMY", 330, 338], ["tension", "OBSERVATION_MODIFIER", 342, 349], ["mechanically ventilated", "OBSERVATION", 353, 376]]], ["The continuous estimation of arterial CO tension is based on instantaneous, correlated measurements of ventilatory flow, airway pressure, and CO tension of exhaled air measured by a capnograph.", [["arterial", "ANATOMY", 29, 37], ["airway", "ANATOMY", 121, 127], ["CO", "CHEMICAL", 38, 40], ["CO", "CHEMICAL", 142, 144], ["arterial", "MULTI-TISSUE_STRUCTURE", 29, 37], ["CO", "MULTI-TISSUE_STRUCTURE", 38, 40], ["airway", "MULTI-TISSUE_STRUCTURE", 121, 127], ["CO", "SIMPLE_CHEMICAL", 142, 144], ["arterial CO tension", "TREATMENT", 29, 48], ["ventilatory flow", "TEST", 103, 119], ["airway pressure", "TEST", 121, 136], ["CO tension of exhaled air", "PROBLEM", 142, 167], ["arterial", "ANATOMY", 29, 37], ["tension", "OBSERVATION", 41, 48], ["ventilatory flow", "OBSERVATION", 103, 119], ["airway pressure", "OBSERVATION", 121, 136], ["tension", "OBSERVATION_MODIFIER", 145, 152], ["exhaled air", "OBSERVATION", 156, 167]]], ["Although end tidal CO tension may approximately follow the variations in arterial CO tension, various studies have shown that utilization of end tidal CO as a noninvasive monitoring substitute for trends in arterial CO tension in critically ill patients may be misleading [6] , [7] .", [["arterial", "ANATOMY", 73, 81], ["arterial", "ANATOMY", 207, 215], ["critically ill", "DISEASE", 230, 244], ["CO", "CHEMICAL", 19, 21], ["CO", "CHEMICAL", 82, 84], ["CO", "CHEMICAL", 151, 153], ["CO", "CHEMICAL", 216, 218], ["arterial", "MULTI-TISSUE_STRUCTURE", 73, 81], ["arterial", "MULTI-TISSUE_STRUCTURE", 207, 215], ["patients", "ORGANISM", 245, 253], ["patients", "SPECIES", 245, 253], ["end tidal CO tension", "PROBLEM", 9, 29], ["arterial CO tension", "TEST", 73, 92], ["various studies", "TEST", 94, 109], ["end tidal CO", "TREATMENT", 141, 153], ["a noninvasive monitoring", "TEST", 157, 181], ["arterial CO tension", "TREATMENT", 207, 226], ["tension", "OBSERVATION", 22, 29], ["arterial", "ANATOMY", 73, 81]]], ["The algorithms described here are based on the efficiency of gas mixing in the lung as oppose to an algorithm based on end tidal CO tension.", [["lung", "ANATOMY", 79, 83], ["CO", "CHEMICAL", 129, 131], ["lung", "ORGAN", 79, 83], ["gas mixing in the lung", "PROBLEM", 61, 83], ["an algorithm", "TEST", 97, 109], ["end tidal CO tension", "PROBLEM", 119, 139], ["gas mixing", "OBSERVATION", 61, 71], ["lung", "ANATOMY", 79, 83], ["tension", "OBSERVATION_MODIFIER", 132, 139]]], ["The efficiency of gas exchange may be defined using Bohr's equation efficiency (6) where is the dead space, is the tidal volume, is the arterial CO tension, and is the average CO tension of exhaled air.", [["arterial", "ANATOMY", 136, 144], ["CO", "CHEMICAL", 145, 147], ["CO", "CHEMICAL", 176, 178], ["arterial", "MULTI-TISSUE_STRUCTURE", 136, 144], ["CO", "SIMPLE_CHEMICAL", 145, 147], ["CO", "SIMPLE_CHEMICAL", 176, 178], ["gas exchange", "PROBLEM", 18, 30], ["Bohr's equation efficiency", "TREATMENT", 52, 78], ["the dead space", "PROBLEM", 92, 106], ["the tidal volume", "TEST", 111, 127], ["the arterial CO tension", "PROBLEM", 132, 155], ["the average CO tension of exhaled air", "PROBLEM", 164, 201], ["gas exchange", "OBSERVATION", 18, 30], ["dead space", "OBSERVATION", 96, 106], ["tidal volume", "OBSERVATION", 115, 127], ["arterial", "ANATOMY", 136, 144], ["tension", "OBSERVATION_MODIFIER", 148, 155], ["tension", "OBSERVATION_MODIFIER", 179, 186], ["exhaled air", "OBSERVATION", 190, 201]]], ["The term represents how well the inhaled tidal volume is used in the lungs for the purpose of gas exchange, and hence the term may be referred to as the efficiency of gas mixing efficiency (7) Experiments carried out on human subjects [5] , [8] have found that the efficiency of gas mixing stays relatively constant for various levels of ventilation.", [["lungs", "ANATOMY", 69, 74], ["lungs", "ORGAN", 69, 74], ["human", "ORGANISM", 220, 225], ["human", "SPECIES", 220, 225], ["human", "SPECIES", 220, 225], ["the inhaled tidal volume", "TREATMENT", 29, 53], ["gas exchange", "TREATMENT", 94, 106], ["gas mixing efficiency", "PROBLEM", 167, 188], ["gas mixing", "PROBLEM", 279, 289], ["ventilation", "TREATMENT", 338, 349], ["lungs", "ANATOMY", 69, 74], ["gas", "OBSERVATION", 279, 282]]], ["Hence, if the efficiency of gas mixing is calculated upon performing a blood test and assumed constant in an individual patient for subsequent breaths following the blood test, the only unknown in (7) is the blood CO tension, provided that the average partial pressure of CO in exhaled air is known.", [["blood", "ANATOMY", 71, 76], ["blood", "ANATOMY", 165, 170], ["blood", "ANATOMY", 208, 213], ["CO", "CHEMICAL", 214, 216], ["CO", "CHEMICAL", 272, 274], ["blood", "ORGANISM_SUBSTANCE", 71, 76], ["patient", "ORGANISM", 120, 127], ["blood", "ORGANISM_SUBSTANCE", 165, 170], ["blood", "ORGANISM_SUBSTANCE", 208, 213], ["CO", "SIMPLE_CHEMICAL", 214, 216], ["CO", "SIMPLE_CHEMICAL", 272, 274], ["patient", "SPECIES", 120, 127], ["gas mixing", "PROBLEM", 28, 38], ["a blood test", "TEST", 69, 81], ["the blood test", "TEST", 161, 175], ["the blood CO tension", "PROBLEM", 204, 224], ["pressure", "OBSERVATION_MODIFIER", 260, 268], ["exhaled air", "OBSERVATION", 278, 289]]], ["ARTERIAL CO TENSION ESTIMATIONis the partial pressure of CO in exhaled air, is mouth pressure, is the flow, is the tidal volume, is the exhalation time, is the barometric pressure, and is the saturated water vapor pressure.", [["mouth", "ANATOMY", 79, 84], ["CO", "CHEMICAL", 57, 59], ["CO", "SIMPLE_CHEMICAL", 57, 59], ["mouth", "ORGANISM_SUBDIVISION", 79, 84], ["ARTERIAL CO TENSION", "TEST", 0, 19], ["mouth pressure", "TEST", 79, 93], ["the tidal volume", "TEST", 111, 127], ["the barometric pressure", "TEST", 156, 179], ["the saturated water vapor pressure", "TREATMENT", 188, 222], ["TENSION", "OBSERVATION", 12, 19], ["partial", "OBSERVATION_MODIFIER", 37, 44], ["pressure", "OBSERVATION_MODIFIER", 45, 53], ["exhaled air", "OBSERVATION", 63, 74], ["mouth pressure", "OBSERVATION", 79, 93], ["flow", "OBSERVATION", 102, 106], ["tidal volume", "OBSERVATION", 115, 127], ["barometric pressure", "OBSERVATION", 160, 179]]], ["It should be noted that the accuracy of estimation can be affected by possible variations in efficiency of gas mixing that may occur.", [["gas mixing", "PROBLEM", 107, 117], ["gas mixing", "OBSERVATION", 107, 117]]], ["The problem of changes in efficiency can be overcome by incorporating a monitoring module to detect such changes and to request the operator to perform a new blood test to calculate the new efficiency of gas mixing thereby improving the accuracy of CO estimation.", [["blood", "ANATOMY", 158, 163], ["CO", "CHEMICAL", 249, 251], ["blood", "ORGANISM_SUBSTANCE", 158, 163], ["CO", "SIMPLE_CHEMICAL", 249, 251], ["a monitoring module", "TEST", 70, 89], ["a new blood test", "TEST", 152, 168], ["gas mixing", "PROBLEM", 204, 214], ["CO estimation", "TEST", 249, 262], ["gas mixing", "OBSERVATION", 204, 214]]], ["The efficiency of gas mixing is considered to change if any of the following events occur three times.III. ARTERIAL CO TENSION ESTIMATION\u2022 If minute volume increases by 800 ml/min or more and endtidal CO tension 3 does not drop by at least 2 mmHg. \u2022 If minute volume decreases by 800 ml/min or more and endtidal CO tension does not increase by at least 2 mmHg. \u2022 If minute volume increases by 800 ml/min or more and estimated CO tension does not drop by at least 2 mmHg. \u2022 If minute volume decreases by 800 ml/min or more and estimated CO tension does not increase by at least 2 mmHg. \u2022 If inspiratory time changes by more than 0.5 s. \u2022 If peak airway pressure changes more than 10 cm H O.III. ARTERIAL CO TENSION ESTIMATION\u2022 If previous PEEP 4 is less than 10 cm H O and changes by more than 5 cm H O. \u2022 If previous PEEP is greater than or equal to 10 cm H O and changes by more than 2 cm H O. Equations (7) and (8) together with a monitoring module for detecting changes in efficiency of gas mixing provide a framework for estimating arterial CO tension.", [["airway", "ANATOMY", 645, 651], ["arterial", "ANATOMY", 1036, 1044], ["CO", "CHEMICAL", 201, 203], ["CO", "CHEMICAL", 312, 314], ["CO", "CHEMICAL", 426, 428], ["CO", "CHEMICAL", 536, 538], ["H O", "CHEMICAL", 764, 767], ["H O", "CHEMICAL", 856, 859], ["CO", "CHEMICAL", 1045, 1047], ["CO", "SIMPLE_CHEMICAL", 312, 314], ["CO", "SIMPLE_CHEMICAL", 426, 428], ["CO", "SIMPLE_CHEMICAL", 536, 538], ["airway", "MULTI-TISSUE_STRUCTURE", 645, 651], ["arterial", "MULTI-TISSUE_STRUCTURE", 1036, 1044], ["gas mixing", "PROBLEM", 18, 28], ["ARTERIAL CO TENSION ESTIMATION", "TEST", 107, 137], ["minute volume", "TEST", 142, 155], ["endtidal CO tension", "TEST", 192, 211], ["endtidal CO tension", "TEST", 303, 322], ["minute volume", "TEST", 366, 379], ["estimated CO tension", "TEST", 416, 436], ["minute volume", "PROBLEM", 476, 489], ["estimated CO tension", "TEST", 526, 546], ["peak airway pressure changes", "PROBLEM", 640, 668], ["ARTERIAL CO TENSION ESTIMATION", "TEST", 694, 724], ["previous PEEP", "TREATMENT", 729, 742], ["previous PEEP", "TEST", 808, 821], ["Equations", "TEST", 895, 904], ["a monitoring module", "TEST", 931, 950], ["gas mixing", "TREATMENT", 990, 1000], ["estimating arterial CO tension", "PROBLEM", 1025, 1055], ["efficiency", "OBSERVATION_MODIFIER", 4, 14], ["gas mixing", "OBSERVATION", 18, 28], ["TENSION", "OBSERVATION", 119, 126], ["volume", "OBSERVATION_MODIFIER", 260, 266], ["decreases", "OBSERVATION_MODIFIER", 267, 276], ["tension", "OBSERVATION", 315, 322], ["volume", "OBSERVATION_MODIFIER", 483, 489], ["decreases", "OBSERVATION_MODIFIER", 490, 499], ["tension", "OBSERVATION", 539, 546], ["airway", "ANATOMY", 645, 651], ["pressure", "OBSERVATION", 652, 660], ["TENSION", "OBSERVATION", 706, 713], ["greater", "OBSERVATION_MODIFIER", 825, 832], ["10 cm", "OBSERVATION_MODIFIER", 850, 855], ["tension", "OBSERVATION", 1048, 1055]]], ["Algorithm 1 outlines a technique for estimating arterial CO tension.Algorithm 1Step one: Based on initial simultaneous and SBT-CO trace Do a blood test and measure Use (8) Step three: Applicable to measurement inAlgorithm 1Step twoAlgorithm 1Has the efficiency changed?", [["arterial", "ANATOMY", 48, 56], ["blood", "ANATOMY", 141, 146], ["CO", "CHEMICAL", 57, 59], ["arterial", "MULTI-TISSUE_STRUCTURE", 48, 56], ["blood", "ORGANISM_SUBSTANCE", 141, 146], ["a technique", "TREATMENT", 21, 32], ["estimating arterial CO tension", "PROBLEM", 37, 67], ["SBT", "TEST", 123, 126], ["a blood test", "TEST", 139, 151], ["arterial", "ANATOMY", 48, 56], ["tension", "OBSERVATION", 60, 67]]], ["Yes: Go to step one No: Go to step two Efficiency of gas mixing can also be defined using the areas of SBT-CO curve [9] EfficiencyAlgorithm 1Area-Area-Area-Algorithm 13 End-tidal CO tension is the partial pressure of CO in a sample of exhaled air taken at the end of exhalation.", [["CO", "CHEMICAL", 107, 109], ["CO", "CHEMICAL", 179, 181], ["CO", "CHEMICAL", 217, 219], ["CO", "SIMPLE_CHEMICAL", 217, 219], ["gas mixing", "TREATMENT", 53, 63], ["SBT", "TEST", 103, 106], ["CO curve", "TEST", 107, 115], ["Algorithm", "TEST", 130, 139], ["Area-Area-Algorithm", "TEST", 146, 165], ["End-tidal CO tension", "TEST", 169, 189], ["the partial pressure of CO", "PROBLEM", 193, 219], ["exhaled air", "PROBLEM", 235, 246], ["partial", "OBSERVATION_MODIFIER", 197, 204], ["pressure", "OBSERVATION_MODIFIER", 205, 213], ["exhaled air", "OBSERVATION", 235, 246]]], ["4 PEEP stands for positive end expiratory pressure.Algorithm 1The algorithm proposed by [5] for CO estimation is based on the efficiency expression derived by Fletcher.", [["CO", "CHEMICAL", 96, 98], ["4 PEEP", "TREATMENT", 0, 6], ["positive end expiratory pressure", "TEST", 18, 50], ["CO estimation", "TEST", 96, 109], ["expiratory pressure", "OBSERVATION", 31, 50]]], ["The method of estimation is shown in Algorithm 2.Algorithm 2Step one: Based on initial simultaneous and SBT-CO trace Step three: Applicable to measurement inAlgorithm 2Step twoAlgorithm 2Has the efficiency changed?", [["CO", "CHEMICAL", 108, 110], ["SBT", "TEST", 104, 107], ["inAlgorithm", "TEST", 155, 166]]], ["Yes: Go to step one No: Go to step twoAlgorithm 2It should be noted that the efficiency expression resulting from Fletcher's equation includes only alveolar dead space and alveolar tidal volume as opposed to total dead space and total tidal volume incorporated in the efficiency expression resulting from Bohr's equation.", [["alveolar", "ANATOMY", 148, 156], ["alveolar", "ANATOMY", 172, 180], ["alveolar", "MULTI-TISSUE_STRUCTURE", 148, 156], ["alveolar tidal", "MULTI-TISSUE_STRUCTURE", 172, 186], ["Fletcher's equation", "TEST", 114, 133], ["alveolar dead space", "PROBLEM", 148, 167], ["alveolar tidal volume", "PROBLEM", 172, 193], ["total dead space", "PROBLEM", 208, 224], ["total tidal volume", "TREATMENT", 229, 247], ["Bohr's equation", "TEST", 305, 320], ["alveolar", "ANATOMY_MODIFIER", 148, 156], ["alveolar", "OBSERVATION", 172, 180], ["tidal volume", "OBSERVATION", 181, 193], ["total", "OBSERVATION_MODIFIER", 229, 234], ["tidal volume", "OBSERVATION", 235, 247], ["efficiency expression", "OBSERVATION", 268, 289]]], ["It has been reported that efficiency defined by Fletcher's equation is less sensitive to changes in ventilation than the efficiency defined using Bohr's equation [5] .", [["Fletcher's equation", "TEST", 48, 67], ["changes in ventilation", "TREATMENT", 89, 111], ["Bohr's equation", "TREATMENT", 146, 161], ["efficiency", "OBSERVATION_MODIFIER", 26, 36]]], ["Hence, it may be expected that incorporating the efficiency expression derived using Fletcher's equation for arterial CO estimation produces more accurate readings of arterial CO than incorporating the efficiency expression derived using Bohr's equation.", [["arterial", "ANATOMY", 109, 117], ["arterial", "ANATOMY", 167, 175], ["CO", "CHEMICAL", 118, 120], ["CO", "CHEMICAL", 176, 178], ["arterial", "MULTI-TISSUE_STRUCTURE", 109, 117], ["arterial", "MULTI-TISSUE_STRUCTURE", 167, 175], ["Fletcher's equation", "TEST", 85, 104], ["arterial CO estimation", "TEST", 109, 131], ["arterial CO", "TEST", 167, 178], ["Bohr's equation", "TEST", 238, 253], ["arterial", "ANATOMY", 167, 175]]], ["The algorithm implemented by [5] claims an accuracy of 4 mmHg.IV. CONTROL OF BY REGULATINGThe level of arterial CO tension is dependent on the CO production in cells and the magnitude of effective alveolar ventilation.", [["arterial", "ANATOMY", 103, 111], ["cells", "ANATOMY", 160, 165], ["alveolar", "ANATOMY", 197, 205], ["CO", "CHEMICAL", 112, 114], ["CO", "CHEMICAL", 143, 145], ["arterial", "MULTI-TISSUE_STRUCTURE", 103, 111], ["CO", "SIMPLE_CHEMICAL", 112, 114], ["CO", "SIMPLE_CHEMICAL", 143, 145], ["cells", "CELL", 160, 165], ["alveolar", "MULTI-TISSUE_STRUCTURE", 197, 205], ["an accuracy", "TEST", 40, 51], ["IV", "TREATMENT", 62, 64], ["arterial CO tension", "PROBLEM", 103, 122], ["the CO production in cells", "PROBLEM", 139, 165], ["effective alveolar ventilation", "TREATMENT", 187, 217], ["arterial", "ANATOMY", 103, 111], ["CO tension", "OBSERVATION", 112, 122], ["dependent", "OBSERVATION_MODIFIER", 126, 135], ["magnitude", "OBSERVATION_MODIFIER", 174, 183], ["effective", "OBSERVATION_MODIFIER", 187, 196], ["alveolar ventilation", "OBSERVATION", 197, 217]]], ["A disturbance in CO production or the magnitude of effective alveolar ventilation will alter the level of arterial CO tension.", [["alveolar", "ANATOMY", 61, 69], ["arterial", "ANATOMY", 106, 114], ["CO", "CHEMICAL", 17, 19], ["CO", "CHEMICAL", 115, 117], ["CO", "SIMPLE_CHEMICAL", 17, 19], ["alveolar", "MULTI-TISSUE_STRUCTURE", 61, 69], ["arterial", "MULTI-TISSUE_STRUCTURE", 106, 114], ["CO", "SIMPLE_CHEMICAL", 115, 117], ["A disturbance in CO production", "PROBLEM", 0, 30], ["effective alveolar ventilation", "TREATMENT", 51, 81], ["arterial CO tension", "PROBLEM", 106, 125], ["disturbance", "OBSERVATION", 2, 13], ["alveolar ventilation", "OBSERVATION", 61, 81], ["arterial", "ANATOMY", 106, 114], ["CO tension", "OBSERVATION", 115, 125]]], ["The relationship between these variables are given by the alveolar air equation [10] (10) Fig. 3 shows the inverse relationship between the blood carbon dioxide tension and the effective alveolar minute ventilation for various CO production values.IV. CONTROL OF BY REGULATINGA one-step-ahead control strategy may be adopted in the regulation of blood CO tension.", [["alveolar", "ANATOMY", 58, 66], ["blood", "ANATOMY", 140, 145], ["alveolar", "ANATOMY", 187, 195], ["blood", "ANATOMY", 346, 351], ["carbon dioxide", "CHEMICAL", 146, 160], ["carbon dioxide", "CHEMICAL", 146, 160], ["CO", "CHEMICAL", 227, 229], ["CO", "CHEMICAL", 352, 354], ["blood", "ORGANISM_SUBSTANCE", 140, 145], ["alveolar", "MULTI-TISSUE_STRUCTURE", 187, 195], ["CO", "SIMPLE_CHEMICAL", 227, 229], ["blood", "ORGANISM_SUBSTANCE", 346, 351], ["CO", "SIMPLE_CHEMICAL", 352, 354], ["the alveolar air equation", "TEST", 54, 79], ["the blood carbon dioxide tension", "TREATMENT", 136, 168], ["the effective alveolar minute ventilation", "TREATMENT", 173, 214], ["various CO production values", "PROBLEM", 219, 247], ["IV", "TREATMENT", 248, 250], ["blood CO tension", "PROBLEM", 346, 362], ["alveolar", "ANATOMY", 58, 66], ["carbon dioxide tension", "OBSERVATION", 146, 168], ["effective", "OBSERVATION_MODIFIER", 177, 186], ["alveolar minute ventilation", "OBSERVATION", 187, 214]]], ["The CO controller takes corrective action every five minutes, which is also the sampling time of the controller.", [["CO", "CHEMICAL", 4, 6], ["The CO controller", "TREATMENT", 0, 17]]], ["The performance of the controller can be explained by referring to the details of Fig. 3 .IV. CONTROL OF BY REGULATINGA patient with an unacceptable blood CO tension of 60 mmHg with an alveolar minute ventilation of 2.8 l/min and CO production of 200 ml/min can be represented at point A on the diagram.", [["blood", "ANATOMY", 149, 154], ["alveolar", "ANATOMY", 185, 193], ["CO", "CHEMICAL", 155, 157], ["CO", "CHEMICAL", 230, 232], ["patient", "ORGANISM", 120, 127], ["blood", "ORGANISM_SUBSTANCE", 149, 154], ["CO", "SIMPLE_CHEMICAL", 155, 157], ["alveolar", "MULTI-TISSUE_STRUCTURE", 185, 193], ["CO", "SIMPLE_CHEMICAL", 230, 232], ["patient", "SPECIES", 120, 127], ["an unacceptable blood CO tension", "TEST", 133, 165], ["an alveolar minute ventilation", "TEST", 182, 212], ["CO production", "TEST", 230, 243], ["alveolar", "ANATOMY_MODIFIER", 185, 193], ["minute ventilation", "OBSERVATION", 194, 212]]], ["The controller in an attempt to push the patient's blood CO tension from the present value to the desired value of 40 mmHg calculates a desired alveolar ventilation of 4.3 l.", [["blood", "ANATOMY", 51, 56], ["alveolar", "ANATOMY", 144, 152], ["CO", "CHEMICAL", 57, 59], ["patient", "ORGANISM", 41, 48], ["blood", "ORGANISM_SUBSTANCE", 51, 56], ["alveolar", "MULTI-TISSUE_STRUCTURE", 144, 152], ["patient", "SPECIES", 41, 48], ["the patient's blood CO tension", "TEST", 37, 67], ["a desired alveolar ventilation", "TEST", 134, 164], ["alveolar ventilation", "OBSERVATION", 144, 164]]], ["If the CO production remains constant until the next sample (i.e., 5 min into the future), the patient descends down line AB and reaches the desired CO level in one step.", [["CO", "CHEMICAL", 7, 9], ["CO", "CHEMICAL", 149, 151], ["CO", "SIMPLE_CHEMICAL", 7, 9], ["patient", "ORGANISM", 95, 102], ["CO", "PROTEIN", 149, 151], ["patient", "SPECIES", 95, 102], ["the CO production", "PROBLEM", 3, 20], ["line AB", "TREATMENT", 117, 124]]], ["The one-step-ahead control law can be written as (11) where is the current effective alveolar ventilation, is the current arterial CO tension, is the desired arterial CO tension, and is the calculated new effective alveolar ventilation to correct the current arterial CO tension.", [["alveolar", "ANATOMY", 85, 93], ["arterial", "ANATOMY", 122, 130], ["arterial", "ANATOMY", 158, 166], ["alveolar", "ANATOMY", 215, 223], ["arterial", "ANATOMY", 259, 267], ["CO", "CHEMICAL", 131, 133], ["CO", "CHEMICAL", 167, 169], ["CO", "CHEMICAL", 268, 270], ["alveolar", "MULTI-TISSUE_STRUCTURE", 85, 93], ["arterial", "MULTI-TISSUE_STRUCTURE", 122, 130], ["arterial", "MULTI-TISSUE_STRUCTURE", 158, 166], ["alveolar", "MULTI-TISSUE_STRUCTURE", 215, 223], ["arterial", "MULTI-TISSUE_STRUCTURE", 259, 267], ["alveolar ventilation", "TREATMENT", 85, 105], ["the current arterial CO tension", "PROBLEM", 110, 141], ["the desired arterial CO tension", "PROBLEM", 146, 177], ["the calculated new effective alveolar ventilation", "TREATMENT", 186, 235], ["the current arterial CO tension", "PROBLEM", 247, 278], ["alveolar ventilation", "OBSERVATION", 85, 105], ["tension", "OBSERVATION", 170, 177], ["new", "OBSERVATION_MODIFIER", 201, 204], ["effective", "OBSERVATION_MODIFIER", 205, 214], ["alveolar ventilation", "OBSERVATION", 215, 235], ["arterial", "ANATOMY", 259, 267], ["CO tension", "OBSERVATION", 268, 278]]], ["The above control strategy is derived using (10) and assuming that is constant between sampling periods.", [["The above control strategy", "TREATMENT", 0, 26]]], ["However, if the CO production changes (e.g., it increases from 200 mL/min to 250 mL/min), the patient instead of descending from point A to point B moves from point A to point C. In this situation, the target value is not reached in one step due to the disturbance in the CO production; the controller again attempts to push the patient from point C to the new desired point D by calculating a new alveolar ventilation of 5.4 L. It is clear that desired performance of the controller can be guaranteed even under sudden changes in CO production, provided it remains stable after the change.", [["alveolar", "ANATOMY", 398, 406], ["CO", "CHEMICAL", 16, 18], ["CO", "CHEMICAL", 272, 274], ["CO", "CHEMICAL", 531, 533], ["CO", "SIMPLE_CHEMICAL", 16, 18], ["patient", "ORGANISM", 94, 101], ["CO", "SIMPLE_CHEMICAL", 272, 274], ["patient", "ORGANISM", 329, 336], ["alveolar", "MULTI-TISSUE_STRUCTURE", 398, 406], ["CO", "SIMPLE_CHEMICAL", 531, 533], ["patient", "SPECIES", 94, 101], ["patient", "SPECIES", 329, 336], ["the CO production changes", "PROBLEM", 12, 37], ["the disturbance", "PROBLEM", 249, 264], ["a new alveolar ventilation", "TREATMENT", 392, 418], ["alveolar", "ANATOMY_MODIFIER", 398, 406], ["stable", "OBSERVATION_MODIFIER", 566, 572]]], ["However, if the CO production is unstable and oscillates about a mean CO production value of with an amplitude of , then from (10) it is clear that blood CO tension oscillates about the desired CO tension with an amplitude of where (12) provided that alveolar ventilation is unchanged.", [["blood", "ANATOMY", 148, 153], ["alveolar", "ANATOMY", 251, 259], ["CO", "CHEMICAL", 16, 18], ["CO", "CHEMICAL", 70, 72], ["CO", "CHEMICAL", 154, 156], ["CO", "CHEMICAL", 194, 196], ["CO", "SIMPLE_CHEMICAL", 16, 18], ["CO", "SIMPLE_CHEMICAL", 70, 72], ["blood", "ORGANISM_SUBSTANCE", 148, 153], ["CO", "SIMPLE_CHEMICAL", 154, 156], ["alveolar", "MULTI-TISSUE_STRUCTURE", 251, 259], ["the CO production", "PROBLEM", 12, 29], ["a mean CO production value", "TEST", 63, 89], ["blood CO tension oscillates", "PROBLEM", 148, 175], ["the desired CO tension", "PROBLEM", 182, 204], ["alveolar ventilation", "TREATMENT", 251, 271], ["alveolar ventilation", "OBSERVATION", 251, 271], ["unchanged", "OBSERVATION_MODIFIER", 275, 284]]], ["Fig. 4 shows this scenario, as the CO production oscillates between 150 to 250 mL/min for a constant effective alveolar minute ventilation of 4.3 L represents an oscillatory movement of a point between and .", [["alveolar", "ANATOMY", 111, 119], ["CO", "CHEMICAL", 35, 37], ["CO", "SIMPLE_CHEMICAL", 35, 37], ["alveolar", "MULTI-TISSUE_STRUCTURE", 111, 119], ["the CO production oscillates", "PROBLEM", 31, 59], ["a constant effective alveolar minute ventilation", "TREATMENT", 90, 138], ["alveolar", "ANATOMY_MODIFIER", 111, 119], ["oscillatory movement", "OBSERVATION", 162, 182]]], ["It is clear that arterial CO tension will oscillate between 30 to 50 mmHg as shown in the horizontal oscillations.", [["arterial", "ANATOMY", 17, 25], ["CO", "CHEMICAL", 26, 28], ["arterial", "MULTI-TISSUE_STRUCTURE", 17, 25], ["arterial CO tension", "PROBLEM", 17, 36], ["clear", "OBSERVATION", 6, 11], ["arterial", "ANATOMY", 17, 25], ["tension", "OBSERVATION", 29, 36], ["horizontal oscillations", "OBSERVATION", 90, 113]]], ["If the magnitude and direction of CO production oscillations are known, the controller can then suppress the oscillations in CO tension by oscillating the alveolar minute ventilation with an amplitude of whereIV.", [["alveolar", "ANATOMY", 155, 163], ["CO", "CHEMICAL", 34, 36], ["CO", "CHEMICAL", 125, 127], ["CO", "SIMPLE_CHEMICAL", 34, 36], ["CO", "SIMPLE_CHEMICAL", 125, 127], ["alveolar", "MULTI-TISSUE_STRUCTURE", 155, 163], ["CO production oscillations", "PROBLEM", 34, 60], ["the oscillations in CO tension", "PROBLEM", 105, 135], ["the alveolar minute ventilation", "TREATMENT", 151, 182], ["IV", "TREATMENT", 209, 211], ["alveolar minute ventilation", "OBSERVATION", 155, 182]]], ["CONTROL OF BY REGULATINGThe suppression only occurs when the CO production oscillations are in phase with the effective alveolar minute ventilation oscillations.", [["alveolar", "ANATOMY", 120, 128], ["CO", "CHEMICAL", 61, 63], ["CO", "SIMPLE_CHEMICAL", 61, 63], ["alveolar", "MULTI-TISSUE_STRUCTURE", 120, 128], ["the CO production oscillations", "PROBLEM", 57, 87], ["the effective alveolar minute ventilation oscillations", "PROBLEM", 106, 160], ["alveolar minute", "OBSERVATION", 120, 135], ["ventilation oscillations", "OBSERVATION", 136, 160]]], ["The vertical oscillations in Fig. 4 indicates how effective alveolar minute ventilation should oscillate in order to suppress the CO tension oscillations.", [["alveolar", "ANATOMY", 60, 68], ["CO", "CHEMICAL", 130, 132], ["alveolar", "MULTI-TISSUE_STRUCTURE", 60, 68], ["CO", "SIMPLE_CHEMICAL", 130, 132], ["The vertical oscillations in Fig.", "PROBLEM", 0, 33], ["alveolar minute ventilation", "TREATMENT", 60, 87], ["the CO tension oscillations", "PROBLEM", 126, 153], ["vertical oscillations", "OBSERVATION", 4, 25], ["effective", "OBSERVATION_MODIFIER", 50, 59], ["alveolar", "OBSERVATION", 60, 68], ["minute ventilation", "OBSERVATION", 69, 87], ["tension oscillations", "OBSERVATION", 133, 153]]], ["If the CO production oscillations and the oscillations are out of phase then from (10) it is clear that the blood CO tension will oscillate with amplitude (14) which is greater than the CO tension oscillations when there is no CO control action present.IV. CONTROL OF BY REGULATINGSince the disturbance in CO production depends on body metabolism, it cannot be predicted, though it can be continuously measured.", [["blood", "ANATOMY", 108, 113], ["body", "ANATOMY", 331, 335], ["CO", "CHEMICAL", 7, 9], ["CO", "CHEMICAL", 114, 116], ["CO", "CHEMICAL", 186, 188], ["CO", "CHEMICAL", 227, 229], ["CO", "CHEMICAL", 306, 308], ["CO", "SIMPLE_CHEMICAL", 7, 9], ["blood", "ORGANISM_SUBSTANCE", 108, 113], ["CO", "SIMPLE_CHEMICAL", 114, 116], ["CO", "SIMPLE_CHEMICAL", 306, 308], ["body", "ORGANISM_SUBDIVISION", 331, 335], ["the CO production oscillations", "PROBLEM", 3, 33], ["the blood CO tension", "PROBLEM", 104, 124], ["amplitude", "TEST", 145, 154], ["the CO tension oscillations", "PROBLEM", 182, 209], ["CO control action", "PROBLEM", 227, 244], ["IV", "TREATMENT", 253, 255], ["the disturbance in CO production", "PROBLEM", 287, 319], ["production oscillations", "OBSERVATION", 10, 33], ["greater", "OBSERVATION_MODIFIER", 169, 176], ["tension oscillations", "OBSERVATION", 189, 209], ["no", "UNCERTAINTY", 224, 226]]], ["Controlling CO tension when oscillatory disturbances are present in CO production may intensify the existing oscillations.", [["CO", "CHEMICAL", 12, 14], ["CO", "CHEMICAL", 68, 70], ["CO", "SIMPLE_CHEMICAL", 12, 14], ["CO", "SIMPLE_CHEMICAL", 68, 70], ["Controlling CO tension", "PROBLEM", 0, 22], ["oscillatory disturbances", "PROBLEM", 28, 52], ["tension", "OBSERVATION_MODIFIER", 15, 22], ["oscillatory disturbances", "OBSERVATION", 28, 52]]], ["When consistent oscillations are present in the CO production, the best performance the controller can achieve is by regulating the CO tension using a running mean CO production value instead of regulating it using the single CO production value at the time of sampling.IV. CONTROL OF BY REGULATINGFrom the above discussion it is clear that to control the arterial CO level, it is necessary that the assumption the CO production is relatively constant be valid and regulation of effective alveolar minute ventilation be possible.", [["arterial", "ANATOMY", 356, 364], ["alveolar", "ANATOMY", 489, 497], ["CO", "CHEMICAL", 48, 50], ["CO", "CHEMICAL", 132, 134], ["CO", "CHEMICAL", 164, 166], ["CO", "CHEMICAL", 226, 228], ["CO", "CHEMICAL", 365, 367], ["CO", "CHEMICAL", 415, 417], ["CO", "SIMPLE_CHEMICAL", 48, 50], ["CO", "SIMPLE_CHEMICAL", 132, 134], ["CO", "SIMPLE_CHEMICAL", 164, 166], ["CO", "SIMPLE_CHEMICAL", 226, 228], ["arterial CO", "MULTI-TISSUE_STRUCTURE", 356, 367], ["CO", "SIMPLE_CHEMICAL", 415, 417], ["alveolar", "MULTI-TISSUE_STRUCTURE", 489, 497], ["the CO tension", "PROBLEM", 128, 142], ["a running mean CO production value", "TREATMENT", 149, 183], ["IV", "TREATMENT", 270, 272], ["the arterial CO level", "TEST", 352, 373], ["the CO production", "PROBLEM", 411, 428], ["effective alveolar minute ventilation", "TREATMENT", 479, 516], ["oscillations", "OBSERVATION", 16, 28], ["arterial", "ANATOMY", 356, 364], ["effective", "OBSERVATION_MODIFIER", 479, 488], ["alveolar minute ventilation", "OBSERVATION", 489, 516]]], ["Fig. 5 shows a typical variation of CO production over a period of 30 min.", [["CO", "CHEMICAL", 36, 38], ["CO", "SIMPLE_CHEMICAL", 36, 38]]], ["Here the average CO production varies within a band of 10 mL and from (12) it is clear that this will cause the arterial CO tension to oscillate with an amplitude provided that effective alveolar minute ventilation is left unaltered.", [["arterial", "ANATOMY", 112, 120], ["alveolar", "ANATOMY", 187, 195], ["CO", "CHEMICAL", 17, 19], ["CO", "CHEMICAL", 121, 123], ["CO", "SIMPLE_CHEMICAL", 17, 19], ["arterial", "MULTI-TISSUE_STRUCTURE", 112, 120], ["CO", "SIMPLE_CHEMICAL", 121, 123], ["alveolar", "MULTI-TISSUE_STRUCTURE", 187, 195], ["the average CO production", "PROBLEM", 5, 30], ["the arterial CO tension", "PROBLEM", 108, 131], ["effective alveolar minute ventilation", "TREATMENT", 177, 214], ["arterial", "ANATOMY", 112, 120], ["effective", "OBSERVATION_MODIFIER", 177, 186], ["alveolar", "OBSERVATION", 187, 195], ["minute ventilation", "OBSERVATION", 196, 214], ["left", "ANATOMY_MODIFIER", 218, 222]]], ["For in the range of 4 to 8 L, the expected arterial CO tension oscillations have amplitudes ranging from 1.1 mmHg to 0.5 mmHg.", [["arterial", "ANATOMY", 43, 51], ["CO", "CHEMICAL", 52, 54], ["arterial", "MULTI-TISSUE_STRUCTURE", 43, 51], ["the expected arterial CO tension oscillations", "TEST", 30, 75], ["amplitudes", "TEST", 81, 91], ["arterial", "ANATOMY", 43, 51], ["tension oscillations", "OBSERVATION", 55, 75], ["amplitudes", "OBSERVATION_MODIFIER", 81, 91], ["ranging", "OBSERVATION_MODIFIER", 92, 99]]], ["Since the target tension is generally set around 40 mmHg, a control system that can regulate the level with in a band of 1.1 mmHg can be considered entirely acceptable.", [["a control system", "TREATMENT", 58, 74], ["a band", "TEST", 111, 117], ["tension", "OBSERVATION", 17, 24]]], ["Such typical variation in CO production is, therefore, not a performance limiting factor of the control system.IV. CONTROL OF BY REGULATINGThe minute ventilation for a mechanically ventilated patient depends on the patient's own respiratory drive and the number of mandatory breaths the operator specifies.", [["respiratory", "ANATOMY", 229, 240], ["CO", "CHEMICAL", 26, 28], ["CO", "SIMPLE_CHEMICAL", 26, 28], ["patient", "ORGANISM", 192, 199], ["patient", "ORGANISM", 215, 222], ["patient", "SPECIES", 192, 199], ["patient", "SPECIES", 215, 222], ["Such typical variation in CO production", "PROBLEM", 0, 39], ["IV", "TREATMENT", 111, 113], ["The minute ventilation", "TREATMENT", 139, 161], ["a mechanically ventilated", "TREATMENT", 166, 191], ["typical", "OBSERVATION_MODIFIER", 5, 12], ["variation", "OBSERVATION_MODIFIER", 13, 22], ["CO production", "OBSERVATION", 26, 39], ["minute ventilation", "OBSERVATION", 143, 161]]], ["The mandatory breaths contribute to a certain mandatory minute ventilation and the patient's respiratory drive contributes to a certain spontaneous minute volume.", [["respiratory", "ANATOMY", 93, 104], ["patient", "ORGANISM", 83, 90], ["patient", "SPECIES", 83, 90], ["a certain mandatory minute ventilation", "TREATMENT", 36, 74], ["the patient's respiratory drive", "PROBLEM", 79, 110], ["a certain spontaneous minute volume", "PROBLEM", 126, 161], ["respiratory drive", "OBSERVATION", 93, 110]]], ["Both the spontaneous and mandatory minute volumes contain respiratory dead space volume, and subtraction of the two gives the effective minute volume carried by spontaneous and mandatory breaths.", [["respiratory dead space volume", "PROBLEM", 58, 87], ["subtraction", "TEST", 93, 104], ["the effective minute volume", "TREATMENT", 122, 149], ["spontaneous", "OBSERVATION_MODIFIER", 9, 20], ["respiratory dead", "OBSERVATION", 58, 74], ["space volume", "OBSERVATION", 75, 87]]], ["The effective alveolar minute ventilation is composed of the effective minute volume contributed by the spontaneous breaths (i.e., ) and also the effective minute volume contributed by the mandatory breaths (i.e., )IV.", [["alveolar", "ANATOMY", 14, 22], ["alveolar", "MULTI-TISSUE_STRUCTURE", 14, 22], ["The effective alveolar minute ventilation", "TREATMENT", 0, 41], ["the effective minute volume", "PROBLEM", 57, 84], ["the effective minute volume", "PROBLEM", 142, 169], ["effective", "OBSERVATION_MODIFIER", 4, 13], ["alveolar minute ventilation", "OBSERVATION", 14, 41]]], ["From this it is clear that the variations in does not necessarily follow the those in .", [["clear", "OBSERVATION", 16, 21]]], ["There is no direct relationship between and , since alterations in does not get reflected in .", [["no", "UNCERTAINTY", 9, 11]]], ["Hence, controlling the level about a target value is not possible in such circumstances.IV. CONTROL OF BY REGULATINGHowever, if a patient receives a certain number of mandatory breaths, then this ensures that the patient is guaranteed a certain level of effective alveolar minute ventilation, i.e.,IV.", [["alveolar", "ANATOMY", 264, 272], ["patient", "ORGANISM", 130, 137], ["patient", "ORGANISM", 213, 220], ["alveolar", "MULTI-TISSUE_STRUCTURE", 264, 272], ["patient", "SPECIES", 130, 137], ["patient", "SPECIES", 213, 220], ["IV.", "SPECIES", 298, 301], ["IV", "TREATMENT", 88, 90], ["effective alveolar minute ventilation", "TREATMENT", 254, 291], ["not possible", "UNCERTAINTY", 53, 65], ["alveolar minute ventilation", "OBSERVATION", 264, 291]]], ["CONTROL OF BY REGULATINGFrom (17), it is clear that using as the control signal and (11) as the control law can only maintain arterial CO level below a certain maximum level (i.e.,IV.", [["arterial", "ANATOMY", 126, 134], ["CO", "CHEMICAL", 135, 137], ["arterial CO", "MULTI-TISSUE_STRUCTURE", 126, 137], ["IV.", "SPECIES", 180, 183], ["the control signal", "TEST", 61, 79], ["arterial CO level", "TEST", 126, 143]]], ["Similarly, (16) and It is clear that in this situation using the MMV setting as the control signal and (11) as the control law, again can only maintain arterial CO tension below a certain maximum level (i.e., ).", [["arterial", "ANATOMY", 152, 160], ["CO", "CHEMICAL", 161, 163], ["arterial", "MULTI-TISSUE_STRUCTURE", 152, 160], ["CO", "SIMPLE_CHEMICAL", 161, 163], ["the MMV setting", "TREATMENT", 61, 76], ["the control signal", "TEST", 80, 98], ["arterial CO tension", "PROBLEM", 152, 171], ["clear", "OBSERVATION", 26, 31], ["arterial", "ANATOMY", 152, 160], ["tension", "OBSERVATION", 164, 171]]], ["Hence, it may be stated that, while arterial CO tension cannot be controlled about a set target level, it is possible to maintain it below a certain maximum level.V. VMMV ALGORITHMTo maintain arterial CO tension below , must be regulated according to (11) periodically.", [["arterial", "ANATOMY", 36, 44], ["arterial", "ANATOMY", 192, 200], ["CO", "CHEMICAL", 45, 47], ["CO", "CHEMICAL", 201, 203], ["arterial", "MULTI-TISSUE_STRUCTURE", 36, 44], ["CO", "SIMPLE_CHEMICAL", 45, 47], ["arterial", "MULTI-TISSUE_STRUCTURE", 192, 200], ["VMMV", "SPECIES", 166, 170], ["arterial CO tension", "PROBLEM", 36, 55], ["arterial CO tension", "TREATMENT", 192, 211], ["arterial", "ANATOMY", 192, 200]]], ["The periodic implementation of can be done in the MMV mode by periodically selecting a MMV setting as follows:V. VMMV ALGORITHMwhere is the deadspace volume corresponding to .", [["the deadspace volume", "TEST", 136, 156], ["deadspace volume", "OBSERVATION", 140, 156]]], ["The new minute dead space volume can be estimated by assuming that minute dead space volume varies proportionally to minute volume [8] A patient who had been receiving mechanical ventilation for the past 72 hs was chosen to trial on the VMMV mode.", [["patient", "ORGANISM", 137, 144], ["patient", "SPECIES", 137, 144], ["The new minute dead space volume", "PROBLEM", 0, 32], ["minute dead space volume", "PROBLEM", 67, 91], ["minute volume", "TEST", 117, 130], ["mechanical ventilation", "TREATMENT", 168, 190], ["the VMMV mode", "TREATMENT", 233, 246], ["new", "OBSERVATION_MODIFIER", 4, 7], ["space volume", "OBSERVATION", 20, 32]]], ["The patient was on a rate of 12 volume control breaths per minute, each carrying a tidal volume of 600 mL.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["a rate of 12 volume control breaths", "TREATMENT", 19, 54], ["a tidal volume", "TEST", 81, 95]]], ["A blood test was performed 4 min into the trial, and it revealed an arterial CO tension of 41 mmHg.", [["blood", "ANATOMY", 2, 7], ["arterial", "ANATOMY", 68, 76], ["CO", "CHEMICAL", 77, 79], ["blood", "ORGANISM_SUBSTANCE", 2, 7], ["arterial", "MULTI-TISSUE_STRUCTURE", 68, 76], ["A blood test", "TEST", 0, 12], ["an arterial CO tension", "TEST", 65, 87], ["arterial", "ANATOMY", 68, 76], ["tension", "OBSERVATION_MODIFIER", 80, 87], ["41 mmHg", "OBSERVATION", 91, 98]]], ["Based on the arterial CO tension in this minute, a blood gas efficiency of 0.646 was calculated (refer to Section III for details of this calculation).", [["arterial", "ANATOMY", 13, 21], ["blood", "ANATOMY", 51, 56], ["CO", "CHEMICAL", 22, 24], ["arterial CO", "MULTI-TISSUE_STRUCTURE", 13, 24], ["blood", "ORGANISM_SUBSTANCE", 51, 56], ["the arterial CO tension", "TEST", 9, 32], ["a blood gas efficiency", "TEST", 49, 71], ["this calculation", "TEST", 133, 149], ["arterial", "ANATOMY", 13, 21], ["tension", "OBSERVATION", 25, 32]]], ["The VMMV mode was not engaged until the 21st minute, until then only the CO estimator was in operation.", [["CO", "CHEMICAL", 73, 75], ["The VMMV mode", "TEST", 0, 13], ["the CO estimator", "PROBLEM", 69, 85]]], ["Within this time span, arterial CO tension varied between 38.9-41.1 mmHg.", [["arterial", "ANATOMY", 23, 31], ["CO", "CHEMICAL", 32, 34], ["arterial", "MULTI-TISSUE_STRUCTURE", 23, 31], ["CO", "MULTI-TISSUE_STRUCTURE", 32, 34], ["arterial CO tension", "TEST", 23, 42], ["arterial", "ANATOMY", 23, 31]]], ["When the VMMV mode was engaged a maximum arterial CO tension setting of 41 mmHg was chosen as the input to the algorithm.V. VMMV ALGORITHMThe minute volume, MMV settings, estimated arterial CO tension, and spontaneous and volume control breaths per minute are shown in Fig. 8 .", [["arterial", "ANATOMY", 41, 49], ["arterial", "ANATOMY", 181, 189], ["CO", "CHEMICAL", 50, 52], ["CO", "CHEMICAL", 190, 192], ["arterial", "MULTI-TISSUE_STRUCTURE", 41, 49], ["arterial", "MULTI-TISSUE_STRUCTURE", 181, 189], ["the VMMV mode", "TEST", 5, 18], ["a maximum arterial CO tension setting", "TEST", 31, 68], ["minute volume", "TEST", 142, 155], ["MMV settings", "TEST", 157, 169], ["estimated arterial CO tension", "PROBLEM", 171, 200], ["spontaneous and volume control breaths", "TREATMENT", 206, 244], ["arterial", "ANATOMY", 181, 189], ["tension", "OBSERVATION_MODIFIER", 193, 200], ["spontaneous", "OBSERVATION_MODIFIER", 206, 217]]], ["By the 61st minute, the patient was receiving no volume control breaths and was breathing spontaneously.", [["patient", "ORGANISM", 24, 31], ["patient", "SPECIES", 24, 31], ["volume control breaths", "TREATMENT", 49, 71]]], ["The minute ventilation then remained above the MMV setting constantly for another 20 min at which point the trial was terminated.", [["The minute ventilation", "TREATMENT", 0, 22], ["minute ventilation", "OBSERVATION", 4, 22]]], ["A blood gas performed in the 78th minute revealed an arterial CO tension of 36.7 mmHg.", [["blood", "ANATOMY", 2, 7], ["arterial", "ANATOMY", 53, 61], ["CO", "CHEMICAL", 62, 64], ["blood", "ORGANISM_SUBSTANCE", 2, 7], ["arterial", "MULTI-TISSUE_STRUCTURE", 53, 61], ["A blood gas", "TEST", 0, 11], ["an arterial CO tension", "PROBLEM", 50, 72], ["arterial", "ANATOMY", 53, 61], ["tension", "OBSERVATION_MODIFIER", 65, 72], ["36.7 mmHg", "OBSERVATION", 76, 85]]], ["The estimated arterial CO tension was 1.6 mmHg different from the value obtained from gas analysis.", [["arterial", "ANATOMY", 14, 22], ["CO", "CHEMICAL", 23, 25], ["arterial", "MULTI-TISSUE_STRUCTURE", 14, 22], ["CO", "MULTI-TISSUE_STRUCTURE", 23, 25], ["The estimated arterial CO tension", "TEST", 0, 33], ["the value", "TEST", 62, 71], ["gas analysis", "TEST", 86, 98], ["arterial", "ANATOMY", 14, 22], ["tension", "OBSERVATION_MODIFIER", 26, 33], ["1.6 mmHg", "OBSERVATION", 38, 46]]], ["It is noted that throughout the trial, the MMV setting has changed at every 5-min interval, and the arterial CO tension has remained below the set maximum limit.", [["arterial", "ANATOMY", 100, 108], ["CO", "CHEMICAL", 109, 111], ["arterial", "MULTI-TISSUE_STRUCTURE", 100, 108], ["the MMV setting", "TREATMENT", 39, 54], ["the arterial CO tension", "TEST", 96, 119], ["arterial", "ANATOMY", 100, 108], ["tension", "OBSERVATION", 112, 119], ["maximum limit", "OBSERVATION", 147, 160]]], ["The new ventilation mode has demonstrated the ability to encourage patient's spontaneous breathing while ensuring that the arterial CO tension remained below the prescribed maximum settings as determined by the clinician.V. VMMV ALGORITHMThe control system cannot raise the arterial CO tension above the level achieved during spontaneous ventilation.", [["arterial", "ANATOMY", 123, 131], ["arterial", "ANATOMY", 274, 282], ["CO", "CHEMICAL", 132, 134], ["CO", "CHEMICAL", 283, 285], ["patient", "ORGANISM", 67, 74], ["arterial", "MULTI-TISSUE_STRUCTURE", 123, 131], ["arterial", "MULTI-TISSUE_STRUCTURE", 274, 282], ["CO", "SIMPLE_CHEMICAL", 283, 285], ["patient", "SPECIES", 67, 74], ["VMMV", "SPECIES", 224, 228], ["The new ventilation mode", "TREATMENT", 0, 24], ["the arterial CO tension", "PROBLEM", 119, 142], ["the arterial CO tension", "PROBLEM", 270, 293], ["spontaneous ventilation", "TREATMENT", 326, 349], ["arterial", "ANATOMY", 123, 131], ["tension", "OBSERVATION", 286, 293], ["spontaneous ventilation", "OBSERVATION", 326, 349]]], ["In situations where arterial CO tension needs to be increased, patient's spontaneous ventilation needs to be suppressed through sedative medication allowing the mechanical ventilator to \"take over\" in regulating effective alveolar ventilation and thereby controlling the arterial CO tension.", [["arterial", "ANATOMY", 20, 28], ["alveolar", "ANATOMY", 222, 230], ["arterial", "ANATOMY", 271, 279], ["CO", "CHEMICAL", 29, 31], ["CO", "CHEMICAL", 280, 282], ["arterial", "MULTI-TISSUE_STRUCTURE", 20, 28], ["CO", "MULTI-TISSUE_STRUCTURE", 29, 31], ["patient", "ORGANISM", 63, 70], ["alveolar", "MULTI-TISSUE_STRUCTURE", 222, 230], ["arterial", "MULTI-TISSUE_STRUCTURE", 271, 279], ["patient", "SPECIES", 63, 70], ["arterial CO tension", "TREATMENT", 20, 39], ["patient's spontaneous ventilation", "TREATMENT", 63, 96], ["sedative medication", "TREATMENT", 128, 147], ["the mechanical ventilator", "TREATMENT", 157, 182], ["alveolar ventilation", "TREATMENT", 222, 242], ["the arterial CO tension", "PROBLEM", 267, 290], ["arterial", "ANATOMY", 20, 28], ["alveolar ventilation", "OBSERVATION", 222, 242], ["arterial", "ANATOMY", 271, 279]]], ["Tighter control of arterial CO tension is possible if spontaneous breathing is suppressed and ventilation is controlled entirely by a ventilator.VI. CONCLUSIONWhen a patient is ventilated in the VMMV mode, the clinician decides the maximum arterial CO level.", [["arterial", "ANATOMY", 19, 27], ["arterial", "ANATOMY", 240, 248], ["CO", "CHEMICAL", 28, 30], ["CO", "CHEMICAL", 249, 251], ["arterial", "MULTI-TISSUE_STRUCTURE", 19, 27], ["CO", "MULTI-TISSUE_STRUCTURE", 28, 30], ["patient", "ORGANISM", 166, 173], ["arterial", "MULTI-TISSUE_STRUCTURE", 240, 248], ["patient", "SPECIES", 166, 173], ["arterial CO tension", "PROBLEM", 19, 38], ["spontaneous breathing", "PROBLEM", 54, 75], ["ventilation", "TREATMENT", 94, 105], ["a ventilator", "TREATMENT", 132, 144], ["the maximum arterial CO level", "TEST", 228, 257], ["arterial", "ANATOMY", 19, 27], ["CO tension", "OBSERVATION", 28, 38], ["ventilated", "OBSERVATION", 177, 187]]], ["Once this decision is made, the ventilation scheme calculates a new MMV setting every 5 min (hence the name variable MMV) to ensure that arterial CO level stays below the set limit.", [["arterial", "ANATOMY", 137, 145], ["CO", "CHEMICAL", 146, 148], ["arterial", "MULTI-TISSUE_STRUCTURE", 137, 145], ["the ventilation scheme", "TREATMENT", 28, 50], ["a new MMV setting", "TREATMENT", 62, 79], ["arterial CO level", "TEST", 137, 154], ["arterial", "ANATOMY", 137, 145]]], ["The ventilation mode while providing all features of the MMV mode can ensure that arterial CO remains below a set limit.", [["arterial", "ANATOMY", 82, 90], ["CO", "CHEMICAL", 91, 93], ["arterial", "MULTI-TISSUE_STRUCTURE", 82, 90], ["The ventilation mode", "TREATMENT", 0, 20], ["the MMV mode", "TREATMENT", 53, 65], ["arterial CO", "TEST", 82, 93], ["arterial", "ANATOMY", 82, 90]]], ["SBT-CO plot and the gradient of SBT-CO .", [["CO", "CHEMICAL", 4, 6], ["CO", "CHEMICAL", 36, 38], ["SBT", "TEST", 0, 3], ["CO plot", "TEST", 4, 11], ["the gradient", "TEST", 16, 28], ["SBT", "TEST", 32, 35]]], ["The CO partial pressure signal was obtained from a Hewlett Packard 78 356A capnograph and the flow signal was obtained from a PB-7200a ventilator.", [["PB-7200a", "CHEMICAL", 126, 134], ["CO", "CHEMICAL", 4, 6], ["CO", "SIMPLE_CHEMICAL", 4, 6], ["The CO partial pressure signal", "TEST", 0, 30], ["the flow signal", "TEST", 90, 105], ["partial", "OBSERVATION_MODIFIER", 7, 14], ["pressure", "OBSERVATION_MODIFIER", 15, 23]]], ["The flow signal was integrated to obtain volume.", [["The flow signal", "TEST", 0, 15], ["volume", "TEST", 41, 47], ["flow signal", "OBSERVATION", 4, 15]]], ["The measurements were made in ICU at RMH.APPENDIXTo form a SBT-CO trace, it is necessary to access the inspiratory flow waveform and CO partial pressure of exhaled air.", [["CO", "CHEMICAL", 63, 65], ["CO", "CHEMICAL", 133, 135], ["The measurements", "TEST", 0, 16], ["a SBT", "TEST", 57, 62], ["the inspiratory flow waveform", "TEST", 99, 128], ["CO partial pressure of exhaled air", "PROBLEM", 133, 167], ["inspiratory flow", "OBSERVATION", 103, 119], ["partial", "OBSERVATION_MODIFIER", 136, 143], ["pressure", "OBSERVATION_MODIFIER", 144, 152], ["exhaled air", "OBSERVATION", 156, 167]]], ["The inspiratory flow waveform was accessed from an analog port in the PB-7200a ventilator and the CO partial pressure of exhaled air was accessed from an analog port of the HP-78 356A capnograph.", [["PB-7200a", "CHEMICAL", 70, 78], ["CO", "CHEMICAL", 98, 100], ["HP-78", "CHEMICAL", 173, 178], ["The inspiratory flow waveform", "TEST", 0, 29], ["an analog port", "TREATMENT", 48, 62], ["ventilator", "TREATMENT", 79, 89], ["the CO partial pressure of exhaled air", "TREATMENT", 94, 132], ["an analog port", "TREATMENT", 151, 165], ["inspiratory", "OBSERVATION", 4, 15], ["flow waveform", "OBSERVATION", 16, 29], ["partial", "OBSERVATION_MODIFIER", 101, 108], ["pressure", "OBSERVATION_MODIFIER", 109, 117], ["exhaled air", "OBSERVATION", 121, 132]]], ["Both analog signals were sampled at a frequency of 100 Hz and processed in an IBM-386 PC.", [["IBM-386 PC", "CANCER", 78, 88], ["an IBM", "TEST", 75, 81]]], ["The top graph of Fig. 9 shows a SBT-CO trace.", [["CO", "CHEMICAL", 36, 38], ["a SBT", "TEST", 30, 35]]], ["The gradient of this curve is shown in the lower graph of Fig. 9 .", [["this curve", "TEST", 16, 26], ["gradient", "OBSERVATION_MODIFIER", 4, 12], ["lower", "ANATOMY_MODIFIER", 43, 48]]], ["The maximum peak in the gradient of SBT-CO plot corresponds to the point of inflection of the SBT-CO plot.", [["CO", "CHEMICAL", 40, 42], ["CO", "CHEMICAL", 98, 100], ["The maximum peak", "TEST", 0, 16], ["SBT", "TEST", 36, 39], ["CO plot", "TEST", 40, 47], ["the SBT", "TEST", 90, 97], ["CO plot", "TEST", 98, 105], ["maximum", "OBSERVATION_MODIFIER", 4, 11], ["peak", "OBSERVATION_MODIFIER", 12, 16], ["gradient", "OBSERVATION_MODIFIER", 24, 32]]], ["The maximum peak in the gradient of SBT-CO plot in this patient occurs when the exhaled volume is 152 ml.", [["CO", "CHEMICAL", 40, 42], ["patient", "ORGANISM", 56, 63], ["patient", "SPECIES", 56, 63], ["The maximum peak", "TEST", 0, 16], ["SBT", "TEST", 36, 39], ["CO plot", "TEST", 40, 47], ["the exhaled volume", "TEST", 76, 94], ["maximum", "OBSERVATION_MODIFIER", 4, 11], ["peak", "OBSERVATION_MODIFIER", 12, 16], ["gradient", "OBSERVATION_MODIFIER", 24, 32]]], ["This point corresponds to the point of inflection of the SBT-CO plot and, therefore, represents the airway dead space.", [["airway", "ANATOMY", 100, 106], ["CO", "CHEMICAL", 61, 63], ["the SBT", "TEST", 53, 60], ["CO plot", "TEST", 61, 68], ["the airway dead space", "PROBLEM", 96, 117], ["airway", "ANATOMY", 100, 106], ["dead space", "OBSERVATION", 107, 117]]], ["The tidal volume of this breath is 408 ml and hence the alveolar tidal volume is 408 152 256 ml.", [["alveolar", "ANATOMY", 56, 64], ["alveolar tidal", "MULTI-TISSUE_STRUCTURE", 56, 70], ["The tidal volume", "TEST", 0, 16], ["the alveolar tidal volume", "TEST", 52, 77], ["tidal volume", "OBSERVATION", 4, 16], ["alveolar", "ANATOMY_MODIFIER", 56, 64], ["tidal volume", "OBSERVATION", 65, 77]]], ["A blood test performed within this time revealed an arterial CO tension of 41 mmHg.", [["blood", "ANATOMY", 2, 7], ["arterial", "ANATOMY", 52, 60], ["CO", "CHEMICAL", 61, 63], ["blood", "ORGANISM_SUBSTANCE", 2, 7], ["arterial", "MULTI-TISSUE_STRUCTURE", 52, 60], ["A blood test", "TEST", 0, 12], ["an arterial CO tension", "TEST", 49, 71], ["arterial", "ANATOMY", 52, 60], ["tension", "OBSERVATION_MODIFIER", 64, 71], ["41 mmHg", "OBSERVATION", 75, 82]]], ["The Areaand Area-for this breath was calculated to be 7138 ml mmHg and 3373 ml mmHg, respectively.", [["this breath", "PROBLEM", 21, 32]]], ["Using (5) alveolar dead space is (256 3373)/(7138 3377) mL.", [["alveolar dead space", "ANATOMY", 10, 29], ["alveolar dead space", "TEST", 10, 29], ["alveolar", "ANATOMY", 10, 18]]], ["The total dead space of the respiratory system is the sum of alveolar dead space and airway dead space, 82 152 234 mL.", [["respiratory system", "ANATOMY", 28, 46], ["alveolar dead space", "ANATOMY", 61, 80], ["airway", "ANATOMY", 85, 91], ["alveolar dead space", "PROBLEM", 61, 80], ["airway dead space", "TEST", 85, 102], ["total", "OBSERVATION_MODIFIER", 4, 9], ["dead space", "OBSERVATION", 10, 20], ["respiratory system", "ANATOMY", 28, 46], ["alveolar", "ANATOMY_MODIFIER", 61, 69], ["dead space", "OBSERVATION", 70, 80], ["airway", "ANATOMY", 85, 91], ["dead space", "OBSERVATION", 92, 102]]]], "48b81081bbcbdbea648394d8bf2adf370b36e44c": [["are efficacious in brief treatment settings, and our outcomes data supports this assertion.", [["brief treatment settings", "TREATMENT", 19, 43], ["efficacious", "OBSERVATION_MODIFIER", 4, 15]]], ["Limitations of the intervention include participant attrition and insufficient access to comprehensive mental health and substance use management resources.", [["the intervention", "TREATMENT", 15, 31]]], ["D. Further Recommendations: For many, maintaining treatment adherence is challenging.", [["treatment adherence", "TREATMENT", 50, 69]]], ["Implementing programs that offer unlimited sessions of mental health counseling and substance use treatment or harm-reduction strategies for people living with HIV could greatly increase treatment adherence.", [["HIV", "DISEASE", 160, 163], ["people", "ORGANISM", 141, 147], ["people", "SPECIES", 141, 147], ["HIV", "SPECIES", 160, 163], ["mental health counseling", "TREATMENT", 55, 79], ["substance use treatment", "TREATMENT", 84, 107], ["harm-reduction strategies", "TREATMENT", 111, 136], ["HIV", "PROBLEM", 160, 163]]], ["Additionally, public health policy could be modified with the aim of de-stigmatizing those living with HIV/AIDS.", [["HIV/AIDS", "DISEASE", 103, 111], ["HIV", "SPECIES", 103, 106]]], ["These changes could help mitigate the shame reported by some people living with HIV/ AIDS, potentially leading to greater help seeking behaviors and lower transmission rates.", [["HIV/ AIDS", "DISEASE", 80, 89], ["people", "ORGANISM", 61, 67], ["people", "SPECIES", 61, 67], ["HIV/ AIDS", "PROBLEM", 80, 89]]], ["Additionally, embracing HIV testing as a routine component of primary care could help to reduce HIV incidence and minimize stigma, potentially leading to a number of positive personal and public health outcomes, including increased treatment adherence.", [["HIV", "ORGANISM", 24, 27], ["HIV", "SPECIES", 24, 27], ["HIV", "SPECIES", 96, 99], ["embracing HIV testing", "TEST", 14, 35], ["primary care", "TREATMENT", 62, 74], ["HIV incidence", "PROBLEM", 96, 109], ["stigma", "PROBLEM", 123, 129], ["increased treatment adherence", "TREATMENT", 222, 251]]], ["The impact of depression on treatment adherence in individuals with End Stage Renal Disease (ESRD) has been well-supported in the literature (Hailey & Moss, 2000) ; however, the influence of anxiety on adherence is less clear.", [["Renal", "ANATOMY", 78, 83], ["depression", "DISEASE", 14, 24], ["End Stage Renal Disease", "DISEASE", 68, 91], ["ESRD", "DISEASE", 93, 97], ["anxiety", "DISEASE", 191, 198], ["Renal", "ORGAN", 78, 83], ["depression", "PROBLEM", 14, 24], ["treatment adherence", "TREATMENT", 28, 47], ["End Stage Renal Disease", "PROBLEM", 68, 91], ["ESRD", "PROBLEM", 93, 97], ["anxiety", "PROBLEM", 191, 198], ["depression", "OBSERVATION", 14, 24], ["Renal", "ANATOMY", 78, 83], ["Disease", "OBSERVATION", 84, 91], ["less", "OBSERVATION_MODIFIER", 215, 219], ["clear", "OBSERVATION", 220, 225]]], ["It has been suggested that the relationship between anxiety and adherence may be indirect and influenced by other cognitive or psychosocial variables such as locus of control or knowledge of disease (Brownbridge & Fielding, 1994 , DiMatteo et al., 2000 .", [["anxiety", "DISEASE", 52, 59], ["anxiety", "PROBLEM", 52, 59], ["disease", "PROBLEM", 191, 198]]], ["Anxiety has been related to adherence with antibiotic regimens (Cockburn et al., 1987) , and for patients with asthma (Baiardini et al., 2006) and COPD (Dowson et al., 2004) .", [["Anxiety", "DISEASE", 0, 7], ["asthma", "DISEASE", 111, 117], ["COPD", "DISEASE", 147, 151], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["Anxiety", "PROBLEM", 0, 7], ["antibiotic regimens", "TREATMENT", 43, 62], ["asthma", "PROBLEM", 111, 117], ["COPD", "PROBLEM", 147, 151], ["COPD", "OBSERVATION", 147, 151]]], ["A limitation of previous research on anxiety and adherence in ESRD is the failure to investigate the differential impact of anxiety on specific components of adherence (e.g., medication, appointment attendance, dietary guidelines).", [["anxiety", "DISEASE", 37, 44], ["ESRD", "DISEASE", 62, 66], ["anxiety", "DISEASE", 124, 131], ["anxiety", "PROBLEM", 37, 44], ["ESRD", "PROBLEM", 62, 66], ["the failure", "PROBLEM", 70, 81], ["anxiety", "PROBLEM", 124, 131]]], ["The goal of the present study was to conduct a preliminary investigation into the relationship of anxiety and renal disease knowledge to treatment adherence.", [["renal", "ANATOMY", 110, 115], ["anxiety", "DISEASE", 98, 105], ["renal", "ORGAN", 110, 115], ["the present study", "TEST", 12, 29], ["anxiety", "PROBLEM", 98, 105], ["renal disease", "PROBLEM", 110, 123], ["treatment adherence", "TREATMENT", 137, 156], ["renal", "ANATOMY", 110, 115], ["disease", "OBSERVATION", 116, 123]]], ["Data includes 124 veterans with ESRD referred for pre-surgical psychological evaluations for renal transplantation.", [["renal", "ANATOMY", 93, 98], ["ESRD", "DISEASE", 32, 36], ["renal", "ORGAN", 93, 98], ["ESRD", "PROBLEM", 32, 36], ["pre-surgical psychological evaluations", "TEST", 50, 88], ["renal transplantation", "TREATMENT", 93, 114], ["renal", "ANATOMY", 93, 98], ["transplantation", "OBSERVATION", 99, 114]]], ["Renal disease knowledge was assessed in several subcategories of diet, medication, and laboratory tests.", [["Renal", "ANATOMY", 0, 5], ["Renal", "ORGAN", 0, 5], ["Renal disease knowledge", "PROBLEM", 0, 23], ["medication", "TREATMENT", 71, 81], ["laboratory tests", "TEST", 87, 103], ["disease", "OBSERVATION", 6, 13]]], ["Adherence was assessed with respect to diet, medication, and appointment attendance.", [["medication", "TREATMENT", 45, 55]]], ["Both knowledge and adherence were rated by clinicians based on patient self-report and renal team staff-report.", [["renal", "ANATOMY", 87, 92], ["patient", "ORGANISM", 63, 70], ["renal", "ORGAN", 87, 92], ["patient", "SPECIES", 63, 70], ["renal", "ANATOMY", 87, 92]]], ["Patients were divided into \"anxious\" and \"non-anxious\" groups based on self-reported presence of anxiety symptoms.", [["anxiety", "DISEASE", 97, 104], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["anxiety symptoms", "PROBLEM", 97, 113]]], ["Data analysis on self-reported compliance revealed that there were no group differences with regard to renal disease knowledge; however, patients in the anxious group were rated as significantly more compliant with renal diet and appointment attendance than non-anxious patients (t > 2.20, p < .05).", [["renal", "ANATOMY", 103, 108], ["renal", "ANATOMY", 215, 220], ["renal disease", "DISEASE", 103, 116], ["renal", "ORGAN", 103, 108], ["patients", "ORGANISM", 137, 145], ["renal", "ORGAN", 215, 220], ["patients", "ORGANISM", 270, 278], ["patients", "SPECIES", 137, 145], ["patients", "SPECIES", 270, 278], ["Data analysis", "TEST", 0, 13], ["renal disease knowledge", "PROBLEM", 103, 126], ["t", "TEST", 280, 281], ["renal", "ANATOMY", 103, 108], ["disease", "OBSERVATION", 109, 116], ["renal", "ANATOMY", 215, 220]]], ["In addition, regression analyses indicated that anxiety and knowledge significantly predicted compliance with appointment attendance [F (1, 116) = 3.68, p = .05] and dietary adherence [F(4,115) = 5.95, p < .001].", [["anxiety", "DISEASE", 48, 55], ["regression analyses", "TEST", 13, 32], ["anxiety", "PROBLEM", 48, 55], ["dietary adherence", "TEST", 166, 183], ["F(", "TEST", 185, 187]]]], "PMC7403461": [["IntroductionCOVID-19, also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in Wuhan, China, in late 2019.", [["acute respiratory syndrome coronavirus", "DISEASE", 43, 81], ["SARS-CoV-2", "ORGANISM", 85, 95], ["severe acute respiratory syndrome coronavirus", "SPECIES", 36, 81], ["SARS-CoV-2", "SPECIES", 85, 95], ["IntroductionCOVID", "TEST", 0, 17], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 36, 81], ["severe", "OBSERVATION_MODIFIER", 36, 42], ["acute", "OBSERVATION_MODIFIER", 43, 48], ["respiratory syndrome", "OBSERVATION", 49, 69]]], ["It is a highly contagious disease with a global average mortality rate of 4.6% (1).", [["a highly contagious disease", "PROBLEM", 6, 33], ["a global average mortality rate", "TEST", 39, 70], ["highly", "OBSERVATION_MODIFIER", 8, 14], ["contagious", "OBSERVATION_MODIFIER", 15, 25], ["disease", "OBSERVATION", 26, 33], ["global", "OBSERVATION_MODIFIER", 41, 47], ["average", "OBSERVATION_MODIFIER", 48, 55], ["mortality", "OBSERVATION_MODIFIER", 56, 65]]], ["There have been ongoing efforts to develop effective treatment modalities for this dreaded pandemic.", [["effective treatment modalities", "TREATMENT", 43, 73], ["this dreaded pandemic", "PROBLEM", 78, 99]]], ["Currently, no specific therapies against SARS-CoV-2 infection exist, and a series of therapeutic agents (e.g., antiviral agents, antibiotics, immune-modulators, inhaled nitric oxide, and convalescent plasma) have been repurposed with negative to inconclusive evidence available (2).", [["plasma", "ANATOMY", 200, 206], ["SARS-CoV-2 infection", "DISEASE", 41, 61], ["nitric oxide", "CHEMICAL", 169, 181], ["nitric oxide", "CHEMICAL", 169, 181], ["SARS-CoV-2", "ORGANISM", 41, 51], ["inhaled nitric oxide", "SIMPLE_CHEMICAL", 161, 181], ["plasma", "ORGANISM_SUBSTANCE", 200, 206], ["CoV-", "SPECIES", 46, 50], ["SARS-CoV", "SPECIES", 41, 49], ["specific therapies", "TREATMENT", 14, 32], ["SARS", "PROBLEM", 41, 45], ["CoV", "PROBLEM", 46, 49], ["2 infection", "PROBLEM", 50, 61], ["therapeutic agents", "TREATMENT", 85, 103], ["antiviral agents", "TREATMENT", 111, 127], ["antibiotics", "TREATMENT", 129, 140], ["immune-modulators", "TREATMENT", 142, 159], ["inhaled nitric oxide", "TREATMENT", 161, 181], ["convalescent plasma", "TEST", 187, 206], ["infection", "OBSERVATION", 52, 61]]], ["There has been an increased interest in two existing anti-malarial drugs belonging to amino-quinoline group (Chloroquine and Hydroxy-chloroquine) to treat COVID-19.", [["amino-quinoline", "CHEMICAL", 86, 101], ["Chloroquine", "CHEMICAL", 109, 120], ["Hydroxy-chloroquine", "CHEMICAL", 125, 144], ["COVID-19", "CHEMICAL", 155, 163], ["amino-quinoline", "CHEMICAL", 86, 101], ["Chloroquine", "CHEMICAL", 109, 120], ["Hydroxy-chloroquine", "CHEMICAL", 125, 144], ["COVID-19", "CHEMICAL", 155, 163], ["amino-quinoline", "SIMPLE_CHEMICAL", 86, 101], ["Chloroquine", "SIMPLE_CHEMICAL", 109, 120], ["Hydroxy-chloroquine", "SIMPLE_CHEMICAL", 125, 144], ["an increased interest", "PROBLEM", 15, 36], ["anti-malarial drugs", "TREATMENT", 53, 72], ["amino-quinoline group", "TREATMENT", 86, 107], ["Chloroquine", "TREATMENT", 109, 120], ["Hydroxy-chloroquine)", "TREATMENT", 125, 145], ["COVID", "TEST", 155, 160], ["increased", "OBSERVATION_MODIFIER", 18, 27], ["interest", "OBSERVATION_MODIFIER", 28, 36]]], ["This is because of the inhibitory effects of these two drugs on other coronaviruses, such as SARS-CoV-1 (2, 3).", [["coronaviruses", "ORGANISM", 70, 83], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 93, 103], ["SARS-CoV-1", "SPECIES", 93, 103], ["these two drugs", "TREATMENT", 45, 60], ["other coronaviruses", "PROBLEM", 64, 83]]], ["The plausible mechanism of actions includes inhibition of angiotensin converting enzyme 2 (ACE-2) present on the cell surface for virus entry (by reduction of glycosylation in the enzyme) (4, 5), inhibition of release of viral particles into intra-cellular space (6, 7), and an anti-inflammatory effect (inhibition of interleukin-6, the tumor necrosis factor, the aberrant interferon, and other pro-inflammatory cytokines that cause lung injury leading to acute respiratory distress syndrome) (6, 8).", [["cell surface", "ANATOMY", 113, 125], ["intra-cellular", "ANATOMY", 242, 256], ["lung", "ANATOMY", 433, 437], ["respiratory", "ANATOMY", 462, 473], ["angiotensin", "CHEMICAL", 58, 69], ["tumor", "DISEASE", 337, 342], ["necrosis", "DISEASE", 343, 351], ["lung injury", "DISEASE", 433, 444], ["acute respiratory distress syndrome", "DISEASE", 456, 491], ["angiotensin converting enzyme 2", "GENE_OR_GENE_PRODUCT", 58, 89], ["ACE-2", "GENE_OR_GENE_PRODUCT", 91, 96], ["cell surface", "CELLULAR_COMPONENT", 113, 125], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 318, 331], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 337, 358], ["interferon", "GENE_OR_GENE_PRODUCT", 373, 383], ["lung", "ORGAN", 433, 437], ["angiotensin converting enzyme 2 (ACE-2", "PROTEIN", 58, 96], ["interleukin-6", "PROTEIN", 318, 331], ["tumor necrosis factor", "PROTEIN", 337, 358], ["aberrant interferon", "PROTEIN", 364, 383], ["pro-inflammatory cytokines", "PROTEIN", 395, 421], ["angiotensin converting enzyme", "TREATMENT", 58, 87], ["ACE", "TEST", 91, 94], ["virus entry", "PROBLEM", 130, 141], ["glycosylation in the enzyme", "TREATMENT", 159, 186], ["viral particles into intra-cellular space", "PROBLEM", 221, 262], ["an anti-inflammatory effect", "TREATMENT", 275, 302], ["interleukin", "TREATMENT", 318, 329], ["the tumor necrosis factor", "PROBLEM", 333, 358], ["the aberrant interferon", "TREATMENT", 360, 383], ["other pro-inflammatory cytokines", "TREATMENT", 389, 421], ["lung injury", "PROBLEM", 433, 444], ["acute respiratory distress syndrome", "PROBLEM", 456, 491], ["viral particles", "OBSERVATION", 221, 236], ["anti-inflammatory effect", "OBSERVATION", 278, 302], ["tumor", "OBSERVATION_MODIFIER", 337, 342], ["necrosis", "OBSERVATION", 343, 351], ["lung", "ANATOMY", 433, 437], ["injury", "OBSERVATION", 438, 444], ["acute", "OBSERVATION_MODIFIER", 456, 461], ["respiratory distress", "OBSERVATION", 462, 482]]], ["Chloroquine and Hydroxy-chloroquine (HCQ) are both cost-effective and considered safe as per their approved indications.", [["Chloroquine", "CHEMICAL", 0, 11], ["Hydroxy-chloroquine", "CHEMICAL", 16, 35], ["HCQ", "CHEMICAL", 37, 40], ["Chloroquine", "CHEMICAL", 0, 11], ["Hydroxy-chloroquine", "CHEMICAL", 16, 35], ["HCQ", "CHEMICAL", 37, 40], ["Chloroquine", "SIMPLE_CHEMICAL", 0, 11], ["Hydroxy-chloroquine", "SIMPLE_CHEMICAL", 16, 35], ["HCQ", "SIMPLE_CHEMICAL", 37, 40], ["Chloroquine", "TREATMENT", 0, 11], ["Hydroxy", "TREATMENT", 16, 23], ["chloroquine (HCQ)", "TREATMENT", 24, 41]]], ["Compared to Chloroquine (CQ), Hydroxy-chloroquine (HCQ) is more soluble and less toxic and is considered safer (9, 10).", [["Chloroquine", "CHEMICAL", 12, 23], ["CQ", "CHEMICAL", 25, 27], ["Hydroxy-chloroquine", "CHEMICAL", 30, 49], ["HCQ", "CHEMICAL", 51, 54], ["Chloroquine", "CHEMICAL", 12, 23], ["CQ", "CHEMICAL", 25, 27], ["Hydroxy-chloroquine", "CHEMICAL", 30, 49], ["HCQ", "CHEMICAL", 51, 54], ["Chloroquine", "SIMPLE_CHEMICAL", 12, 23], ["CQ", "SIMPLE_CHEMICAL", 25, 27], ["Hydroxy-chloroquine", "SIMPLE_CHEMICAL", 30, 49], ["HCQ", "SIMPLE_CHEMICAL", 51, 54], ["Chloroquine (CQ)", "TREATMENT", 12, 28], ["Hydroxy-chloroquine (HCQ)", "TREATMENT", 30, 55], ["more soluble", "OBSERVATION_MODIFIER", 59, 71], ["less toxic", "OBSERVATION_MODIFIER", 76, 86]]], ["It has to be kept in mind that these drugs are not entirely safe because of the risk of some serious side-effects (e.g., neuro-psychiatric, retinal, cardiac, and hypoglycemia), and there have been reports of toxicities in people who are self-medicating (11, 12).IntroductionThere have been published studies evaluating the safety and/or efficacy of these agents (alone or in combination) compared to a control arm or parallel intervention, to treat patients with COVID-19 (13\u201332).", [["retinal", "ANATOMY", 140, 147], ["cardiac", "ANATOMY", 149, 156], ["psychiatric", "DISEASE", 127, 138], ["retinal, cardiac, and hypoglycemia", "DISEASE", 140, 174], ["toxicities", "DISEASE", 208, 218], ["COVID-19", "CHEMICAL", 463, 471], ["retinal", "MULTI-TISSUE_STRUCTURE", 140, 147], ["cardiac", "ORGAN", 149, 156], ["people", "ORGANISM", 222, 228], ["patients", "ORGANISM", 449, 457], ["people", "SPECIES", 222, 228], ["patients", "SPECIES", 449, 457], ["these drugs", "TREATMENT", 31, 42], ["some serious side-effects", "PROBLEM", 88, 113], ["neuro-psychiatric", "PROBLEM", 121, 138], ["hypoglycemia", "PROBLEM", 162, 174], ["toxicities", "PROBLEM", 208, 218], ["published studies", "TEST", 290, 307], ["these agents", "TREATMENT", 349, 361], ["parallel intervention", "TREATMENT", 417, 438], ["COVID", "TEST", 463, 468], ["retinal", "ANATOMY", 140, 147], ["cardiac", "ANATOMY", 149, 156]]], ["Earlier published rapid systematic reviews have concluded the role of anti-malarial drugs in patients with COVID-19 is still uncertain, and its routine use should not be recommended until more evidence is available from ongoing studies (33, 34).", [["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["anti-malarial drugs", "TREATMENT", 70, 89], ["COVID", "TEST", 107, 112], ["ongoing studies", "TEST", 220, 235]]], ["However, these systematic reviews neither included larger observational studies and randomized clinical trials (RCTs) published recently nor provided quality (GRADE) of evidence in a more systematic manner.", [["larger observational studies", "TEST", 51, 79]]], ["In addition, findings from an ORCHID (Outcomes Related to COVID-19 treated with hydrox-ychloroquine among In-patients with symptomatic Disease) study have shown that HCQ neither harms nor benefits patients with COVID-19 infection (35).", [["hydrox-ychloroquine", "CHEMICAL", 80, 99], ["HCQ", "CHEMICAL", 166, 169], ["COVID-19", "CHEMICAL", 211, 219], ["infection", "DISEASE", 220, 229], ["hydrox-ychloroquine", "CHEMICAL", 80, 99], ["HCQ", "CHEMICAL", 166, 169], ["hydrox-ychloroquine", "SIMPLE_CHEMICAL", 80, 99], ["patients", "ORGANISM", 109, 117], ["HCQ", "SIMPLE_CHEMICAL", 166, 169], ["patients", "ORGANISM", 197, 205], ["patients", "SPECIES", 109, 117], ["patients", "SPECIES", 197, 205], ["COVID", "TEST", 58, 63], ["hydrox", "TREATMENT", 80, 86], ["ychloroquine", "TREATMENT", 87, 99], ["symptomatic Disease) study", "PROBLEM", 123, 149], ["COVID-19 infection", "PROBLEM", 211, 229]]], ["The present systematic review is an endeavor in this direction to synthesize the available evidences to inform clinical practice and guide the international agencies to formulate recommendations.Types of Studies ::: Materials and MethodsBoth clinical trials (randomized, quasi- randomized, and non-randomized) and observational studies comparing anti-malarial drugs (Chloroquine and Hydroxy-chloroquine) alone or in combination with other drugs vs. a control (standard of care) or other treatment were included.", [["Chloroquine", "CHEMICAL", 367, 378], ["Hydroxy-chloroquine", "CHEMICAL", 383, 402], ["Chloroquine", "CHEMICAL", 367, 378], ["Hydroxy-chloroquine", "CHEMICAL", 383, 402], ["Chloroquine", "SIMPLE_CHEMICAL", 367, 378], ["Hydroxy-chloroquine", "SIMPLE_CHEMICAL", 383, 402], ["observational studies", "TEST", 314, 335], ["anti-malarial drugs", "TREATMENT", 346, 365], ["Chloroquine", "TREATMENT", 367, 378], ["Hydroxy-chloroquine)", "TREATMENT", 383, 403], ["a control (standard of care", "TREATMENT", 449, 476], ["other treatment", "TREATMENT", 481, 496]]], ["As a majority of the studies were published on pre-print servers (for rapid dissemination of knowledge) prior to publication in peer-reviewed journals, we planned to include these studies in the present meta-analysis after taking permission from the study authors.Types of Participants ::: Materials and MethodsChildren of 12\u201318 years of age and adults with RT-PCR-confirmed SARS Cov-2 (COVID-19) cases treated in the hospital were included.", [["SARS", "DISEASE", 375, 379], ["Children", "ORGANISM", 311, 319], ["adults", "ORGANISM", 346, 352], ["Participants", "SPECIES", 273, 285], ["Children", "SPECIES", 311, 319], ["the studies", "TEST", 17, 28], ["these studies", "TEST", 174, 187], ["the study", "TEST", 246, 255], ["RT-PCR", "TEST", 358, 364], ["SARS Cov-", "TEST", 375, 384], ["COVID", "TEST", 387, 392]]], ["Exclusion criteria were an allergy to anti-malarial drugs [Chloroquine (CQ) and Hydroxy-chloroquine (HCQ)], retinopathy, hearing loss, and severe neuro-psychiatric diseases.Search Methodology ::: Materials and MethodsThe following major databases were searched systematically from 1970 till June 5, 2020: Cochrane Central Register of Controlled Trials (CENTRAL), PubMed/MEDLINE, Google Scholar, and EMBASE (Appendix 1).", [["allergy", "DISEASE", 27, 34], ["Chloroquine", "CHEMICAL", 59, 70], ["CQ", "CHEMICAL", 72, 74], ["Hydroxy-chloroquine", "CHEMICAL", 80, 99], ["HCQ", "CHEMICAL", 101, 104], ["retinopathy", "DISEASE", 108, 119], ["hearing loss", "DISEASE", 121, 133], ["neuro-psychiatric diseases", "DISEASE", 146, 172], ["Chloroquine", "CHEMICAL", 59, 70], ["CQ", "CHEMICAL", 72, 74], ["Hydroxy-chloroquine", "CHEMICAL", 80, 99], ["HCQ", "CHEMICAL", 101, 104], ["Chloroquine", "SIMPLE_CHEMICAL", 59, 70], ["CQ", "SIMPLE_CHEMICAL", 72, 74], ["Hydroxy-chloroquine", "SIMPLE_CHEMICAL", 80, 99], ["HCQ", "SIMPLE_CHEMICAL", 101, 104], ["an allergy", "PROBLEM", 24, 34], ["anti-malarial drugs", "TREATMENT", 38, 57], ["Chloroquine (CQ)", "TREATMENT", 59, 75], ["Hydroxy", "TREATMENT", 80, 87], ["chloroquine (HCQ)", "TREATMENT", 88, 105], ["retinopathy", "PROBLEM", 108, 119], ["hearing loss", "PROBLEM", 121, 133], ["severe neuro-psychiatric diseases", "PROBLEM", 139, 172], ["retinopathy", "OBSERVATION", 108, 119], ["hearing loss", "OBSERVATION", 121, 133], ["severe", "OBSERVATION_MODIFIER", 139, 145], ["neuro-psychiatric diseases", "OBSERVATION", 146, 172]]], ["We also searched the Pre-print servers (medRxiv, bioRxiv, OSF pre-prints, Pre-prints.org) till June 5, 2020.", [["medRxiv", "TREATMENT", 40, 47], ["bioRxiv", "TREATMENT", 49, 56]]], ["The PubMed/Medline search strategy used the various MeSH and free text terms for \u201cnovel corona virus,\u201d \u201cCOVID 19,\u201d \u201cHydroxychloroquine,\u201d and \u201cChloroquine\u201d combined using the Boolean operators.", [["Hydroxychloroquine", "CHEMICAL", 116, 134], ["Chloroquine", "CHEMICAL", 142, 153], ["Hydroxychloroquine", "CHEMICAL", 116, 134], ["Chloroquine", "CHEMICAL", 142, 153], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 116, 134], ["Chloroquine", "SIMPLE_CHEMICAL", 142, 153], ["the various MeSH", "TREATMENT", 40, 56], ["novel corona virus", "PROBLEM", 82, 100], ["Hydroxychloroquine", "TREATMENT", 116, 134], ["\u201d", "TREATMENT", 135, 136], ["Chloroquine", "TREATMENT", 142, 153]]], ["No language restrictions were applied.", [["language restrictions", "TREATMENT", 3, 24], ["language restrictions", "OBSERVATION", 3, 24]]], ["Three reviewers (RRD, NJ, and ND) reviewed the search results to identify relevant studies.Data Extraction ::: Materials and MethodsData extraction was done using a data extraction form that was designed and pilot tested a priori.", [["MethodsData extraction", "TEST", 125, 147], ["a data extraction", "TREATMENT", 163, 180]]], ["Three authors (NJ, ND, and SSN) independently extracted the following information from each study: author; year; location (country); study design (clinical trial or observational study); setting (hospital or community); method of recruitment; inclusion criteria; unit of analysis; allocation ratio In case of RCT); risk of bias; participants (age, sex, sample size, and disease severity); intervention (dosage, duration, frequency, and co-intervention if any); outcomes (outcome definition, valid unit of measurement, time points of collection and reporting); loss to follow-up; and miscellaneous (key conclusions, references to other relevant trials, and additional data required).Assessment of Risk of Bias in the Included Studies ::: Materials and MethodsTwo review authors independently (NJ and SSN) assessed the methodological quality of the selected trials by using methodological quality assessment forms and the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (38).", [["participants", "SPECIES", 329, 341], ["observational study", "TEST", 165, 184], ["analysis", "TEST", 271, 279], ["allocation ratio", "TEST", 281, 297], ["disease severity", "PROBLEM", 370, 386], ["intervention", "TREATMENT", 389, 401], ["methodological quality assessment", "TEST", 872, 905]]], ["Quality assessment was undertaken using the Newcastle Ottawa Scale (NOS) for observational studies.", [["Quality assessment", "TEST", 0, 18], ["observational studies", "TEST", 77, 98]]], ["This scale assesses the quality under three major headings, namely, selection of the studies (representativeness and the exposure assessment/control selection), comparability (adjustment for main/additional confounders), and outcome/exposure (adequacy of outcome measured, exposure measured vs. self-report) (39).", [["This scale", "TEST", 0, 10], ["the studies", "TEST", 81, 92], ["the exposure assessment", "TEST", 117, 140]]], ["Quality assessment was undertaken using the ROBINS-I tool for non-randomized trials (40).", [["Quality assessment", "TEST", 0, 18], ["non-randomized trials", "TREATMENT", 62, 83]]], ["Any disagreements between the two review authors were resolved through discussion with a third author (JS).Dealing With Missing Data ::: Materials and MethodsWe described missing data, including dropouts in included studies.", [["studies", "TEST", 216, 223]]], ["Differential dropout rates can lead to biased estimates of the effect size, and bias may arise if the reasons for dropping out differ across groups.", [["Differential dropout rates", "PROBLEM", 0, 26], ["the effect size", "PROBLEM", 59, 74], ["dropping out differ across groups", "PROBLEM", 114, 147], ["size", "OBSERVATION_MODIFIER", 70, 74]]], ["We reported reasons participants dropped out of studies as mentioned by the authors.", [["participants", "SPECIES", 20, 32]]], ["The data from various studies were pooled and expressed as mean difference (MD) with 95% confidence interval (CI) in case of continuous data, and odds ratio (OR) with 95% CI in case of categorical data.", [["various studies", "TEST", 14, 29], ["continuous data", "TEST", 125, 140], ["categorical data", "TEST", 185, 201]]], ["The primary pooled analysis of all the reports was conducted using the Generic Inverse Variance method using random effects weighting (43), where the log RRs for cohort studies or log ORs for case\u2013control studies were weighted by the inverse of the variance to obtain a pooled RR estimate.", [["the Generic Inverse Variance method", "TREATMENT", 67, 102], ["the log RRs", "TEST", 146, 157], ["cohort studies", "TEST", 162, 176], ["case\u2013control studies", "TEST", 192, 212], ["a pooled RR estimate", "TEST", 268, 288]]], ["Since nested case-cohort and nested case\u2013control studies are temporally prospective, we analyzed data from these studies with the prospective studies.", [["nested case\u2013control studies", "TEST", 29, 56], ["these studies", "TEST", 107, 120], ["the prospective studies", "TEST", 126, 149]]], ["An I2 \u2265 50% indicated \u201csubstantial\u201d heterogeneity and \u226575% indicated \u201cconsiderable\u201d heterogeneity (44).", [["An I2", "TEST", 0, 5], ["substantial\u201d heterogeneity", "PROBLEM", 23, 49], ["considerable\u201d heterogeneity", "PROBLEM", 70, 97], ["substantial", "OBSERVATION_MODIFIER", 23, 34]]], ["The cause of substantial and considerable heterogeneity was explored, and sensitivity and/or sub-group analyses were carried out.Publication Bias ::: Materials and MethodsTo evaluate for any possible publication bias, we constructed the funnel plot from primary outcome data (45).Grade of Evidence ::: Materials and MethodsTo assess the quality of evidence we used GRADE Profiler software (V.3.2) (46, 47).", [["considerable heterogeneity", "PROBLEM", 29, 55], ["sensitivity", "TEST", 74, 85], ["sub-group analyses", "TEST", 93, 111], ["Methods", "TREATMENT", 164, 171], ["publication bias", "PROBLEM", 200, 216], ["the funnel plot", "TEST", 233, 248], ["primary outcome data", "TEST", 254, 274], ["Methods", "TREATMENT", 316, 323], ["GRADE Profiler software", "TEST", 365, 388], ["substantial", "OBSERVATION_MODIFIER", 13, 24], ["considerable", "OBSERVATION_MODIFIER", 29, 41], ["heterogeneity", "OBSERVATION", 42, 55]]], ["The parameters used were limitations to design of randomized controlled trials, inconsistency of results or unexplained heterogeneity, indirectness of evidence, imprecision of results, and publication bias.", [["randomized controlled trials", "TREATMENT", 50, 78], ["unexplained heterogeneity", "PROBLEM", 108, 133]]], ["The rating was determined as no, serious, or very serious limitations.Description of Studies ::: ResultsOf 3,472 total citations retrieved, the full texts of 49 papers were assessed for eligibility, and 29 were excluded for various reasons (Figure 1).", [["The rating", "TEST", 0, 10], ["eligibility", "TEST", 186, 197]]], ["Of the remaining 20 eligible studies, 14 were published in peer-reviewed journals (13\u201329) and six in pre-print servers (not peer-reviewed) (17, 28\u201332).", [["the remaining 20 eligible studies", "TEST", 3, 36]]], ["We contacted the authors of these six studies to give us their permission to use their data in the meta-analysis, but only three authors gave their permission (17, 28, 29).", [["these six studies", "TEST", 28, 45]]], ["We therefore included the data of three studies in the meta-analysis and described the characteristics of the remaining three studies using a separate table (Supplementary Table 1).", [["three studies", "TEST", 34, 47], ["the meta-analysis", "TEST", 51, 68]]], ["Finally, we were able to conduct a meta-analysis of a total of 17 studies (six clinical trials and 11 observational studies) including 8,071 patients (Adults = 8,041; Adolescents = 30) (Table 1).", [["patients", "ORGANISM", 141, 149], ["patients", "SPECIES", 141, 149], ["observational studies", "TEST", 102, 123], ["Adolescents", "TEST", 167, 178]]], ["Twenty-nine studies were excluded for the following reasons: 19 were case series (without having a control/comparator that is inclusion criteria of present review), nine studies mentioned about intervention but did not provide outcome data for them separately, and one study reported use of anti-malarial drugs with or without AZM in rheumatoid arthritis (RA) patients for non-RA indications (including viral and other infections).Description of Studies ::: ResultsOf 17 published peer-reviewed studies included, six clinical trials provide data of 381 patients, and the 11 observational studies provided data of 8,071 patients.", [["AZM", "CHEMICAL", 327, 330], ["rheumatoid arthritis", "DISEASE", 334, 354], ["RA", "DISEASE", 356, 358], ["viral and other infections", "DISEASE", 403, 429], ["AZM", "CHEMICAL", 327, 330], ["AZM", "SIMPLE_CHEMICAL", 327, 330], ["patients", "ORGANISM", 360, 368], ["patients", "ORGANISM", 553, 561], ["patients", "ORGANISM", 619, 627], ["patients", "SPECIES", 360, 368], ["patients", "SPECIES", 553, 561], ["patients", "SPECIES", 619, 627], ["nine studies", "TEST", 7, 19], ["nine studies", "TEST", 165, 177], ["intervention", "TREATMENT", 194, 206], ["anti-malarial drugs", "TREATMENT", 291, 310], ["AZM in rheumatoid arthritis", "PROBLEM", 327, 354], ["non-RA indications", "PROBLEM", 373, 391], ["viral and other infections", "PROBLEM", 403, 429], ["the 11 observational studies", "TEST", 567, 595], ["rheumatoid", "ANATOMY", 334, 344], ["arthritis", "OBSERVATION", 345, 354], ["infections", "OBSERVATION", 419, 429]]], ["A total of 4,009 patients received HCQ or CQ (clinical trials = 226, observational studies = 3,783), and 1,255 received a combination of HCQ plus Azithromycin (clinical trials = 06, observational studies = 1,249).", [["HCQ", "CHEMICAL", 35, 38], ["CQ", "CHEMICAL", 42, 44], ["HCQ", "CHEMICAL", 137, 140], ["Azithromycin", "CHEMICAL", 146, 158], ["HCQ", "CHEMICAL", 35, 38], ["HCQ", "CHEMICAL", 137, 140], ["Azithromycin", "CHEMICAL", 146, 158], ["patients", "ORGANISM", 17, 25], ["HCQ", "SIMPLE_CHEMICAL", 35, 38], ["CQ", "SIMPLE_CHEMICAL", 42, 44], ["HCQ", "SIMPLE_CHEMICAL", 137, 140], ["Azithromycin", "SIMPLE_CHEMICAL", 146, 158], ["patients", "SPECIES", 17, 25], ["HCQ", "TREATMENT", 35, 38], ["observational studies", "TEST", 69, 90], ["HCQ", "TREATMENT", 137, 140], ["Azithromycin", "TREATMENT", 146, 158], ["observational studies", "TEST", 182, 203]]], ["The studies were conducted in following countries: USA (five studies, 3,985 patients), Spain (two studies, 2,185 patients), China (four studies, 752 patients), France (two studies, 217 patients), Brazil (one study, 81 patients), and the UAE (one study, 34 patients).", [["patients", "ORGANISM", 76, 84], ["patients", "ORGANISM", 113, 121], ["patients", "ORGANISM", 149, 157], ["patients", "ORGANISM", 185, 193], ["patients", "ORGANISM", 218, 226], ["patients", "ORGANISM", 256, 264], ["patients", "SPECIES", 76, 84], ["patients", "SPECIES", 113, 121], ["patients", "SPECIES", 149, 157], ["patients", "SPECIES", 185, 193], ["patients", "SPECIES", 218, 226], ["patients", "SPECIES", 256, 264], ["The studies", "TEST", 0, 11], ["the UAE", "TEST", 233, 240], ["one study", "TEST", 242, 251]]], ["One trial compared high vs. low-dose of Chloroquine (18).", [["Chloroquine", "CHEMICAL", 40, 51], ["Chloroquine", "CHEMICAL", 40, 51], ["Chloroquine", "SIMPLE_CHEMICAL", 40, 51], ["Chloroquine", "TREATMENT", 40, 51]]], ["One clinical trial (13) and six observational studies (19\u201322, 25, 27); each had three arms of comparison (HCQ, HCQ+AZM, and Control).", [["HCQ", "CHEMICAL", 106, 109], ["HCQ", "CHEMICAL", 111, 114], ["AZM", "CHEMICAL", 115, 118], ["HCQ", "CHEMICAL", 106, 109], ["HCQ", "CHEMICAL", 111, 114], ["AZM", "CHEMICAL", 115, 118], ["HCQ", "SIMPLE_CHEMICAL", 106, 109], ["HCQ", "SIMPLE_CHEMICAL", 111, 114], ["six observational studies", "TEST", 28, 53], ["HCQ", "TEST", 106, 109], ["HCQ", "TREATMENT", 111, 114], ["AZM", "TREATMENT", 115, 118]]], ["Two studies included data on adolescents (<18 years) (13, 21).", [["adolescents", "SPECIES", 29, 40], ["Two studies", "TEST", 0, 11]]], ["Two studies used Azithromycin but did not provide separate outcome data for both the groups (19, 20).", [["Azithromycin", "CHEMICAL", 17, 29], ["Azithromycin", "CHEMICAL", 17, 29], ["Azithromycin", "SIMPLE_CHEMICAL", 17, 29], ["Two studies", "TEST", 0, 11], ["Azithromycin", "TREATMENT", 17, 29]]], ["Of the six clinical trials, three were described as double blinded, two were open label, and one was a non-randomized trial.Description of Studies ::: ResultsAs shown in Table 1, the age of included participants, severity of illness, dose schedule, and timing of administration of intervention (HCQ/CQ) varied widely among the studies.", [["illness", "DISEASE", 225, 232], ["HCQ", "CHEMICAL", 295, 298], ["CQ", "CHEMICAL", 299, 301], ["participants", "SPECIES", 199, 211], ["a non-randomized trial", "TREATMENT", 101, 123], ["dose schedule", "TREATMENT", 234, 247], ["intervention (HCQ/CQ", "TREATMENT", 281, 301], ["the studies", "TEST", 323, 334]]], ["Majority of the participants in the clinical trials were \u2264 50 yr of age, whereas, majority of the participants in the observational studies (except one) were \u226560 yr of age.", [["participants", "ORGANISM", 16, 28], ["participants", "SPECIES", 16, 28], ["participants", "SPECIES", 98, 110]]], ["Around 72% of participants in the clinical trials were having mild and moderate illness, whereas <40% of the participants in the observational studies were having mild and moderate illness.", [["illness", "DISEASE", 80, 87], ["illness", "DISEASE", 181, 188], ["participants", "ORGANISM", 14, 26], ["participants", "ORGANISM", 109, 121], ["participants", "SPECIES", 14, 26], ["participants", "SPECIES", 109, 121], ["mild and moderate illness", "PROBLEM", 62, 87], ["the observational studies", "TEST", 125, 150], ["mild and moderate illness", "PROBLEM", 163, 188], ["mild", "OBSERVATION_MODIFIER", 62, 66], ["moderate", "OBSERVATION_MODIFIER", 71, 79], ["illness", "OBSERVATION", 80, 87], ["mild", "OBSERVATION_MODIFIER", 163, 167], ["moderate", "OBSERVATION_MODIFIER", 172, 180], ["illness", "OBSERVATION", 181, 188]]], ["One study included only cancer patients (27).", [["cancer", "ANATOMY", 24, 30], ["cancer", "DISEASE", 24, 30], ["cancer", "CANCER", 24, 30], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["One study", "TEST", 0, 9], ["cancer", "OBSERVATION", 24, 30]]], ["The dose of CQ was nearly uniform (except one RCT comparing high and low-dose) with duration varying from 5 to 10 days.", [["CQ", "CHEMICAL", 12, 14], ["CQ", "SIMPLE_CHEMICAL", 12, 14], ["CQ", "PROBLEM", 12, 14]]], ["The dose of HCQ varied widely with the lowest dose being 200 mg/d\u22121,200 mg on day 1 followed by variable doses for variable period (sometime till discharge/death).", [["HCQ", "CHEMICAL", 12, 15], ["death", "DISEASE", 156, 161], ["HCQ", "CHEMICAL", 12, 15], ["HCQ", "SIMPLE_CHEMICAL", 12, 15], ["HCQ", "TREATMENT", 12, 15], ["the lowest dose", "TREATMENT", 35, 50]]], ["Two studies did not provide any information on dose schedule of HCQ (26, 27).", [["HCQ", "CHEMICAL", 64, 67], ["HCQ", "CHEMICAL", 64, 67], ["HCQ", "SIMPLE_CHEMICAL", 64, 67], ["Two studies", "TEST", 0, 11], ["HCQ", "TREATMENT", 64, 67]]], ["The median time from onset of symptom to admission or treatment initiation was \u2264 8 days in all but two studies (one RCT has 17 days, and one observational study has 10 days).", [["symptom", "PROBLEM", 30, 37], ["treatment initiation", "TREATMENT", 54, 74], ["two studies", "TEST", 99, 110], ["one observational study", "TEST", 137, 160]]], ["Two studies did not provide any information on the timing of initiation of HCQ (26, 27).", [["HCQ", "CHEMICAL", 75, 78], ["HCQ", "CHEMICAL", 75, 78], ["HCQ", "SIMPLE_CHEMICAL", 75, 78], ["Two studies", "TEST", 0, 11], ["HCQ", "TREATMENT", 75, 78]]], ["Except one study (17), no other study was able to start the intervention (HCQ/CQ) in the early phase of illness (within 48 h of symptom onset), which is regarded as the golden window for antiviral treatment (e.g., in influenza) (48).Risk of Bias in Included Studies ::: ResultsThe details have been provided in Appendix 2.", [["HCQ", "CHEMICAL", 74, 77], ["CQ", "CHEMICAL", 78, 80], ["illness", "DISEASE", 104, 111], ["influenza", "DISEASE", 217, 226], ["one study", "TEST", 7, 16], ["other study", "TEST", 26, 37], ["the intervention", "TREATMENT", 56, 72], ["HCQ/CQ", "TREATMENT", 74, 80], ["antiviral treatment", "TREATMENT", 187, 206], ["influenza", "PROBLEM", 217, 226]]], ["Except two trials (17, 18), others had low to high-risk of bias in different domains.", [["bias in different domains", "PROBLEM", 59, 84]]], ["Of the 11 observational studies, five were at a high risk of bias for selection of cases (22, 23, 25, 28, 29).", [["the 11 observational studies", "TEST", 3, 31], ["cases", "TEST", 83, 88]]], ["Except for one study (27), the remaining 10 studies were at a high risk of bias for selection of controls and a low risk of bias for the exposure parameters.HCQ plus azithromycin (AZM) ::: Primary Outcomes (All-Cause Mortality) ::: Effect of Interventions ::: ResultsFour studies (N = 2,310) reported a significant increase in the mortality rate in the HCQ plus AZM group compared to the control group (OR 2.84; 95% CI 2.19\u20133.69; p < 0.001) (19, 21, 25, 27) (Figure 3).", [["HCQ", "CHEMICAL", 157, 160], ["azithromycin", "CHEMICAL", 166, 178], ["AZM", "CHEMICAL", 180, 183], ["HCQ", "CHEMICAL", 353, 356], ["AZM", "CHEMICAL", 362, 365], ["HCQ", "CHEMICAL", 157, 160], ["azithromycin", "CHEMICAL", 166, 178], ["AZM", "CHEMICAL", 180, 183], ["HCQ", "CHEMICAL", 353, 356], ["AZM", "CHEMICAL", 362, 365], ["HCQ", "SIMPLE_CHEMICAL", 157, 160], ["azithromycin", "SIMPLE_CHEMICAL", 166, 178], ["AZM", "SIMPLE_CHEMICAL", 180, 183], ["HCQ", "SIMPLE_CHEMICAL", 353, 356], ["AZM", "SIMPLE_CHEMICAL", 362, 365], ["one study", "TEST", 11, 20], ["the remaining 10 studies", "TEST", 27, 51], ["selection of controls", "TREATMENT", 84, 105], ["the exposure parameters", "TEST", 133, 156], ["HCQ", "TREATMENT", 157, 160], ["azithromycin (AZM", "TREATMENT", 166, 183], ["ResultsFour studies", "TEST", 260, 279], ["the mortality rate", "TEST", 327, 345], ["AZM group", "TREATMENT", 362, 371], ["CI", "TEST", 416, 418], ["p", "TEST", 430, 431], ["significant", "OBSERVATION_MODIFIER", 303, 314], ["increase", "OBSERVATION_MODIFIER", 315, 323]]], ["Another study used Azithromycin in treatment but did not provide separate data (19).HCQ vs. HCQ plus AZM ::: Primary Outcomes (All-Cause Mortality) ::: Effect of Interventions ::: ResultsFive studies (N = 1,988) reported mortality rate, and found a significant decrease in HCQ group (OR 0.7; 95% CI 0.54\u20130.9; p = 0.006; I2 = 0%) (19, 21, 22, 25, 27).High-dose vs. low-dose CQ ::: Primary Outcomes (All-Cause Mortality) ::: Effect of Interventions ::: ResultsOne RCT (N = 81) found a significantly higher mortality rate in the high-dose group (OR 3.63; 95% CI 1.24\u201310.58; p = 0.02) (Supplementary Figure 2) (18).Secondary Outcomes ::: Effect of Interventions ::: ResultsDetails have been provided in Table 2.", [["Azithromycin", "CHEMICAL", 19, 31], ["HCQ", "CHEMICAL", 84, 87], ["HCQ", "CHEMICAL", 92, 95], ["AZM", "CHEMICAL", 101, 104], ["HCQ", "CHEMICAL", 273, 276], ["CQ", "CHEMICAL", 373, 375], ["Azithromycin", "CHEMICAL", 19, 31], ["HCQ", "CHEMICAL", 84, 87], ["HCQ", "CHEMICAL", 92, 95], ["AZM", "CHEMICAL", 101, 104], ["HCQ", "CHEMICAL", 273, 276], ["Azithromycin", "SIMPLE_CHEMICAL", 19, 31], ["HCQ", "SIMPLE_CHEMICAL", 84, 87], ["HCQ", "SIMPLE_CHEMICAL", 92, 95], ["AZM", "SIMPLE_CHEMICAL", 101, 104], ["HCQ", "SIMPLE_CHEMICAL", 273, 276], ["Another study", "TEST", 0, 13], ["Azithromycin in treatment", "TREATMENT", 19, 44], ["HCQ", "TEST", 84, 87], ["mortality rate", "TEST", 221, 235], ["a significant decrease in HCQ group", "PROBLEM", 247, 282], ["CI", "TEST", 296, 298], ["p", "TEST", 309, 310], ["I2", "TEST", 320, 322], ["a significantly higher mortality rate", "PROBLEM", 481, 518], ["CI", "TEST", 556, 558], ["p", "TEST", 571, 572], ["significant", "OBSERVATION_MODIFIER", 249, 260], ["decrease", "OBSERVATION_MODIFIER", 261, 269], ["HCQ", "OBSERVATION_MODIFIER", 273, 276]]], ["A majority of the outcome measures favored the Control group (i.e., the Control was better than HCQ\u00b1AZM), and these were the occurrence of adverse events [any events (Supplementary Figure 3), or only cardiac events, or only vomiting], development of severe disease, and duration of hospitalization.", [["cardiac", "ANATOMY", 200, 207], ["HCQ", "CHEMICAL", 96, 99], ["cardiac events", "DISEASE", 200, 214], ["vomiting", "DISEASE", 224, 232], ["HCQ", "CHEMICAL", 96, 99], ["cardiac", "ORGAN", 200, 207], ["adverse events", "PROBLEM", 139, 153], ["any events", "PROBLEM", 155, 165], ["cardiac events", "PROBLEM", 200, 214], ["vomiting", "PROBLEM", 224, 232], ["severe disease", "PROBLEM", 250, 264], ["majority", "OBSERVATION_MODIFIER", 2, 10], ["severe", "OBSERVATION_MODIFIER", 250, 256], ["disease", "OBSERVATION", 257, 264]]], ["Those favored HCQ group (i.e., HCQ\u00b1AZM was better than Control) were resolution of cough, proportion of patients with negative COVID-19 PCR after days 5, 10, and 14, proportion of patients with improved radiological features after day 5, change in IL-6 level (pg/mL), and change in total leukocyte count (/cumm).", [["leukocyte", "ANATOMY", 288, 297], ["HCQ", "CHEMICAL", 14, 17], ["HCQ", "CHEMICAL", 31, 34], ["AZM", "CHEMICAL", 35, 38], ["cough", "DISEASE", 83, 88], ["HCQ", "CHEMICAL", 14, 17], ["HCQ", "CHEMICAL", 31, 34], ["AZM", "CHEMICAL", 35, 38], ["HCQ", "SIMPLE_CHEMICAL", 14, 17], ["patients", "ORGANISM", 104, 112], ["patients", "ORGANISM", 180, 188], ["IL-6", "GENE_OR_GENE_PRODUCT", 248, 252], ["leukocyte", "CELL", 288, 297], ["IL", "PROTEIN", 248, 250], ["patients", "SPECIES", 104, 112], ["patients", "SPECIES", 180, 188], ["HCQ\u00b1AZM", "TREATMENT", 31, 38], ["cough", "PROBLEM", 83, 88], ["COVID", "TEST", 127, 132], ["total leukocyte count", "TEST", 282, 303], ["cough", "OBSERVATION", 83, 88], ["total leukocyte count", "OBSERVATION", 282, 303]]], ["The outcomes that favored HCQ over HCQ plus AZM were mortality rate and the development of severe disease.", [["HCQ", "CHEMICAL", 26, 29], ["HCQ", "CHEMICAL", 35, 38], ["AZM", "CHEMICAL", 44, 47], ["HCQ", "CHEMICAL", 26, 29], ["HCQ", "CHEMICAL", 35, 38], ["AZM", "CHEMICAL", 44, 47], ["HCQ", "SIMPLE_CHEMICAL", 26, 29], ["HCQ", "SIMPLE_CHEMICAL", 35, 38], ["AZM", "SIMPLE_CHEMICAL", 44, 47], ["HCQ over HCQ", "TREATMENT", 26, 38], ["AZM", "TREATMENT", 44, 47], ["mortality rate", "TEST", 53, 67], ["severe disease", "PROBLEM", 91, 105], ["severe", "OBSERVATION_MODIFIER", 91, 97], ["disease", "OBSERVATION", 98, 105]]], ["Contrary to common belief, no difference between HCQ and HCQ plus AZM was found for any type of adverse cardiac events.Publication Bias ::: ResultsThe funnel plot was asymmetrical showing publication bias (Supplementary Figure 4).", [["cardiac", "ANATOMY", 104, 111], ["HCQ", "CHEMICAL", 49, 52], ["HCQ", "CHEMICAL", 57, 60], ["AZM", "CHEMICAL", 66, 69], ["adverse cardiac events", "DISEASE", 96, 118], ["HCQ", "CHEMICAL", 49, 52], ["HCQ", "CHEMICAL", 57, 60], ["AZM", "CHEMICAL", 66, 69], ["HCQ", "SIMPLE_CHEMICAL", 49, 52], ["HCQ", "SIMPLE_CHEMICAL", 57, 60], ["AZM", "SIMPLE_CHEMICAL", 66, 69], ["cardiac", "ORGAN", 104, 111], ["HCQ", "TEST", 49, 52], ["AZM", "TREATMENT", 66, 69], ["adverse cardiac events", "PROBLEM", 96, 118], ["The funnel plot", "TEST", 147, 162], ["publication bias", "PROBLEM", 188, 204]]], ["The reasons for publication bias were heterogeneity among studies, poor methodological design, and selective outcome reporting.Grade of Evidence ::: ResultsThe evidence generated was of \u201cvery low quality\u201d for all the outcomes (primary and secondary).", [["publication bias", "PROBLEM", 16, 32], ["\u201cvery low quality\u201d", "PROBLEM", 186, 204]]], ["A detailed analysis of the summary of evidence is provided in Table 3.Summary of Evidence ::: DiscussionAfter an extensive search of the literature, we included 17 studies with data of 8,071 participants.", [["participants", "SPECIES", 191, 203], ["A detailed analysis", "TEST", 0, 19], ["17 studies", "TEST", 161, 171]]], ["Compared to control, HCQ alone (not HCQ+AZM combination) has no significant effect on mortality or risk of adverse cardiac events.", [["cardiac", "ANATOMY", 115, 122], ["HCQ", "CHEMICAL", 21, 24], ["HCQ", "CHEMICAL", 36, 39], ["AZM", "CHEMICAL", 40, 43], ["HCQ", "CHEMICAL", 21, 24], ["HCQ", "CHEMICAL", 36, 39], ["AZM", "CHEMICAL", 40, 43], ["HCQ", "SIMPLE_CHEMICAL", 21, 24], ["HCQ", "SIMPLE_CHEMICAL", 36, 39], ["AZM", "SIMPLE_CHEMICAL", 40, 43], ["cardiac", "ORGAN", 115, 122], ["HCQ", "TREATMENT", 21, 24], ["AZM", "TREATMENT", 40, 43], ["adverse cardiac events", "PROBLEM", 107, 129], ["no", "UNCERTAINTY", 61, 63], ["significant", "OBSERVATION_MODIFIER", 64, 75], ["effect", "OBSERVATION_MODIFIER", 76, 82]]], ["The evidence for all the outcomes was of \u201cvery low quality.\u201dSummary of Evidence ::: DiscussionThe high mortality and increased risk of adverse events with anti-malarial drugs noted by some studies may be overestimated because of the inclusion of an older population with underlying co-morbidities (including cardiac conditions) and simultaneous use of other cardiotoxic drugs (e.g., Azithromycin, and Oseltamivir).", [["cardiac", "ANATOMY", 308, 315], ["cardiotoxic", "DISEASE", 358, 369], ["Azithromycin", "CHEMICAL", 383, 395], ["Oseltamivir", "CHEMICAL", 401, 412], ["Azithromycin", "CHEMICAL", 383, 395], ["Oseltamivir", "CHEMICAL", 401, 412], ["cardiac", "ORGAN", 308, 315], ["Azithromycin", "SIMPLE_CHEMICAL", 383, 395], ["Oseltamivir", "SIMPLE_CHEMICAL", 401, 412], ["\u201cvery low quality", "PROBLEM", 41, 58], ["The high mortality", "PROBLEM", 94, 112], ["adverse events", "PROBLEM", 135, 149], ["anti-malarial drugs", "TREATMENT", 155, 174], ["some studies", "TEST", 184, 196], ["underlying co-morbidities", "PROBLEM", 271, 296], ["cardiac conditions", "PROBLEM", 308, 326], ["other cardiotoxic drugs", "TREATMENT", 352, 375], ["Azithromycin", "TREATMENT", 383, 395], ["Oseltamivir", "TREATMENT", 401, 412], ["high", "OBSERVATION_MODIFIER", 98, 102], ["mortality", "OBSERVATION_MODIFIER", 103, 112], ["increased", "OBSERVATION_MODIFIER", 117, 126]]], ["The same may be difficult to know during the current pandemic as there is no definitive treatment, and healthcare professionals all over the world want to administer these experimental drugs with the hope of saving some lives.", [["these experimental drugs", "TREATMENT", 166, 190], ["no definitive", "UNCERTAINTY", 74, 87]]], ["The use of HCQ+AZM has drawn attention, and there are differences in opinion regarding use of this combination.", [["HCQ", "CHEMICAL", 11, 14], ["AZM", "CHEMICAL", 15, 18], ["HCQ", "CHEMICAL", 11, 14], ["AZM", "CHEMICAL", 15, 18], ["HCQ", "SIMPLE_CHEMICAL", 11, 14], ["AZM", "SIMPLE_CHEMICAL", 15, 18], ["HCQ+AZM", "TREATMENT", 11, 18], ["this combination", "TREATMENT", 94, 110]]], ["Compared to control, HCQ+AZM combination was found to increase the mortality rate significantly, in contrast to HCQ alone.", [["HCQ", "CHEMICAL", 21, 24], ["AZM", "CHEMICAL", 25, 28], ["HCQ", "CHEMICAL", 112, 115], ["HCQ", "CHEMICAL", 21, 24], ["AZM", "CHEMICAL", 25, 28], ["HCQ", "CHEMICAL", 112, 115], ["HCQ", "SIMPLE_CHEMICAL", 21, 24], ["AZM", "SIMPLE_CHEMICAL", 25, 28], ["HCQ", "SIMPLE_CHEMICAL", 112, 115], ["HCQ", "TREATMENT", 21, 24], ["AZM", "TREATMENT", 25, 28], ["the mortality rate", "TEST", 63, 81]]], ["Compared to HCQ+AZM combination, HCQ alone was significantly decreasing the mortality rate.", [["HCQ", "CHEMICAL", 12, 15], ["AZM", "CHEMICAL", 16, 19], ["HCQ", "CHEMICAL", 33, 36], ["HCQ", "CHEMICAL", 12, 15], ["AZM", "CHEMICAL", 16, 19], ["HCQ", "CHEMICAL", 33, 36], ["HCQ", "SIMPLE_CHEMICAL", 12, 15], ["AZM", "SIMPLE_CHEMICAL", 16, 19], ["HCQ", "SIMPLE_CHEMICAL", 33, 36], ["HCQ", "TREATMENT", 12, 15], ["AZM combination", "TREATMENT", 16, 31], ["HCQ", "TREATMENT", 33, 36]]], ["These indirect evidences suggest that HCQ+AZM might increase the mortality rate, and caution should be exercised while using this combination in vulnerable population (e.g., those with advanced age, underlying cardiac conditions, and those receiving medication with cardiac side-effects, as noted in the included studies).Summary of Evidence ::: DiscussionIt has to be kept in mind that, the anti-viral action of anti-malarial drugs against COVID-19 is still largely unknown (49, 50).", [["cardiac", "ANATOMY", 210, 217], ["cardiac", "ANATOMY", 266, 273], ["HCQ", "CHEMICAL", 38, 41], ["AZM", "CHEMICAL", 42, 45], ["COVID-19", "CHEMICAL", 441, 449], ["HCQ", "CHEMICAL", 38, 41], ["AZM", "CHEMICAL", 42, 45], ["COVID-19", "CHEMICAL", 441, 449], ["HCQ", "SIMPLE_CHEMICAL", 38, 41], ["AZM", "SIMPLE_CHEMICAL", 42, 45], ["cardiac", "ORGAN", 210, 217], ["COVID-19", "ORGANISM", 441, 449], ["HCQ", "TEST", 38, 41], ["AZM", "PROBLEM", 42, 45], ["the mortality rate", "TEST", 61, 79], ["underlying cardiac conditions", "PROBLEM", 199, 228], ["medication", "TREATMENT", 250, 260], ["cardiac side", "TREATMENT", 266, 278], ["anti-malarial drugs", "TREATMENT", 413, 432], ["COVID", "TEST", 441, 446]]], ["An acute systemic inflammatory reaction/cytokine storm (besides the viral infection itself) is the hallmark of COVID-19 infection (51).", [["viral infection", "DISEASE", 68, 83], ["COVID-19", "CHEMICAL", 111, 119], ["infection", "DISEASE", 120, 129], ["COVID-19", "ORGANISM", 111, 119], ["cytokine", "PROTEIN", 40, 48], ["An acute systemic inflammatory reaction", "PROBLEM", 0, 39], ["cytokine storm", "PROBLEM", 40, 54], ["the viral infection", "PROBLEM", 64, 83], ["COVID-19 infection", "PROBLEM", 111, 129], ["acute", "OBSERVATION_MODIFIER", 3, 8], ["systemic", "OBSERVATION_MODIFIER", 9, 17], ["inflammatory", "OBSERVATION", 18, 30], ["cytokine storm", "OBSERVATION", 40, 54], ["viral", "OBSERVATION_MODIFIER", 68, 73], ["infection", "OBSERVATION", 74, 83], ["infection", "OBSERVATION", 120, 129]]], ["This reaction, once well-established, can cause rapid disease progression leading to death (52, 53).", [["death", "DISEASE", 85, 90], ["This reaction", "PROBLEM", 0, 13], ["rapid disease progression", "PROBLEM", 48, 73], ["death", "PROBLEM", 85, 90], ["rapid", "OBSERVATION_MODIFIER", 48, 53], ["disease", "OBSERVATION", 54, 61]]], ["However, except for three studies (15, 23, 28), no studies have reported the effect of anti-malarial drugs on the inflammatory markers and blood counts (lymphocyte, neutrophil).", [["blood", "ANATOMY", 139, 144], ["lymphocyte", "ANATOMY", 153, 163], ["neutrophil", "ANATOMY", 165, 175], ["blood", "ORGANISM_SUBSTANCE", 139, 144], ["lymphocyte", "CELL", 153, 163], ["neutrophil", "CELL", 165, 175], ["inflammatory markers", "PROTEIN", 114, 134], ["lymphocyte", "CELL_TYPE", 153, 163], ["neutrophil", "CELL_TYPE", 165, 175], ["three studies", "TEST", 20, 33], ["studies", "TEST", 51, 58], ["anti-malarial drugs", "TREATMENT", 87, 106], ["the inflammatory markers", "TEST", 110, 134], ["blood counts", "TEST", 139, 151], ["lymphocyte", "TEST", 153, 163], ["neutrophil", "TEST", 165, 175]]], ["As supportive treatments were not uniform across the included studies, one may argue that simultaneous use of other drugs (anti-viral drugs, and/or interferon-\u03b1) as a part of supportive treatment might have confounded (increased or decreased) the efficacy of the anti-malarial drugs (15).", [["interferon-\u03b1", "CHEMICAL", 148, 160], ["interferon-\u03b1", "GENE_OR_GENE_PRODUCT", 148, 160], ["interferon", "PROTEIN", 148, 158], ["supportive treatments", "TREATMENT", 3, 24], ["other drugs", "TREATMENT", 110, 121], ["anti-viral drugs", "TREATMENT", 123, 139], ["interferon", "TREATMENT", 148, 158], ["supportive treatment", "TREATMENT", 175, 195], ["the anti-malarial drugs", "TREATMENT", 259, 282], ["increased", "OBSERVATION_MODIFIER", 219, 228], ["decreased", "OBSERVATION_MODIFIER", 232, 241]]], ["This possibility, however, seems less likely, as few studies have found no difference after excluding patients receiving these drugs (15).Summary of Evidence ::: DiscussionAn interesting observation was that, studies from USA showed a significantly increased risk of mortality compared to those from outside USA.", [["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["these drugs", "TREATMENT", 121, 132], ["a significantly increased risk of mortality", "PROBLEM", 233, 276], ["less likely", "UNCERTAINTY", 33, 44], ["mortality", "OBSERVATION", 267, 276]]], ["The same could be explained by the following points in the USA study cohort: inclusion of a higher proportion of patients with severe or critical illness, advanced age, and co-morbidities.", [["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["severe or critical illness", "PROBLEM", 127, 153], ["co-morbidities", "PROBLEM", 173, 187], ["could be explained", "UNCERTAINTY", 9, 27], ["severe", "OBSERVATION_MODIFIER", 127, 133]]], ["Among the included studies in the present review, marked variation (high heterogeneity) was noted in the age group (in the clinical trials majority were \u2264 50 yr of age, whereas, in the observational studies majority were \u226560 yr of age), severity of COVID-19 illness (around 72% of participants in the clinical trials were having mild and moderate illness, whereas <40% of the participants in the observational studies exhibited mild and moderate illness), and inclusion of patients with co-morbidities (diabetes, cardio-vascular disease, chronic lung disease, etc.) among the study cohorts.", [["cardio-vascular", "ANATOMY", 513, 528], ["lung", "ANATOMY", 546, 550], ["COVID", "DISEASE", 249, 254], ["illness", "DISEASE", 258, 265], ["illness", "DISEASE", 347, 354], ["illness", "DISEASE", 446, 453], ["co-morbidities", "DISEASE", 487, 501], ["diabetes", "DISEASE", 503, 511], ["cardio-vascular disease", "DISEASE", 513, 536], ["chronic lung disease", "DISEASE", 538, 558], ["patients", "ORGANISM", 473, 481], ["vascular", "MULTI-TISSUE_STRUCTURE", 520, 528], ["lung", "ORGAN", 546, 550], ["participants", "SPECIES", 281, 293], ["participants", "SPECIES", 376, 388], ["patients", "SPECIES", 473, 481], ["marked variation (high heterogeneity)", "PROBLEM", 50, 87], ["COVID", "PROBLEM", 249, 254], ["mild and moderate illness", "PROBLEM", 329, 354], ["the observational studies", "TEST", 392, 417], ["mild and moderate illness)", "PROBLEM", 428, 454], ["co-morbidities", "PROBLEM", 487, 501], ["diabetes", "PROBLEM", 503, 511], ["cardio-vascular disease", "PROBLEM", 513, 536], ["chronic lung disease", "PROBLEM", 538, 558], ["the study cohorts", "TEST", 572, 589], ["marked", "OBSERVATION_MODIFIER", 50, 56], ["variation", "OBSERVATION_MODIFIER", 57, 66], ["high heterogeneity", "OBSERVATION_MODIFIER", 68, 86], ["moderate", "OBSERVATION_MODIFIER", 338, 346], ["moderate", "OBSERVATION_MODIFIER", 437, 445], ["illness", "OBSERVATION", 446, 453], ["cardio", "ANATOMY", 513, 519], ["vascular", "ANATOMY", 520, 528], ["disease", "OBSERVATION", 529, 536], ["chronic", "OBSERVATION_MODIFIER", 538, 545], ["lung", "ANATOMY", 546, 550], ["disease", "OBSERVATION", 551, 558]]], ["Except for the severity of COVID-19 illness, the remaining two characteristics (age group and inclusion of patients with co-morbidities) of the study cohort could increase mortality that is independent of the effect of CQ/HCQ (\u00b1Azithromycin).", [["illness", "DISEASE", 36, 43], ["CQ", "CHEMICAL", 219, 221], ["HCQ", "CHEMICAL", 222, 225], ["Azithromycin", "CHEMICAL", 228, 240], ["HCQ", "CHEMICAL", 222, 225], ["Azithromycin", "CHEMICAL", 228, 240], ["patients", "ORGANISM", 107, 115], ["CQ", "SIMPLE_CHEMICAL", 219, 221], ["HCQ", "SIMPLE_CHEMICAL", 222, 225], ["Azithromycin", "SIMPLE_CHEMICAL", 228, 240], ["patients", "SPECIES", 107, 115], ["COVID-19 illness", "PROBLEM", 27, 43], ["the study", "TEST", 140, 149], ["CQ/HCQ", "TREATMENT", 219, 225], ["Azithromycin", "TREATMENT", 228, 240]]], ["This emphasizes the role of randomized double-blind trials in establishing the actual efficacy (if any) of anti-malarial drugs, as the chance of selection bias would be very low, and the groups would be comparable.", [["randomized double-blind trials", "TREATMENT", 28, 58], ["anti-malarial drugs", "TREATMENT", 107, 126], ["selection bias", "TEST", 145, 159]]], ["The dose schedule of CQ was nearly uniform; however, the dose schedule of HCQ varied widely among the studies (except for one large study, the cumulative dose was equal or higher than the recommended schedule in the remaining studies).", [["CQ", "CHEMICAL", 21, 23], ["HCQ", "CHEMICAL", 74, 77], ["HCQ", "CHEMICAL", 74, 77], ["CQ", "SIMPLE_CHEMICAL", 21, 23], ["HCQ", "SIMPLE_CHEMICAL", 74, 77], ["The dose schedule of CQ", "TREATMENT", 0, 23], ["HCQ", "TREATMENT", 74, 77], ["the studies", "TEST", 98, 109], ["one large study", "TEST", 122, 137], ["the remaining studies", "TEST", 212, 233]]], ["There was, however, no difference in the mortality rate.", [["the mortality rate", "TEST", 37, 55], ["no", "UNCERTAINTY", 20, 22], ["difference", "OBSERVATION_MODIFIER", 23, 33]]], ["The median time from onset of symptom to admission or treatment initiation was nearly \u2264 8 days in all but two studies, and, apart from one study, others used CQ/HCQ within 48 h of admission/hospitalization (not symptom onset).", [["CQ", "CHEMICAL", 158, 160], ["HCQ", "CHEMICAL", 161, 164], ["HCQ", "CHEMICAL", 161, 164], ["CQ", "SIMPLE_CHEMICAL", 158, 160], ["HCQ", "SIMPLE_CHEMICAL", 161, 164], ["symptom", "PROBLEM", 30, 37], ["treatment", "TREATMENT", 54, 63], ["two studies", "TEST", 106, 117], ["one study", "TEST", 135, 144]]], ["There was no significant difference in the mortality rate between exposure/interventions and controls in these sub-groups.", [["significant difference", "PROBLEM", 13, 35], ["interventions", "TREATMENT", 75, 88], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35]]], ["This might be due to the fact that starting anti-viral drugs (including HCQ/CQ) after 48 h of symptom onset might not be beneficial as the golden window for antiviral treatment (e.g., in influenza) is lost (48).", [["HCQ", "CHEMICAL", 72, 75], ["CQ", "CHEMICAL", 76, 78], ["influenza", "DISEASE", 187, 196], ["HCQ", "CHEMICAL", 72, 75], ["HCQ", "SIMPLE_CHEMICAL", 72, 75], ["CQ", "SIMPLE_CHEMICAL", 76, 78], ["anti-viral drugs", "TREATMENT", 44, 60], ["HCQ/CQ", "TREATMENT", 72, 78], ["symptom", "PROBLEM", 94, 101], ["antiviral treatment", "TREATMENT", 157, 176], ["influenza", "PROBLEM", 187, 196]]], ["This is difficult in a hospitalized setting (may be possible in outpatient or community setting); however, one RCT could able to use it within 48 h of symptom onset (found a significantly shorter time to clinical recovery and pneumonia resolution without any mortality) (17).Limitations ::: DiscussionThe studies were variable in many aspects (blinding of participants and outcome assessors, patient selection, severity of illness, dose schedule of the anti-malarial drugs, timing of administration, measurement of inflammatory markers and effect of the drugs on these markers, outcome definition, and measurements).", [["pneumonia", "DISEASE", 226, 235], ["illness", "DISEASE", 423, 430], ["patient", "ORGANISM", 392, 399], ["inflammatory markers", "PROTEIN", 515, 535], ["participants", "SPECIES", 356, 368], ["patient", "SPECIES", 392, 399], ["symptom onset", "PROBLEM", 151, 164], ["pneumonia", "PROBLEM", 226, 235], ["The studies", "TEST", 301, 312], ["outcome assessors", "TEST", 373, 390], ["illness", "PROBLEM", 423, 430], ["the anti-malarial drugs", "TREATMENT", 449, 472], ["administration", "TREATMENT", 484, 498], ["inflammatory markers", "PROBLEM", 515, 535], ["the drugs", "TREATMENT", 550, 559], ["these markers", "TEST", 563, 576], ["outcome definition", "TEST", 578, 596], ["pneumonia", "OBSERVATION", 226, 235], ["inflammatory", "OBSERVATION", 515, 527]]], ["We could not determine the effect of anti-malarial drugs in Covid-19 infection in pediatric and adolescent population.", [["Covid-19", "CHEMICAL", 60, 68], ["infection", "DISEASE", 69, 78], ["Covid-19", "ORGANISM", 60, 68], ["Covid-19", "SPECIES", 60, 68], ["anti-malarial drugs", "TREATMENT", 37, 56], ["infection", "OBSERVATION", 69, 78]]], ["As there were few studies, results from all the secondary outcomes could not be pooled.Future Areas of Research ::: DiscussionFuture clinical trials should include good quality RCTs with adequate sample size, should ideally be multi-centric, and should focus on the variability noted in the present review.", [["few studies", "TEST", 14, 25], ["size", "OBSERVATION_MODIFIER", 203, 207]]], ["Pediatric and adolescent population also need to be included in the ongoing studies to guide recommendation in this group of patients.", [["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["the ongoing studies", "TEST", 64, 83]]], ["Both CQ/HCQ should also be evaluated in non-hospitalized patients with COVID-19 infection.ConclusionsAs very low quality evidence suggests an increased risk of mortality and adverse event with HCQ plus Azithromycin combination (not HCQ alone); caution should be exercised while prescribing this combination for treatment of hospitalized adults with COVID-19 infection.", [["CQ", "CHEMICAL", 5, 7], ["HCQ", "CHEMICAL", 8, 11], ["COVID-19", "CHEMICAL", 71, 79], ["infection", "DISEASE", 80, 89], ["HCQ", "CHEMICAL", 193, 196], ["Azithromycin", "CHEMICAL", 202, 214], ["HCQ", "CHEMICAL", 232, 235], ["COVID-19", "CHEMICAL", 349, 357], ["infection", "DISEASE", 358, 367], ["HCQ", "CHEMICAL", 8, 11], ["HCQ", "CHEMICAL", 193, 196], ["Azithromycin", "CHEMICAL", 202, 214], ["HCQ", "CHEMICAL", 232, 235], ["CQ", "SIMPLE_CHEMICAL", 5, 7], ["HCQ", "SIMPLE_CHEMICAL", 8, 11], ["patients", "ORGANISM", 57, 65], ["HCQ", "SIMPLE_CHEMICAL", 193, 196], ["Azithromycin", "SIMPLE_CHEMICAL", 202, 214], ["HCQ", "SIMPLE_CHEMICAL", 232, 235], ["patients", "SPECIES", 57, 65], ["Both CQ/HCQ", "TREATMENT", 0, 11], ["COVID-19 infection", "PROBLEM", 71, 89], ["an increased risk of mortality", "PROBLEM", 139, 169], ["adverse event", "PROBLEM", 174, 187], ["HCQ", "TREATMENT", 193, 196], ["Azithromycin combination", "TREATMENT", 202, 226], ["COVID", "TREATMENT", 349, 354], ["19 infection", "PROBLEM", 355, 367], ["infection", "OBSERVATION", 80, 89], ["increased", "OBSERVATION_MODIFIER", 142, 151], ["infection", "OBSERVATION", 358, 367]]], ["Multi-centric RCTs (including both hospitalized and non-hospitalized patients) of a good quality are required for any firm recommendation to be made during the ongoing pandemic.Data Availability StatementAll datasets generated for this study are included in the article/Supplementary Material.Author ContributionsRD developed the concept, abstracted data from papers, managed data for the review, performed the statistical analysis, interpreted data, made statistical inferences, wrote the review, and serves as guarantor for the review.", [["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["Multi-centric RCTs", "TEST", 0, 18], ["pandemic", "PROBLEM", 168, 176], ["this study", "TEST", 231, 241], ["the statistical analysis", "TEST", 407, 431]]], ["JS developed the concept, performed the statistical analysis and made inferences, and wrote the review.", [["the statistical analysis", "TEST", 36, 60]]]], "PMC7365885": [["IntroductionThe outbreak of COVID-19, officially termed by the World Health Organization (WHO) on 11 February, 2020 (1), was first reported in Wuhan, China, in December 2019.", [["COVID-19", "CHEMICAL", 28, 36]]], ["The novel coronavirus can cause severe pneumonia and acute respiratory distress syndrome (2).", [["respiratory", "ANATOMY", 59, 70], ["coronavirus", "DISEASE", 10, 21], ["pneumonia", "DISEASE", 39, 48], ["acute respiratory distress syndrome", "DISEASE", 53, 88], ["coronavirus", "ORGANISM", 10, 21], ["coronavirus", "SPECIES", 10, 21], ["The novel coronavirus", "PROBLEM", 0, 21], ["severe pneumonia", "PROBLEM", 32, 48], ["acute respiratory distress syndrome", "PROBLEM", 53, 88], ["coronavirus", "OBSERVATION", 10, 21], ["severe", "OBSERVATION_MODIFIER", 32, 38], ["pneumonia", "OBSERVATION", 39, 48], ["acute", "OBSERVATION_MODIFIER", 53, 58], ["respiratory distress syndrome", "OBSERVATION", 59, 88]]], ["Moreover, it can induce vascular inflammation, myocarditis, and cardiac arrhythmias (3).", [["vascular", "ANATOMY", 24, 32], ["cardiac", "ANATOMY", 64, 71], ["vascular inflammation", "DISEASE", 24, 45], ["myocarditis", "DISEASE", 47, 58], ["cardiac arrhythmias", "DISEASE", 64, 83], ["vascular", "MULTI-TISSUE_STRUCTURE", 24, 32], ["cardiac", "ORGAN", 64, 71], ["vascular inflammation", "PROBLEM", 24, 45], ["myocarditis", "PROBLEM", 47, 58], ["cardiac arrhythmias", "PROBLEM", 64, 83], ["vascular", "ANATOMY", 24, 32], ["inflammation", "OBSERVATION", 33, 45], ["myocarditis", "OBSERVATION", 47, 58], ["cardiac", "ANATOMY", 64, 71], ["arrhythmias", "OBSERVATION", 72, 83]]], ["This is a disease with a high fatality rate.", [["a disease", "PROBLEM", 8, 17], ["a high fatality rate", "PROBLEM", 23, 43], ["disease", "OBSERVATION", 10, 17]]], ["Previous investigations have reported on the virus' route of transmission and its control measures, including the rapid diagnosis and immediate isolation of the victims, rigorous tracking, social distancing, and precautionary self-isolation (4\u20136).", [["Previous investigations", "TEST", 0, 23]]], ["Some studies were quite concerned about the particular therapy (7\u20139) and the correlation of the clinical characteristics and lab indexes with the risk of death (10).", [["death", "DISEASE", 154, 159], ["Some studies", "TEST", 0, 12], ["lab indexes", "TEST", 125, 136], ["death", "PROBLEM", 154, 159]]], ["Additionally, many others focused on the characteristics of CT imaging, but their focus was often placed on the comparison between pre- and post-treatment or on the analysis of the characteristics of lung computerized tomography (CT) in patients with different severities (11\u201313).", [["lung", "ANATOMY", 200, 204], ["lung", "ORGAN", 200, 204], ["patients", "ORGANISM", 237, 245], ["patients", "SPECIES", 237, 245], ["CT imaging", "TEST", 60, 70], ["the analysis", "TEST", 161, 173], ["lung computerized tomography (CT", "TEST", 200, 232], ["different severities", "PROBLEM", 251, 271], ["lung", "ANATOMY", 200, 204]]], ["In fact, the importance of early identification cannot be overemphasized; therefore, it is imperative that the early symptoms, lab indexes, and lung CT imaging of the young and middle-aged patients be better understood, especially the interrelation of early clinical symptoms with lab indexes and lung CT imaging.IntroductionAs the global outbreak of COVID-19 intensified, a growing number of overseas Chinese nationals became anxious, longing for return to their own country.", [["lung", "ANATOMY", 144, 148], ["lung", "ANATOMY", 297, 301], ["COVID", "DISEASE", 351, 356], ["lung", "ORGAN", 144, 148], ["patients", "ORGANISM", 189, 197], ["lung", "ORGAN", 297, 301], ["patients", "SPECIES", 189, 197], ["the early symptoms", "PROBLEM", 107, 125], ["lab indexes", "TEST", 127, 138], ["lung CT imaging", "TEST", 144, 159], ["early clinical symptoms", "PROBLEM", 252, 275], ["lab indexes", "TEST", 281, 292], ["lung CT imaging", "TEST", 297, 312], ["COVID", "TEST", 351, 356], ["anxious", "PROBLEM", 427, 434], ["lung", "ANATOMY", 144, 148], ["lung", "ANATOMY", 297, 301], ["growing", "OBSERVATION_MODIFIER", 375, 382], ["number", "OBSERVATION_MODIFIER", 383, 389]]], ["Working for Shanghai Pudong New Area People's Hospital, a hospital which is close to Shanghai Pudong International Airport, our doctors had the privilege of carrying out the mission of screening for the potential carriers of the novel coronavirus so that we could conduct their prompt isolation and proper treatment in our hospital.IntroductionBy analyzing their clinical symptoms, blood routine indexes, and CT imaging, we came to summarize the typical characteristics in the current study.", [["blood", "ANATOMY", 382, 387], ["coronavirus", "ORGANISM", 235, 246], ["blood", "ORGANISM_SUBSTANCE", 382, 387], ["screening", "TREATMENT", 185, 194], ["the novel coronavirus", "PROBLEM", 225, 246], ["proper treatment", "TREATMENT", 299, 315], ["their clinical symptoms", "PROBLEM", 357, 380], ["blood routine indexes", "TEST", 382, 403], ["CT imaging", "TEST", 409, 419], ["the current study", "TEST", 473, 490]]], ["Since the returnees who tested positive were all either young or middle-aged without any disease history, the characteristics of the clinical symptoms and the changes of blood routine indexes and lung CT imaging could be typically different from those of other age groups.", [["blood", "ANATOMY", 170, 175], ["lung", "ANATOMY", 196, 200], ["blood", "ORGANISM_SUBSTANCE", 170, 175], ["lung", "ORGAN", 196, 200], ["any disease history", "PROBLEM", 85, 104], ["the clinical symptoms", "PROBLEM", 129, 150], ["blood routine indexes", "TEST", 170, 191], ["lung CT imaging", "TEST", 196, 211], ["lung", "ANATOMY", 196, 200]]], ["We believed that the current study could help the world better understand the clinical characteristics of the novel coronavirus in a particular age group.Ethics Statement ::: Materials and MethodsThis study was approved by the Medical Ethics Committee of Shanghai Pudong New Area People's Hospital, Shanghai, China.", [["coronavirus", "DISEASE", 116, 127], ["coronavirus", "ORGANISM", 116, 127], ["the current study", "TEST", 17, 34], ["the novel coronavirus", "PROBLEM", 106, 127], ["coronavirus", "OBSERVATION", 116, 127]]], ["Written informed consent was obtained from all participants or their legally acceptable representatives.Patient Registration and Medical Examination ::: Materials and MethodsAll overseas returnees, whose nasopharyngeal swab assays tested positive for SARS-CoV-2 by PCR at Shanghai Pudong New Area People's Hospital, were enrolled, the period of which had a time range of 1\u201323 March, 2020.", [["nasopharyngeal swab", "ANATOMY", 204, 223], ["participants", "SPECIES", 47, 59], ["Patient", "SPECIES", 104, 111], ["SARS-CoV", "SPECIES", 251, 259], ["Medical Examination", "TEST", 129, 148], ["whose nasopharyngeal swab assays", "TEST", 198, 230], ["SARS", "PROBLEM", 251, 255], ["CoV", "TEST", 256, 259], ["nasopharyngeal", "ANATOMY", 204, 218]]], ["As required by the National Health Commission, we performed the uniformed screening for the coronavirus as follows: (1) Ask for any travel history to or from the epidemic area(s); (2) Ask for symptoms such as a fever, dry cough, expectoration, pharyngalia, pharynoxerosis, rhinobyon, rhinorrhea, hypodynamic, muscular soreness, and diarrhea; (3) Perform a routine analysis of blood tests pertaining to hemoglobin, red blood cell count, hematocrit, mean corpuscular volume, average hemoglobin content, red cell distribution width, blood platelet count, thrombocytocrit, platelet distribution width, mean platelet volume, neutrophils percentage, eosinophils percentage, basophilic granulocyte percentage, monocyte percentage, and C-reactive protein; and (4) Administer CT to scan the lungs.", [["muscular", "ANATOMY", 309, 317], ["blood", "ANATOMY", 376, 381], ["red blood cell", "ANATOMY", 414, 428], ["corpuscular", "ANATOMY", 453, 464], ["red cell", "ANATOMY", 501, 509], ["blood platelet", "ANATOMY", 530, 544], ["platelet", "ANATOMY", 569, 577], ["platelet", "ANATOMY", 603, 611], ["neutrophils", "ANATOMY", 620, 631], ["eosinophils", "ANATOMY", 644, 655], ["basophilic granulocyte", "ANATOMY", 668, 690], ["monocyte", "ANATOMY", 703, 711], ["lungs", "ANATOMY", 782, 787], ["coronavirus", "DISEASE", 92, 103], ["fever", "DISEASE", 211, 216], ["dry cough", "DISEASE", 218, 227], ["expectoration", "DISEASE", 229, 242], ["pharyngalia", "DISEASE", 244, 255], ["pharynoxerosis", "DISEASE", 257, 271], ["rhinobyon", "DISEASE", 273, 282], ["rhinorrhea", "DISEASE", 284, 294], ["hypodynamic", "DISEASE", 296, 307], ["muscular soreness", "DISEASE", 309, 326], ["diarrhea", "DISEASE", 332, 340], ["coronavirus", "ORGANISM", 92, 103], ["blood", "ORGANISM_SUBSTANCE", 376, 381], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 402, 412], ["red blood cell", "CELL", 414, 428], ["corpuscular", "ORGANISM_SUBSTANCE", 453, 464], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 481, 491], ["cell", "CELL", 505, 509], ["blood", "ORGANISM_SUBSTANCE", 530, 535], ["platelet", "CELL", 536, 544], ["platelet", "CELL", 569, 577], ["platelet", "CELL", 603, 611], ["neutrophils", "CELL", 620, 631], ["eosinophils", "CELL", 644, 655], ["basophilic granulocyte", "CELL", 668, 690], ["monocyte", "CELL", 703, 711], ["lungs", "ORGAN", 782, 787], ["hemoglobin", "PROTEIN", 402, 412], ["hemoglobin", "PROTEIN", 481, 491], ["neutrophils", "CELL_TYPE", 620, 631], ["eosinophils", "CELL_TYPE", 644, 655], ["basophilic granulocyte", "CELL_TYPE", 668, 690], ["C-reactive protein", "PROTEIN", 728, 746], ["the uniformed screening", "TEST", 60, 83], ["the coronavirus", "PROBLEM", 88, 103], ["symptoms", "PROBLEM", 192, 200], ["a fever", "PROBLEM", 209, 216], ["dry cough", "PROBLEM", 218, 227], ["expectoration", "PROBLEM", 229, 242], ["pharyngalia", "PROBLEM", 244, 255], ["pharynoxerosis", "PROBLEM", 257, 271], ["rhinobyon", "PROBLEM", 273, 282], ["rhinorrhea", "PROBLEM", 284, 294], ["hypodynamic, muscular soreness", "PROBLEM", 296, 326], ["diarrhea", "PROBLEM", 332, 340], ["a routine analysis", "TEST", 354, 372], ["blood tests", "TEST", 376, 387], ["hemoglobin", "TEST", 402, 412], ["red blood cell count", "TEST", 414, 434], ["hematocrit", "TEST", 436, 446], ["mean corpuscular volume", "TEST", 448, 471], ["average hemoglobin content", "TEST", 473, 499], ["red cell distribution width", "TEST", 501, 528], ["blood platelet count", "TEST", 530, 550], ["thrombocytocrit", "TEST", 552, 567], ["platelet distribution width", "TEST", 569, 596], ["mean platelet volume", "TEST", 598, 618], ["neutrophils percentage", "TEST", 620, 642], ["eosinophils percentage", "TEST", 644, 666], ["basophilic granulocyte percentage", "TEST", 668, 701], ["monocyte percentage", "TEST", 703, 722], ["C-reactive protein", "PROBLEM", 728, 746], ["CT to scan the lungs", "TEST", 767, 787], ["muscular soreness", "ANATOMY", 309, 326], ["hemoglobin content", "OBSERVATION", 481, 499], ["red cell distribution", "OBSERVATION", 501, 522], ["platelet count", "OBSERVATION", 536, 550], ["platelet distribution", "OBSERVATION", 569, 590], ["mean platelet volume", "OBSERVATION", 598, 618], ["basophilic granulocyte percentage", "OBSERVATION", 668, 701], ["reactive protein", "OBSERVATION", 730, 746], ["lungs", "ANATOMY", 782, 787]]], ["We performed PCR assays to test the viral nucleic acids of SARS-CoV-2, used CT of SOMATOM Definition Flash (Germany), and performed a routine analysis of blood tests using Sysmex XT-4000i (Japan).Statistical Analysis ::: Materials and MethodsStatistical Package for the Social Sciences version 19.0 (SPSS Inc., Chicago, IL) was applied to the current statistical analysis; descriptive statistics were used to calculate by percentage the clinical characteristics of the infected returnees; chi-squared test was used to assess the rate differences; and t-test was used to assess the differences of age and lymphocyte between fever and no fever.", [["blood", "ANATOMY", 154, 159], ["lymphocyte", "ANATOMY", 604, 614], ["nucleic acids", "CHEMICAL", 42, 55], ["XT-4000i", "CHEMICAL", 179, 187], ["fever", "DISEASE", 623, 628], ["fever", "DISEASE", 636, 641], ["blood", "ORGANISM_SUBSTANCE", 154, 159], ["lymphocyte", "CELL", 604, 614], ["SARS-CoV", "SPECIES", 59, 67], ["PCR assays", "TEST", 13, 23], ["the viral nucleic acids", "TEST", 32, 55], ["SARS", "PROBLEM", 59, 63], ["CoV", "TEST", 64, 67], ["CT", "TEST", 76, 78], ["a routine analysis", "TEST", 132, 150], ["blood tests", "TEST", 154, 165], ["Sysmex XT", "TEST", 172, 181], ["MethodsStatistical Package", "TREATMENT", 235, 261], ["Chicago, IL)", "TREATMENT", 311, 323], ["the infected returnees", "PROBLEM", 465, 487], ["chi-squared test", "TEST", 489, 505], ["t-test", "TEST", 551, 557], ["fever", "PROBLEM", 623, 628], ["fever", "PROBLEM", 636, 641], ["infected", "OBSERVATION", 469, 477], ["no", "UNCERTAINTY", 633, 635], ["fever", "OBSERVATION", 636, 641]]], ["The analyses of binary regression and spearman correlation were used to assess the correlation of eosinophils percentage, fever, and pneumonia.", [["eosinophils", "ANATOMY", 98, 109], ["fever", "DISEASE", 122, 127], ["pneumonia", "DISEASE", 133, 142], ["eosinophils", "CELL", 98, 109], ["eosinophils", "CELL_TYPE", 98, 109], ["spearman correlation", "TEST", 38, 58], ["eosinophils percentage", "PROBLEM", 98, 120], ["fever", "PROBLEM", 122, 127], ["pneumonia", "PROBLEM", 133, 142], ["eosinophils", "OBSERVATION", 98, 109], ["fever", "OBSERVATION", 122, 127], ["pneumonia", "OBSERVATION", 133, 142]]], ["Linear regression was used to assess the correlation of four kinds of blood cells with fever and pneumonia severity.Clinical Symptoms ::: ResultsA total of 37 overseas returnees who were diagnosed with COVID-19 were recruited for the current study.", [["blood cells", "ANATOMY", 70, 81], ["fever", "DISEASE", 87, 92], ["pneumonia", "DISEASE", 97, 106], ["blood cells", "CELL", 70, 81], ["blood cells", "CELL_TYPE", 70, 81], ["Linear regression", "PROBLEM", 0, 17], ["blood cells", "PROBLEM", 70, 81], ["fever", "PROBLEM", 87, 92], ["pneumonia severity", "PROBLEM", 97, 115], ["Clinical Symptoms", "PROBLEM", 116, 133], ["COVID", "TEST", 202, 207], ["the current study", "TEST", 230, 247], ["regression", "OBSERVATION", 7, 17], ["fever", "OBSERVATION", 87, 92], ["pneumonia", "OBSERVATION", 97, 106]]], ["Nineteen of the returnees complained of fever, and eight of them reported close contact with those who were confirmed positive.", [["fever", "DISEASE", 40, 45], ["fever", "PROBLEM", 40, 45], ["fever", "OBSERVATION", 40, 45]]], ["As indicated in Table 1, the base characteristics and clinical symptoms were acquired as the results, fever being the most common symptom (51.40%); as to the blood routine indexes, WBC and lymphocyte count were not recorded as \u201cup or down,\u201d but as what they were, while the others were recorded as \u201cup or down.\u201d", [["blood", "ANATOMY", 158, 163], ["WBC", "ANATOMY", 181, 184], ["lymphocyte", "ANATOMY", 189, 199], ["fever", "DISEASE", 102, 107], ["blood", "ORGANISM_SUBSTANCE", 158, 163], ["WBC", "CELL", 181, 184], ["lymphocyte", "CELL", 189, 199], ["WBC", "CELL_TYPE", 181, 184], ["clinical symptoms", "PROBLEM", 54, 71], ["fever", "PROBLEM", 102, 107], ["the blood routine indexes", "TEST", 154, 179], ["WBC", "TEST", 181, 184], ["lymphocyte count", "TEST", 189, 205], ["lymphocyte count", "OBSERVATION", 189, 205]]], ["PDW percentage and MPV and eosinophils percentage were significantly changed; their rates were 89.20, 81.10, and 45.90, respectively.", [["eosinophils", "ANATOMY", 27, 38], ["eosinophils", "CELL", 27, 38], ["eosinophils", "CELL_TYPE", 27, 38], ["PDW percentage", "TEST", 0, 14], ["MPV", "TEST", 19, 22], ["eosinophils percentage", "TEST", 27, 49], ["their rates", "TEST", 78, 89], ["MPV", "ANATOMY", 19, 22]]], ["Furthermore, eosinophils percentage was observed to be down as a single change, but when using other indexes, the changes reported were not unique.", [["eosinophils", "ANATOMY", 13, 24], ["eosinophils", "CELL", 13, 24], ["eosinophils", "CELL_TYPE", 13, 24], ["eosinophils percentage", "TEST", 13, 35]]], ["Without exception, the returnees received a lung CT scan, from which the pneumonic changes were characterized by four signs: the latticed ground glass sign, white-lung sign, roadstone-like sign, and vascular cluster sign (Figure 1).", [["lung", "ANATOMY", 44, 48], ["lung", "ANATOMY", 163, 167], ["vascular", "ANATOMY", 199, 207], ["pneumonic", "DISEASE", 73, 82], ["lung", "ORGAN", 44, 48], ["lung", "ORGAN", 163, 167], ["vascular", "MULTI-TISSUE_STRUCTURE", 199, 207], ["a lung CT scan", "TEST", 42, 56], ["the pneumonic changes", "PROBLEM", 69, 90], ["the latticed ground glass sign", "TEST", 125, 155], ["white-lung sign", "TEST", 157, 172], ["roadstone-like sign", "PROBLEM", 174, 193], ["lung", "ANATOMY", 44, 48], ["pneumonic", "OBSERVATION", 73, 82], ["ground glass sign", "OBSERVATION", 138, 155], ["lung", "ANATOMY", 163, 167], ["vascular", "ANATOMY", 199, 207]]], ["The number of lung lesions ranged from 1 to 41, which suggested different degrees of pneumonia severity.", [["lung lesions", "ANATOMY", 14, 26], ["pneumonia", "DISEASE", 85, 94], ["lung lesions", "CANCER", 14, 26], ["lung lesions", "PROBLEM", 14, 26], ["pneumonia severity", "PROBLEM", 85, 103], ["number", "OBSERVATION_MODIFIER", 4, 10], ["lung", "ANATOMY", 14, 18], ["lesions", "OBSERVATION", 19, 26], ["different degrees", "OBSERVATION_MODIFIER", 64, 81], ["pneumonia", "OBSERVATION", 85, 94], ["severity", "OBSERVATION_MODIFIER", 95, 103]]], ["Each of the five lobes, three of the right, and two of the left, was affected by the coronavirus, with the margin damaged already.", [["lobes", "ANATOMY", 17, 22], ["right", "ANATOMY", 37, 42], ["lobes", "CANCER", 17, 22], ["coronavirus", "ORGANISM", 85, 96], ["the coronavirus", "PROBLEM", 81, 96], ["five lobes", "ANATOMY_MODIFIER", 12, 22], ["three", "OBSERVATION_MODIFIER", 24, 29], ["right", "ANATOMY_MODIFIER", 37, 42], ["left", "ANATOMY_MODIFIER", 59, 63], ["coronavirus", "OBSERVATION", 85, 96], ["margin", "OBSERVATION_MODIFIER", 107, 113], ["damaged", "OBSERVATION", 114, 121]]], ["The rate of pneumonia was significantly high (81.10%).The Correlative Analysis of Eosinophils Percentage, Fever, and Pneumonia ::: ResultsAs indicated in Table 2, we made a correlative analysis of eosinophils percentage, fever, and pneumonia using three methods of statistical analysis.", [["Eosinophils", "ANATOMY", 82, 93], ["eosinophils", "ANATOMY", 197, 208], ["pneumonia", "DISEASE", 12, 21], ["Fever", "DISEASE", 106, 111], ["Pneumonia", "DISEASE", 117, 126], ["fever", "DISEASE", 221, 226], ["pneumonia", "DISEASE", 232, 241], ["Eosinophils", "CELL", 82, 93], ["eosinophils", "CELL", 197, 208], ["Eosinophils", "CELL_TYPE", 82, 93], ["eosinophils", "CELL_TYPE", 197, 208], ["pneumonia", "PROBLEM", 12, 21], ["Eosinophils Percentage", "TEST", 82, 104], ["Fever", "PROBLEM", 106, 111], ["Pneumonia", "PROBLEM", 117, 126], ["a correlative analysis", "TEST", 171, 193], ["eosinophils percentage", "PROBLEM", 197, 219], ["fever", "PROBLEM", 221, 226], ["pneumonia", "PROBLEM", 232, 241], ["statistical analysis", "TEST", 265, 285], ["pneumonia", "OBSERVATION", 12, 21], ["significantly", "OBSERVATION_MODIFIER", 26, 39], ["high", "OBSERVATION_MODIFIER", 40, 44], ["Eosinophils Percentage", "OBSERVATION", 82, 104], ["Pneumonia", "OBSERVATION", 117, 126], ["pneumonia", "OBSERVATION", 232, 241]]], ["As fever was the most common symptom, all the returnees were subdivided into a fever group and no fever group; as rate of pneumonia was significantly high, all the returnees were subdivided into a pneumonia group and a no pneumonia group.", [["fever", "DISEASE", 3, 8], ["fever", "DISEASE", 79, 84], ["fever", "DISEASE", 98, 103], ["pneumonia", "DISEASE", 122, 131], ["pneumonia", "DISEASE", 197, 206], ["pneumonia", "DISEASE", 222, 231], ["fever", "PROBLEM", 3, 8], ["the most common symptom", "PROBLEM", 13, 36], ["a fever group", "PROBLEM", 77, 90], ["fever group", "PROBLEM", 98, 109], ["pneumonia", "PROBLEM", 122, 131], ["a pneumonia group", "PROBLEM", 195, 212], ["pneumonia group", "PROBLEM", 222, 237], ["no", "UNCERTAINTY", 95, 97], ["pneumonia", "OBSERVATION", 122, 131], ["high", "OBSERVATION_MODIFIER", 150, 154], ["pneumonia", "OBSERVATION", 197, 206], ["no", "UNCERTAINTY", 219, 221], ["pneumonia", "OBSERVATION", 222, 231]]], ["The results of the Chi-squared test showed that between the two groups we analyzed the differences of the clinical symptoms, blood routine indexes, and lung CT images.", [["blood", "ANATOMY", 125, 130], ["lung", "ANATOMY", 152, 156], ["blood", "ORGANISM_SUBSTANCE", 125, 130], ["lung", "ORGAN", 152, 156], ["the Chi-squared test", "TEST", 15, 35], ["the clinical symptoms", "PROBLEM", 102, 123], ["blood routine indexes", "TEST", 125, 146], ["lung CT images", "TEST", 152, 166], ["lung", "ANATOMY", 152, 156]]], ["As one of the blood routine indexes, eosinophils percentage was lower in those who had a fever than in those who did not (P < 0.05), and it was lower in the group with pneumonia than in the group without (P < 0.01).", [["blood", "ANATOMY", 14, 19], ["eosinophils", "ANATOMY", 37, 48], ["fever", "DISEASE", 89, 94], ["pneumonia", "DISEASE", 168, 177], ["blood", "ORGANISM_SUBSTANCE", 14, 19], ["eosinophils", "CELL", 37, 48], ["eosinophils", "CELL_TYPE", 37, 48], ["the blood routine indexes", "TEST", 10, 35], ["eosinophils percentage", "TEST", 37, 59], ["a fever", "PROBLEM", 87, 94], ["pneumonia", "PROBLEM", 168, 177], ["lower", "OBSERVATION_MODIFIER", 144, 149], ["pneumonia", "OBSERVATION", 168, 177]]], ["As indicated by the other indexes, no significant difference was observed between the fever and no fever group, and neither was it between the pneumonia and no pneumonia group (P > 0.05).The Correlative Analysis of Eosinophils Percentage, Fever, and Pneumonia ::: ResultsThe results of Spearman correlation analysis showed that pneumonia is negatively correlated with the eosinophils percentage (P < 0.01); fever is negatively correlated with eosinophils (P < 0.01), but it was not correlated with pneumonia (P > 0.05).", [["Eosinophils", "ANATOMY", 215, 226], ["eosinophils", "ANATOMY", 372, 383], ["eosinophils", "ANATOMY", 443, 454], ["fever", "DISEASE", 86, 91], ["fever", "DISEASE", 99, 104], ["pneumonia", "DISEASE", 143, 152], ["pneumonia", "DISEASE", 160, 169], ["Fever", "DISEASE", 239, 244], ["Pneumonia", "DISEASE", 250, 259], ["pneumonia", "DISEASE", 328, 337], ["fever", "DISEASE", 407, 412], ["pneumonia", "DISEASE", 498, 507], ["Eosinophils", "CELL", 215, 226], ["eosinophils", "CELL", 372, 383], ["eosinophils", "CELL", 443, 454], ["Eosinophils", "CELL_TYPE", 215, 226], ["eosinophils", "CELL_TYPE", 372, 383], ["eosinophils", "CELL_TYPE", 443, 454], ["the fever", "PROBLEM", 82, 91], ["fever group", "PROBLEM", 99, 110], ["the pneumonia", "PROBLEM", 139, 152], ["pneumonia", "PROBLEM", 160, 169], ["P", "TEST", 177, 178], ["Eosinophils Percentage", "TEST", 215, 237], ["Fever", "PROBLEM", 239, 244], ["Pneumonia", "PROBLEM", 250, 259], ["Spearman correlation analysis", "TEST", 286, 315], ["pneumonia", "PROBLEM", 328, 337], ["the eosinophils percentage", "TEST", 368, 394], ["P", "TEST", 396, 397], ["fever", "PROBLEM", 407, 412], ["eosinophils", "TEST", 443, 454], ["pneumonia", "PROBLEM", 498, 507], ["P", "TEST", 509, 510], ["no", "UNCERTAINTY", 35, 37], ["significant", "OBSERVATION_MODIFIER", 38, 49], ["difference", "OBSERVATION", 50, 60], ["no", "UNCERTAINTY", 96, 98], ["pneumonia", "OBSERVATION", 143, 152], ["no", "UNCERTAINTY", 157, 159], ["pneumonia", "OBSERVATION", 160, 169], ["Eosinophils Percentage", "OBSERVATION", 215, 237], ["Pneumonia", "OBSERVATION", 250, 259], ["pneumonia", "OBSERVATION", 328, 337], ["pneumonia", "OBSERVATION", 498, 507]]], ["Moreover, lymphocyte count and lymphocyte percentage were positively correlated with pneumonia (P = 0.02, P = 0.005), and the neutrophils percentage was negatively correlated with pneumonia (P < 0.05), while the neutrophils count was not correlated with pneumonia (P > 0.05).The Correlative Analysis of Eosinophils Percentage, Fever, and Pneumonia ::: ResultsAs indicated by the results of the Binary regression analysis, fever was negatively correlated with eosinophils percentage (P < 0.05), but pneumonia was not (P > 0.05).", [["lymphocyte", "ANATOMY", 10, 20], ["lymphocyte", "ANATOMY", 31, 41], ["neutrophils", "ANATOMY", 126, 137], ["neutrophils", "ANATOMY", 212, 223], ["Eosinophils", "ANATOMY", 303, 314], ["eosinophils", "ANATOMY", 459, 470], ["pneumonia", "DISEASE", 85, 94], ["pneumonia", "DISEASE", 180, 189], ["pneumonia", "DISEASE", 254, 263], ["Fever", "DISEASE", 327, 332], ["Pneumonia", "DISEASE", 338, 347], ["fever", "DISEASE", 422, 427], ["pneumonia", "DISEASE", 498, 507], ["lymphocyte", "CELL", 10, 20], ["lymphocyte", "CELL", 31, 41], ["neutrophils", "CELL", 126, 137], ["neutrophils", "CELL", 212, 223], ["Eosinophils", "CELL", 303, 314], ["eosinophils", "CELL", 459, 470], ["neutrophils", "CELL_TYPE", 126, 137], ["neutrophils", "CELL_TYPE", 212, 223], ["Eosinophils", "CELL_TYPE", 303, 314], ["eosinophils", "CELL_TYPE", 459, 470], ["lymphocyte count", "TEST", 10, 26], ["lymphocyte percentage", "TEST", 31, 52], ["pneumonia", "PROBLEM", 85, 94], ["P", "TEST", 96, 97], ["P", "TEST", 106, 107], ["the neutrophils percentage", "TEST", 122, 148], ["pneumonia", "PROBLEM", 180, 189], ["the neutrophils count", "TEST", 208, 229], ["pneumonia", "PROBLEM", 254, 263], ["P", "TEST", 265, 266], ["Eosinophils Percentage", "TEST", 303, 325], ["Fever", "PROBLEM", 327, 332], ["Pneumonia", "PROBLEM", 338, 347], ["the Binary regression analysis", "TEST", 390, 420], ["fever", "PROBLEM", 422, 427], ["eosinophils percentage", "TEST", 459, 481], ["P", "TEST", 483, 484], ["pneumonia", "PROBLEM", 498, 507], ["lymphocyte count", "OBSERVATION", 10, 26], ["lymphocyte percentage", "OBSERVATION", 31, 52], ["pneumonia", "OBSERVATION", 85, 94], ["pneumonia", "OBSERVATION", 180, 189], ["pneumonia", "OBSERVATION", 254, 263], ["Eosinophils Percentage", "OBSERVATION", 303, 325], ["Pneumonia", "OBSERVATION", 338, 347], ["pneumonia", "OBSERVATION", 498, 507]]], ["Additionally, the results of the Binary regression analysis demonstrated that the P-value in the correlation of lymphocytes with fever was low (P = 0.05), but as indicated by the Confidence intervals, it was not significant enough.", [["lymphocytes", "ANATOMY", 112, 123], ["fever", "DISEASE", 129, 134], ["lymphocytes", "CELL", 112, 123], ["P", "DNA", 82, 83], ["lymphocytes", "CELL_TYPE", 112, 123], ["the Binary regression analysis", "TEST", 29, 59], ["the P-value", "TEST", 78, 89], ["lymphocytes", "PROBLEM", 112, 123], ["fever", "PROBLEM", 129, 134], ["lymphocytes", "ANATOMY", 112, 123]]], ["The other blood routine indexes were not correlated with fever or with pneumonia (P > 0.05).The Correlative Analysis of Eosinophils Percentage, Fever, and Pneumonia ::: ResultsThe results of Linear regression analysis showed that fever was negatively correlated with eosinophils percentage and eosinophils/neutrophils ratio (P < 0.05), but not with pneumonia severity (P > 0.05).", [["blood", "ANATOMY", 10, 15], ["Eosinophils", "ANATOMY", 120, 131], ["eosinophils", "ANATOMY", 267, 278], ["eosinophils", "ANATOMY", 294, 305], ["neutrophils", "ANATOMY", 306, 317], ["fever", "DISEASE", 57, 62], ["pneumonia", "DISEASE", 71, 80], ["Fever", "DISEASE", 144, 149], ["Pneumonia", "DISEASE", 155, 164], ["fever", "DISEASE", 230, 235], ["pneumonia", "DISEASE", 349, 358], ["blood", "ORGANISM_SUBSTANCE", 10, 15], ["Eosinophils", "CELL", 120, 131], ["eosinophils", "CELL", 267, 278], ["eosinophils", "CELL", 294, 305], ["neutrophils", "CELL", 306, 317], ["Eosinophils", "CELL_TYPE", 120, 131], ["eosinophils", "CELL_TYPE", 267, 278], ["eosinophils", "CELL_TYPE", 294, 305], ["neutrophils", "CELL_TYPE", 306, 317], ["The other blood routine indexes", "TEST", 0, 31], ["fever", "PROBLEM", 57, 62], ["pneumonia", "PROBLEM", 71, 80], ["P", "TEST", 82, 83], ["Eosinophils Percentage", "TEST", 120, 142], ["Fever", "PROBLEM", 144, 149], ["Pneumonia", "PROBLEM", 155, 164], ["Linear regression analysis", "TEST", 191, 217], ["fever", "PROBLEM", 230, 235], ["eosinophils percentage", "TEST", 267, 289], ["eosinophils", "TEST", 294, 305], ["neutrophils ratio", "TEST", 306, 323], ["P", "TEST", 325, 326], ["pneumonia severity", "PROBLEM", 349, 367], ["P", "TEST", 369, 370], ["pneumonia", "OBSERVATION", 71, 80], ["Eosinophils Percentage", "OBSERVATION", 120, 142], ["Pneumonia", "OBSERVATION", 155, 164], ["not with", "UNCERTAINTY", 340, 348], ["pneumonia", "OBSERVATION", 349, 358]]], ["The eosinophils percentage, eosinophils/neutrophils ratio, lymphocytes percentage, and neutrophils percentage were not associated with pneumonia severity, either (P > 0.05) (as indicated in Table 3).The Correlative Analysis of Eosinophils Percentage, Fever, and Pneumonia ::: ResultsAll the detailed data analysis are available as six tables in the Supplementary Materials.DiscussionsIn the current study, we found that the young and middle-aged returnees who tested positive for SARS-CoV-2 had symptoms including fever, dry cough, expectoration, pharyngalia, pharynoxerosis, rhinobyon, rhinorrhea, hypodynamic, muscular soreness, and diarrhea.", [["eosinophils", "ANATOMY", 4, 15], ["eosinophils", "ANATOMY", 28, 39], ["neutrophils", "ANATOMY", 40, 51], ["lymphocytes", "ANATOMY", 59, 70], ["neutrophils", "ANATOMY", 87, 98], ["Eosinophils", "ANATOMY", 227, 238], ["muscular", "ANATOMY", 612, 620], ["pneumonia", "DISEASE", 135, 144], ["Fever", "DISEASE", 251, 256], ["Pneumonia", "DISEASE", 262, 271], ["SARS", "DISEASE", 480, 484], ["fever", "DISEASE", 514, 519], ["dry cough", "DISEASE", 521, 530], ["expectoration", "DISEASE", 532, 545], ["pharyngalia", "DISEASE", 547, 558], ["pharynoxerosis", "DISEASE", 560, 574], ["rhinobyon", "DISEASE", 576, 585], ["rhinorrhea", "DISEASE", 587, 597], ["hypodynamic", "DISEASE", 599, 610], ["muscular soreness", "DISEASE", 612, 629], ["diarrhea", "DISEASE", 635, 643], ["eosinophils", "CELL", 4, 15], ["eosinophils", "CELL", 28, 39], ["neutrophils", "CELL", 40, 51], ["lymphocytes", "CELL", 59, 70], ["neutrophils", "CELL", 87, 98], ["Eosinophils", "CELL", 227, 238], ["returnees", "ORGANISM", 446, 455], ["SARS-CoV-2", "ORGANISM", 480, 490], ["eosinophils", "CELL_TYPE", 4, 15], ["eosinophils", "CELL_TYPE", 28, 39], ["neutrophils", "CELL_TYPE", 40, 51], ["lymphocytes", "CELL_TYPE", 59, 70], ["neutrophils", "CELL_TYPE", 87, 98], ["Eosinophils", "CELL_TYPE", 227, 238], ["SARS-CoV", "SPECIES", 480, 488], ["The eosinophils percentage", "TEST", 0, 26], ["eosinophils", "TEST", 28, 39], ["neutrophils ratio", "TEST", 40, 57], ["lymphocytes percentage", "TEST", 59, 81], ["neutrophils percentage", "TEST", 87, 109], ["pneumonia severity", "PROBLEM", 135, 153], ["Eosinophils Percentage", "TEST", 227, 249], ["Fever", "PROBLEM", 251, 256], ["Pneumonia", "PROBLEM", 262, 271], ["All the detailed data analysis", "TEST", 283, 313], ["the current study", "TEST", 387, 404], ["SARS", "PROBLEM", 480, 484], ["CoV", "TEST", 485, 488], ["symptoms", "PROBLEM", 495, 503], ["fever", "PROBLEM", 514, 519], ["dry cough", "PROBLEM", 521, 530], ["expectoration", "PROBLEM", 532, 545], ["pharyngalia", "PROBLEM", 547, 558], ["pharynoxerosis", "PROBLEM", 560, 574], ["rhinobyon", "PROBLEM", 576, 585], ["rhinorrhea", "PROBLEM", 587, 597], ["hypodynamic", "PROBLEM", 599, 610], ["muscular soreness", "PROBLEM", 612, 629], ["diarrhea", "PROBLEM", 635, 643], ["eosinophils percentage", "OBSERVATION", 4, 26], ["lymphocytes percentage", "OBSERVATION", 59, 81], ["neutrophils percentage", "OBSERVATION", 87, 109], ["not associated with", "UNCERTAINTY", 115, 134], ["pneumonia", "OBSERVATION", 135, 144], ["Eosinophils Percentage", "OBSERVATION", 227, 249], ["Pneumonia", "OBSERVATION", 262, 271], ["rhinorrhea", "OBSERVATION", 587, 597], ["hypodynamic", "OBSERVATION_MODIFIER", 599, 610], ["muscular soreness", "ANATOMY", 612, 629], ["diarrhea", "OBSERVATION", 635, 643]]], ["Fever was clearly the most common symptom.", [["Fever", "DISEASE", 0, 5], ["Fever", "PROBLEM", 0, 5], ["most common", "OBSERVATION_MODIFIER", 22, 33]]], ["One previous study reported that the clinical symptoms were fever (57.1%), cough (35.7%), chest tightness/pain (21.4%), fatigue (21.4%), and sore throat (7.1%) (14), which coincided with our findings of fever (51.4%), dry cough (13.5%), expectoration (27.0%), hypodynamic (21.6%), and pharyngalia (10.8%).", [["chest", "ANATOMY", 90, 95], ["pharyngalia", "ANATOMY", 285, 296], ["fever", "DISEASE", 60, 65], ["cough", "DISEASE", 75, 80], ["chest tightness", "DISEASE", 90, 105], ["pain", "DISEASE", 106, 110], ["fatigue", "DISEASE", 120, 127], ["sore throat", "DISEASE", 141, 152], ["fever", "DISEASE", 203, 208], ["dry cough", "DISEASE", 218, 227], ["expectoration", "DISEASE", 237, 250], ["hypodynamic", "DISEASE", 260, 271], ["pharyngalia", "DISEASE", 285, 296], ["chest", "ORGANISM_SUBDIVISION", 90, 95], ["One previous study", "TEST", 0, 18], ["the clinical symptoms", "PROBLEM", 33, 54], ["fever", "PROBLEM", 60, 65], ["cough", "PROBLEM", 75, 80], ["chest tightness/pain", "PROBLEM", 90, 110], ["fatigue", "PROBLEM", 120, 127], ["sore throat", "PROBLEM", 141, 152], ["fever", "PROBLEM", 203, 208], ["dry cough", "PROBLEM", 218, 227], ["expectoration", "TEST", 237, 250], ["hypodynamic", "PROBLEM", 260, 271], ["pharyngalia", "TEST", 285, 296], ["chest", "ANATOMY", 90, 95], ["sore throat", "ANATOMY", 141, 152], ["hypodynamic", "OBSERVATION_MODIFIER", 260, 271]]], ["Moreover, we observed the clinical symptoms of pharynoxerosis (8.1%), rhinobyon (13.5%), rhinorrhea (8.1%), muscular soreness (16.2%), and diarrhea (2.7%).DiscussionsMoreover, we found that the young and middle-aged returnees with COVID-19 had abnormal blood routine indexes.", [["muscular", "ANATOMY", 108, 116], ["blood", "ANATOMY", 253, 258], ["pharynoxerosis", "DISEASE", 47, 61], ["rhinobyon", "DISEASE", 70, 79], ["rhinorrhea", "DISEASE", 89, 99], ["muscular soreness", "DISEASE", 108, 125], ["diarrhea", "DISEASE", 139, 147], ["muscular", "ORGAN", 108, 116], ["returnees", "ORGANISM", 216, 225], ["blood", "ORGANISM_SUBSTANCE", 253, 258], ["the clinical symptoms of pharynoxerosis", "PROBLEM", 22, 61], ["rhinobyon", "TEST", 70, 79], ["rhinorrhea", "PROBLEM", 89, 99], ["muscular soreness", "PROBLEM", 108, 125], ["diarrhea", "PROBLEM", 139, 147], ["COVID", "TEST", 231, 236], ["abnormal blood routine indexes", "PROBLEM", 244, 274], ["rhinorrhea", "OBSERVATION", 89, 99], ["muscular soreness", "ANATOMY", 108, 125], ["middle", "ANATOMY_MODIFIER", 204, 210]]], ["The eosinophils percentage was observed to be down as a single change, but using the other indexes they were observed to be up or down, the changes of which were not unique.", [["eosinophils", "ANATOMY", 4, 15], ["eosinophils", "CELL", 4, 15], ["eosinophils", "CELL_TYPE", 4, 15], ["The eosinophils percentage", "TEST", 0, 26], ["eosinophils percentage", "OBSERVATION", 4, 26]]], ["This finding indicated that eosinophils percentage may serve as an important biomarker of COVID-19.", [["eosinophils", "ANATOMY", 28, 39], ["eosinophils", "CELL", 28, 39], ["eosinophils", "CELL_TYPE", 28, 39], ["eosinophils percentage", "PROBLEM", 28, 50], ["COVID", "TEST", 90, 95], ["eosinophils", "OBSERVATION", 28, 39]]], ["The evidence that WBC was down or normal and lymphocyte percentage was down had been confirmed in one of the previous investigations that reported that nearly 70% of the patients had normal or decreased white blood cell counts (71.4 vs. 28.6%), and that 50% had lymphocytopenia (14).", [["WBC", "ANATOMY", 18, 21], ["lymphocyte", "ANATOMY", 45, 55], ["white blood cell", "ANATOMY", 203, 219], ["lymphocytopenia", "DISEASE", 262, 277], ["WBC", "CELL", 18, 21], ["lymphocyte", "CELL", 45, 55], ["patients", "ORGANISM", 170, 178], ["blood cell", "CELL", 209, 219], ["WBC", "CELL_TYPE", 18, 21], ["patients", "SPECIES", 170, 178], ["WBC", "TEST", 18, 21], ["lymphocyte percentage", "TEST", 45, 66], ["decreased white blood cell counts", "PROBLEM", 193, 226], ["lymphocytopenia", "PROBLEM", 262, 277], ["WBC", "OBSERVATION", 18, 21], ["decreased", "OBSERVATION_MODIFIER", 193, 202]]], ["But we came to realize that a low percentage of eosinophils could be correlated with COVID-19.DiscussionsWe also found that the rate of pneumonia was significantly high (81.10%), with such pneumonic changes as latticed ground glass imaging, white-lung imaging, and consolidated shadow.", [["eosinophils", "ANATOMY", 48, 59], ["lung", "ANATOMY", 247, 251], ["pneumonia", "DISEASE", 136, 145], ["pneumonic", "DISEASE", 189, 198], ["eosinophils", "CELL", 48, 59], ["lung", "ORGAN", 247, 251], ["eosinophils", "CELL_TYPE", 48, 59], ["COVID", "PROTEIN", 85, 90], ["a low percentage of eosinophils", "PROBLEM", 28, 59], ["COVID", "TEST", 85, 90], ["pneumonia", "PROBLEM", 136, 145], ["such pneumonic changes", "PROBLEM", 184, 206], ["latticed ground glass imaging", "TEST", 210, 239], ["white-lung imaging", "TEST", 241, 259], ["consolidated shadow", "PROBLEM", 265, 284], ["pneumonia", "OBSERVATION", 136, 145], ["high", "OBSERVATION_MODIFIER", 164, 168], ["pneumonic", "OBSERVATION", 189, 198], ["lung", "ANATOMY", 247, 251], ["consolidated shadow", "OBSERVATION", 265, 284]]], ["It was previously reported that COVID-19 individuals would present with typical ground-grass opacities and other CT features (15), which coincided with our findings.DiscussionsIn the case of COVID-19, the most common symptom was fever; the eosinophils percentage was significantly low, and the rate of pneumonia was high, as indicated by lung CT.", [["eosinophils", "ANATOMY", 240, 251], ["lung", "ANATOMY", 338, 342], ["fever", "DISEASE", 229, 234], ["pneumonia", "DISEASE", 302, 311], ["eosinophils", "CELL", 240, 251], ["lung", "ORGAN", 338, 342], ["eosinophils", "CELL_TYPE", 240, 251], ["COVID", "TEST", 32, 37], ["typical ground-grass opacities", "PROBLEM", 72, 102], ["other CT features", "TEST", 107, 124], ["COVID", "TEST", 191, 196], ["fever", "PROBLEM", 229, 234], ["the eosinophils percentage", "TEST", 236, 262], ["pneumonia", "PROBLEM", 302, 311], ["lung CT", "TEST", 338, 345], ["grass opacities", "OBSERVATION", 87, 102], ["pneumonia", "OBSERVATION", 302, 311], ["lung", "ANATOMY", 338, 342]]], ["We used a Chi-squared test to assess the different percentages of eosinophils between the patients with fever and those without, and between the patients with pneumonia and those without.", [["eosinophils", "ANATOMY", 66, 77], ["fever", "DISEASE", 104, 109], ["pneumonia", "DISEASE", 159, 168], ["eosinophils", "CELL", 66, 77], ["patients", "ORGANISM", 90, 98], ["patients", "ORGANISM", 145, 153], ["eosinophils", "CELL_TYPE", 66, 77], ["patients", "SPECIES", 90, 98], ["patients", "SPECIES", 145, 153], ["a Chi-squared test", "TEST", 8, 26], ["eosinophils", "PROBLEM", 66, 77], ["fever", "PROBLEM", 104, 109], ["pneumonia", "PROBLEM", 159, 168], ["eosinophils", "OBSERVATION", 66, 77], ["pneumonia", "OBSERVATION", 159, 168]]], ["We used Spearman correlation analysis and binary regression analysis to examine the correlation of eosinophils percentage, fever, and pneumonia.DiscussionsThe differences in clinical symptoms, blood routine index, and lung CT imaging between the COVID-19 patients with a fever and without showed that the percentage of eosinophils was lower in those who had a fever than in those who did not.", [["eosinophils", "ANATOMY", 99, 110], ["blood", "ANATOMY", 193, 198], ["lung", "ANATOMY", 218, 222], ["eosinophils", "ANATOMY", 319, 330], ["fever", "DISEASE", 123, 128], ["pneumonia", "DISEASE", 134, 143], ["fever", "DISEASE", 271, 276], ["fever", "DISEASE", 360, 365], ["eosinophils", "CELL", 99, 110], ["blood", "ORGANISM_SUBSTANCE", 193, 198], ["lung", "ORGAN", 218, 222], ["patients", "ORGANISM", 255, 263], ["eosinophils", "CELL", 319, 330], ["eosinophils", "CELL_TYPE", 99, 110], ["eosinophils", "CELL_TYPE", 319, 330], ["patients", "SPECIES", 255, 263], ["Spearman correlation analysis", "TEST", 8, 37], ["binary regression analysis", "TEST", 42, 68], ["eosinophils percentage", "PROBLEM", 99, 121], ["fever", "PROBLEM", 123, 128], ["pneumonia", "PROBLEM", 134, 143], ["clinical symptoms", "PROBLEM", 174, 191], ["blood routine index", "TEST", 193, 212], ["lung CT imaging", "TEST", 218, 233], ["the COVID", "TEST", 242, 251], ["a fever", "PROBLEM", 269, 276], ["eosinophils", "PROBLEM", 319, 330], ["a fever", "PROBLEM", 358, 365], ["fever", "OBSERVATION", 123, 128], ["pneumonia", "OBSERVATION", 134, 143], ["lung", "ANATOMY", 218, 222], ["eosinophils", "OBSERVATION", 319, 330]]], ["These findings indicated that the low percentage of eosinophils was correlated with a fever in COVID-19 patients.", [["eosinophils", "ANATOMY", 52, 63], ["fever", "DISEASE", 86, 91], ["eosinophils", "CELL", 52, 63], ["patients", "ORGANISM", 104, 112], ["eosinophils", "CELL_TYPE", 52, 63], ["patients", "SPECIES", 104, 112], ["the low percentage of eosinophils", "PROBLEM", 30, 63], ["a fever in COVID", "PROBLEM", 84, 100], ["low", "OBSERVATION_MODIFIER", 34, 37], ["eosinophils", "OBSERVATION", 52, 63]]], ["As indicated by the differences in clinical symptom and blood routine index between the patients with pneumonia and those without, the percentage of eosinophils was low in the COVID-19 patients afflicted with pneumonia.", [["blood", "ANATOMY", 56, 61], ["eosinophils", "ANATOMY", 149, 160], ["pneumonia", "DISEASE", 102, 111], ["pneumonia", "DISEASE", 209, 218], ["blood", "ORGANISM_SUBSTANCE", 56, 61], ["patients", "ORGANISM", 88, 96], ["eosinophils", "CELL", 149, 160], ["patients", "ORGANISM", 185, 193], ["eosinophils", "CELL_TYPE", 149, 160], ["patients", "SPECIES", 88, 96], ["patients", "SPECIES", 185, 193], ["clinical symptom", "PROBLEM", 35, 51], ["blood routine index", "TEST", 56, 75], ["pneumonia", "PROBLEM", 102, 111], ["eosinophils", "TEST", 149, 160], ["pneumonia", "PROBLEM", 209, 218], ["pneumonia", "OBSERVATION", 102, 111], ["eosinophils", "OBSERVATION", 149, 160], ["low", "OBSERVATION_MODIFIER", 165, 168], ["pneumonia", "OBSERVATION", 209, 218]]], ["These findings indicated that the low percentage of eosinophils could be correlated with pneumonia in COVID-19 patients.DiscussionsAs indicated by the results of the Spearman correlation analysis, a significant correlation of low eosinophils percentage was observed with fever and with pneumonia, while no correlation was found between fever and pneumonia.", [["eosinophils", "ANATOMY", 52, 63], ["eosinophils", "ANATOMY", 230, 241], ["pneumonia", "DISEASE", 89, 98], ["fever", "DISEASE", 271, 276], ["pneumonia", "DISEASE", 286, 295], ["fever", "DISEASE", 336, 341], ["pneumonia", "DISEASE", 346, 355], ["eosinophils", "CELL", 52, 63], ["patients", "ORGANISM", 111, 119], ["eosinophils", "CELL", 230, 241], ["eosinophils", "CELL_TYPE", 52, 63], ["eosinophils", "CELL_TYPE", 230, 241], ["patients", "SPECIES", 111, 119], ["the low percentage of eosinophils", "PROBLEM", 30, 63], ["pneumonia", "PROBLEM", 89, 98], ["the Spearman correlation analysis", "TEST", 162, 195], ["low eosinophils percentage", "PROBLEM", 226, 252], ["fever", "PROBLEM", 271, 276], ["pneumonia", "PROBLEM", 286, 295], ["fever", "PROBLEM", 336, 341], ["pneumonia", "PROBLEM", 346, 355], ["low percentage", "OBSERVATION_MODIFIER", 34, 48], ["eosinophils", "OBSERVATION", 52, 63], ["pneumonia", "OBSERVATION", 89, 98], ["low eosinophils", "OBSERVATION", 226, 241], ["pneumonia", "OBSERVATION", 286, 295], ["pneumonia", "OBSERVATION", 346, 355]]], ["These findings verified the conclusion we made based on the results of the Chi-squared test and Linear regression.", [["the Chi-squared test", "TEST", 71, 91]]], ["Furthermore, the results of the Binary regression analysis suggested that fever was negatively correlated with the percentage of eosinophils.", [["eosinophils", "ANATOMY", 129, 140], ["fever", "DISEASE", 74, 79], ["eosinophils", "CELL", 129, 140], ["eosinophils", "CELL_TYPE", 129, 140], ["the Binary regression analysis", "TEST", 28, 58], ["fever", "PROBLEM", 74, 79], ["eosinophils", "TEST", 129, 140]]], ["Although the Binary regression analysis demonstrated that pneumonia was not correlated with the percentage of eosinophils, we considered that the small-sized data of this study could have affected the result.", [["eosinophils", "ANATOMY", 110, 121], ["pneumonia", "DISEASE", 58, 67], ["eosinophils", "CELL", 110, 121], ["eosinophils", "CELL_TYPE", 110, 121], ["the Binary regression analysis", "TEST", 9, 39], ["pneumonia", "PROBLEM", 58, 67], ["eosinophils", "TEST", 110, 121], ["this study", "TEST", 166, 176], ["pneumonia", "OBSERVATION", 58, 67], ["small", "OBSERVATION_MODIFIER", 146, 151], ["sized", "OBSERVATION_MODIFIER", 152, 157]]], ["Although it was not statistically significant enough, this finding was clinically significant enough to be taken seriously, because pneumonia was negatively correlated with the percentage of eosinophils, as indicated in the results of the Chi-squared test and Spearman correlation analysis.", [["eosinophils", "ANATOMY", 191, 202], ["pneumonia", "DISEASE", 132, 141], ["eosinophils", "CELL", 191, 202], ["eosinophils", "CELL_TYPE", 191, 202], ["pneumonia", "PROBLEM", 132, 141], ["eosinophils", "TEST", 191, 202], ["the Chi-squared test", "TEST", 235, 255], ["Spearman correlation analysis", "TEST", 260, 289], ["pneumonia", "OBSERVATION", 132, 141]]], ["The Spearman correlation analysis also showed that lymphocytes count and percentage were positively correlated with pneumonia (P = 0.02, P = 0.005); the percentage of neutrophils was also negatively correlated with pneumonia (P < 0.05), while the count of neutrophils was not correlated with pneumonia (P > 0.05).", [["lymphocytes", "ANATOMY", 51, 62], ["neutrophils", "ANATOMY", 167, 178], ["neutrophils", "ANATOMY", 256, 267], ["pneumonia", "DISEASE", 116, 125], ["pneumonia", "DISEASE", 215, 224], ["pneumonia", "DISEASE", 292, 301], ["lymphocytes", "CELL", 51, 62], ["neutrophils", "CELL", 167, 178], ["neutrophils", "CELL", 256, 267], ["lymphocytes", "CELL_TYPE", 51, 62], ["neutrophils", "CELL_TYPE", 167, 178], ["neutrophils", "CELL_TYPE", 256, 267], ["The Spearman correlation analysis", "TEST", 0, 33], ["lymphocytes count", "TEST", 51, 68], ["percentage", "TEST", 73, 83], ["pneumonia", "PROBLEM", 116, 125], ["P", "TEST", 127, 128], ["P", "TEST", 137, 138], ["the percentage of neutrophils", "TEST", 149, 178], ["pneumonia", "PROBLEM", 215, 224], ["the count of neutrophils", "TEST", 243, 267], ["pneumonia", "PROBLEM", 292, 301], ["P", "TEST", 303, 304], ["lymphocytes count", "OBSERVATION", 51, 68], ["pneumonia", "OBSERVATION", 116, 125], ["pneumonia", "OBSERVATION", 215, 224], ["pneumonia", "OBSERVATION", 292, 301]]], ["The different P-value suggested that the percentage of lymphocytes and neutrophils was more sensitive than the count of lymphocytes and neutrophils.", [["lymphocytes", "ANATOMY", 55, 66], ["neutrophils", "ANATOMY", 71, 82], ["lymphocytes", "ANATOMY", 120, 131], ["neutrophils", "ANATOMY", 136, 147], ["lymphocytes", "CELL", 55, 66], ["neutrophils", "CELL", 71, 82], ["lymphocytes", "CELL", 120, 131], ["neutrophils", "CELL", 136, 147], ["P", "DNA", 14, 15], ["lymphocytes", "CELL_TYPE", 55, 66], ["neutrophils", "CELL_TYPE", 71, 82], ["lymphocytes", "CELL_TYPE", 120, 131], ["neutrophils", "CELL_TYPE", 136, 147], ["The different P-value", "TEST", 0, 21], ["lymphocytes", "TEST", 55, 66], ["neutrophils", "TEST", 71, 82], ["lymphocytes", "TEST", 120, 131], ["neutrophils", "TEST", 136, 147], ["lymphocytes", "ANATOMY", 55, 66]]], ["Furthermore, low eosinophils percentage, high lymphocytes percentage, and low neutrophils percentage could be biomarkers of pneumonia as well, although this was not supported by the Chi-squared test.", [["eosinophils", "ANATOMY", 17, 28], ["lymphocytes", "ANATOMY", 46, 57], ["neutrophils", "ANATOMY", 78, 89], ["pneumonia", "DISEASE", 124, 133], ["eosinophils", "CELL", 17, 28], ["lymphocytes", "CELL", 46, 57], ["neutrophils", "CELL", 78, 89], ["eosinophils", "CELL_TYPE", 17, 28], ["lymphocytes", "CELL_TYPE", 46, 57], ["neutrophils", "CELL_TYPE", 78, 89], ["low eosinophils percentage", "PROBLEM", 13, 39], ["high lymphocytes percentage", "PROBLEM", 41, 68], ["low neutrophils percentage", "PROBLEM", 74, 100], ["pneumonia", "PROBLEM", 124, 133], ["the Chi-squared test", "TEST", 178, 198], ["low eosinophils", "OBSERVATION_MODIFIER", 13, 28], ["percentage", "OBSERVATION_MODIFIER", 29, 39], ["high lymphocytes", "OBSERVATION", 41, 57], ["percentage", "OBSERVATION_MODIFIER", 58, 68], ["low neutrophils", "OBSERVATION_MODIFIER", 74, 89], ["pneumonia", "OBSERVATION", 124, 133]]], ["Additionally, the results of the Binary regression analysis demonstrated that the P-value in the correlation of lymphocytes with fever was low, but as indicated by the confidence intervals, it was not significant enough.", [["lymphocytes", "ANATOMY", 112, 123], ["fever", "DISEASE", 129, 134], ["lymphocytes", "CELL", 112, 123], ["P", "DNA", 82, 83], ["lymphocytes", "CELL_TYPE", 112, 123], ["the Binary regression analysis", "TEST", 29, 59], ["the P-value", "TEST", 78, 89], ["lymphocytes", "PROBLEM", 112, 123], ["fever", "PROBLEM", 129, 134], ["lymphocytes", "ANATOMY", 112, 123]]], ["Therefore, we believe that the proof of lymphocytes correlating with fever was not absolute.DiscussionsFrom the results of the interrelation of the clinical symptoms and Lung CT imaging with the percentage of eosinophils, we found that COVID-19 patients with a low percentage of eosinophils were likely to develop a fever and pneumonia, which indicated an interrelation between both.", [["lymphocytes", "ANATOMY", 40, 51], ["Lung", "ANATOMY", 170, 174], ["eosinophils", "ANATOMY", 209, 220], ["eosinophils", "ANATOMY", 279, 290], ["fever", "DISEASE", 69, 74], ["fever", "DISEASE", 316, 321], ["pneumonia", "DISEASE", 326, 335], ["lymphocytes", "CELL", 40, 51], ["Lung", "ORGAN", 170, 174], ["eosinophils", "CELL", 209, 220], ["patients", "ORGANISM", 245, 253], ["eosinophils", "CELL", 279, 290], ["lymphocytes", "CELL_TYPE", 40, 51], ["eosinophils", "CELL_TYPE", 209, 220], ["eosinophils", "CELL_TYPE", 279, 290], ["patients", "SPECIES", 245, 253], ["lymphocytes", "PROBLEM", 40, 51], ["fever", "PROBLEM", 69, 74], ["the clinical symptoms", "PROBLEM", 144, 165], ["Lung CT imaging", "TEST", 170, 185], ["eosinophils", "TEST", 209, 220], ["COVID", "TEST", 236, 241], ["a low percentage of eosinophils", "PROBLEM", 259, 290], ["a fever", "PROBLEM", 314, 321], ["pneumonia", "PROBLEM", 326, 335], ["Lung", "ANATOMY", 170, 174], ["eosinophils", "OBSERVATION", 279, 290], ["fever", "OBSERVATION", 316, 321], ["pneumonia", "OBSERVATION", 326, 335]]], ["Our findings had been supported by the previously reported studies in terms of eosinophils percentage in COVID-19 (16).", [["eosinophils", "ANATOMY", 79, 90], ["eosinophils", "CELL", 79, 90], ["eosinophils", "CELL_TYPE", 79, 90], ["eosinophils percentage", "TEST", 79, 101], ["COVID", "TEST", 105, 110]]], ["Eosinophils percentage was considered to be a pro-inflammatory factor, playing a pleotropic role as regulatory cells involved in protective immunity, including antiviral responses and diverse physiological responses (17).", [["Eosinophils", "ANATOMY", 0, 11], ["cells", "ANATOMY", 111, 116], ["Eosinophils", "CELL", 0, 11], ["cells", "CELL", 111, 116], ["Eosinophils", "CELL_TYPE", 0, 11], ["pro-inflammatory factor", "PROTEIN", 46, 69], ["regulatory cells", "CELL_TYPE", 100, 116], ["Eosinophils percentage", "TEST", 0, 22], ["a pro-inflammatory factor", "PROBLEM", 44, 69], ["antiviral responses", "TREATMENT", 160, 179]]], ["All these functions could explain why a low percentage of eosinophils meant a patient was more likely to develop a fever and pneumonia in our study.", [["eosinophils", "ANATOMY", 58, 69], ["fever", "DISEASE", 115, 120], ["pneumonia", "DISEASE", 125, 134], ["eosinophils", "CELL", 58, 69], ["patient", "ORGANISM", 78, 85], ["eosinophils", "CELL_TYPE", 58, 69], ["patient", "SPECIES", 78, 85], ["a low percentage of eosinophils", "PROBLEM", 38, 69], ["a fever", "PROBLEM", 113, 120], ["pneumonia", "PROBLEM", 125, 134], ["our study", "TEST", 138, 147], ["eosinophils", "OBSERVATION", 58, 69], ["fever", "OBSERVATION", 115, 120], ["pneumonia", "OBSERVATION", 125, 134]]], ["Furthermore, another study concluded that SARS-CoV-2 vaccine candidates might induce eosinophil-associated disease (18), which also supported our conclusion.", [["eosinophil", "ANATOMY", 85, 95], ["SARS", "DISEASE", 42, 46], ["SARS-CoV-2", "ORGANISM", 42, 52], ["eosinophil", "CELL", 85, 95], ["another study", "TEST", 13, 26], ["SARS", "TEST", 42, 46], ["CoV-2 vaccine", "TREATMENT", 47, 60], ["eosinophil-associated disease", "PROBLEM", 85, 114]]], ["A previous meta-analysis pooled three studies, which covered 294 patients, 25.5% of whom had severe COVID-19, the conclusion of which suggested that eosinopenia may not be associated with an unfavorable progression of COVID-19 (19).", [["eosinopenia", "DISEASE", 149, 160], ["COVID-19", "CHEMICAL", 218, 226], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["A previous meta-analysis", "TEST", 0, 24], ["three studies", "TEST", 32, 45], ["severe COVID", "PROBLEM", 93, 105], ["eosinopenia", "PROBLEM", 149, 160], ["COVID", "TEST", 218, 223], ["unfavorable", "OBSERVATION_MODIFIER", 191, 202], ["progression", "OBSERVATION_MODIFIER", 203, 214]]], ["This was in line with our conclusion that low percentage of eosinophils may be considered as a biomarker of pneumonia due to COVID-19, but not as a biomarker of pneumonia severity.", [["eosinophils", "ANATOMY", 60, 71], ["pneumonia", "DISEASE", 108, 117], ["pneumonia", "DISEASE", 161, 170], ["eosinophils", "CELL", 60, 71], ["eosinophils", "CELL_TYPE", 60, 71], ["low percentage of eosinophils", "PROBLEM", 42, 71], ["pneumonia", "PROBLEM", 108, 117], ["COVID", "TEST", 125, 130], ["pneumonia severity", "PROBLEM", 161, 179], ["eosinophils", "OBSERVATION", 60, 71], ["pneumonia", "OBSERVATION", 108, 117], ["pneumonia", "OBSERVATION", 161, 170]]], ["Further verification merits a larger number of samples for investigation and analysis.ConclusionBy investigating the young and middle-aged returnees infected with SARS-CoV-2, we acquired a deep insight into the correlation among fever, low eosinophils percentage, and pneumonia.", [["samples", "ANATOMY", 47, 54], ["eosinophils", "ANATOMY", 240, 251], ["SARS", "DISEASE", 163, 167], ["fever", "DISEASE", 229, 234], ["pneumonia", "DISEASE", 268, 277], ["samples", "CANCER", 47, 54], ["SARS-CoV-2", "ORGANISM", 163, 173], ["eosinophils", "CELL", 240, 251], ["eosinophils", "CELL_TYPE", 240, 251], ["SARS-CoV", "SPECIES", 163, 171], ["Further verification", "TEST", 0, 20], ["investigation and analysis", "TEST", 59, 85], ["fever", "PROBLEM", 229, 234], ["low eosinophils percentage", "PROBLEM", 236, 262], ["pneumonia", "PROBLEM", 268, 277], ["low eosinophils", "OBSERVATION_MODIFIER", 236, 251], ["pneumonia", "OBSERVATION", 268, 277]]], ["Our findings indicated that a correlation was observed between eosinophils percentage and fever and between low eosinophils percentage and pneumonia, and that no correlation was observed between fever and pneumonia.", [["eosinophils", "ANATOMY", 63, 74], ["eosinophils", "ANATOMY", 112, 123], ["fever", "DISEASE", 90, 95], ["pneumonia", "DISEASE", 139, 148], ["fever", "DISEASE", 195, 200], ["pneumonia", "DISEASE", 205, 214], ["eosinophils", "CELL", 63, 74], ["eosinophils", "CELL", 112, 123], ["eosinophils", "CELL_TYPE", 63, 74], ["eosinophils", "CELL_TYPE", 112, 123], ["eosinophils percentage", "TEST", 63, 85], ["fever", "PROBLEM", 90, 95], ["low eosinophils percentage", "PROBLEM", 108, 134], ["pneumonia", "PROBLEM", 139, 148], ["fever", "PROBLEM", 195, 200], ["pneumonia", "PROBLEM", 205, 214], ["low eosinophils", "OBSERVATION_MODIFIER", 108, 123], ["pneumonia", "OBSERVATION", 139, 148], ["pneumonia", "OBSERVATION", 205, 214]]], ["With a low percentage of eosinophils, fever and pneumonia were more likely to develop in COVID-19 patients.", [["eosinophils", "ANATOMY", 25, 36], ["fever", "DISEASE", 38, 43], ["pneumonia", "DISEASE", 48, 57], ["eosinophils", "CELL", 25, 36], ["patients", "ORGANISM", 98, 106], ["eosinophils", "CELL_TYPE", 25, 36], ["patients", "SPECIES", 98, 106], ["a low percentage of eosinophils", "PROBLEM", 5, 36], ["fever", "PROBLEM", 38, 43], ["pneumonia", "PROBLEM", 48, 57], ["low percentage", "OBSERVATION_MODIFIER", 7, 21], ["eosinophils", "OBSERVATION", 25, 36], ["fever", "OBSERVATION", 38, 43], ["pneumonia", "OBSERVATION", 48, 57], ["more likely", "UNCERTAINTY", 63, 74]]], ["Thus, a low percentage of eosinophils could serve as a biomarker of COVID-19 pneumonia, but not as a biomarker of pneumonia severity.LimitationThis was a small sample study, which, to a great extent, was decided by the context in which we conducted the investigation.", [["eosinophils", "ANATOMY", 26, 37], ["pneumonia", "DISEASE", 77, 86], ["pneumonia", "DISEASE", 114, 123], ["eosinophils", "CELL", 26, 37], ["eosinophils", "CELL_TYPE", 26, 37], ["a low percentage of eosinophils", "PROBLEM", 6, 37], ["COVID", "TEST", 68, 73], ["pneumonia", "PROBLEM", 77, 86], ["pneumonia severity", "PROBLEM", 114, 132], ["a small sample study", "TEST", 152, 172], ["the investigation", "TEST", 249, 266], ["low percentage", "OBSERVATION_MODIFIER", 8, 22], ["eosinophils", "OBSERVATION", 26, 37], ["pneumonia", "OBSERVATION", 77, 86], ["pneumonia", "OBSERVATION", 114, 123], ["great extent", "OBSERVATION_MODIFIER", 186, 198]]], ["The viral load was not tested; the test result of SARS-CoV-2 was just recorded as negative or positive.Data Availability StatementThe datasets presented in this study can be found in online repositories.", [["SARS", "DISEASE", 50, 54], ["SARS-CoV-2", "ORGANISM", 50, 60], ["SARS-CoV", "SPECIES", 50, 58], ["The viral load", "TEST", 0, 14], ["the test", "TEST", 31, 39], ["SARS", "PROBLEM", 50, 54], ["CoV", "TEST", 55, 58], ["this study", "TEST", 156, 166], ["viral load", "OBSERVATION", 4, 14], ["positive", "OBSERVATION", 94, 102]]], ["The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.Ethics StatementThe studies involving human participants were reviewed and approved by the Medical Ethics Committee of Shanghai Pudong New Area People's Hospital, Shanghai, China.", [["human", "ORGANISM", 154, 159], ["human", "SPECIES", 154, 159], ["participants", "SPECIES", 160, 172], ["human", "SPECIES", 154, 159]]], ["The patients/participants provided their written informed consent to participate in this study.Author ContributionsJY and HS conceived and designed the project.", [["patients", "ORGANISM", 4, 12], ["participants", "ORGANISM", 13, 25], ["patients", "SPECIES", 4, 12], ["participants", "SPECIES", 13, 25], ["this study", "TEST", 84, 94]]]], "53326420d7eb607538a248c0da27d3b092f651e2": [["INTRODUCTIONTwenty-six countries worldwide have declared cases of the novel coronavirus, COVID-19, as of February 20, 2020 1 .", [["coronavirus", "DISEASE", 76, 87], ["coronavirus", "ORGANISM", 76, 87], ["the novel coronavirus", "PROBLEM", 66, 87]]], ["Only China so far registered a widespread epidemic 2 , and authorities have implemented massive intervention measures to curtail it 3 .", [["massive intervention measures", "TREATMENT", 88, 117], ["widespread", "OBSERVATION_MODIFIER", 31, 41], ["epidemic", "OBSERVATION", 42, 50], ["massive", "OBSERVATION_MODIFIER", 88, 95]]], ["Outside China, affected countries are facing importations of cases and clusters of local transmission 1, 4, 5 Border controls have been reinforced in many countries, and active surveillance has been intensified to rapidly detect and isolate importations, trace contacts and isolate suspect cases 6,7 .INTRODUCTIONThe effectiveness of such measures, however, critically depends on COVID-19 epidemiology and natural history 8, 9 , as well as the volume of importations 6 .", [["isolate suspect cases", "TEST", 274, 295], ["such measures", "TREATMENT", 334, 347], ["COVID", "TEST", 380, 385]]], ["The presence of an incubation period, during which infected individuals carry on their usual activities (including travel), is a major challenge for screening controls at airports 8 .", [["incubation", "OBSERVATION", 19, 29]]], ["Moreover, mild non-specific symptoms and transmission before the onset of clinical symptoms 2,10 may compromise infection control measures for importations and onward transmissions 9 .", [["infection", "DISEASE", 112, 121], ["mild non-specific symptoms", "PROBLEM", 10, 36], ["clinical symptoms", "PROBLEM", 74, 91], ["infection control measures", "TREATMENT", 112, 138], ["mild", "OBSERVATION_MODIFIER", 10, 14], ["non-specific", "OBSERVATION_MODIFIER", 15, 27], ["infection", "OBSERVATION", 112, 121]]], ["There is concern that imported cases may have gone undetected and contribute unknowingly to the global spread of the disease 11-15 .INTRODUCTIONHere we systematically collected and analyzed data on 288 COVID-19 confirmed cases outside China.", [["the disease", "PROBLEM", 113, 124], ["COVID", "TEST", 202, 207]]], ["We developed a statistical model to nowcast trends in importations and quantify the proportion of undetected imported cases.Data collection and synthesisWe collected all international cases confirmed by official public health sources in the period from January 3 to February 13, 2020.", [["Data collection", "TEST", 124, 139]]], ["Case history included: dates of travel and symptoms onset, date of COVID-19 confirmation, date of hospital admission, date of case isolation, travel history, epidemiological link with other cases, hospitalization history.", [["symptoms", "PROBLEM", 43, 51], ["COVID", "TEST", 67, 72]]], ["Cases from cruises were not considered here.", [["not considered", "UNCERTAINTY", 24, 38]]], ["We used analysis of variance to compare groups of imported cases that generated or did not generate local transmissions.", [["analysis of variance", "TREATMENT", 8, 28]]], ["We used the analysis of variance and multiple imputation for the missing data.", [["the analysis", "TEST", 8, 20], ["multiple imputation", "TREATMENT", 37, 56]]], ["Results were combined using Rubin's approach 17 .Modeling and predicting importationsWe modeled the total number of imported cases out of China over time accounting for date of travel, delay in reporting, and source areas.Modeling and predicting importationsWe distinguished between three different sources: Hubei province (H), the rest of China (C), other countries (O).", [["Rubin's approach", "TREATMENT", 28, 44], ["total", "OBSERVATION_MODIFIER", 100, 105]]], ["We modeled imported cases over time as a piecewise exponential function depending on the source and on travel restrictions in place.", [["a piecewise exponential function", "TREATMENT", 39, 71], ["travel restrictions", "TREATMENT", 103, 122]]], ["We assumed a different situation in Hubei province and the rest of the world due to the level of awareness in the different phases of the outbreak.", [["different", "OBSERVATION_MODIFIER", 13, 22]]], ["Travel restrictions were modelled by assuming a discontinuity in the growth rate.", [["a discontinuity in the growth rate", "PROBLEM", 46, 80]]], ["For Hubei, we assumed the growth rate to change from @ '() to @ '45$ after the travel ban of January 23, 2020 (indicated with @ );Modeling and predicting importationsfor the rest of China, we assumed an analogous change from A '() to A '45$ after January 29, 2020Modeling and predicting importations( A ), date of first flight cancellations 18 .", [["the growth rate", "PROBLEM", 22, 37]]], ["No change was considered for the other countries ( = constant over time), as no restrictions of travel were established towards these countries.", [["change", "OBSERVATION", 3, 9]]], ["The scale parameters of the exponential functions ( @ '() , @ '45$ , A '() , A '45$ , = ) were assumed to be different among the three sources, to account for different traveling volumes and dates of beginning of importations.Modeling and predicting importationsWe modelled the time from importation to detection of a case with a gamma distribution, $ ( ), conditioned to the date of case importation, . $ ( ) was assumed to have constant coefficient of variation (SD/mean) achieved by a constant shape parameter and a rate parameter varying smoothly in time to capture change in surveillance efficiency.Modeling and predicting importationsWe used a Bayesian framework to fit the model to imported cases by origin, travel date, and confirmation date.", [["The scale parameters", "TEST", 0, 20], ["the exponential functions", "TEST", 24, 49], ["a constant shape parameter", "TREATMENT", 486, 512], ["a rate parameter", "TREATMENT", 517, 533]]], ["All details of the analysis are reported in the Appendix.Estimation of under-detection of imported casesWe analyzed clusters of transmission generated by imported cases (index case(s) in each cluster) to estimate undetected importations.", [["the analysis", "TEST", 15, 27], ["Appendix", "ANATOMY", 48, 56]]], ["We modelled the number of such 'cluster seeds', i.e. groups of index cases, with a multinomial distribution depending on the portion of cluster seeds of size 1 or greater than 1 (for simplicity, this was taken as 2), on the probability of detection of a seed, and on occurrence of secondary transmission.", [["seed", "ANATOMY", 254, 258], ["a multinomial distribution", "PROBLEM", 81, 107], ["secondary transmission", "PROBLEM", 281, 303], ["seeds", "OBSERVATION_MODIFIER", 144, 149], ["size", "OBSERVATION_MODIFIER", 153, 157], ["secondary transmission", "OBSERVATION", 281, 303]]], ["The likelihood function was a function of: the number G of observed clusters with one index case; the number H of observed clusters with more than 1 index cases; the number J of detected index cases not leading to onward transmission; the number of clusters whose index cases have not been identified; and the number of undetected imported cases that did not generate any cluster. can be estimated through likelihood maximization from the records of G , H , J, .Timeline of travel-related casesWe collected 288 cases, including 163 imported cases, 109 local transmissions, 30 repatriations, and 1 case of unknown origin.", [["local transmissions", "TEST", 552, 571], ["repatriations", "TEST", 576, 589]]], ["Fifteen cases were classified as both imported and local transmissions, since they contracted the infection outside China and traveled to a different country once infected (ES01, ES02, GB03, GB04, GB05, GB06, GB07, GB08, KR12, KR16, KR17, KR19, MY09, TH20, TH21 in our database 16 ).", [["infection", "DISEASE", 98, 107], ["KR16", "GENE_OR_GENE_PRODUCT", 227, 231], ["the infection", "PROBLEM", 94, 107], ["ES01", "TEST", 173, 177], ["ES02", "TEST", 179, 183], ["GB03", "TEST", 185, 189], ["GB04", "TEST", 191, 195], ["GB05", "TEST", 197, 201], ["GB06", "TEST", 203, 207], ["GB07", "TEST", 209, 213], ["GB08", "TEST", 215, 219], ["KR12", "TEST", 221, 225], ["KR16", "TEST", 227, 231], ["KR17", "TEST", 233, 237], ["KR19", "TEST", 239, 243], ["MY09", "TEST", 245, 249], ["infection", "OBSERVATION", 98, 107]]], ["Symptoms onset occurred after the travel to the destination country for almost all cases for which date of travel and of onset are available (68 out of 73, 93%).", [["Symptoms", "PROBLEM", 0, 8]]], ["Complete information was available for 51 (31%) imported cases, with quality of information decreasing over time ( Figure S1 of the Appendix). .", [["Appendix", "ANATOMY", 132, 140]]], ["CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Timeline of travel-related casesis the (which was not peer-reviewed) The copyright holder for this preprint .Timeline of travel-related casesAmong imported cases with full information, the delay from travel to hospitalization was longer in cases that generated secondary transmissions (mean of 10 \u00b1 0.97 days compared to 5.5 \u00b1 0.67 days, p=0.003).", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 220, 240], ["this preprint", "TREATMENT", 245, 258], ["med", "ANATOMY", 95, 98]]], ["Durations of hospitalization were instead comparable among the two groups of cases (1.5 \u00b1 0.7 days vs. 2.6 \u00b1 0.4 days for cases that generated or did not generate secondary transmissions, respectively).", [["hospitalization", "TREATMENT", 13, 28]]], ["Including imported cases with missing information through imputation, we found the same trend though smaller in magnitude and not statistically significant (delay from travel to hospitalization 9.8 \u00b1 1.2 vs. 8.3 \u00b1 0.5 days p= 0.3; delay from travel to onset 5.8 \u00b11.1 vs. 4.2 \u00b10.5 p= 0.16, for cases that generated or did not generate secondary transmissions, respectively).", [["hospitalization", "TEST", 178, 193], ["onset", "TEST", 252, 257], ["p", "TEST", 280, 281], ["smaller", "OBSERVATION_MODIFIER", 101, 108]]], ["This suggests that importations with missing information may be closer in characteristics to index cases leading to onward transmission.Timeline of travel-related casesThe statistical model predicted a decrease in the average time from travel to detection from 14.5 \u00b1 5.5 days on January 5, 2020 to 6 \u00b1 3.5 days on February 1, 2020 ( Figure 2 ).Nowcasting travel-related casesThe model predicted a rapid exponential growth of importations from Hubei, with a growth rate The predicted trend of all imported cases over time is shown in Figure 3 , compared with the observed data.", [["a growth rate", "TEST", 456, 469], ["the observed data", "TEST", 559, 576], ["decrease", "OBSERVATION_MODIFIER", 202, 210], ["rapid", "OBSERVATION_MODIFIER", 398, 403], ["exponential", "OBSERVATION_MODIFIER", 404, 415], ["growth", "OBSERVATION_MODIFIER", 416, 422], ["trend", "OBSERVATION_MODIFIER", 484, 489]]], ["Table 1 summarizes the size and country of each cluster.", [["size", "OBSERVATION_MODIFIER", 23, 27]]], ["CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Trasmission clusters outside Chinais the (which was not peer-reviewed) The copyright holder for this preprint .Trasmission clusters outside Chinaincreased the number of undetected cases to 225 [186, 369], i.e. detected cases would correspond to only 36% of the total.Trasmission clusters outside China(2), cJP05 (2), cJP07 (2), cSG03 (2), cSG05 (2), cSG06 (2), cSG07 (2), cSG08 (2), cSG10 (2), cSG12 (2), cTH01 (2), cTH02Trasmission clusters outside China(2), cTH03 (2), cAE01(****) \u00a7 Cluster associated to two traveling cases No connection with other case or source of infection has been identified yet ****Insufficient informationDISCUSSIONAs the COVID-19 epidemic in China shows effects of mitigation 2 , increasingly larger clusters of infections reported outside China are raising concern that other territories may start sustaining the outbreak 4,5 .", [["CC", "CHEMICAL", 0, 2], ["infection", "DISEASE", 721, 730], ["infections", "DISEASE", 891, 901], ["cTH02Trasmission clusters", "DNA", 567, 592], ["cAE01", "DNA", 622, 627], ["The copyright holder", "TREATMENT", 222, 242], ["this preprint", "TREATMENT", 247, 260], ["infection", "PROBLEM", 721, 730], ["the COVID", "TEST", 796, 805], ["infections", "PROBLEM", 891, 901], ["med", "ANATOMY", 95, 98], ["infection", "OBSERVATION", 721, 730], ["larger", "OBSERVATION_MODIFIER", 872, 878], ["clusters", "OBSERVATION_MODIFIER", 879, 887], ["infections", "OBSERVATION", 891, 901]]], ["To contain it globally, identification, rapid management of cases, and contact tracing are key.", [["contact tracing", "TEST", 71, 86]]], ["The success of these response measures depends critically on the volume of importations 19 and the sensitivity of active surveillance 13,15 .DISCUSSIONWe reviewed here all confirmed cases out of China from January 3 to February 13, 2020 and gathered detailed information on case history and epidemiological links.", [["active surveillance", "TEST", 114, 133]]], ["We identified salient epidemiological features, and modeled the number of importations over time.", [["salient epidemiological features", "PROBLEM", 14, 46], ["salient", "OBSERVATION_MODIFIER", 14, 21]]], ["This is related to the difference in the increase of cases between Hubei province, origin of the outbreak, and the rest of the affected areas 1 .", [["the outbreak", "PROBLEM", 93, 105], ["increase", "OBSERVATION_MODIFIER", 41, 49], ["origin", "OBSERVATION_MODIFIER", 83, 89], ["outbreak", "OBSERVATION", 97, 105], ["affected", "OBSERVATION", 127, 135]]], ["Such difference is likely an outcome of the implementation of containment measures in China 3,20,21 , and of the increased awareness at different phases of the outbreak 22-26 (i.e. before and after containment measures) leading to self-isolation and quarantine.DISCUSSION. CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DISCUSSIONis the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.02.", [["CC", "CHEMICAL", 273, 275], ["containment measures", "TREATMENT", 62, 82], ["the increased awareness", "PROBLEM", 109, 132], ["containment measures", "TREATMENT", 198, 218], ["self-isolation", "TREATMENT", 231, 245], ["quarantine", "TREATMENT", 250, 260], ["The copyright holder", "TREATMENT", 471, 491], ["this preprint", "TREATMENT", 496, 509], ["is likely", "UNCERTAINTY", 16, 25], ["increased", "OBSERVATION_MODIFIER", 113, 122], ["med", "ANATOMY", 368, 371]]], ["24.20027326 doi: medRxiv preprint The reduced volume of exported cases worldwide following the travel ban may have given countries the time to prepare and strengthen their surveillance systems, as signaled by a reduction of the interval from travel date to detection over time.DISCUSSIONOur model predicts that exportations will likely rise from areas outside China.", [["reduced", "OBSERVATION_MODIFIER", 38, 45], ["volume", "OBSERVATION_MODIFIER", 46, 52]]], ["The number of local transmissions is rapidly increasing in the Republic of Korea, Japan, and Singapore 27 , and few importations in Asia and Europe were registered already from travelers from Japan and Singapore.", [["number", "OBSERVATION_MODIFIER", 4, 10], ["local", "OBSERVATION_MODIFIER", 14, 19], ["rapidly", "OBSERVATION_MODIFIER", 37, 44], ["increasing", "OBSERVATION_MODIFIER", 45, 55]]], ["ECDC and WHO currently base their case definition on travel from China only 30,31 , but this may rapidly change in the next days.DISCUSSIONBefore the likely rebound of exportations, identification and isolation of possible clusters outside China remain essential to contain local transmission.", [["isolation", "TREATMENT", 201, 210], ["likely", "UNCERTAINTY", 150, 156], ["rebound", "OBSERVATION_MODIFIER", 157, 164], ["local transmission", "OBSERVATION", 274, 292]]], ["The increasing reporting of clusters outside China with no known epidemiological link 1,14 raises important concerns on the possibility to contain COVID-19 epidemic worldwide.", [["COVID", "TEST", 147, 152], ["increasing", "OBSERVATION_MODIFIER", 4, 14]]], ["Previous estimates range from 27% 13 to 38% 13,15 detection rates, with variations across countries 13, 15 .", [["Previous estimates", "TEST", 0, 18], ["detection rates", "TEST", 50, 65], ["range", "OBSERVATION_MODIFIER", 19, 24]]], ["Ascertainment was estimated to be even lower (approximately 10%) when assessed on repatriations 31 .", [["Ascertainment", "TEST", 0, 13], ["lower", "OBSERVATION_MODIFIER", 39, 44]]], ["Here, we excluded from this analysis all repatriation events and cruises with outbreaks, as conditions for detection and identification may be different.DISCUSSIONUnderdetection may be due to several different factors including asymptomatic infections, infections with mild clinical symptoms, health-seeking behavior and declaration of travel history, case definition, and underdiagnosis.", [["infections", "DISEASE", 241, 251], ["infections", "DISEASE", 253, 263], ["health-seeking behavior", "DISEASE", 293, 316], ["this analysis", "TEST", 23, 36], ["cruises", "PROBLEM", 65, 72], ["asymptomatic infections", "PROBLEM", 228, 251], ["infections", "PROBLEM", 253, 263], ["mild clinical symptoms", "PROBLEM", 269, 291], ["asymptomatic", "OBSERVATION_MODIFIER", 228, 240], ["infections", "OBSERVATION", 241, 251], ["mild", "OBSERVATION_MODIFIER", 269, 273]]], ["Underdetection of imported cases is likely to be higher than what we estimate here, as our analysis is conditional to the identification of clusters of cases.", [["our analysis", "TEST", 87, 99]]], ["The current situation in Italy, with different clusters emerging in the timeframe of few hours in different areas in the North of the country 14 , shows that clusters have gone undetected and epidemiological links with the index case are still missing.", [["clusters", "OBSERVATION_MODIFIER", 47, 55], ["North", "ANATOMY_MODIFIER", 121, 126]]], ["If that situation occurs, countries should be ready to step-up their response and take preparatory steps for community interventions.13.MRC Centre for Global Infectious Disease Analysis.", [["Infectious Disease", "DISEASE", 158, 176], ["community interventions", "TREATMENT", 109, 132], ["Global Infectious Disease Analysis", "PROBLEM", 151, 185], ["Infectious", "OBSERVATION", 158, 168]]], ["Report 6: Relative sensitivity of international surveillance. https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/news-wuhan-coronavirus/.13.14.13.Salute, M. della.", [["M. della", "ORGANISM", 169, 177], ["international surveillance", "TEST", 34, 60], ["M. della", "OBSERVATION", 169, 177]]], ["Covid-19 -Situazione in Italia e nel mondo. http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioContenutiNuovoCoronavirus.jsp?lingua =italiano&id=5338&area=nuovoCoronavirus&menu=vuoto.13..", [["Covid-19 -Situazione", "CHEMICAL", 0, 20], ["Covid", "TEST", 0, 5], ["Situazione", "TREATMENT", 10, 20]]], ["CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.13.is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.02.24.20027326 doi: medRxiv preprint 29.13.The Times of Israel.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 191, 211], ["this preprint", "TREATMENT", 216, 229], ["med", "ANATOMY", 95, 98]]], ["Israel bans foreigners coming from East Asian countries over virus fears. https://www.timesofisrael.com/israel-bans-foreigners-coming-from-east-asian-countries-over-virusfears/.30.Case definition and European surveillance for human infection with novel coronavirus (SARS-CoV-2).", [["human infection", "DISEASE", 226, 241], ["human", "ORGANISM", 226, 231], ["SARS-CoV-2", "ORGANISM", 266, 276], ["human", "SPECIES", 226, 231], ["human", "SPECIES", 226, 231], ["European surveillance", "TEST", 200, 221], ["human infection", "PROBLEM", 226, 241], ["novel coronavirus", "PROBLEM", 247, 264], ["CoV", "TEST", 271, 274]]], ["European Centre for Disease Prevention and Control https://www.ecdc.europa.eu/en/casedefinition-and-european-surveillance-human-infection-novel-coronavirus-2019-ncov.31.World Health Organization (WHO).", [["Disease Prevention", "TREATMENT", 20, 38]]], ["Global Surveillance for human infection with coronavirus disease (COVID-2019). https://www.who.int/publications-detail/global-surveillance-for-humaninfection-with-novel-coronavirus-(2019-ncov).32.Nishiura .", [["human infection", "DISEASE", 24, 39], ["coronavirus disease", "DISEASE", 45, 64], ["human", "ORGANISM", 24, 29], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 24, 29], ["human infection", "PROBLEM", 24, 39], ["coronavirus disease", "PROBLEM", 45, 64], ["infection", "OBSERVATION", 30, 39], ["coronavirus disease", "OBSERVATION", 45, 64]]], ["CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.32.is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.02.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 191, 211], ["this preprint", "TREATMENT", 216, 229], ["med", "ANATOMY", 95, 98]]], ["24Modelling traveling cases and delay from arrival to detectionDataset: The individual data consists of t-uples ( , , ), where:Modelling traveling cases and delay from arrival to detection\u2022 indicates place of departure as Hubei province ( ), China other than Hubei ( ), outside China ( ); \u2022 \u2208 {1, \u2026 , } is the day the case arrived at destination, counted from January 5 th up to current date ; \u2022 \u2208 {1, \u2026 , } is the day the case was confirmed, counted from January 5 th .Modelling traveling cases and delay from arrival to detectionModelling the detection delay: The difference = \u2212 corresponds to the time from arrival to confirmation.", [["the case", "TEST", 419, 427]]], ["To account for changes in detection efficiency, we modelled as a (discretized) gamma distribution with parameters changing with time.", [["changes in detection efficiency", "PROBLEM", 15, 46], ["a (discretized) gamma distribution", "TREATMENT", 63, 97], ["gamma distribution", "OBSERVATION", 79, 97]]], ["The shape parameter was constant, leading to a constant coefficient of variationModelling traveling cases and delay from arrival to detectionWe truncated the distribution at ^= 25 days and computed probabilities that was \u03c4 days as :Modelling traveling cases and delay from arrival to detectionwhere is a normalization constant accounting for the truncation at ^.Modelling traveling cases and delay from arrival to detectionWe denote the corresponding cumulative distribution function of D by X ( ) = ( \u2264 + 0.5| X , ).Modelling traveling cases and delay from arrival to detectionModelling cases arrival: We computed \" = n \",$ o $ the total number of such cases arriving from location .Modelling traveling cases and delay from arrival to detectionDue to the time lag between arrival and confirmation, some cases arriving on time t from location S can be undetected as of time T. We denote \",$ the number of such cases.", [["the truncation", "PROBLEM", 342, 356], ["confirmation", "TEST", 785, 797], ["shape", "OBSERVATION_MODIFIER", 4, 9]]], ["Then, the total count of cases arriving on day t is given by \",$ + \",$ .", [["the total count", "TEST", 6, 21]]], ["We assumed a Poisson distribution for this count, \",$ + \", ), where \",$ represents the expected number of imported cases from location on day .Modelling traveling cases and delay from arrival to detectionWe modelled \",$ as a piecewise exponential function in each location of origin S, the exponential growth parameter changing in Hubei after the ban instated on January 23 rd and in the rest of China after flight cancellation by major airline companies on January 29 th . \",$ was therefore: .", [["this count", "TEST", 38, 48], ["a piecewise exponential function", "TREATMENT", 223, 255]]], ["CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Modelling traveling cases and delay from arrival to detectionis the (which was not peer-reviewed) The copyright holder for this preprint .Modelling traveling cases and delay from arrival to detectionOutside China we assumed a single exponential function with the same growth rate as in China outside Hubei before travel restrictions were put in place ( = = A '() ) and a different scale :Modelling traveling cases and delay from arrival to detection=,$ = = * ( > $ 49 confirmed cases had no information on date of arrival and/or origin of travel.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 249, 269], ["this preprint", "TREATMENT", 274, 287], ["detection", "TEST", 591, 600], ["med", "ANATOMY", 95, 98]]], ["These cases were described with latent variables as follows:Modelling traveling cases and delay from arrival to detection, the time series that accounts for case counts with unknown date of arrival; \u2022 \" = n \",$ o + \",$ (z) + \",$ + \",$ + \",$ (z)~ ( \",$ ) to be the number of cases arriving from destination S on time t.Modelling traveling cases and delay from arrival to detectionLikelihood function: The components of the estimated parameters \u03b8 and prior distributions are listed in Table S2 .", [["case counts", "TEST", 157, 168], ["\"", "TEST", 215, 216], ["\"", "TEST", 225, 226], ["\"", "TEST", 231, 232], ["\"", "TEST", 237, 238], ["z", "TEST", 242, 243], ["the estimated parameters", "TEST", 418, 442]]], ["CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Modelling traveling cases and delay from arrival to detectionis the (which was not peer-reviewed) The copyright holder for this preprint .Modelling traveling cases and delay from arrival to detectionconfirmed on day , e.g. the average value as well as upper and lower quantiles, using Poisson distribution with mean ( ) = \u2211 \" ( ) \"p@,A,= .Modelling index case detection probabilityDataset: We define as seed an imported case or a group of cases that could have started a cluster of local transmission outside China.", [["CC", "CHEMICAL", 0, 2], ["upper", "ORGANISM_SUBDIVISION", 403, 408], ["The copyright holder", "TREATMENT", 249, 269], ["this preprint", "TREATMENT", 274, 287], ["med", "ANATOMY", 95, 98], ["upper", "ANATOMY_MODIFIER", 403, 408]]], ["We computed the number G of transmission clusters where a seed of size 1 was among the cases identified in the cluster and likewise H with seeds of size >1.", [["size", "OBSERVATION_MODIFIER", 66, 70], ["size", "OBSERVATION_MODIFIER", 148, 152]]], ["We also computed the number J of imported cases that did not start a transmission cluster and the number of clusters for which a seed was not observed among the tested cases, i.e. clusters without a direct link to an imported case.Modelling index case detection probabilityModeling index case detection: We assumed that seeds could be of size 1 with probability or of size 2 with probability 1 \u2212 .", [["size", "OBSERVATION_MODIFIER", 338, 342], ["size", "OBSERVATION_MODIFIER", 368, 372]]], ["A seed could be observed with probability and started a cluster with probability .Modelling index case detection probabilityThe number J of imported cases that did not start a cluster consist of y1 and y2 seeds of size 1 and 2 such that y1 + 2 y2 = J and y1 + y2 = ; however the grouping of these cases is unknown.", [["size", "TEST", 214, 218]]], ["We computed y out of J using a plug-in estimate where the mean of the fraction y1/y2 was /(1 \u2212 ), i.e.= J/(2 \u2212 ).Denote the number of seeds of any size that went undetected and did not give start to a cluster, with probability: (1 \u2212 )(1 \u2212 ). is latent and estimated together with , and .= J/(2 \u2212 ).Likelihood function: The likelihood is based on a multinomial distribution for G , H , , and : ).", [["a plug", "PROBLEM", 29, 35], ["plug", "OBSERVATION", 31, 35], ["size", "OBSERVATION_MODIFIER", 147, 151], ["latent", "OBSERVATION_MODIFIER", 245, 251]]], ["CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.= J/(2 \u2212 ).is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.02.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 199, 219], ["this preprint", "TREATMENT", 224, 237], ["med", "ANATOMY", 95, 98]]], ["CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Dataset of international casesis the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.02.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 218, 238], ["this preprint", "TREATMENT", 243, 256], ["med", "ANATOMY", 95, 98]]], ["The convergence of the MCMC and the posterior distribution of key parameters are shown in Figure S2 . .", [["posterior", "ANATOMY_MODIFIER", 36, 45], ["Figure S2", "OBSERVATION", 90, 99]]], ["CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Results of likelihood estimationis the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.02.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 220, 240], ["this preprint", "TREATMENT", 245, 258], ["med", "ANATOMY", 95, 98]]], ["Convergence of MCMC fitting procedure.", [["MCMC fitting procedure", "TREATMENT", 15, 37]]], ["On the left we show the evolution of each chain for every individual parameter.", [["left", "ANATOMY_MODIFIER", 7, 11]]], ["On the right we plot the corresponding posterior distribution (shaded histogram) as well as the posterior distribution (black line).Results of likelihood estimation.", [["likelihood estimation", "TEST", 143, 164], ["right", "ANATOMY_MODIFIER", 7, 12], ["posterior", "OBSERVATION_MODIFIER", 39, 48], ["distribution", "OBSERVATION_MODIFIER", 49, 61], ["posterior", "ANATOMY_MODIFIER", 96, 105], ["black line", "OBSERVATION", 120, 130], ["likelihood estimation", "OBSERVATION", 143, 164]]], ["CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Results of likelihood estimationis the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.02.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 220, 240], ["this preprint", "TREATMENT", 245, 258], ["med", "ANATOMY", 95, 98]]], ["We accounted for the possibility that this ban was initially not completely effective, e.g. people at the point of departing were still able to get out of the area with private transports.", [["people", "ORGANISM", 92, 98], ["people", "SPECIES", 92, 98]]], ["We found that growth rates changed slightly with respect to the baseline case; in particular: @ '() = 0.", [["growth rates", "PROBLEM", 14, 26], ["growth", "OBSERVATION_MODIFIER", 14, 20]]], ["22Analysis of imported clusters: summary of parameter estimatesHere we report Maximum Likelihood estimates of parameters in the analysis of imported clusters.", [["the analysis", "TEST", 124, 136]]], ["CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Analysis of imported clusters: summary of parameter estimatesis the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.02.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 249, 269], ["this preprint", "TREATMENT", 274, 287], ["med", "ANATOMY", 95, 98]]]]}